<SEC-DOCUMENT>0001437749-24-025611.txt : 20240808
<SEC-HEADER>0001437749-24-025611.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808171251
ACCESSION NUMBER:		0001437749-24-025611
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41905
		FILM NUMBER:		241189601

	BUSINESS ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sava20240630_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:sava="http://www.cassavasciences.com/20240630" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>sava20240630_10q.htm</title>
  <!-- Generated by ThunderDome Portal - 8/8/2024 8:42:01 PM -->
  <meta http-equiv="Content-Type" content="text/html"/></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001069530</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="dei:AmendmentFlag" format="ixt:fixed-false" id="ixv-6831">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="dei:CurrentFiscalYearEndDate" id="ixv-6832">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="dei:DocumentFiscalPeriodFocus" id="ixv-6833">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="dei:DocumentFiscalYearFocus" id="ixv-6834">2024</ix:nonNumeric>
<ix:nonFraction id="c115657423" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"/>
<ix:nonFraction id="c115657424" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"/>
<ix:nonFraction id="c115657428" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c115657429" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c115657430" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c115657431" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c115657432" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115657433" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115657434" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115657435" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115657438" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c115657439" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c115657440" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c115657441" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c115657442" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">47,976,166</ix:nonFraction>
<ix:nonFraction id="c115657444" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">47,976,166</ix:nonFraction>
<ix:nonFraction id="c115657443" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction>
<ix:nonFraction id="c115657445" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction>
<ix:nonFraction id="c115657898" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c115657804" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c115657815" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.5</ix:nonFraction>
<ix:nonFraction id="c115658082" contextRef="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115659235" contextRef="d_2024-01-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115658098" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115659238" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c115658124" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c115658171" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115659233" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115658175" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115659234" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c115658255" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c115658256" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c115658257" contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c115658262" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c115658263" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c115658266" contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c115658348" contextRef="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c115658350" contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightIssuedDuringPeriod" scale="6" format="ixt:num-dot-decimal" decimals="-5">16.9</ix:nonFraction>
<ix:nonFraction id="c115658352" contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.5</ix:nonFraction>
<ix:nonFraction id="c115658354" contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Pure" name="sava:RedemptionPercentageOfWarrants" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.1</ix:nonFraction>
<ix:nonFraction id="c115658356" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-04-01_2024-06-30" name="ecd:Rule10b51ArrAdoptedFlag" id="c115658401" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-04-01_2024-06-30" name="ecd:NonRule10b51ArrAdoptedFlag" id="c115659230" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-04-01_2024-06-30" name="ecd:Rule10b51ArrTrmntdFlag" id="c115659231" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-04-01_2024-06-30" name="ecd:NonRule10b51ArrTrmntdFlag" id="c115659232" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="sava-20240630.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2024-01-01_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-08-05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2024-04-01_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-16</xbrli:startDate><xbrli:endDate>2023-03-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-06-30_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-28</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-05</xbrli:startDate><xbrli:endDate>2022-07-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-03</xbrli:startDate><xbrli:endDate>2024-01-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-05-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-03</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Form <ix:nonNumeric name="dei:DocumentType" contextRef="d_2024-01-01_2024-06-30" id="ixv-8112">10-Q</ix:nonNumeric></b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 35%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>(Mark One)</b></p> </td><td style="vertical-align: top; width: 35%;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-06-30" id="ixv-8113">&#9745;</ix:nonNumeric>&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</b></p> </td><td style="vertical-align: top; width: 35%;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td><td style="vertical-align: top; width: 35%;">&#160;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Quarterly Period Ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" contextRef="d_2024-01-01_2024-06-30" id="ixv-8114">June 30, 2024</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>or</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 35%;">&#160;</td><td style="vertical-align: top; width: 30%;">&#160;</td><td style="vertical-align: top; width: 35%;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-06-30" id="ixv-8115">&#9744;</ix:nonNumeric>&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td><td style="vertical-align: top; width: 35%;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 35%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">For the Transition Period from ___________ to ___________</p> </td><td style="vertical-align: top; width: 35%;">&#160;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2024-01-01_2024-06-30" id="ixv-8116">001-41905</ix:nonNumeric></b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>Cassava Sciences, Inc.</b></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i>(Exact name of registrant as specified in its charter)</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 20%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2024-01-01_2024-06-30" id="ixv-8117">Delaware</ix:nonNumeric> </b></p> </td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2024-01-01_2024-06-30" id="ixv-8118">91-1911336</ix:nonNumeric> </b></p> </td><td style="vertical-align: top; width: 20%;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 20%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(State</i>&#160;<i>or</i>&#160;<i>other</i>&#160;<i>jurisdiction</i>&#160;<i>of</i></p> </td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(I.R.S.</i>&#160;&#160;<i>Employer</i></p> </td><td style="vertical-align: top; width: 20%;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 20%;">&#160;</td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>incorporation</i>&#160;<i>or</i>&#160;<i>organization)</i></p> </td><td style="vertical-align: top; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Identification</i>&#160;<i>Number)</i></p> </td><td style="vertical-align: top; width: 20%;">&#160;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2024-01-01_2024-06-30" id="ixv-8119">6801 N. Capital of Texas Highway, Building 1; Suite 300</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2024-01-01_2024-06-30" id="ixv-8120">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2024-01-01_2024-06-30" id="ixv-8121">TX</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2024-01-01_2024-06-30" id="ixv-8122">78731</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2024-01-01_2024-06-30" id="ixv-8123">512</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2024-01-01_2024-06-30" id="ixv-8124">501-2444</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Address, including zip code, of registrant</i>&#8217;<i>s principal executive offices and</i></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>telephone number, including area code)</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p> </td></tr>
<tr><td style="vertical-align: top; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2024-01-01_2024-06-30" id="ixv-8125">Common Stock, $0.001 par value</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2024-01-01_2024-06-30" id="ixv-8126">SAVA</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2024-01-01_2024-06-30" id="ixv-8127">Nasdaq</ix:nonNumeric>&#160;Capital Market</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2024-01-01_2024-06-30" id="ixv-8128">Yes</ix:nonNumeric>&#160;&#9745;&#160; &#160;No&#160;&#9744;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2024-01-01_2024-06-30" id="ixv-8129">Yes</ix:nonNumeric>&#160;&#9745;&#160;&#160;&#160;No&#160;&#9744;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4.1%;">&#160;</td><td style="vertical-align:top;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2024-01-01_2024-06-30" id="ixv-8130">Large Accelerated Filer</ix:nonNumeric> &#9745;</p> </td><td style="vertical-align:top;width:33.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accelerated Filer &#9744;</p> </td></tr>
<tr><td style="vertical-align:top;width:4.1%;">&#160;</td><td style="vertical-align:top;width:16.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Non-accelerated Filer &#9744;</p> </td><td style="vertical-align:top;width:33.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Smaller Reporting Company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-06-30" id="ixv-8131">&#9744;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:4.1%;">&#160;</td><td style="vertical-align:top;width:16.2%;">&#160;</td><td style="vertical-align:top;width:33.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Emerging Growth Company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-06-30" id="ixv-8132">&#9744;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2024-01-01_2024-06-30" id="ixv-8133">&#9744;</ix:nonNumeric>&#160;&#160;&#160;No&#160;&#9745;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 10%;">&#160;</td><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; ">Common Stock, $0.001 par value</span></p> </td><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2024-08-05" id="ixv-8134">47,976,166</ix:nonFraction></span></p> </td><td style="vertical-align: top; width: 10%;">&#160;</td></tr>
<tr><td style="vertical-align: top; width: 10%;">&#160;</td><td style="vertical-align: top; width: 40%;">&#160;</td><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares&#160;Outstanding&#160;as&#160;of August 5, 2024</p> </td><td style="vertical-align: top; width: 10%;">&#160;</td></tr>
</tbody></table>
<div>
 &#160;
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></div>
  <div>
    &#160;
  </div>
  <div>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="toc" title="toc" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">TABLE OF CONTENTS</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="text-decoration: underline; ">Page No.</span></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART I.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FINANCIAL INFORMATION</p> </td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 1.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#bs" style="-sec-extract:exhibit;">Financial Statements</a></p> </td>
      <td style="vertical-align: top; width: 7%; text-align: right;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#bs" style="-sec-extract:exhibit;">Condensed Consolidated Balance Sheets &#8211; June 30, 2024 and December 31, 2023</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#bs">3</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#income" style="-sec-extract:exhibit;">Condensed Consolidated Statements of Operations &#8211;&#160;Three and Six Months Ended June 30, 2024 and 2023</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#income">4</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#equity" style="-sec-extract:exhibit;">Condensed Consolidated Statements of Changes in Stockholders&#8217;&#160;Equity - Three and Six Months Ended June 30, 2024 and 2023</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#equity">5</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#cashflow" style="-sec-extract:exhibit;">Condensed Consolidated Statements of Cash Flows &#8211; Six&#160;Months Ended June 30, 2024 and 2023</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#cashflow">6</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;">Notes to Condensed Consolidated Financial Statements</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#notes">7</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 2.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#mda" style="-sec-extract:exhibit;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#mda">21</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 3.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#qqd" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#qqd">47</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 4.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#controls" style="-sec-extract:exhibit;">Controls and Procedures</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#controls">48</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART II.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OTHER INFORMATION</p> </td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 1.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#legal" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#legal">48</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 1A</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#risk" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#risk">49</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 2.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#unregistered" style="-sec-extract:exhibit;">Unregistered Sales of Equity Securities and Use of Proceeds</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#unregistered">50</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 3.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#defaults" style="-sec-extract:exhibit;">Defaults Upon Senior Securities</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#defaults">50</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 4.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#mine" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#mine">50</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 5.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#other" style="-sec-extract:exhibit;">Other Information</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#other">50</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Item 6.</p> </td>
      <td style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#exhibits" style="-sec-extract:exhibit;">Exhibits</a></p> </td>
      <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#exhibits">51</a></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 15%;">&#160;</td>
      <td style="vertical-align: top; width: 78%;">&#160;</td>
      <td style="vertical-align: top; width: 7%;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#signatures" style="-sec-extract:exhibit;">Signatures</a></p> </td>
      <td colspan="2" style="vertical-align: top; width: 78%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#signatures">52</a></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        2
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>PART I. FINANCIAL INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 1. </b><b><i>Financial Statements</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="bs" title="bs" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, In thousands, except share and par value data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30, 2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">ASSETS</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657397" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">207,291</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657398" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657399" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,831</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657400" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657401" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">222,122</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657402" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">129,633</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657403" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,364</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657404" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,854</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657405" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">82</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657406" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657407" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">243,568</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657408" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">151,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">LIABILITIES AND STOCKHOLDERS' EQUITY</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657412" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">52,552</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657413" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,573</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued development expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657414" contextRef="i_2024-06-30" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,596</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657415" contextRef="i_2023-12-31" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,037</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued compensation and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657416" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">218</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657417" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-5">200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657418" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">228</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657419" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">385</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657420" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">54,594</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657421" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and contingencies (Notes 9, 10 and 11)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c115657423">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c115657424">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders' equity:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Preferred stock, $<span style="-sec-ix-hidden:c115657428"><span style="-sec-ix-hidden:c115657429">0.001</span></span> par value; <span style="-sec-ix-hidden:c115657430"><span style="-sec-ix-hidden:c115657431">10,000,000</span></span> shares authorized, <span style="-sec-ix-hidden:c115657432"><span style="-sec-ix-hidden:c115657433"><span style="-sec-ix-hidden:c115657434"><span style="-sec-ix-hidden:c115657435">none</span></span></span></span> issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657426" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657427" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c115657438"><span style="-sec-ix-hidden:c115657439">0.001</span></span> par value; <span style="-sec-ix-hidden:c115657440"><span style="-sec-ix-hidden:c115657441">120,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c115657442"><span style="-sec-ix-hidden:c115657444">47,976,166</span></span> and <span style="-sec-ix-hidden:c115657443"><span style="-sec-ix-hidden:c115657445">42,236,919</span></span> shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657436" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">48</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657437" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657446" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">538,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657447" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">518,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657448" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">349,571</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657449" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">380,769</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657450" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">188,974</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657451" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,468</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities and stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657452" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">243,568</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657453" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">151,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 14pt;text-indent:-14pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     3
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="income" title="income" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, in thousands, except per share data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657467" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,198</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657468" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,969</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657469" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,431</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657470" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,089</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657471" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,204</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657472" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,808</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657473" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">49,905</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657474" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-5">8,200</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total operating expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657475" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">61,402</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657476" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,777</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657477" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">81,336</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657478" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">55,289</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657479" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">61,402</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657480" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">28,777</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657481" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">81,336</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657482" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">55,289</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657483" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,316</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657484" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,198</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657485" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,092</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657486" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,249</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other income, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657487" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">99</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657488" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">203</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657489" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">259</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657490" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">393</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Gain from change in fair value of warrant liabilities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657491" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">65,142</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657492" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657493" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">108,183</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657494" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income (loss)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657495" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657496" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657497" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,198</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657498" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,647</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Shares used in computing net income (loss) per share, basic</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657499" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,202</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657500" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,793</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657501" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,601</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657502" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,766</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income (loss) per share, basic</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657503" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.13</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657504" contextRef="d_2023-04-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.63</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657505" contextRef="d_2024-01-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.70</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657506" contextRef="d_2023-01-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.21</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net income (loss)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657508" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657509" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657510" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,198</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657511" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,647</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657512" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657513" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657514" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,793</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657515" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Adjusted numerator, diluted</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657516" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657517" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657518" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">12,595</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657519" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,647</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Shares used in computing net income (loss) per share, diluted</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657520" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,202</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657521" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,793</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657522" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">45,152</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657523" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,766</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net income (loss) per share, diluted</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657524" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.13</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657525" contextRef="d_2023-04-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.63</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657526" contextRef="d_2024-01-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.28</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657527" contextRef="d_2023-01-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.21</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="equity" title="equity" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, in thousands, except share data)</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Common stock</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">stockholders'</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Par value</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">paid-in capital</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">deficit</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">equity</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657543" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657544" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657545" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,049</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657546" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">283,552</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657547" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">227,539</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657550" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657551" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-4">650</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657552" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657553" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-4">650</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657555" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657556" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657557" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657558" contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657559" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,878</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657560" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657561" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">64</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657562" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657563" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">64</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c115657565" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c115657566" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657567" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,271</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657568" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,271</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2023</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657569" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,749,435</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657570" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657571" contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,786</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657572" contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">307,823</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657573" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">204,005</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657576" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657577" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">812</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657578" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657579" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">812</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657581" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657582" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657583" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657584" contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657585" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">170,092</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657586" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657587" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">889</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657588" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657589" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">889</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657591" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657592" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657593" contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657594" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Balance at June 30, 2023</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657595" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,919,527</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657596" contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657597" contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">513,510</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657598" contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">334,199</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657599" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">179,353</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
      <td>&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657600" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657601" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657602" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">518,195</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657603" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">380,769</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657604" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,468</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657607" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657608" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,312</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657609" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657610" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,312</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657612" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657613" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657614" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657615" contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Issuance of warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657617" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657618" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,363</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657619" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657620" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,363</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657621" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,011,497</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657622" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657623" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,159</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657624" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657625" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-4">22,160</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Derecognition of warrant liabilities upon exercise of warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657627" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657628" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,954</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657629" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657630" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,954</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Net income</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657632" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657633" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657634" contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">25,043</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657635" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">25,043</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2024</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657636" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,248,416</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657637" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">43</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657638" contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">434,280</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657639" contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">355,726</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657640" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">78,597</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock-based compensation for:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657643" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657644" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,581</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657645" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657646" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,581</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657648" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657649" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657650" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657651" contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Issuance of common stock pursuant to exercise of warrants</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c115657652" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,727,750</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c115657653" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c115657654" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">101,387</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c115657655" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c115657656" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">101,392</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Derecognition of warrant liabilities upon exercise of warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657658" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657659" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">226</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657660" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; vertical-align: top;"><ix:nonFraction id="c115657661" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">226</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net income</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657663" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657664" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657665" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657666" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Balance at June 30, 2024</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657667" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">47,976,166</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657668" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">48</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657669" contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">538,497</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657670" contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">349,571</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657671" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">188,974</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     5
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="cashflow" title="cashflow" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(Unaudited, in thousands)</b></p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended June 30,</em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from operating activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net income (loss)</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657677" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,198</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657678" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,647</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657680" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,939</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657681" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,508</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Gain from change in fair value of warrant liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657682" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">108,183</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657683" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657684" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">496</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657685" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">544</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of intangible assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657686" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">117</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657687" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">238</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Prepaid and other current assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657689" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,334</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657690" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,116</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Operating lease right-of-use assets and liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657691" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657692" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accounts payable and accrued expenses</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657693" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,979</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657694" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,661</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accrued development expense</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657695" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,441</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657696" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,764</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accrued compensation and benefits</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657697" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">18</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657698" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-4">50</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Other liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657699" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">157</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657700" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">396</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in operating activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657701" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">37,368</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657702" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">33,179</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from investing activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchases of property and equipment</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657704" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">29</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657705" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">351</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in investing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657706" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">29</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657707" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">351</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from financing activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Proceeds from exercise of common stock warrants, net of exercise costs</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657709" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">123,552</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657710" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from issuance of common stock upon exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657711" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657712" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">953</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657713" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">123,552</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657714" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">953</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net increase (decrease) in cash and cash equivalents</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657715" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">86,155</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657716" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,577</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657717" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657718" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of period</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657719" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">207,291</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657720" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">168,438</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Supplemental cash flow information:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Non-cash financing activities</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Issuance of warrants resulting in recognition of warrant liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657723" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">113,363</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657724" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Derecognition of warrant liabilities upon exercise of warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657725" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="sava:DerecognitionOfWarrantLiabilitiesThroughExercises" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">5,180</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657726" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="sava:DerecognitionOfWarrantLiabilitiesThroughExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     6
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a id="notes" title="notes" href="#"></a>Cassava Sciences, Inc.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Notes to Condensed Consolidated Financial Statements</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2709907" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">1.</em> General and Liquidity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> All intercompany transactions and balances have been eliminated in consolidation. Accordingly, the condensed consolidated financial statements do <em style="font: inherit;">not</em> include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em> are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for any other interim period or for the year <em style="font: inherit;">2024.</em> For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form&#160;<em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $<ix:nonFraction id="c115657737" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">349.6</ix:nonFraction>&#160;million at <em style="font: inherit;"> June 30, 2024</em>. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2709908" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">2.</em></b>&#160;&#160;<b>Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:UseOfEstimates" id="c115659237" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c115659239" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c115659240" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> June 30, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The fair value of common stock warrants of $<ix:nonFraction id="c115657793" contextRef="i_2024-01-03" unitRef="USDPerShare" name="sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.71</ix:nonFraction> per warrant was determined at distribution on <em style="font: inherit;"> January 3, 2024 </em>using a Monte Carlo valuation model since the warrants were&#160;<em style="font: inherit;">not</em> traded on the open market on <em style="font: inherit;"> January 3, 2024. </em>Warrant trading on Nasdaq began on <em style="font: inherit;"> January 4, 2024. </em>Quantitative information regarding Level <em style="font: inherit;">3</em> fair value measurements for common stock warrants are as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="c2709909" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657892" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657893" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.50</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657894" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">23.72</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657895" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">75</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657896" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">5.40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c115657897" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c115657898">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The common stock warrants stopped&#160;trading on Nasdaq after <em style="font: inherit;"> May 2, 2024 </em>and subsequently had little or <em style="font: inherit;">no</em> market activity. As of <em style="font: inherit;"> May 7, 2024,&#160;</em>the warrants were presumed to have <em style="font: inherit;">no</em> value since they&#160;were redeemed for a nominal payment of $<ix:nonFraction id="c115657801" contextRef="i_2024-05-07" unitRef="USDPerShare" name="sava:ClassOfWarrantOrRightRedemptionPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per warrant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c115659241" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Segments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to <ix:nonFraction id="c115657803" contextRef="d_2024-04-01_2024-06-30" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="c115659242" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c115657804">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c115659243" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Income (Loss) per Share </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be antidilutive. A net loss&#160;causes all potentially dilutive securities to be antidilutive. Potentially dilutive securities consist of outstanding common stock options,&#160;warrants and Performance Awards.&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net income (loss) and comprehensive net income (loss). The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="c2709910" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657912" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657913" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657914" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,198</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115657915" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,647</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657917" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657918" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,793</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657919" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,601</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657920" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,766</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net income (loss) per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657921" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.13</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657922" contextRef="d_2023-04-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.63</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657923" contextRef="d_2024-01-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.70</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657924" contextRef="d_2023-01-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.21</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657926" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657927" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657928" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,198</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657929" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,647</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657930" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:DilutiveSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657931" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:DilutiveSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115657932" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:DilutiveSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">43,793</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657933" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:DilutiveSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657934" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,155</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657935" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,376</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657936" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">12,595</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c115657937" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,647</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657939" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657940" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,793</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657941" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,601</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657942" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,766</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657943" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657944" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657945" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" format="ixt:num-dot-decimal" decimals="-3">551</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657946" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657947" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,202</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657948" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,793</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657949" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">45,152</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657950" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,766</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657951" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.13</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657952" contextRef="d_2023-04-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.63</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657953" contextRef="d_2024-01-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.28</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c115657954" contextRef="d_2023-01-01_2023-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.21</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Dilutive common stock options excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657955" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,703</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657956" contextRef="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,001</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657957" contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,674</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657958" contextRef="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,018</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657959" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657960" contextRef="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657961" contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657962" contextRef="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em> from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti<b>-</b>dilutive. The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em> from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti<b>-</b>dilutive. Warrants were included for&#160;the calculation of net loss per share, diluted, for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>assuming each warrant was&#160;exercisable for <span style="-sec-ix-hidden:c115657815">one</span> and <em style="font: inherit;">one</em>-half shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:DerivativesPolicyTextBlock" id="c115659244" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><b><i>Warrant Liabilities</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8220;) Accounting Standards Codification (&#8220;ASC&#8220;) <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC <em style="font: inherit;">480&#8220;</em>), and ASC <em style="font: inherit;">815,</em> &#8220;Derivatives and Hedging&#8221; (&#8220;ASC <em style="font: inherit;">815&#8220;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-align: justify;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c115659245" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b>&#160; &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses, accrued development expense and other&#160;liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense and other liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c115659246" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research Contracts, Prepaids&#160;and Accruals </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c115659247" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;CIB Plan&#8221;) to incentivize Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">10</em> for further discussion of the CIB Plan.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:nonNumeric><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c115659248" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities. As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c115659249" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of <ix:nonNumeric contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c115657844" format="ixt-sec:duryear">39</ix:nonNumeric> years and approximately <ix:nonNumeric contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c115657845" format="ixt-sec:duryear">10</ix:nonNumeric> years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c115659250" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements. Intangible assets also include&#160;leasing commissions which are amortized over the life of the lease agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="c115659251" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Insurance Recoveries</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense. There was approximately $<ix:nonFraction id="c115657849" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.8</ix:nonFraction>&#160;million&#160;of insurance recoveries recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024. </em>There were&#160;<ix:nonFraction id="c115657851" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> insurance recoveries recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2023. </em>There was approximately $<ix:nonFraction id="c115657854" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.8</ix:nonFraction>&#160;million&#160;and $<ix:nonFraction id="c115657855" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million of insurance recoveries recorded during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. The applicable policy has a $<ix:nonFraction id="c115657859" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="sava:InsuranceSettlementsMaximumRecoveryLimit" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction> million recovery limit.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c115659252" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s condensed consolidated financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c115659253" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b>Recently Issued Accounting Pronouncements</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> November 2023, </em>the&#160;FASB&#160;issued Accounting Standards Update, or ASU, <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses and other segment items by reportable segment. The ASU becomes effective for annual periods beginning in <em style="font: inherit;">2024</em> and interim periods in <em style="font: inherit;">2025.</em> The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. This standard enhances disclosures related to income taxes, including the rate reconciliation and information on income taxes paid. The ASU becomes effective <em style="font: inherit;"> January 1, 2025.&#160;</em>The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;"></div></div></div></ix:exclude></ix:nonNumeric><ix:exclude><div class="PGFTR" style="text-align: center; width: 100%"><div class="hf-row"><div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="sava:PrepaidExpensesAndOtherCurrentAssetsTextBock" id="c2709911" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid expenses and other current assets at <em style="font: inherit;"> June 30, 2024</em> and&#160;<em style="font: inherit;"> December 31, 2023</em> consisted of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c2709912" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657968" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657969" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">759</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657970" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,432</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657971" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,489</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115657972" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,433</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115657973" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">962</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Insurance recoveries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657974" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:InsuranceSettlementsReceivableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,800</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115657975" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:InsuranceSettlementsReceivableCurrent" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657976" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">161</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115657977" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">287</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657978" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,831</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115657979" contextRef="i_2023-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:RealEstateOwnedTextBlock" id="c2709913" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">4.</em> Real Property&#160;and Other Income, Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s potential growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex has&#160;approximately <ix:nonFraction id="c115657982" contextRef="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="SquareFoot" name="us-gaap:NetRentableArea" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,000</ix:nonFraction> square feet of rentable space. At <em style="font: inherit;"> June 30, 2024</em>, the Company occupied&#160;approximately <ix:nonFraction id="c115657983" contextRef="i_2024-06-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="Pure" name="sava:PercentageOfOccupancy" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% of the property with the remainder&#160;either leased or available for lease to <em style="font: inherit;">third</em> parties.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#8217;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is&#160;allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="c2709914" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658000" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">314</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658001" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">559</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658002" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">717</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658003" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,116</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658004" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">215</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658005" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">356</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658006" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">458</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658007" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">723</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658008" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658009" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">203</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658010" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">259</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658011" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">393</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2709915" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">5.</em> Property and equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of <em style="font: inherit;"> June 30, 2024</em>&#160;and&#160;<em style="font: inherit;"> December 31, 2023</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2709916" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658026" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658027" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658028" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658029" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658030" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658031" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658032" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,062</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658033" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,062</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658034" contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">873</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658035" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">868</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658036" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,143</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658037" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,138</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658038" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,779</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658039" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,284</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658040" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,364</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658041" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,854</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#160;$<ix:nonFraction id="c115658013" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">244,000</ix:nonFraction>&#160;and&#160;$<ix:nonFraction id="c115658014" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">272,000</ix:nonFraction>&#160;for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em>, respectively.&#160;Depreciation expense for property and equipment was $<ix:nonFraction id="c115658017" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">496,000</ix:nonFraction> and $<ix:nonFraction id="c115658018" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">544,000</ix:nonFraction> for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024&#160;</em>and <em style="font: inherit;">2023,</em> respectively.</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="c2709917" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">6.</em> Intangible assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#160;<em style="font: inherit;"> June 30, 2024</em> and&#160;<em style="font: inherit;"> December 31, 2023</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="c2709918" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658059" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658060" contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658061" contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">317</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658062" contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">293</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658063" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,370</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658064" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,346</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658065" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,288</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658066" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,170</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658067" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">82</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658068" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was $<ix:nonFraction id="c115658043" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">56,000</ix:nonFraction> and $<ix:nonFraction id="c115658044" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">119,000</ix:nonFraction> for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023,</em> respectively.&#160;Amortization expense for intangible assets was&#160;$<ix:nonFraction id="c115658049" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,000</ix:nonFraction> and $<ix:nonFraction id="c115658050" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">238,000</ix:nonFraction> for the <em style="font: inherit;">six</em> months ended&#160;<em style="font: inherit;"> June 30, 2024&#160;</em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets as of <em style="font: inherit;"> June 30, 2024</em> is expected to be as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="c2709919" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658070" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" format="ixt:num-dot-decimal" decimals="-4">60</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658071" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">11</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c115658072" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">8</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658073" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658074" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">82</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="c2709920" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">7.</em> Stockholders</b>&#8217;<b> Equity and Stock-Based Compensation Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Common Stock Warrant Distribution</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">See Notes <em style="font: inherit;">2</em> and <em style="font: inherit;">12</em> regarding the distribution of common stock warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>At-the-Market Common Stock Offering </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction id="c115658079" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="USD" name="sava:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction> million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to <ix:nonFraction id="c115658080" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Pure" name="sava:EquityOfferingPercentageOfCommission" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>% of the gross proceeds from the sale of shares of common stock in the offering. The Company is <em style="font: inherit;">not</em> obligated to sell any shares in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were <span style="-sec-ix-hidden:c115658082"><span style="-sec-ix-hidden:c115659235">no</span></span> common stock sales under the ATM during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> March 2020, </em>the Company entered into an at-the-market offering program (<em style="font: inherit;">&#8220;2020</em> Program&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction id="c115658086" contextRef="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="USD" name="sava:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">100</ix:nonFraction> million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on <em style="font: inherit;"> May 5, 2020. </em>The Company gave notice of termination for the <em style="font: inherit;">2020</em> Program on <em style="font: inherit;"> April 26, 2023, </em>which was effective <em style="font: inherit;"> May 1, 2023. </em>There were <em style="font: inherit;">no</em> common stock sales under the <em style="font: inherit;">2020</em> Program through its termination.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock Option and Performance Award Activity in <em style="font: inherit;">2024</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>, stock options and unvested Performance Awards outstanding under the Company&#8217;s stock option plans changed as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="c2709921" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658136" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,039,029</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658137" contextRef="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658138" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">193,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115658139" contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658140" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115658141" contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658142" contextRef="d_2024-01-01_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">154,700</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c115658143" contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of June 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658144" contextRef="i_2024-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,077,329</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658145" contextRef="i_2024-06-30_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The weighted average exercise price per share of options outstanding at <em style="font: inherit;"> June 30, 2024</em> was $<ix:nonFraction id="c115658092" contextRef="i_2024-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">14.57</ix:nonFraction>. As outstanding options vest over the current remaining vesting period of <ix:nonNumeric contextRef="d_2024-04-01_2024-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c115658093" format="ixt-sec:duryear">2.4</ix:nonNumeric>&#160;years, the Company expects to recognize stock-based compensation expense of $<ix:nonFraction id="c115658094" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">22.6</ix:nonFraction>&#160;million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $<ix:nonFraction id="c115658095" contextRef="i_2024-06-30_AwardTypeAxis-PerformanceSharesMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million over the implicit service period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>, there were <span style="-sec-ix-hidden:c115658098"><span style="-sec-ix-hidden:c115659238">no</span></span> stock options exercised.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2023, </em>there were <ix:nonFraction id="c115658100" contextRef="d_2023-04-01_2023-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">262,158</ix:nonFraction> stock options exercised. Of the stock options exercised, <ix:nonFraction id="c115658101" contextRef="d_2023-04-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">92,066</ix:nonFraction> stock options were net settled in satisfaction of the exercise price, with <ix:nonFraction id="c115658102" contextRef="d_2023-04-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $<ix:nonFraction id="c115658104" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">889,000</ix:nonFraction> during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023, </em>there were <ix:nonFraction id="c115658107" contextRef="d_2023-01-01_2023-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">281,175</ix:nonFraction> stock options exercised. Of the stock options exercised, <ix:nonFraction id="c115658108" contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">97,205</ix:nonFraction> stock options were net settled in satisfaction of the exercise price, with <ix:nonFraction id="c115658109" contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $<ix:nonFraction id="c115658111" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">953,000</ix:nonFraction> during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock-based Compensation Expense in <em style="font: inherit;">2024</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em>, the Company&#8217;s stock-based compensation expense was as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2709922" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658158" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">972</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658159" contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">392</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658160" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,945</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658161" contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">781</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658162" contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,632</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658163" contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">443</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658164" contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,994</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c115658165" contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">727</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658166" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,604</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658167" contextRef="d_2023-04-01_2023-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">835</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658168" contextRef="d_2024-01-01_2024-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,939</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115658169" contextRef="d_2023-01-01_2023-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,508</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a designated committee of the Board is responsible for administration of the Company&#8217;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan, as amended (the <em style="font: inherit;">&#8220;2018</em> Plan&#8221;) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and Performance Awards. Share-based awards generally expire <span style="-sec-ix-hidden:c115658124">10</span> years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended in <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">2022,</em> provides for issuance of up to <ix:nonFraction id="c115658127" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction id="c115658128" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2709923" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">8.</em> Income Taxes</b><b><i> </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <span style="-sec-ix-hidden:c115658171"><span style="-sec-ix-hidden:c115659233">not</span></span> provide for income taxes during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>, because it has projected a taxable net loss for the full year <em style="font: inherit;">2024</em>&#160;for which any benefit will be offset by an increase in the valuation allowance. There was also <span style="-sec-ix-hidden:c115658175"><span style="-sec-ix-hidden:c115659234">no</span></span> provision for income taxes for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="sava:LeasesAndCommitmentsDisclosureTextBlock" id="c2709924" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">9.</em> Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="sava:CashIncentiveBonusPlanTextBlock" id="c2709925" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note</b>&#160;<b><em style="font: inherit;">10.</em></b>&#160;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the CIB Plan. The CIB Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;CIB Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The CIB Plan is considered &#8220;at-risk&#8221; because CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em> receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the CIB Plan&#160;are met.&#160;Specifically, CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em>&#160;be paid&#160;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#160;(the "Compensation Committee") determines the Company has sufficient cash on hand, as defined in the CIB Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;CIB Plan&#160;grant date has <em style="font: inherit;">not</em> occurred&#160;as of <em style="font: inherit;"> June 30, 2024</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">CIB Plan participants will be paid all earned cash bonuses allocated under the CIB&#160;Plan in the event of a Merger Transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company&#8217;s independent directors were participants in the CIB Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#160;amended the CIB Plan to remove all independent directors as participants in the CIB Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the CIB Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the CIB Plan. The Company&#8217;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the CIB Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization for purposes of the CIB Plan&#160;is&#160;determined based on either (<em style="font: inherit;">1</em>) the closing price&#160;of <em style="font: inherit;">one</em> share&#160;of the Company&#8217;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;Any warrants outstanding are excluded from the determination of market capitalization. This constitutes a market condition under applicable accounting guidance.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;<em style="font: inherit;">$5</em>&#160;billion in market capitalization. The CIB Plan specifies <ix:nonFraction id="c115658213" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#160;incremental&#160;amounts&#160;between&#160;$<ix:nonFraction id="c115658214" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction id="c115658215" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the CIB Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c115658217" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days for&#160;CIB Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately <ix:nonFraction id="c115658218" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" scale="-2" format="ixt:num-dot-decimal" decimals="2">67</ix:nonFraction>% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#160;are&#160;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $<ix:nonFraction id="c115658221" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#160;billion market capitalization&#160;for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c115658223" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$<ix:nonFraction id="c115658224" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">111.4</ix:nonFraction>&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$<ix:nonFraction id="c115658225" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">289.7</ix:nonFraction>&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(<em style="font: inherit;">1</em>)&#160;the Company completes a Merger Transaction, or&#160;(<em style="font: inherit;">2</em>)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#160;CIB Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the CIB Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the <ix:nonFraction id="c115658229" contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#160;achieved&#160;the <em style="font: inherit;">first</em>&#160;Valuation&#160;Milestone.&#160;Subsequently in <em style="font: inherit;">2020,</em> the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$<ix:nonFraction id="c115658232" contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="sava:CashIncentiveBonusAward" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction>&#160;million&#160;in total&#160;for&#160;all CIB Plan participants (after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment), subject to future satisfaction of a Performance Condition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company achieved <ix:nonFraction id="c115658235" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">11</ix:nonFraction> additional Valuation Milestones triggering potential Company obligations to all CIB Plan participants from a minimum of $<ix:nonFraction id="c115658236" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">74.9</ix:nonFraction>&#160;million up to a hypothetical maximum of $<ix:nonFraction id="c115658237" contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">202.3</ix:nonFraction>&#160;million (after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment), to be determined, approved and allocated by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;<ix:nonFraction id="c115658238" contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#160;compensation expense was recorded&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.&#160;There is <em style="font: inherit;">no</em> continuing service requirement for CIB Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during the years ended <em style="font: inherit;"> December 31, 2023&#160;</em>and <em style="font: inherit;">2022</em> or the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><ix:nonFraction id="c115658245" contextRef="d_2024-01-01_2024-06-30_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="sava:PaymentsForCashIncentiveBonus" scale="6" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> actual cash payments were authorized or made to participants under the CIB Plan through the date of filing of this Form <em style="font: inherit;">10</em>-Q.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:LossContingencyDisclosures" id="c2709926" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em> Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Company is, and from time to time, the Company <em style="font: inherit;"> may </em>become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time <em style="font: inherit;"> may </em>receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company other than as disclosed below. The Company believes that its total provisions for legal matters are adequate based upon currently available information.</p>
   <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><i>Update on Government Investigations</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">Beginning in <em style="font: inherit;"> August 2021, </em>the Company has received subpoenas, a Civil Investigative Demand (&#8220;CID&#8221;) and other requests for documents and information from the Department of Justice and document requests from the Securities and Exchange Commission, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, CID and requests for information and intends to continue to cooperate with these&#160;government&#160;inquiries. The Company cannot predict the outcome or impact of these ongoing matters, including whether a government authority <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">The Company is in the advanced stages of discussions with the SEC staff to resolve the SEC&#8217;s nearly <em style="font: inherit;">three</em>-year investigation of the Company's disclosures regarding its Phase <em style="font: inherit;">2b</em> study of simufilam for the treatment of Alzheimer&#8217;s disease (the &#8220;Phase <em style="font: inherit;">2b</em> Study&#8221;). The Company has reserved a loss contingency of <em style="font: inherit;">$40</em>&#160;million&#160;on its consolidated balance sheet as of <em style="font: inherit;"> June 30, 2024 </em>relating to this potential settlement with the SEC.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">The Company continues to cooperate with the DOJ related to conduct alleged in the indictment of Dr. Hoau-Yan Wang announced by the Department of Justice on <em style="font: inherit;"> June 28, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><span style="-sec-ix-hidden:c115658255">four</span> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <span style="-sec-ix-hidden:c115658256">four</span> class action lawsuits into <span style="-sec-ix-hidden:c115658257">one</span> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>On <em style="font: inherit;"> February 22, 2024, </em>plaintiffs filed a motion to supplement their complaint to extend the putative class period through <em style="font: inherit;"> October 12, 2023.&#160; </em>The court granted that Motion on <em style="font: inherit;"> June 12, 2024, </em>and plaintiffs filed a supplemental complaint on <em style="font: inherit;"> June 13, 2023.&#160; </em>On <em style="font: inherit;"> March 13, 2024, </em>plaintiffs filed a Motion for Class Certification.&#160; The Company has opposed that Motion.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendants&#8217; alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between <em style="font: inherit;"> November 4, 2021 </em>and <em style="font: inherit;"> June 20, 2023, </em><ix:nonFraction id="c115658261" contextRef="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> additional shareholder derivative actions were filed alleging substantially similar claims, <span style="-sec-ix-hidden:c115658262">two</span> in the U.S. District Court for the Western District of Texas, <span style="-sec-ix-hidden:c115658263">one</span> in Texas state court (Travis County District Court) and <ix:nonFraction id="c115658265" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <span style="-sec-ix-hidden:c115658266">three</span> actions in the Western District of Texas were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On <em style="font: inherit;"> November 9, 2023, </em>another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> February 2, 2024, </em>a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> August 18, 2022 </em>and <em style="font: inherit;"> October 12, 2023. </em>On <em style="font: inherit;"> May 28, 2024, </em>the Northern District of Illinois transferred this action to the Western District of Texas.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Beginning on <em style="font: inherit;"> March 18, 2024, </em><ix:nonFraction id="c115658268" contextRef="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">two</ix:nonFraction> related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. The complaints rely on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaints allege, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative cases seek, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiffs in these derivative cases do <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The Company believes the foregoing claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> May 28, 2024, </em>the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the &#8220;Stipulation&#8221;) to resolve the Action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the &#8220;Notice&#8221;) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the &#8220;Scheduling Order&#8221;), were filed in the Delaware Court of Chancery on <em style="font: inherit;"> May 28, 2024.&#160; </em>The Stipulation is subject to final approval by the Delaware Court of Chancery. The Stipulation, if finally approved, will cause the dismissal with prejudice of the Action.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> June 26, 2024, </em>the Delaware Court of Chancery entered the Scheduling Order, which includes approval of the Notice.&#160; Resolution of the Action is subject to approval from the Delaware Court of Chancery. The Delaware Court of Chancery set a final settlement hearing for <em style="font: inherit;"> September 9, 2024, </em>at <em style="font: inherit;">3:15</em> p.m. ET in the Delaware Court of Chancery, Leonard L. Williams Justice Center, <em style="font: inherit;">500</em> North King Street, Wilmington, Delaware <em style="font: inherit;">19801.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Anti-SLAPP Lawsuit</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">On <em style="font: inherit;"> August 6, 2024, </em>a lawsuit was filed in the District Court for the Southern District of New York asserting claims under the New York Anti-SLAPP Law.&#160; The complaint seeks costs and damages relating to a defamation action filed by the Company against the plaintiffs and subsequently dismissed voluntarily and without prejudice by the Company.&#160;The Company will defend the lawsuit vigorously.&#160;The Company is unable to estimate the possible loss or range of loss, if any, associated with this lawsuit.</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="sava:WarrantDividendDistributionTextBlock" id="c2709927" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -11pt; text-indent: 9pt;"><b>Note <em style="font: inherit;">12.</em> Warrant Dividend Distribution</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;"> January 3, 2024, </em>the Company&#160;made a distribution&#160;to the holders of record of the Company&#8217;s&#160;common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on <em style="font: inherit;"> December 22, 2023 </em>received <span style="-sec-ix-hidden:c115658348">four</span> warrants for every <ix:nonFraction id="c115658349" contextRef="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">10</ix:nonFraction>&#160;shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately <span style="-sec-ix-hidden:c115658350">16.9</span> million&#160;warrants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Each warrant entitled&#160;the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $<ix:nonFraction id="c115658351" contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.00</ix:nonFraction> per warrant, <span style="-sec-ix-hidden:c115658352">one</span> and <em style="font: inherit;">one</em>-half shares of common stock (rounded down&#160;for any fractional shares). Payment for shares of common stock upon exercise of warrants was required to&#160;be in cash.</p>
   <p style="margin: 0pt 0pt 0pt -9pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;"> April 15, 2024, </em>the Company announced&#160;that all outstanding warrants would&#160;be redeemed on <em style="font: inherit;"> May 7, 2024&#160;(</em>the &#8220;Redemption Date&#8221;). The redemption price was equal to <span style="-sec-ix-hidden:c115658354">1/10</span> of $<ix:nonFraction id="c115658355" contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USDPerShare" name="sava:WarrantRedemptionPrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.01</ix:nonFraction> per warrant. The warrants were exercisable at any time starting on <em style="font: inherit;"> January 3, 2024&#160;</em>until the business day prior to the Redemption Date. There are <span style="-sec-ix-hidden:c115658356">no</span> remaining warrants currently outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The warrants were subject to the terms and conditions of the Warrant Agreement (including Form of Warrant), dated <em style="font: inherit;"> January 3, 2024, </em>between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A. as filed in a Current Report on&#160;Form <em style="font: inherit;">8</em>-K with the SEC on <em style="font: inherit;"> January 3, 2024. </em>The warrants were&#160;listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#8220;SAVAW&#8221;.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">From <em style="font: inherit;"> January 3, 2024 </em>to <em style="font: inherit;"> March 31, 2024, </em>a total of approximately <ix:nonFraction id="c115658358" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">674,000</ix:nonFraction>&#160;warrants were exercised resulting in net proceeds to the Company of approximately $<ix:nonFraction id="c115658359" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:num-dot-decimal" decimals="-5">22.3</ix:nonFraction>&#160;million. The Company issued approximately <ix:nonFraction id="c115658360" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.0</ix:nonFraction> million&#160;shares of common stock&#160;from the exercise of warrants through <em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Subsequent to <em style="font: inherit;"> March 31, 2024 </em>and through the Redemption Date, a total of approximately <em style="font: inherit;">3.15</em> million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately <em style="font: inherit;">$104.0</em>&#160;million. The Company issued approximately <ix:nonFraction id="c115658363" contextRef="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.7</ix:nonFraction> million shares of common stock&#160;from the exercise of warrants from <em style="font: inherit;"> March 31, 2024 </em>through the Redemption Date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Gross proceeds in <em style="font: inherit;">2024</em> from the warrant distribution totaled approximately $<ix:nonFraction id="c115658365" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:GrossProceedsFromIssuanceOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">126.3</ix:nonFraction>&#160;million from the issuance of approximately <ix:nonFraction id="c115658366" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.7</ix:nonFraction> million common shares at $<ix:nonFraction id="c115658367" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">22.00</ix:nonFraction> per share. Total net proceeds of the warrant distribution were approximately $<ix:nonFraction id="c115658368" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">123.6</ix:nonFraction>&#160;million&#160;after deducting estimated exercise&#160;expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">After the <em style="font: inherit;">first</em> $<ix:nonFraction id="c115658371" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission" scale="6" format="ixt:num-dot-decimal" decimals="-7">20</ix:nonFraction> million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;<ix:nonFraction id="c115658372" contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Pure" name="sava:CommissionPercentageOfGrossProceeds" scale="-2" format="ixt:num-dot-decimal" decimals="3">2.5</ix:nonFraction>% of the gross proceeds from the sale of shares of common stock from&#160;warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $<ix:nonFraction id="c115658373" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:PaymentsOfWarrantExerciseCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.7</ix:nonFraction>&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Costs of the warrant distribution totaling&#160;approximately $<ix:nonFraction id="c115658374" contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">537,000</ix:nonFraction> were recorded&#160;as general and administrative expenses in the statements of operations upon distribution of the warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">The outstanding warrants are classified as liabilities in accordance with ASC <em style="font: inherit;">480</em> and ASC <em style="font: inherit;">815,</em> which requires&#160;the warrants to be measured at initial fair value&#160;on <em style="font: inherit;"> January 3, 2024&#160;</em>and at each reporting period thereafter, with the changes in fair value recognized as a non-cash gain or loss&#160;in our consolidated statements of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;During the period from common stock warrant distribution on <em style="font: inherit;"> January 3, 2024 </em>to the Redemption Date, changes in the Company's common stock warrants liability and&#160;warrants outstanding were as follows (in thousands):</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2709928" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Common Stock Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Common Stock Warrant Liability</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Distribution of common stock warrants on January 3, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658382" contextRef="i_2024-01-02" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,895</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658384" contextRef="i_2024-01-02" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">113,363</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115658385" contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightExercisedDuringPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">674</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115658387" contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,954</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c115658389" contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,041</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balance at March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658390" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,221</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115658391" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,368</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115658392" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightExercisedDuringPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,152</ix:nonFraction></td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115658393" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">226</ix:nonFraction></td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115658395" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">65,142</ix:nonFraction></td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Redemption of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c115658396" contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,069</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;<ix:nonFraction id="c115658398" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" format="ixt:fixed-zero" decimals="-3"></ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;<ix:nonFraction id="c115658399" contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" format="ixt:fixed-zero" decimals="-3"></ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">See Note <em style="font: inherit;">2</em> for additional information regarding common stock warrants and associated warrant liability.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="mda" title="mda" href="#"></a>Item 2. </b><b><i>Management</i></b>&#8217;<b><i>s Discussion and Analysis of Financial Condition and Results of Operations</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This discussion and analysis should be read in conjunction with Cassava Sciences, Inc.&#8217;s (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) condensed consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report on Form 10-Q. Operating results are not necessarily indicative of results that may occur in future periods.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b>Forward-looking Statements and Notices</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This Quarterly Report on Form 10-Q contains certain statements that are considered forward-looking statements within the meaning of the Private Securities Reform Act of 1995. We intend that such statements be protected by the safe harbor created thereby. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would&#8221; or the negatives of these terms or other comparable terminology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Examples of such forward-looking statements include, but are not limited to statements about:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the expected safety profile or treatment benefits, if any, of simufilam for people with Alzheimer&#8217;s disease in our on-going Phase 3 studies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">our reliance on third-party contractors to conduct all of our clinical and non-clinical trials and to make drug supply on a large-scale for our Phase 3 clinical program, or their ability to do so on-time or on-budget;</td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our ability to extend our 1-year open-label extension study for an additional period of time;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">limitations around data interpretation from results of any of the three clinical phases of our 2-year safety study of simufilam in patients with Alzheimer&#8217;s disease, as compared to clinical&#160;results from randomized controlled trials;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the ability of clinical scales to assess cognition or health in our trials of Alzheimer&#8217;s disease;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">any significant changes we may make, or anticipate making, to the design of any of our on-going Phase 3 studies of simufilam in patients with Alzheimer&#8217;s disease;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at Alzheimer&#8217;s disease and other neurodegenerative diseases;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">the impact of pre-clinical findings on our ability to develop our product candidates;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the interpretation of results from our pre-clinical or early clinical studies, such as Phase 1 and Phase 2 studies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">our plans to further develop SavaDx, our investigational blood-based diagnostic product candidate;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability or willingness to expand therapeutic indications for simufilam outside of Alzheimer&#8217;s disease;</p> </td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">the&#160;safety, efficacy, or potential therapeutic benefits of our product candidates;</td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our use of exploratory &#8216;research use only&#8217; non-safety related biomarkers in our clinical studies;</td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to file for and obtain regulatory approval of our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our strategy and ability to establish an infrastructure to commercialize any product candidates, if approved;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the potential future revenues of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the market acceptance of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the pricing and reimbursement of our product candidates, if approved and commercialized;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the utility of protection, or the sufficiency, of our intellectual property;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our potential competitors or competitive products for the treatment of Alzheimer&#8217;s disease;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our need to raise new capital from time to time to continue our operations or to expand our operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our use of multiple third-party vendors and collaborators, including a Clinical Research Organization ("CRO"), to conduct clinical and non-clinical studies of our lead product candidate;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our expenses or incurred costs increasing by material amounts in excess of budgeted amounts due to unexpected cost overruns, inflation, imperfect forecasting, increased scope of activities or other causes;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">fluctuations in our financial or operating results;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our operating losses, anticipated operating and capital expenditures and legal expenses;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">expectations regarding the issuance of shares of common stock, options or other equity to employees or directors pursuant to equity compensation awards, net of employment taxes;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the development and maintenance of our internal information systems and infrastructure;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;">&#9679;</td>
     <td style="vertical-align:top;">our ability to minimize the likelihood and impact of adverse cybersecurity incidents in our information systems and infrastructure;</td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our need to hire additional personnel and our ability to attract and retain such personnel;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">existing or emerging regulations and regulatory developments in the United States and other jurisdictions in which we operate;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our plans to expand the size and scope of our operations;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the sufficiency of our cash&#160;resources to continue to fund our operations;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">potential future agreements with third parties in connection with the commercialization of our product candidates;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the accuracy of our estimates regarding expenses, loss contingency reserves, capital requirements, and needs for additional financing;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">assumptions and estimates used for our disclosures regarding stock-based compensation;</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the expense, timing and outcome of pending or future litigation or other legal proceedings and claims, including U.S. government inquiries and their potential resolution; and</p> </td>
    </tr>

    <tr>
     <td style="width:18pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">litigation, claims or other uncertainties that may arise from allegations made against us or our former employees or collaborators.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Please also refer to the section entitled &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as such risk factors may be amended, updated or modified periodically in our reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) for further information on these and other risks affecting us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We caution you not to place undue reliance on forward-looking statements because our future results may differ materially from those expressed or implied by them. We do not intend to update any forward-looking statement, whether written or oral, relating to the matters discussed in this Quarterly Report on Form 10-Q, except as required by law.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This Quarterly Report on Form 10-Q may also contain statistical data and drug information received from our&#160;independent consultants or based on industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these&#160;sources of data and information. Accordingly, we make no representations as to the accuracy or completeness of such data and&#160;information. You are cautioned not to give undue weight to such data and information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our research programs in neurodegeneration have historically benefited from scientific and financial support from the National Institutes of Health (&#8220;NIH&#8221;). The contents of this Quarterly Report on Form 10-Q are solely our responsibility and do not necessarily represent any official views of NIH, the Department of Health and Human Services, or any other agency of the United States government, or any of our vendors, collaborators or unrelated third-parties<i>.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the Alzheimer&#8217;s brain. Our lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer&#8217;s disease dementia in Phase 3 clinical studies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">For over 12 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#8217;s disease and other neurodegenerative diseases. Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for treating neurodegenerative diseases, such as Alzheimer&#8217;s&#8212;a degenerative disease of the brain, where a patient&#8217;s cognition and health functions decline over time as the disease progresses and the patient moves from mild to moderate to, eventually, severe Alzheimer&#8217;s disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We currently have two biopharmaceutical assets under development:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our lead therapeutic product candidate, called simufilam, is a novel oral treatment for Alzheimer&#8217;s disease dementia; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#8217;s disease from a small sample of blood.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our scientific approach for the treatment of Alzheimer&#8217;s disease seeks to simultaneously suppress <i>both</i> neurodegeneration and neuroinflammation. We believe our ability to potentially improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our lead product candidate, simufilam, is a proprietary small molecule drug. Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer&#8217;s brain. Published studies have demonstrated that the altered form of FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. Specifically, we&#160;believe&#160;simufilam disrupts amyloid binding to the &#945;7 nicotinic acetylcholine receptor (&#945;7nAChR), which underlies our drug&#8217;s primary mechanism of action in Alzheimer&#8217;s disease. More recent data also suggest a meaningful impact of simufilam on mTOR signaling. Because mTOR contributes to age-related cellular changes, simufilam&#8217;s suppression of mTOR overactivation, concurrent with improved insulin sensitivity, may slow certain aging processes and attenuate this pathological feature, potentially benefiting brain function and memory in Alzheimer&#8217;s disease and in aging.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We own exclusive, worldwide rights to our drug and diagnostic assets and related technologies, without royalty obligations to any third party. Our patent protection with respect to simufilam and use of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases currently runs through 2039 and includes nine&#160;issued U.S. patents. Corresponding foreign filings have been made for each of the U.S. filings.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 19pt;">We are currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia.&#160;Both trials are fully enrolled. The trials have randomized a total of approximately 1,900 patients with mild-to-moderate Alzheimer&#8217;s disease at baseline. All efficacy data from our Phase 3 program remain blinded. There are no interim analyses on efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 19pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Our first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of simufilam 100 mg tablets versus placebo over 52 weeks (NCT04994483). Top-line results of our 52-week Phase 3 study are anticipated by the end of 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Our second Phase 3 study, called REFOCUS-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg tablets versus placebo over 76 weeks (NCT05026177). Top-line results of our 76-week Phase 3 study are anticipated approximately mid-year 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Phase 3 data and samples for bioanalysis will be directly provided to and analyzed by independent, third-party commercial consulting firms.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt;"><b>Business Update </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><i>Indictment of Dr. Hoau-Yan Wang</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Wang. The indictment alleges that Dr. Wang caused Cassava to submit grant applications to the U.S. National Institutes of Health (&#8220;NIH&#8221;) that contained false and fraudulent representations about his research. Among other things, the indictment alleges that Dr. Wang made materially false, fraudulent, and misleading statements to NIH regarding the mechanism by which the Company&#8217;s therapeutic product candidate, simufilam, was designed to treat Alzheimer&#8217;s disease and the improvement of certain Alzheimer&#8217;s disease indicators in patients treated with simufilam, and that Dr. Wang manipulated or otherwise fabricated research results, including Western Blot images that he prepared.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Dr. Wang, who is employed as a professor at the School of Medicine of the City University of New York (&#8220;CUNY&#8221;), previously served as a scientific collaborator and advisor to Cassava. Dr. Wang&#8217;s research, including foundational research published together with Dr. Lindsay Burns, Cassava&#8217;s former SVP, Neuroscience, led to the discovery of simufilam. Among other work for Cassava, Dr. Wang&#8217;s laboratory at CUNY conducted the final bioanalysis for the Phase 2b Study, which the Company reported as part of the final results of the Phase 2b Study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Dr. Wang received compensation from the Company for his consulting and advisory work for Cassava. For over a decade until Cassava&#8217;s termination of its consulting relationship with him, Dr. Wang was paid a cash stipend of $2,000 per month. He has also been awarded stock options pursuant to the Company&#8217;s equity incentive plans, none of which have been exercised through August 5, 2024. As of August 5, 2024, Dr. Wang held&#160;18,571 stock options, all of which were granted between 2015 and 2019 and are fully vested, with a weighted average exercise price of $4.22 per share. Dr. Wang was previously a participant in the Company&#8217;s CIB Plan, during which time the Company achieved target valuation milestones that established aggregate bonus payment amounts. The determination whether to award such amounts to participants and, if so, the allocation of amounts among participants (other than the Company&#8217;s chief executive officer), has not yet occurred and remains subject to the discretion of the Compensation Committee of the Board. In all cases, the payment of cash bonuses under the CIB Plan is subject to (i) Cassava&#8217;s completion of a merger transaction or (2) the determination by the Compensation Committee of the Board that the Company has sufficient cash on hand to render such payment, neither of which may ever occur. To date, Dr. Wang has not been allocated any cash bonus award pursuant to the CIB Plan. The Company has not paid any cash bonus to Dr. Wang or to any other participant under the CIB Plan as of this Quarterly Report on Form 10-Q. Prior to Dr. Wang&#8217;s indictment, the Company terminated its consulting relationship with him, and the Board removed him as a participant in the CIB Plan.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Neither Dr. Wang nor his laboratory at CUNY has had any involvement at any time in the Company&#8217;s ongoing Phase 3 clinical trials of simufilam.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Lawsuit Against Perpetrators of </i>&#8220;<i>Short and Distort</i>&#8221;<i> Campaign </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On November 3, 2022, we announced that we had filed a lawsuit in federal district court for the Southern District of New York against certain individuals who executed a &#8220;short and distort&#8221; campaign against Cassava Sciences. On March 29, 2024, the court dismissed our complaint, but provided leave for the Company to file an amended complaint against certain defendants whom the Court found had published defamatory statements about the Company.&#160; The Company filed its Second Amended Complaint against these defendants on April 29, 2024.&#160; On August 2, 2024, the Company voluntarily dismissed its claims against the defendants named in the Second Amended Complaint without prejudice.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -27pt; text-indent: 27pt;"><b>Leadership Updates</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -9pt; text-indent: 9pt;"><i>Appointment of Executive Chairman of the Board of Directors</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On July 15, 2024, Richard J. Barry, an independent director, was appointed by the Board as its Executive Chairman.&#160;Mr. Barry will&#160;serve as the Company&#8217;s principal executive officer until a permanent Chief Executive Officer is identified.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Mr. Barry, 65, has served as a director since June 2021. Since June 2015, Mr. Barry has served as a director of Sarepta Therapeutics, Inc. (Nasdaq: SRPT) and from June 2019 through October 2020, he served as a director of MiMedx Group Inc. (Nasdaq: MDXG). Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry holds a Bachelor of Arts from Pennsylvania State University. The Board has concluded that Mr. Barry&#8217;s experience as founder and managing director of investment funds and as a director to public companies, including service on Audit, Compensation, and Nominating and Governance Committees, qualifies him to serve as Executive Chairman.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -27pt; text-indent: 27pt;"><i>Resignation of Chief Executive Office and Chairman of the Board of Directors</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On July 15, 2024, Remi Barbier, President and Chief Executive Officer of the Company resigned from the Company, effective as of September 13, 2024 (the &#8220;Effective Date&#8221;). Mr. Barbier will remain employed by the Company through the Effective Date in a non-executive capacity, without duties or responsibilities. Pursuant to the terms of Mr. Barbier&#8217;s Employment Agreement, Mr. Barbier will receive severance compensation equal to $1.23 million over twelve months following the Effective Date, together with accrued salary through the Effective Date.&#160;Mr. Barbier will continue to participate in the Company&#8217;s medical plan at Cassava&#8217;s expense and will receive a payment sufficient to provide insurance coverage equivalent to existing third-party plans, in each case for a period of twelve months following separation. In addition, on July 15, 2024, the Company&#8217;s Board accepted Mr. Barbier&#8217;s resignation as Chairman of the Board and from board membership, effective on that date.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><i>Other Management Changes</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On July 16, 2024, Cassava and Lindsay Burns, Ph.D., SVP, Neuroscience, at the Company, agreed that Dr. Burns would&#160;step down from her employment with the Company, effective on that date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The terms of Dr. Burns&#8217; separation are set forth in a Consulting Agreement (the &#8220;Burns Agreement&#8221;), which includes a Release Agreement, between Dr. Burns and the Company, dated July 16, 2024.&#160; Pursuant to the Burns Agreement, following her separation from the Company and for a one-year period, Dr. Burns will furnish consulting services as, and to the extent, reasonably requested by Cassava for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company&#8217;s products. Cassava may, in its sole discretion, extend the term of the Burns Agreement for up to an additional year. The Company may also terminate the Burns Agreement at any time for cause, including, without limitation, for any actions that discredit Cassava&#8217;s business reputation. Dr. Burns will be paid $500 per hour for such consulting services, which will constitute continuous service for purposes of outstanding equity awards held by Dr. Burns.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Pursuant to the Burns Agreement, Dr. Burns will receive severance compensation equal to $0.5 million in quarterly installments over twelve months, together with accrued salary through July 16, 2024.&#160; Dr. Burns will continue to participate in the Company&#8217;s medical plan at Cassava&#8217;s expense for a period of twelve months following separation, which may be extended to eighteen months in connection with an extension of the term of the Burns Agreement. Dr. Burns will remain eligible for applicable indemnification rights under Dr. Burns&#8217; existing indemnification agreement, the Company&#8217;s by-laws and the Company&#8217;s insurance policies, in each case, subject to the terms and conditions and limitations thereof.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The Burns Agreement provides for Dr. Burns&#8217; general release of claims in favor of the Company, subject to certain exceptions. In addition, Dr. Burns is&#160;subject to a one-year non-competition covenant, a two-year non-solicitation covenant, and indefinite non-disparagement and confidentiality covenants. Dr. Burns will remain subject to her existing assignment of inventions agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Risk is Fundamental to the Drug Development Process</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We are in the business of new drug discovery and&#160;development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read this Quarterly Report on Form 10-Q as well as our 2023 Annual Report on Form 10-K in its entirety, including &#8220;Item 1A. Risk Factors&#8221;. <i>Because risk is fundamental to the process of drug discovery and</i>&#160;<i>development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>About Alzheimer</b>&#8217;<b>s Disease</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Alzheimer&#8217;s is a degenerative disease of the brain that affects cognition, function and behavior. Over time, a patient&#8217;s cognition and health functions decline as the disease takes its toll. With disease progression, patients move from mild to moderate to, eventually, severe Alzheimer&#8217;s disease. Cognitive decline becomes more pronounced, and presumably more difficult to treat, in advanced stages of the disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">An estimated 6.7 million Americans age 65 and older were&#160;living with Alzheimer's dementia in 2023, according to the Alzheimer&#8217;s Association. According to the same source, in 2011, the largest ever demographic generation of the American population &#8212; the baby-boom generation &#8212; started reaching age 65. By 2030, the segment of the U.S. population age 65 and older will have grown substantially, and the projected 74 million older Americans will make up over 20% of the total population. Because age is a well-known risk factor for Alzheimer&#8217;s dementia, new cases of Alzheimer&#8217;s dementia are expected to climb with the growth in the number of elderly Americans.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Our Scientific Approach is Different</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Given the biopharmaceutical industry&#8217;s challenging track record in Alzheimer&#8217;s research and drug development, we believe there is an urgent need to consider innovative approaches to combat this disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">For more than twelve years, we have developed a new and promising scientific approach for the treatment and diagnosis of neurodegenerative diseases, such as Alzheimer&#8217;s disease. Importantly, we do not seek to clear amyloid out of the brain. Rather, our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Our scientific approach is to treat neurodegeneration by targeting an altered form of a scaffold protein called FLNA. Through years of basic research, we and our academic collaborators identified FLNA as a structurally altered protein that enables neurodegeneration and neuroinflammation pathways in the Alzheimer&#8217;s brain. We have shown that the altered form of FLNA is pervasive in the Alzheimer&#8217;s brain and essentially undetectable in healthy control brains.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Using scientific insight and lab techniques, we believe we have elucidated this protein dysfunction. Through this work, we have produced experimental evidence that altered FLNA plays a critical role in Alzheimer&#8217;s disease. We engineered a family of high-affinity, small molecules to target this structurally altered protein and restore its normal shape and function. This family of small molecules, including our lead therapeutic product candidate, simufilam, was designed in-house and characterized by our academic collaborators.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Our lead drug candidate, simufilam, is a small molecule (oral) drug with a novel mechanism of action. The target of simufilam is altered FLNA, the structurally altered protein in the brain that we seek to stabilize. Importantly, since simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with existing drug treatments for Alzheimer&#8217;s disease dementia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><i>Our science is based on stabilizing a critical protein in the brain</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Proteins are essential for cell function because they participate in virtually every biological process. If protein function is impaired, the health consequences can be devastating. Technological advances in medicine and improvements in lifestyle are making our lives longer. But with age, genetic mutations and other factors conspire against healthy cells, resulting in altered proteins. Sometimes a cell can rid itself of altered proteins. However, when disease changes the shape and function of critical proteins, multiple downstream processes are impaired. There are many clinical conditions in which proteins become structurally altered and impair the normal function of cells, tissues and organs, leading to disease. Conversely, restoring altered proteins back to health &#8211;called proteostasis &#8211; is a well-accepted therapeutic strategy in clinical medicine.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">For over 100 years, scientists have ascribed various neurodegenerative diseases to proteins that misfold and are rendered pathological. In Alzheimer&#8217;s disease, certain proteins, such as amyloid and tau, lose their normal shape and function. Such misfolded proteins can break down or aggregate in clumps and form plaque or tangles in the brain. Destruction of neuronal synapses, accelerated death of neurons, and dysfunction of the brain support cells, are all widely believed to be direct consequences of misfolded proteins.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">FLNA is a scaffolding protein found in high levels in the brain. A healthy scaffolding protein brings multiple proteins together, coordinating their interaction. However, an altered form of FLNA protein is found in the Alzheimer&#8217;s brain. Our experimental evidence shows that altered FLNA protein contributes to Alzheimer&#8217;s disease by disrupting the normal function of neurons, leading to neurodegeneration and brain inflammation. Our product candidate, simufilam, aims to counter the altered and toxic form of FLNA in the brain, thus restoring the normal function of this critical protein.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><i>One drug, multiple effects </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Simufilam binds to altered FLNA with very high (femtomolar) affinity. We believe simufilam&#160;improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering downstream toxic effects of altered FLNA. This drug effect restores the normal function of key brain receptors, including: the alpha-7 nicotinic acetylcholine receptor; the N-methyl-D-aspartate (NMDA) receptor; and the insulin receptor. These receptors have pivotal roles in brain cell survival, cognition and memory. In addition, recent data suggest a beneficial&#160;impact of simufilam on mTOR signaling.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We have generated and published experimental evidence of improved brain health by restoring altered FLNA with simufilam. In animal models, treatment with simufilam resulted in dramatic improvements in brain health, such as reduced amyloid and tau deposits, improved receptor signaling and improved learning and memory. In addition, simufilam has another beneficial treatment effect of significantly reducing inflammatory cytokines in the brain. In animal models of disease, treatment with simufilam greatly reduced levels of IL-6 and suppressed TNF-alpha and IL-1beta levels by 86% and 80%, respectively, illustrating a powerful anti-neuroinflammatory effect.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">By restoring function to multiple receptors and exerting powerful anti-inflammatory effects, we believe our approach has potential to slow the progression of Alzheimer&#8217;s disease in patients. We also believe our scientific approach may broaden the range of possible treatment approaches for this complex disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -4pt;"><i>Publication Confirming Mechanism of Action of Simufilam</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">In September 2023, we&#160;announced the publication of new research that confirms the biological activity of simufilam. Researchers at the Cochin Institute (Paris, France) used a highly precise cell-based assay based on TR-FRET to show that simufilam interrupts amyloid binding to the &#945;7 nicotinic acetylcholine receptor (&#945;7nAChR). We&#160;believe&#160;disruption of amyloid binding to &#945;7nAChR underlies simufilam&#8217;s primary mechanism of action in Alzheimer&#8217;s disease. The research paper was co-authored by Hoau-Yan Wang and Zhe Pei of the City University of New York, Erika Cecon, Julie Dam and Ralf Jockers of the Institut Cochin, and Lindsay Burns, a former employee of Cassava Sciences, and appeared in a special<i> </i>issue of <i>International Journal of Molecular Sciences, </i>a peer-reviewed journal. See Figure 1.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 18pt;">Figure 1. Experiment conducted by Erika Cecon, Universit&#233; Paris Cit&#233;, Institut Cochin in an assay she developed: Cecon et al 2019; <i>Br J Pharmacol;</i> 176:3475-3488. Data shown are means of pooled data from 4 separate experiments &#177;SEM.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 4pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 4pt; text-indent: 18pt; text-align: center;"><img alt="cab1ac4300e0img001.jpg" src="cab1ac4300e0img001.jpg"/></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><i>Publication Showing Simufilam Suppresses Overactive mTOR</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 18pt;">In June 2023, we&#160;announced the publication of new research that showed the effects of simufilam on the mechanistic Target of Rapamycin&#160;(mTOR). Scientific literature shows overactive mTOR plays a key role in aging, Alzheimer&#8217;s disease and other conditions. When functioning normally, mTOR monitors cellular needs and is activated by insulin. The new published research shows mTOR is overactive in lymphocytes isolated from blood collected from Alzheimer's patients versus healthy controls. After oral administration of simufilam 100 mg twice daily to Alzheimer's patients for 28 days, lymphocytes showed normalized mTOR activity and restored&#160;sensitivity to insulin.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">These data suggest a meaningful impact of simufilam on mTOR signaling. The suppression of overactive mTOR signaling and its improved responsiveness to insulin represents a mechanistic benefit of simufilam beyond the disruption of pathogenic signaling pathways of soluble amyloid. These improvements in mTOR signaling may also result from reversing an altered conformation of FLNA, allowing FLNA to dissociate from the insulin receptor when insulin binds and initiates signaling. Because mTOR contributes to age-related cellular changes, simufilam&#8217;s suppression of mTOR overactivation, concurrent with improved insulin sensitivity, may slow certain aging processes and attenuate this pathological feature of Alzheimer&#8217;s disease, potentially benefiting brain function and memory in Alzheimer&#8217;s disease and in aging. This mTOR research paper was co-authored by Hoau-Yan Wang, Zhe Pei and Kuo-Chieh Lee of the City University of New York, Boris Nikolov, Tamara Doehner and John Puente, who are investigators in the clinical trial protocols, and Lindsay Burns, a former employee of Cassava Sciences, and appeared in <i>Frontiers in Aging</i>, a peer-reviewed journal.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><b>Simufilam Drug Development</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><i>IND submission to FDA, Drug Safety in Early Clinical Studies</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">For over a decade, we conducted basic research, in vitro studies and preclinical studies in support of a successful Investigational New Drug (IND) submission to FDA for simufilam, including requisite studies around safety pharmacology, toxicology, genotoxicity and bioanalytical methods. In 2017 we filed an IND with FDA for simufilam.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Following FDA acceptance of our IND in 2017, we investigated the safety, dosing and pharmacokinetic profile of simufilam in healthy human volunteers. The design of our first-in-human Phase 1 study was based on regulatory feedback, clinical and scientific rationale and observations from previously conducted preclinical and in vitro studies. In a Phase 1 study, simufilam was evaluated in 24 healthy human volunteers (18 simufilam, 6 placebo) in a single site in the U.S. for safety, tolerability and pharmacokinetics. Study subjects were administered a single oral dose of 50, 100 or 200 mg of simufilam or placebo. Drug appeared&#160;safe and well-tolerated. Importantly, simufilam showed no treatment-related adverse effects and no dose-limiting safety findings. Pharmacokinetic measurements demonstrated that simufilam, a small molecule, was rapidly absorbed. Dose-proportionality was observed over the full dose range of 50 to 200 mg.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>24-Month Clinical Safety</b> <b>Study</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Much of the strategic value of our 24 month clinical safety study&#160;is to support simufilam&#8217;s long-term safety profile in patients. We believe a well-designed, long-term, safety study is a prudent risk-management undertaking. Clinical results may serve to help inform and manage the inherent risks and uncertainties of drug development while we undertake a large, expensive Phase 3 clinical testing program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In March 2020, we initiated a clinical safety study of&#160;simufilam, our lead drug candidate,&#160;in patients with Alzheimer&#8217;s disease (NCT04388254).&#160;This study&#160;was funded in part by a research grant award from NIH. This study was designed to evaluate the long-term clinical safety and tolerability of&#160;simufilam&#160;in patients with Alzheimer&#8217;s disease over 24 months. The study&#160;included a pre-specified exploratory efficacy endpoint of mean change in ADAS-Cog11 scores, a cognitive scale widely used in Alzheimer&#8217;s clinical research. This study enrolled over 200 patients with mild-to-moderate Alzheimer&#8217;s disease (Mini-Mental State Examination (MMSE) 16-26) who were recruited from 16 U.S. clinical sites. Alzheimer&#8217;s is a progressive disease, with severity of disease typically assessed by MMSE score. In this study, mild patients are MMSE 21-26, and moderate patients are MMSE 16-20.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We conducted the 24-month safety study in three continuous phases:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:7.3%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a 12-month, open-label treatment phase, followed by</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:7.3%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a 6-month randomized, placebo-controlled withdrawal phase (previously referred to as the &#8220;Cognition Maintenance Study&#8221;&#160;or CMS), followed by</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:7.3%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6 additional months of open-label treatment.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Study participants received simufilam oral tablets 100 mg twice-daily in the open-label treatment phases, and simufilam or matching placebo during the randomized withdrawal phase. In an open-label study design, both the health providers and the patients are aware of the drug treatment being given.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">All study participants who completed 12 months of open-label simufilam treatment were eligible to participate in the 6-month randomized, placebo-controlled withdrawal phase. Likewise, all study participants who completed the randomized, placebo-controlled withdrawal phase were eligible for 6 additional months of open-label treatment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Study Results for the 12-month, Open-label Treatment Phase </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In January 2023, we announced positive top-line results for the 12-month, open-label treatment phase of the safety study. The pre-specified, exploratory efficacy endpoint was change in baseline on ADAS-Cog11, a cognitive scale widely used in Alzheimer&#8217;s clinical research. Other exploratory endpoints included the Mini-Mental State Examination (MMSE) to assess disease stage by cognitive impairment; the Neuropsychiatric Inventory (NPI) to assess dementia related behavior; and the Geriatric Depression Scale (GDS). Endpoints were measured at baseline (study entry) and month 12.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Top-line Results </b>&#8211;<b> mean scores, baseline to month 12 </b>(<i>lower is better, except for MMSE)</i><b>:</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ADAS-Cog11 scores changed from 19.1 (&#177;9.2) to 19.6 (&#177;13.3)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">MMSE scores changed from 21.5 (&#177;3.6) to 20.2 (&#177;6.4)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NPI10 scores changed from 3.2 (&#177;4.6) to 2.9 (&#177;4.6)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GDS scores changed from 1.8 (&#177;1.8) to 1.4 (&#177;1.9)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Response Analysis </i></b>&#8211;<b><i> baseline to month 12</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ADAS-Cog scores improved in 47% of patients; this group had a mean change of -4.7 (&#177;3.8) points (lower is better).</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In an additional 23% of patients, ADAS-Cog declined less than 5 points; this group had a mean change of 2.5 (&#177;1.4) points.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patients with an NPI10 score of zero increased from 42% to 54%, indicating reduced dementia-related neuropsychiatric symptoms after 1 year on simufilam.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The Full Analysis Set (FAS) population (N=216) was used for the statistical analysis of efficacy endpoints.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Mild and moderate sub-groups showed notable differences on changes in ADAS-Cog mean scores, baseline to month 12 (lower is better):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the <i>mild</i>&#160;sub-group (MMSE 21-26), mean&#160;ADAS-Cog scores improved, from 15.0 (&#177;6.3) to 12.6 (&#177;7.8)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the <i>moderate</i>&#160;sub-group (MMSE 16-20), mean ADAS-Cog scores worsened, from 25.7 (&#177;9.2) to 30.1 (&#177;13.1)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We believe the improvement in ADAS-Cog over 1 year in mild patients taking simufilam is well outside the expected range of historic placebo decline rates from numerous other studies. Figure 2: historical declines on ADAS-Cog in early disease (MCI + mild) and mild disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div style="text-align: center;">
   <img alt="figure01.jpg" src="figure01.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><i>Figure 1:</i></b><i> Statistical model of simufilam versus historical 1-year placebo declines on ADAS-Cog in early disease and mild disease. Forest plot by Pentara Corporation, independent biostatisticians. Data was sourced from non-randomized studies (i.e., ADNI) and randomized, controlled trials conducted by other sponsors in patients with early (i.e., MCI + mild) and mild Alzheimer</i>&#8217;<i>s disease.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Safety Data</i></b>&#160;- Simufilam 100 mg tablets twice daily appeared safe and well tolerated in this treatment phase of the open-label study. There were no drug-related serious adverse events. Three treatment-emergent adverse events (TEAEs) occurred in 7% or more of study patients: COVID-19 (12%), urinary tract infection (10%) and headache (9%). Reported TEAEs are based on all study patients who received at least one dose of drug.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Study Results for the 6-month,</b>&#160;<b>Randomized Withdrawal Study Phase</b>&#160;<b>("Cognition Maintenance Study")</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In May 2021, we initiated the randomized, withdrawal phase of the 24 month safety study, which has been previously referred to as the &#8216;Cognition Maintenance Study' or CMS. The CMS has a randomized, withdrawal study design. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) explains that in a randomized withdrawal study,<i> </i>&#8220;<i>subjects receiving a test</i>&#160;<i>treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy) </i>&#8230;&#160;<i>Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment</i>.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The design of the randomized, withdrawal phase of the study was intended to evaluate simufilam&#8217;s effects on cognition and health outcomes in Alzheimer&#8217;s patients who continue with drug treatment versus patients who discontinue drug treatment. This was a double-blind, randomized, placebo-controlled study of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Study patients were randomized (1:1) to simufilam or placebo for six months. To enroll in the CMS, patients must have previously completed 12 months or more of open-label treatment with simufilam. Final enrollment was 157 patients. See Figure 3.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;"><b>Figure 3. Design</b>&#160;<b>of the Randomized Withdrawal Phase (CMS) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="figure03.jpg" src="figure03.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 7pt;"><b><i>Top-line Results</i></b>&#160;- Simufilam treatment for 6 months slowed cognitive decline by 38% compared to placebo in mild-to-moderate Alzheimer&#8217;s disease (MMSE 16-26) patients. The placebo arm declined 1.5 points on ADAS-Cog, and this arm declined at all measured timepoints. The simufilam arm declined 0.9 points on ADAS-Cog, a 38% difference in favor of drug at month 6 (95% CI, &#8211; 2.1 to 1.0; not significant for sample sizes). See Table 1 and Chart 1.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><b>Table 1: Results of Randomized Withdrawal Study </b>&#8211;<b> cognitive change, full analysis set (FAS)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:80%;margin-left:0pt;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Full Analysis Set</i></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Simufilam 100 mg</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N = 78)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Placebo</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N = 77)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Numerical</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Difference</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percent Difference</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6-month Change in</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ADAS-Cog</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.9 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Decline</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.5 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Decline</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#8211;0.6</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">38% in favor of drug</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="a03.jpg" src="a03.jpg"/></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Upon randomization into the randomized, withdrawal phase, mean baseline MMSE scores were 18.6 and 18.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores were 19.3 and 21.9 for the simufilam and placebo arms, respectively.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b><i>Simufilam Drug Effects Favored Patients with Mild Alzheimer</i></b>&#8217;<b><i>s Disease </i></b>&#8211;&#160;Simufilam treatment for 6 months slowed cognitive decline &gt; 200% compared to placebo in mild Alzheimer&#8217;s disease. Patients with mild Alzheimer&#8217;s (MMSE 21-26) on placebo declined 0.6 points on ADAS-Cog over 6 months as a group. Patients with mild Alzheimer&#8217;s on simufilam improved 0.6 points over 6 months as a group, a 205% difference in favor of drug (95% CI, &#8211; 2.6 to 0.4; not significant for sample sizes). See Table 2 and Chart 2.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;"><b>Table 2: Results of Randomized Withdrawal Study </b>&#8211;<b> cognitive change, mild patients</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:80%;margin-left:0pt;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Mild Patients</i></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Simufilam 100 mg</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N= 40)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Placebo</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N= 36)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Numerical</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Difference</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percent Difference</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6-month Changes in</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ADAS-Cog</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.6 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Improvement</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.6 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Decline</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#8211;1.1</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">205% in favor of drug</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="chart_2.jpg" src="chart_2.jpg"/></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Upon randomization into the randomized, withdrawal phase of the study, mean baseline MMSE scores for mild patients were MMSE 24.0 and MMSE 24.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores for mild patients were 11.0 and 11.2 for the simufilam and placebo arms, respectively.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b><i>Simufilam for 18 months stabilized cognition in mild Alzheimer</i></b>&#8217;<b><i>s disease </i></b>&#8211;&#160;After taking open-label simufilam for 12 months, 76 patients with mild Alzheimer&#8217;s disease (MMSE 21-26) enrolled in the randomized, withdrawal phase and were randomized to receive either simufilam (N=40) or placebo (N=36) for 6 months. Mild patients randomized to simufilam in the CMS showed no material decline in ADAS-Cog scores over 18 months as a group, indicating stable cognition. Mild patients randomized to placebo in the randomized, withdrawal phase (and therefore withdrawn from simufilam treatment for 6 months) declined by 0.8 points in ADAS-Cog over 18 months as a group. See Figure 4.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt -19pt;"><b>Figure 4. Historical declines on ADAS-Cog over 18 months in Alzheimer's disease (MMSE 20-30), placebo arms vs simufilam treatment.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="figure04.jpg" src="figure04.jpg"/></div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Figure 4</b>: Forest plot by Pentara Corporation, independent biostatisticians. Data was sourced from the placebo groups in randomized, controlled trials of monoclonal antibodies conducted by other sponsors in Alzheimer&#8217;s disease (MMSE 20-30). Results shown for CLARITY P3 trial of lecanemab; EMERGE and ENGAGE P3 studies of aducanumab; and TRAILBLAZER P3 trial of donanemab; in this figure, the randomized, withdrawal phase is referred to as the &#8216;PTI-125-04&#8217; study; &#8216;Simufilam100mg-Simufilam100mg&#8217; refers to patients who received simufilam in both the open-label phase and the randomized, withdrawal phase; &#8216;Simufilam100mg-Placebo&#8217; refers to patients who received simufilam in the open-label phase and placebo in the randomized, withdrawal phase.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b><i>Safety Data</i></b>&#160;&#8211; Simufilam 100 mg tablets twice daily appeared safe and well tolerated in the 6-month the randomized, withdrawal phase of the 24 month safety study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt;"><b><i>Discussion</i></b>&#160;&#8211; Patients who completed 12 months of open-label simufilam treatment were invited to participate in the randomized, withdrawal phase. It is not known how long a washout period may be needed to remove lingering drug effects, if any, from prior treatment with open-label simufilam for 12 months. In this small randomized, withdrawal study phase in patients with mild-to-moderate Alzheimer&#8217;s disease, simufilam slowed cognitive decline by 38% on ADAS-Cog over six months (not statistically significant), with good drug safety. Effects were pronounced in mild patients. Mean baseline MMSE and ADAS-Cog scores were approximately balanced given the small size of each arm.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Study Results for the 24-Month Safety Study</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In February 2024, we reported top-line results of the 24-month clinical safety study. Average changes in ADAS-Cog scores, baseline to month 24, indicate the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:7.3%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients with mild Alzheimer&#8217;s disease who received simufilam treatment continuously for two years (n=47) had no decline in ADAS-Cog scores (&#177;&#160;1.51 SE) as a group.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:7.3%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients with mild Alzheimer&#8217;s who received simufilam treatment non-continuously (n=40) declined 1 point on ADAS-Cog (&#177;&#160;1.65 SE) as a group. Non-continuous treatment consisted of one year on open-label drug, six months on placebo and six months back on open-label drug.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:7.3%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In patients with mild Alzheimer's, the largest separation between the continuous and non-continuous treatment groups occurred at the end of the 6-month randomized, placebo-controlled withdrawal phase.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:7.3%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients with moderate Alzheimer&#8217;s who received simufilam treatment continuously for two years (n=32) declined 11.05 points on ADAS-Cog (&#177;&#160;1.91 SE) as a group.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Patients with mild Alzheimer&#8217;s disease (n=87) started the 24 months study with MMSE 21-26, with ten exceptions (<i>i.e., </i>patients with MMSE &gt; 26 due to prior participation in a study of simufilam (n=2) or evidence of Alzheimer&#8217;s disease pathology (n=8)). Patients with moderate Alzheimer&#8217;s started the 24 months study with MMSE 16-20, with one patient who entered with MMSE 15.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">The pre-specified cognition endpoints were analyzed on the Full Analysis Set (FAS) by an independent consulting firm that specializes in complex statistical analysis of clinical trial results. The FAS population consists of all study participants who received at least one dose of treatment and have both baseline and at least one post-baseline assessment. (Because FAS data is specific to each phase of a study, the FAS for the&#160;24-month study&#160;may differ from the FAS for other study phases).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Mild patients who received simufilam for 24 continuous months (n=47) showed an average change of 0.07 points on ADAS-Cog11 (&#177; 1.51 SE), baseline to month 24, as a group.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Mild Alzheimer&#8217;s patients who received 12 months of open-label simufilam, followed by placebo in the 6-month randomized, placebo-controlled withdrawal phase, followed by an additional 6 months of open-label simufilam (n=40), declined by an average of 1.04 points on ADAS-Cog11 (&#177; 1.65 SE), baseline to month 24, as a group. See Figure 4B.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="figure4b02.jpg" src="figure4b02.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Mean ADAS-Cog scores at baseline were approximately balanced in the group of mild Alzheimer&#8217;s patients who received drug continuously versus non-continuously (15.2 and 14.6, respectively).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b><i>Safety Data</i></b>&#160;&#8211; Oral simufilam 100 mg tablets twice daily appeared safe and well tolerated in this study. There were no drug-related serious adverse events. The most common treatment-emergent adverse events (TEAEs) were Covid-19 and urinary tract infection.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>End-of-Phase 2 (EOP2) Meeting with FDA</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In January 2021, we held an End-of-phase 2 (EOP2) meeting for simufilam with the U.S. Food and Drug Administration (FDA). The purpose of this EOP2 meeting was to gain general agreement around key elements of a pivotal Phase 3 program to treat Alzheimer&#8217;s disease dementia. FDA attendees included Robert Temple, MD, Deputy Center Director for Clinical Science and Senior Advisor in the Office of New Drugs; Billy Dunn, MD, Director, Office of Neuroscience; Eric Bastings, MD, Director, Division of Neurology, and others.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In February 2021, we announced the successful completion of our EOP2 meeting. Official meeting minutes confirm that we and FDA are aligned on key elements of a Phase 3 clinical program for simufilam. FDA agreed that the completed Phase 2 program, together with an ongoing and well-defined Phase 3 clinical program, are sufficient to potentially show evidence of clinical efficacy for simufilam in Alzheimer&#8217;s disease. There was also agreement that the use of separate clinical scales to assess cognition (ADAS-cog<sup style="vertical-align:top;line-height:120%;">1</sup>) and function (ADCS-ADL<sup style="vertical-align:top;line-height:120%;">2</sup>) are appropriate endpoints of efficacy. iADRS<sup style="vertical-align:top;line-height:120%;">3</sup> is an efficacy endpoint that combines scores for ADAS-cog and ADCS-ADL, and thereby provide a single composite measure of cognition and health function. Other endpoints include the NPI<sup style="vertical-align:top;line-height:120%;">4</sup>.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><sup style="vertical-align:top;line-height:120%;">1</sup></i><i> ADAS-Cog = The Alzheimer</i>&#8217;<i>s Disease Assessment Scale </i>&#8211;<i> Cognitive Subscale, a measure of cognition </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><sup style="vertical-align:top;line-height:120%;">2</sup></i><i> ADCS-ADL = Alzheimer</i>&#8217;<i>s Disease Cooperative Study </i>&#8211;<i> Activities of Daily Living, a measure of health function</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i><sup style="vertical-align:top;line-height:120%;">3</sup></i><i>iADRS = integrated Alzheimer</i>&#8217;<i>s Disease Rating Scale, a composite measure of cognition and health function</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><i><sup style="vertical-align:top;line-height:120%;">4</sup></i><i>NPI = Neuropsychiatric Inventory, a clinical tool that assesses the presence and severity of dementia-related behavior </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Special Protocol Assessments</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In August 2021, we announced we had reached agreement with FDA under a Special Protocol Assessment (SPA) for both Phase 3 studies. These SPA agreements document that FDA has reviewed and agreed upon the key design features of our Phase 3 study protocols of simufilam for the treatment of patients with Alzheimer&#8217;s disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">An SPA agreement indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, etc.). These elements are critical to ensure that our planned Phase 3 studies of simufilam in Alzheimer&#8217;s disease can potentially be considered adequate and well-controlled studies in support of a future regulatory submission and marketing application.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The first clinical study protocol under the SPA is titled &#8220;<i>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of One Dose of Simufilam in Subjects with Mild-to-Moderate Alzheimer</i>&#8217;<i>s Disease</i>.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The second clinical study protocol under the SPA is titled &#8220;<i>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer</i>&#8217;<i>s Disease</i>.&#8221;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Phase 3 Clinical Program Overview</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our Phase 3 program consists of two large, double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia. Both studies are designed to measure changes in cognition and function during their treatment period. Some highlights of this clinical program are summarized in Figure 5.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Premier Research International is the&#160;CRO supporting the&#160;conduct of our Phase 3 clinical program. Our Phase 3 clinical sites are currently located in the United States, Canada, Puerto Rico, Australia, and South Korea.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Phase 3 data and samples for bioanalysis will be directly provided to and analyzed by independent, third-party commercial consulting firms.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -10pt; text-indent: 18pt;"><b>Figure 5. Summary of Our Phase 3 Clinical Program</b>&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <div>
    <img alt="fig5.jpg" src="fig5.jpg"/></div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>RETHINK-ALZ and REFOCUS-ALZ</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In Fall 2021, we announced initiation of&#160;two Phase 3 studies of simufilam in mild-to-moderate Alzheimer&#8217;s disease dementia. In&#160;November 2023, we had announced the completion of patient enrollment in both Phase 3 studies. A total of approximately 1,900 patients are randomized&#160;into these studies.&#160;Approximately 70% of randomized patients entered our Phase 3 studies with mild Alzheimer&#8217;s disease (MMSE 20 to 27).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg over 52 weeks (NCT04994483).&#160;Details of the RETHINK-ALZ Phase 3 study include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Approximately 800&#160;patients are randomized into this study.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patients are randomized (1:1) to simufilam 100 mg tablets or matching placebo twice daily.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients are&#160;treated for 52 weeks.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Efficacy endpoints are ADAS-Cog12, a cognitive scale, and ADCS-ADL, a functional scale and iADRS, (which is a combination of scores from ADAS-Cog &amp; ADCS-ADL). All three clinical measurements are standard psychometric assessment tools in trials of Alzheimer&#8217;s disease.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other endpoints include plasma biomarkers of disease and NPI, a clinical tool that assesses the presence and severity of dementia-related behavior.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">No interim analyses on efficacy are planned.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our second Phase 3 study, called REFOCUS-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 76 weeks (NCT05026177). Details of the REFOCUS-ALZ Phase 3 study include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Approximately 1,100 patients are randomized into this study.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patients are randomized (1:1:1) to simufilam 100 mg tablets, 50 mg tablets, or matching placebo twice daily.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patients are treated for 76 weeks.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Efficacy endpoints are ADAS-Cog12, a cognitive scale, and ADCS-ADL, a functional scale and iADRS, (which is a combination of scores from ADAS-Cog &amp; ADCS-ADL). All three clinical measurements are standard psychometric assessment tools in trials of Alzheimer&#8217;s disease.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Other endpoints include biomarkers of disease, MRI imaging and NPI, a clinical tool that assesses the presence and severity of dementia-related behavior.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:4%;">&#160;</td>
     <td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9658;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">No interim analyses on efficacy are planned.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Phase 3 Entry Criteria </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In our Phase 3 clinical studies, eligibility criteria are the requirements that patients must meet to be included in a study. These requirements help make sure that study participants are substantially and closely matched as a group in terms of specific factors such as age, disease or stage of disease, general health, and other key factors. Eligibility criteria can consist of inclusion criteria, which are required for a person to participate in the study, or exclusion criteria, which prevent a person from participating. See Figure 5A.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="figure5b02.jpg" src="figure5b02.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 7pt; text-indent: -9pt;"><b>Use of Plasma Phosphorylated-tau181 (p</b>&#8208;<b>tau181) </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We believe plasma p&#8208;tau181 is a biomarker qualifier of Alzheimer&#8217;s neuropathology. RETHINK-ALZ and REFOCUS-ALZ Phase 3 studies use a &#8216;research use only&#8217;, non-safety related exploratory p-tau181 plasma assay to qualify mild-to-moderate Alzheimer&#8217;s patients. The plasma assay we use does not rely on age, APOE-gene status or complex algorithms to provide a result. P-Tau181 testing was performed by an independent commercial laboratory.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt; text-indent: -9pt;"><b>Data and Safety Monitoring Board (DSMB)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In March 2024, we announced that another routine, scheduled meeting of a DSMB&#160;recommended that both of our&#160;Phase 3 studies continue as planned, without modification. This was consistent with a&#160;DSMB meeting finding&#160;in September 2023. The&#160;DSMB only reviewed&#160;patient safety. It did&#160;not assess drug efficacy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b>Interim MRI Safety Data</b>&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In October&#160;2023, we announced&#160;a potentially significant safety finding based on interim magnetic resonance imaging (MRI) brain data from Alzheimer&#8217;s patients who are enrolled in a Phase 3 clinical trial of simufilam. These MRI data suggest simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities, or ARIA. MRIs were all analyzed for ARIA by independent, board-certified neuroradiologists.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">ARIA is a medical term used to describe a spectrum of brain MRI imaging abnormalities, such as brain swelling&#160;and brain bleeds. ARIA is&#160;a known risk factor for Alzheimer&#8217;s patients taking the class of drugs known as monoclonal antibodies directed against&#160;amyloid. In contrast to that&#160;class of drugs, simufilam is a&#160;small-molecule (oral) drug candidate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">The new safety finding is based on an independent, interim neuroradiological evaluation of brain MRIs taken at week 40 in a blinded sub-study of 180 Alzheimer&#8217;s patients enrolled in&#160;REFOCUS-ALZ, our&#160;on-going 76-week Phase 3 clinical trial of simufilam in mild-to-moderate Alzheimer&#8217;s. Final MRI data is expected at the conclusion of this Phase 3 study.&#160;See Figure 6.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="slide05.jpg" src="slide05.jpg"/></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -4pt;"><b>Status of Phase 3 Clinical Program</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 19pt;">Our Phase 3 trials have randomized a total of approximately 1,900 patients with mild to moderate stages of Alzheimer&#8217;s disease at baseline (MMSE 16-27), with approximately 800 patients randomized&#160;in the 52-week study (RETHINK-ALZ) and approximately 1,100 patients randomized&#160;in the 76-week study (REFOCUS-ALZ).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 19pt;">Approximately 70% of patients enrolled in our Phase 3 trials are diagnosed with mild Alzheimer&#8217;s disease (MMSE 20-27), with remaining patients entering the study with moderate disease (MMSE 16-19). Since the distribution of patients randomized&#160;in these trials is numerically&#160;skewed towards mild patients, we expect to rely predominantly on outcomes from mild patients to evaluate drug safety and efficacy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 19pt;">Over 555&#160;patients have completed the 52-week RETHINK-ALZ study. Over 420&#160;patients have completed the 76-week REFOCUS-ALZ study, for a total of over 975&#160;completers.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 19pt;">All efficacy data from our Phase 3 program remain blinded. There are no interim analyses on efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -5pt; text-indent: 19pt;">We anticipate top-line data readout for our 52-week study (RETHINK-ALZ) by the end of 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">We anticipate top-line data readout for our 76-week study (REFOCUS-ALZ) approximately mid-year 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In July 2024, we submitted to FDA for review a statistical analysis plan (SAP), which is a formal document defining the detailed analysis that our independent biostatisticians will undertake as to efficacy data collected in our Phase 3 trials. The SAP includes in-depth technical details and descriptions on the intended clinical trial analysis, the statistical methods and models that will be used, the population being analyzed, the data variables that will be analyzed, how missing data will be accounted for, descriptions of covariates to be included in the statistical model, and other statistical factors, all of which will be prospectively defined, documented and finalized prior to unblinding of any efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt;"><b>Phase 3 Drug Supply</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">We have a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik supplies and is expected to continue to supply us with large-scale, clinical-grade quantities of simufilam. Evonik is one of the world&#8217;s largest contract development and manufacturing organizations for pharmaceutical ingredients. Other vendors supply excipients, the finished dosage form (i.e., simufilam tablets), drug packaging, package labeling and other critical components of&#160;the supply chain for Phase 3 drug supply.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b>Open-label Extension Study for the Phase 3 Program</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In October 2022, we announced the initiation of an open-label extension study for our Phase 3 program. This study is designed to provide no-cost access to oral simufilam for up to one year to Alzheimer&#8217;s patients who have successfully completed a Phase 3 study of simufilam and who meet other entry criteria and to generate additional long-term clinical safety data for oral&#160;simufilam 100 mg twice daily over 52 weeks. Each clinical investigational site and each patient chooses whether to participate in this open-label extension study with no obligation to participate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Patient enrollment for this study began in November 2022, with approximately 89% of patients in Cassava&#8217;s ongoing Phase 3 program have elected to continue with open-label treatment with simufilam after completion of the blinded trials.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 2pt;"><b>Expansion of Open-Label Extension Studies</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">In July 2024, we announced our intention to extend the Phase 3 open-label extension trial as well as an ongoing open-label extension trial for patients in the Company&#8217;s Phase 2 clinical programs, in each case by up to an additional 36 months.&#160;These amendments to the protocols will allow patients who have previously participated in an underlying trial of simufilam in Alzheimer&#8217;s disease, if they desire, to continue open-label treatment with simufilam. This expansion of the open-label extension trials offers a bridge for any gap between patients ending treatment in a clinical trial and the Company reporting to regulatory authorities the results of the ongoing, randomized, placebo-controlled Phase 3 trials. The open-label extension can continue for up to 36 months or until a new drug application for simufilam has been reviewed by FDA.&#160;Cassava also announced that it plans to add cognition and plasma biomarker monitoring to its open-label extension trial for patients who have completed the Phase 3 trials in order to gather additional long-term data on the potential impact of simufilam treatment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">These expanded extension studies are designed to provide no-cost access to oral simufilam to Alzheimer&#8217;s patients who have successfully completed a Phase 2 or Phase 3 study of simufilam and who meet other entry criteria. Each clinical investigational site must choose whether to participate in the open-label extension studies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>SavaDx</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our investigational product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. For business, technical and personnel reasons, we continue to prioritize the development of simufilam, our novel drug candidate, over SavaDx, our novel diagnostic candidate. SavaDx is a research-use only, non-safety related exploratory biomarker. Development activity related to SavaDx accounts for less than 1% of our research budget.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The regulatory pathway for SavaDx may eventually include formal analytical validation studies and clinical studies that support evidence of sensitivity, specificity and other variables in various healthy and diseased patient populations. We have not conducted such studies and do not expect to conduct such studies in 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">SavaDx is currently designed as an antibody-based detection system for altered filamin A (FLNA). Working with third parties, we are evaluating the use of mass spectrometry to detect FLNA, i.e., without the use of antibodies. These evaluations are on-going.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Expansion of Our Science to Other Indications</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Protein misfolds occur in a wide variety of biological processes and diseases. We may leverage our scientific insights in neurodegeneration and neuroinflammation and advanced tools in molecular biology, biochemistry, and imaging to expand our science to other diseases. New indications and new drug development approaches may complement our initial focus on Alzheimer&#8217;s disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Preclinical programs are always visionary, sometimes innovative and often of high biomedical potential. By definition, such programs are exploratory and risky. Most preclinical programs fail for scientific or other reasons, regardless of the amount of effort or resources that are brought to bear. For these reasons, we do not intend to disclose our preclinical programs until&#160;they become material to our pipeline of product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>We Own Worldwide Rights to Our Neurodegeneration Program</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We own intellectual property, including patents, patent applications, technology, trade secrets and know-how in the U.S. and other countries. The protection of patents, designs, trademarks and other proprietary rights that we own or license is critical to our success and competitive position. We consider the overall protection of our patents and other intellectual property rights to be of material value and act to protect these rights from infringement.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We seek to protect our technology by, among other methods, filing and prosecuting U.S. and foreign patents and patent applications with respect to our technology and products and their uses. The focus of our patent strategy is to secure and maintain intellectual property rights to technology for our program in neurodegeneration.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. SavaDx is being developed in-house with outside collaborators. We own exclusive, worldwide rights to those drug and diagnostic assets and related technologies, without royalty obligations to any third party. Our patent protection with respect to simufilam and use of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases currently runs through 2039 and includes nine&#160;issued U.S. patents. In addition, we have patent protection with respect to simufilam for use in treating certain cancers that runs through 2033. Our patent estate further includes patents and patent applications for related compounds and treatments. Corresponding foreign filings have been made for each of the U.S. filings.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have yet to generate any revenues from product sales. We have an accumulated deficit of $349.6&#160;million at June 30, 2024. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and general corporate expenses. Research and development activities include costs of clinical and preclinical trials as well as clinical supplies associated with our product candidates. Salaries and other personnel-related costs include stock-based compensation associated with stock options and other equity awards granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of enrollment rates of clinical trials for our product candidates, timing of preclinical activities and our need for clinical supplies.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">We expect to continue to use significant cash resources in our operations for the next several years. Our cash requirements for operating activities and capital expenditures may increase in the future as we:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">continue our ongoing Phase 3 program with simufilam;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">manufacture large-scale supplies for simufilam;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">conduct other preclinical and clinical studies for our product candidates;&#160;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">seek regulatory approvals for our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">develop, formulate, manufacture and commercialize our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">implement additional internal systems and develop new infrastructure;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">acquire or in-license additional products or technologies, or expand the use of our technology;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">maintain, defend and expand the scope of our intellectual property;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">incur costs related to legal proceedings and claims, including U.S. government inquiries; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">hire additional personnel.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. If our development efforts result in regulatory approval and successful commercialization of our product candidates, we expect to generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, certain collaborators, contract development and manufacturing organizations (CDMOs), CROs and clinical research sites for a significant portion of our product development efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We focus substantially all of our research and development efforts in the development of simufilam. Research and development expenses for our investigational diagnostic product candidate, SavaDx, represented less than 1% of total research and development expenses for the periods presented. The following table summarizes expenses by category for research and development efforts (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three months ended</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Six months ended</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trials</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,877</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,271</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,169</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,535</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-clinical projects</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">867</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,104</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,999</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,174</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chemical, Manufacturing and Controls costs (&#8220;CMC costs&#8221;)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">398</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,518</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,193</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,232</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel related</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,615</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,398</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,260</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,823</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">972</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">392</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,945</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">781</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">469</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">286</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">865</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">544</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,198</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,969</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,431</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,089</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical trial costs include the costs of our CRO. CMC costs include&#160;costs related to our contract development and manufacturing organizations. Research and development expenses include compensation, contractor fees and supplies as well as allocated common costs such as facilities.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Estimating the dates of completion of clinical development, and the costs to complete development, of our product candidates would be highly speculative and subjective. Pharmaceutical products take a significant amount of time to research, develop and commercialize. The clinical study portion of the development of a new drug alone usually spans several years. We expect our research and development expenses to decrease modestly in 2024 as a result of decreased spending for our Phase 3 program, as patient screening and enrollment are now complete for the Phase 3 clinical studies. The decrease in Phase 3 program costs is expected to be partially offset by increased enrollment in the open-label study as well as higher stock-based compensation expense. We expect to reassess our future research and development plans based on our review of data we receive from our current research and development activities. The cost and pace of our future research and development activities are linked and subject to change.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with&#160;U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Valuation of Common Stock Warrant Liabilities</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 27pt;">The fair value of common stock warrant liabilities was&#160;determined on the January 3, 2024 warrant distribution date using a Monte Carlo valuation model. Determining the appropriate fair value model and calculating the fair value of common stock warrants requires considerable judgment. Any change in the estimates used may cause the value to be higher or lower than that reported. Subsequent to&#160;their&#160;distribution, the common stock warrants were&#160;traded on the Nasdaq&#160;Capital Market under the trading symbol "SAVAW". The fair value of common stock warrant liabilities at March 31, 2024 was determined using the closing price for the common stock warrants&#160;on that date. May 2, 2024 was the final day of trading for the common stock warrants on the Nasdaq&#160;Capital Market. Subsequent to that date and through the Warrant Redemption beginning May 7, 2024, the warrants were considered to have no value since there was no active market for trading. All changes in the fair value are recorded in the statements of operations each reporting period.&#160;Fair value changes&#160;may be significantly different from those recorded in the financial statements due to&#160;of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments in the initial valuation as of January 3, 2024, the warrant distribution date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 27pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Legal and other&#160;contingencies</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Company is currently involved in various claims and legal and regulatory proceedings. The Company regularly reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required in both the determination of probability and whether an exposure is reasonably estimable. Our judgments are subjective based on the status of the legal or regulatory proceedings, the merits of our defenses and consultation with in-house and outside legal counsel. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to its pending claims and legal and regulatory proceedings and may revise its estimates. Due to the inherent uncertainties of the legal and regulatory process, our judgments may be materially different than the actual outcomes.&#160;</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Other than as described above, there have been no material changes to our critical accounting estimates during the&#160;six months ended June 30, 2024 from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on&#160;February 28, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Results of Operations </b>&#8211;<b> Three and&#160;Six Months Ended&#160;June 30, 2024 and 2023</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses consist primarily of costs of drug development work associated with our product candidates, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">clinical trials,</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">pre-clinical testing,</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">clinical supplies and related formulation and design costs, and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">compensation and other personnel-related expenses.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses were $15.2&#160;million and $25.0&#160;million during the three months ended June 30, 2024 and 2023, respectively. This 39% decrease was due primarily to the completion of patient screening and enrollment for our Phase 3 clinical program in the fall of 2023. Patients are continually&#160;completing the Phase 3 program and a portion of completers are enrolling in the lower&#160;cost&#160;open-label extension study.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses were $31.4&#160;million and $47.1&#160;million during the&#160;six months ended June 30, 2024 and 2023, respectively. This 33% decrease was due primarily to the completion of patient screening and enrollment for our Phase 3 clinical program in the fall of 2023.&#160;Patients are continually&#160;completing the Phase 3 program and a portion of completers are enrolling in the lower&#160;cost&#160;open-label extension study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We expect research and development expense to decrease modestly in future periods since&#160;patient screening and enrollment is complete for our Phase 3 clinical program. The decrease in Phase 3 program costs is expected to be partially offset by increased enrollment in the open-label study as well as higher stock-based compensation expense due to new grant awards in 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>General and Administrative Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. Allocated expenses consist primarily of facility costs for our Company owned office complex in Austin, Texas. Depreciation and amortization for office space leased but not occupied by the Company is included in general and administrative expense. Depreciation and amortization for office space occupied by the Company is allocated between general and administrative expense and research and development expense. We also incur expenses associated with operating as a public company, including additional legal fees, expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance and audit expenses, investor relations activities, Sarbanes-Oxley compliance expenses and other administrative expenses and professional services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expenses were $46.2&#160;million and $3.8&#160;million during the three months ended June 30, 2024 and 2023, respectively. The significant&#160;increase was due primarily to a $40.0 million accrual for an estimated legal related loss contingency&#160;as well as a $1.2&#160;million increase in stock-based compensation expense due to new grant awards in late 2023 and 2024, increased compensation costs and higher legal related expenses.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expenses were $49.9&#160;million and $8.2&#160;million during the six months ended June 30, 2024 and 2023, respectively. The significant increase was due primarily to a $40.0 million estimated legal related loss contingency as well as&#160;$2.3&#160;million increase in stock-based compensation expense due to new grant awards in late 2023 and 2024 and&#160;increased compensation costs. The increases were partially offset by a $1.2&#160;million decrease in&#160;legal expenses as the Company met its insurance deductible in Q4 2023 and has recorded approximately $8.8&#160;million&#160;in insurance recoveries&#160;during the six months ended June 30, 2024.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We expect general and administrative&#160;expense for&#160;2024 will remain at high historic levels due to&#160;professional fees related to ongoing securities class action and derivative lawsuits and&#160;governmental investigations. In addition, stock-based compensation expense will be higher than historic levels due to 2023 and 2024 stock option grants and our anticipated hiring of a new Chief Executive Officer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Interest Income </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest income was $2.3&#160;million and $2.2&#160;million during the three months ended June 30, 2024 and 2023, respectively.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest income was $4.1&#160;million and $4.2&#160;million during the six months ended June 30, 2024 and 2023, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We expect interest income to decrease modestly over the remainder of 2024 as we utilize cash in our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Change in fair value of warrants</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The change in&#160;fair value of warrants was&#160;$65.1&#160;million&#160;for the three months ended June 30, 2024. The change in&#160;fair value of warrants was&#160;$108.2&#160;million&#160;for the six&#160;months ended June 30, 2024. There were no common stock warrants outstanding or change in fair value of warrants&#160;for the three and six months ended June 30, 2023.&#160;The 2024&#160;change was attributable to a&#160;gain on the change in fair value of our liability-classified warrants&#160;from distribution on January 3, 2024&#160;to their redemption in May 2024. The change in fair value was primarily driven by a decrease in fair value at redemption as there was little or no market trading activity&#160;and the warrants were redeemed for a nominal payment of $0.001 per warrant.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other income, net</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We record the activities related to leasing office space to third parties in buildings we own as other income, net, as leasing is not core to the Company&#8217;s operations. Other income, net, was $99,000 and $203,000 during the three months ended June 30, 2024 and 2023, respectively.&#160; Other income, net, was $259,000 and $393,000 during the&#160;six months ended June 30, 2024 and 2023, respectively. Other income, net, was lower in the three and six months ended June 30, 2024 as due to higher vacancy rates in 2024 compared to the prior year periods. We expect other income, net, to decrease in 2024 as higher vacancy rates are expected to further lower rental income.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation and amortization for the office complex is included in general and administrative and research and development expense, and thus not reflected in other income, net.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity and Capital Resources</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Since inception, we have financed our operations primarily through public and private stock offerings, payments received under collaboration agreements and interest earned on our cash and cash equivalents balances. We intend to continue to use our capital resources to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of June 30, 2024, cash and cash equivalents were $207.3&#160;million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b><i>2024 Common Stock Warrant Distribution</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On January 3, 2024, we made&#160;a distribution of approximately 16.9 million&#160;warrants&#160;to purchase shares of our common stock to holders of record of our&#160;common stock as of the close of business on December 22, 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Each warrant entitled&#160;the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, one and one-half shares of common stock (rounded down&#160;for any fractional shares).</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On April 15, 2024, the Company announced&#160;that all outstanding warrants were to be redeemed on May 7, 2024&#160;(the &#8220;Redemption Date&#8221;). The redemption price&#160;was equal to 1/10 of $0.01 per warrant. The warrants were&#160;exercisable&#160;at any time starting on January 3, 2024&#160;until the business day prior to the Redemption Date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">From January 3, 2024 to March 31, 2024, a total of approximately 674,000&#160;warrants were exercised resulting in net proceeds to the Company of approximately $22.3&#160;million. The Company issued approximately 1.0 million&#160;shares of common stock&#160;from the exercise of warrants through March 31, 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Subsequent to March 31, 2024 and through the Redemption Date, a total of approximately 3.15 million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately $104.0&#160;million. The Company issued approximately 4.7 million shares of common stock&#160;from the exercise of warrants from March 31, 2024 through the Redemption Date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Gross proceeds in 2024 from the warrant distribution totaled approximately $126.3&#160;million from the issuance of approximately 5.7 million common shares at $22.00 per share. Total net proceeds of the warrant distribution were approximately $123.6&#160;million after deducting estimated exercise&#160;expenses.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">After the first $20 million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock from warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $2.7&#160;million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At-the-Market Common Stock Offering </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On May 1, 2023, we entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of our common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the SEC on May 1, 2023 and became effective immediately upon filing. We are obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock in the offering. We are not obligated to sell any shares in the offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were no common stock sales under the ATM during the three and six months ended June 30, 2024, and up to $200 million in common stock remains available under the ATM.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In March 2020, we entered into&#160;an at-the-market offering program (&#8220;2020 Program&#8221;) to sell shares of our common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on May 5, 2020. We gave notice of termination for the 2020 Program effective on April 26, 2023, which was effective May 1, 2023. There were no common stock sales under the 2020 Program through its termination.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>2020 Cash Incentive Bonus Plan Obligations</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In August 2020, the Company's Board of Directors (the "Board") approved the 2020 Cash Incentive Bonus Plan (the "Plan"). The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (2) the Compensation Committee&#160;determines the Company has sufficient cash on hand, as defined in the Plan. Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2022, the Company&#8217;s independent directors were participants in the Plan. However, effective March 16, 2023, the Board&#160;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will not be allocated to any other participant under the Plan. Our independent directors have not received, and as a result of such amendment will never receive, any payments under the Plan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization, including all outstanding stock options, was $89.4&#160;million at the inception of the Plan in August 2020. If the Company were to exceed a $5&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, and conditions noted above for payment are met, all&#160;Plan milestones would be deemed achieved, in which case total cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s potential financial obligation to plan participants at June 30, 2024 totaled $6.5&#160;million (after taking into account the March 2023 Plan amendment), based upon the achievement of one Plan milestone in the Company&#8217;s market capitalization in 2020. No actual cash bonus payments have been made to any Plan participant, as the Company has not yet satisfied all the conditions necessary for amounts to be paid under the Plan. During the year ended December&#160;31, 2021, the Company&#8217;s market capitalization increased substantially. These increases triggered the achievement of 11 additional Plan milestones. Collectively, the achievement of such milestones could trigger potential Company obligations to Plan participants ranging from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million, with exact amounts to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No Valuation Milestones were achieved during the years ended December 31, 2023 and 2022 or the six months ended June 30, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the Plan as of June 30, 2024, or through the filing date of this Quarterly Report on&#160;Form 10-Q.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Cash</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in operating activities was $37.4&#160;million for the six months ended June 30, 2024, resulting primarily from the net income&#160;of $31.2&#160;million, stock-based compensation expense of $4.9&#160;million and an increase in accounts payable and accrued expenses of $42.0 million, offset by a change in fair value of warrants of $108.2&#160;million, an decrease in accrued developmental expenses of $1.4&#160;million and&#160;a decrease in in prepaid and other current assets of $6.3&#160;million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Net cash used in operating activities was $33.2 million for the six months ended June 30, 2023, resulting primarily from the net loss of $50.6 million, partially offset by an increase in accounts payable and accrued expenses of $6.7 million, an increase in accrued developmental expenses of $4.8 million, a decrease in in prepaid and other current assets of $4.1 million and stock-based compensation expense of $1.5 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities during the&#160;six months ended June 30, 2024&#160; was $29,000 for computers and equipment and other assets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Net cash used in investing activities during the six months ended June 30, 2023 was $0.4 million as final payment was made on renovations and fixtures for our corporate headquarters.</p>
  <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities during the six months ended June 30, 2024 was $123.6&#160;million of net proceeds from the exercise of warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">Net cash provided by financing activities during the six&#160;months ended June 30, 2023 was $1.0&#160;million, from the exercise of stock options.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and Leases</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. This property is intended to accommodate our potential growth and expansion of our operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet. At June 30, 2024, we occupied approximately 25% of the property with the remainder either leased or available for lease to third parties. Most tenant leases will expire in 2024. We believe tenant leases that expire in 2024 may likely not be extended, renewed or re-leased beyond their expiry date, in which case we will no longer receive rental payments or reimbursement for shared expense for such office space.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Other Commitments</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have an accumulated deficit of $349.6&#160;million as of June 30, 2024. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our drug candidates, the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products and other corporate needs. We believe that our current cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months. We may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to us. However, there are no assurances that additional financing will be available on favorable terms, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><a id="qqd" title="qqd" href="#"></a>Item 3. </b><b><i>Quantitative and Qualitative Disclosures About Market Risk</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate sensitivities and, to a lesser extent, currency fluctuations related to our clinical operations outside the U.S.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Interest Rate Sensitivity</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents of $207.3&#160;million as of June 30, 2024, which consisted primarily of U.S. Treasury securities and money market accounts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain investment vehicles with high credit quality and short-term duration, in accordance with our Board-approved investment policy. Such interest-earning instruments carry a degree of interest rate risk. However, due to the generally short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point increase or decrease in interest rates during any of the periods presented would increase or decrease our annual net loss by less than $2.1&#160;million in our condensed consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="controls" title="controls" href="#"></a>Item 4. </b><b><i>Controls and Procedures</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Evaluation of disclosure controls and procedures. </i>Our management, with the participation of our Executive Chairman of the Board of Directors and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Executive Chairman of the Board of Directors (as Principal Executive Officer) and our Chief Financial Officer (as Principal Financial Officer) have concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2024, our Executive Chairman of the Board of Directors and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Changes in internal control over financial reporting. </i>There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified during the three months ended&#160;June 30, 2024 that has materially affected, or is reasonable likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>PART II </b>&#8211;<b> OTHER INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="legal" title="legal" href="#"></a>Item 1. </b><b><i>Legal Proceedings</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are, and&#160;from time to time, we may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, we have received and from time to time&#160;may receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us. We&#160;believe&#160;that our&#160;total provisions for legal matters are adequate based upon currently available information.&#160;Additional information regarding our legal proceedings is included in this Quarterly Report on Form 10-Q in Note 11 to our condensed consolidated financial statements entitled, &#8220;Contingencies.&#8221;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="risk" title="risk" href="#"></a>Item 1A. </b><b><i>Risk Factors</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Please refer to </i>&#8220;<i>Risk Factors</i>&#8221;<i> in Part I, Item 1A of our</i>&#160;<i>2023 Annual Report on Form 10</i>&#8209;<i>K for additional information on our current risks. Other than the supplemental risk factors provided below, there have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K. The risks and uncertainties described in our</i>&#160;<i>2023</i> <i>Annual Report on Form 10</i>&#8209;<i>K and provided below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition or results of operations.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><b>The validity of CSF biomarker assays and bioanalysis conducted by CUNY for the Company</b>&#8217;<b>s Phase 2b Study has been called into question.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Company&#8217;s Phase 2b Study was designed as a 28-day, approximately 60-patient, randomized, double-blind, placebo-controlled, multiple dose study.&#160; A primary objective of the Phase 2b Study was to measure changes in levels of cerebral spinal fluid (&#8220;CSF&#8221;) biomarkers in study participants from baseline value to Day 28. CSF biomarker assays and related bioanalysis for the Phase 2b Study (the &#8220;CUNY Bioanalysis&#8221;) were conducted by the laboratory at CUNY of Dr. Hoau-Yan Wang, formerly a paid scientific collaborator, consultant and advisor to Cassava. Based on the CUNY Bioanalysis, Cassava reported statistically significant improvements in CSF biomarkers in treatment groups as compared to the placebo group for the Phase 2b Study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Wang alleging that he caused Cassava to submit grant applications to NIH that contained false and fraudulent representations about his research. Among other things, the indictment alleges that Dr. Wang made materially false, fraudulent, and misleading statements to NIH regarding the mechanism by which simufilam was designed to treat Alzheimer&#8217;s disease and the improvement of certain Alzheimer&#8217;s disease indicators in patients treated with simufilam, and that Dr. Wang manipulated or otherwise fabricated research results, including Western Blot images that he prepared.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">As part of the Internal Investigation being conducted by the Ad Hoc Investigation Committee of the Company&#8217;s Board of Directors, the Committee is evaluating information contained in the DOJ indictment of Dr. Wang as well as information from the Company&#8217;s ongoing discussions with the SEC. To date, the Internal Investigation has determined that certain statistical information contained in an attachment to an email sent by a former senior employee of Cassava to Dr. Wang before the CUNY Bioanalysis of CSF biomarkers was conducted could have been used to unblind him as to some number of Phase 2b Study participants. Unblinded information, if accessed in connection with bioanalysis, could be improperly utilized to manipulate underlying samples or data to skew reported results.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Internal Investigation has not, to date, determined, and may never be able to determine with any reasonable degree of certainty, whether Dr. Wang unblinded himself as to some number of Phase 2b Study participants.&#160;Nevertheless, the fact that Dr. Wang possessed information that could have been used to so unblind himself, together with the allegations in the DOJ indictment, undermine the blinded study design and create substantial uncertainty about the validity of the CUNY Bioanalysis of CSF biomarkers. There can be no assurance that such uncertainty will not adversely impact the FDA&#8217;s review of an NDA with respect to simufilam following completion of our Phase 3 clinical studies or cause the FDA to request additional information regarding simufilam.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Accordingly, in light of the foregoing uncertainties, you should not place undue reliance on the CUNY Bioanalysis of CSF biomarkers reported by the Company in connection with the Phase 2b Study.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><b>We are subject to lawsuits and governmental investigations and inquiries. </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We are defending ourselves in a number of lawsuits, including securities class action and shareholder derivative actions, and the Company, as well as two former senior employees of the Company, have been and may continue to be subject to governmental investigations and inquiries. Defending litigation and responding to governmental investigations is expensive and time consuming and may divert the time and attention of our management away from the conduct of our primary business.&#160; Moreover, the allegations underlying such litigation and governmental investigations have&#160;damaged our business reputation, which may make it difficult to, among other things: raise capital or engage in a strategic transaction on acceptable terms or at all; hire and retain third-party consultants and collaborators; recruit and retain patients for our studies; and attract and retain qualified executive officers, other employees and directors.&#160; The foregoing matters may exacerbate other risks discussed in our Annual Report on Form 10-K under the Caption &#8220;Item 1A. Risk Factors&#8221; and have a negative impact on the perception of our company by investors, patients, investigators, collaborators, and others.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">As a result of current or future lawsuits, we may have to pay significant damages or amounts in settlement above insurance coverage, including amounts in respect of indemnification obligations of the Company to former officers and senior employees. An unfavorable outcome or prolonged litigation could materially and adversely impact our business, operating results, and financial condition, including our cash runway. In addition, current or future government investigations and inquiries could subject us to various sanctions, including significant penalties, our being prevented from receiving government grants, and other punitive measures.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">While we cannot estimate our potential exposure to future litigation, regulatory claims, investigations or proceedings at this time, we have already incurred significant expense related to litigation, government investigations and the Internal Investigation and expect to continue&#160;to incur significant expense.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="unregistered" title="unregistered" href="#"></a>Item 2. </b><b><i>Unregistered Sales of Equity Securities and Use of Proceeds</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="defaults" title="defaults" href="#"></a>Item 3. </b><b><i>Defaults Upon Senior Securities</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="mine" title="mine" href="#"></a>Item 4. </b><b><i>Mine Safety Disclosures</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-01-01_2024-06-30" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c2709929" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="other" title="other" href="#"></a>Item <em style="font: inherit;">5.</em> </b><b><i>Other Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the quarter ended <em style="font: inherit;"> June 30, 2024</em>, <span style="-sec-ix-hidden:c115658401"><span style="-sec-ix-hidden:c115659230"><span style="-sec-ix-hidden:c115659231"><span style="-sec-ix-hidden:c115659232">none</span></span></span></span> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) of the Exchange Act) informed us of the adoption or termination of a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item <em style="font: inherit;">408.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     <em style="font: inherit;">50</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="exhibits" title="exhibits" href="#"></a>Item 6. </b><b><i>Exhibits </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 122pt;text-indent:-111pt;">The following exhibits have been filed with this report:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
     <td style="vertical-align: middle; width: 57%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="5" style="vertical-align: middle; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporated by</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
     <td style="vertical-align: middle; width: 57%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Reference</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;Description</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filing</b></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filed</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>No.</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 57%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>No.</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Herewith</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit;">Amended and Restated Certificate of Incorporation.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/29/2005</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit;">Certificate of Amendment of Restated Certificate of Incorporation.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/8/2017</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit;">Certificate of Amendment of Restated Certificate of Incorporation.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/29/2019</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000047/sava-20230908xex3_4.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of Cassava Sciences, Inc.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/13/2023</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.4</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">4.1</td>
     <td style="vertical-align: middle; width: 57%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315224000209/ex4-1.htm" style="-sec-extract:exhibit;">Warrant Agreement (including Form of Warrant), dated January 3, 2024, between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A.</a></td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%; text-indent: 0pt; padding-left: 0pt; text-align: center;">8-K</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; text-align: center;">1/3/2024</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%; text-align: center;">4.1</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">10.1</td>
     <td style="vertical-align: middle; width: 57%;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1069530/000143774924018029/sava20240521_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment agreement amendment, dated May 20, 2024, by and between Cassava Sciences, Inc. and Eric J. Schoen</span></a></td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%; padding-left: 0pt; text-align: center;">8-K</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%; text-align: center;">5/22/2024</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%; text-align: center;">10.1</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.1</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_677282.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.2</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_677283.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.1+</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_677284.htm" style="-sec-extract:exhibit;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document - (the instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104.</p> </td>
     <td style="vertical-align: middle; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File &#8211;(formatted as Inline XBRL and contained in Exhibit 101).</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 9%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 7%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">+The certification furnished in Exhibit&#160;32.1 hereto is deemed to accompany this Quarterly Report on Form&#160;10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act of 1934. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     51
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="signatures" title="signatures" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cassava Sciences, Inc.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Registrant)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ RICHARD J. BARRY</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Richard J. Barry,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Executive Chairman of the Board of Directors,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Date: August 8, 2024</p> </td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Executive Officer)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Eric J. Schoen,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;">&#160;</td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 60%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Date: August 8, 2024</p> </td>
     <td colspan="1" style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Financial and Accounting Officer)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex_677282.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_677282.htm</title>
	<!-- Generated by ThunderDome Portal - 7/29/2024 7:55:10 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 11pt;text-indent:-11pt;">Exhibit 31.1</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER&nbsp;PURSUANT TO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#65279; </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I, Richard J. Barry, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Cassava Sciences, Inc.;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:36.1%;">/s/ RICHARD J. BARRY</td>
			<td style="vertical-align:top;width:19.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Richard J. Barry,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Executive Chairman of the Board of Directors,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:&nbsp; August 8, 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex_677283.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_677283.htm</title>
	<!-- Generated by ThunderDome Portal - 7/29/2024 7:56:03 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 11pt;text-indent:-11pt;">Exhibit 31.2</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER&nbsp;PURSUANT TO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#65279; </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">I, Eric J. Schoen, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Cassava Sciences, Inc.;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p>
			</td>
			<td style="vertical-align: top; width: 18%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Eric J. Schoen,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 36%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:&nbsp; August 8, 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex_677284.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_677284.htm</title>
	<!-- Generated by ThunderDome Portal - 8/3/2024 4:36:54 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Exhibit 32.1</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CERTIFICATION OF THE EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS AND CHIEF FINANCIAL OFFICER&nbsp;PURSUANT TO</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(18 U.S.C. Section 1350)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Cassava Sciences, Inc. (the &#8220;Company&#8221;), hereby certifies that to the best of such officer&#8217;s knowledge:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended <a data-tblloc="5x1" data-tblname="457195" data-tblv="16" id="led457195F2024241709592849098">June 30, 2024</a>, and to which this certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13-(a) or 15-(d) of the Securities Exchange Act of 1934, and</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 180pt;text-indent:36pt;">Date:&nbsp; August 8, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 288pt;text-indent:36pt;">&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:36.1%;">/s/ RICHARD J. BARRY</td>
			<td style="vertical-align:top;width:19.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">Richard J. Barry</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Executive Chairman&nbsp;of the Board of Directors,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">(Principal Executive Officer)</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 55.7%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Eric J. Schoen,</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:46.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:top;width:55.7%;">(Principal Financial and Accounting Officer)</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#65279;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sava-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:02PM UTC 2024-08-08--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sava="http://www.cassavasciences.com/20240630" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cassavasciences.com/20240630">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-unaudited" roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-and-liquidity" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - General and Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-and-other-current-assets" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Prepaid and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Real Property and Other Income, Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-9-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-2020-cash-incentive-bonus-plan" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-contingencies" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-warrant-dividend-distribution" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Warrant Dividend Distribution</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995464 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-tables" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995465 - Disclosure - Note 2 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-and-other-current-assets-tables" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995466 - Disclosure - Note 3 - Prepaid and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-tables" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995467 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-tables" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995468 - Disclosure - Note 5 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-tables" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995469 - Disclosure - Note 6 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995470 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-warrant-dividend-distribution-tables" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995471 - Disclosure - Note 12 - Warrant Dividend Distribution (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-and-liquidity-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995472 - Disclosure - Note 1 - General and Liquidity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995473 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995474 - Disclosure - Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995475 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995476 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995477 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995478 - Disclosure - Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995479 - Disclosure - Note 5 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-components-of-property-and-equipment-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995480 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995481 - Disclosure - Note 6 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-components-of-intangible-assets-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995482 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995483 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995484 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995485 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995486 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995487 - Disclosure - Note 8 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-2020-cash-incentive-bonus-plan-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995488 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-contingencies-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995489 - Disclosure - Note 11 - Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-warrant-dividend-distribution-details-textual" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995490 - Disclosure - Note 12 - Warrant Dividend Distribution (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995491 - Disclosure - Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sava_AccruedDevelopmentExpenseCurrent" name="AccruedDevelopmentExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" name="AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_AtthemarketCommonStockOfferingMember" name="AtthemarketCommonStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashBonusIncentiveIncrementalAmounts" name="CashBonusIncentiveIncrementalAmounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAward" name="CashIncentiveBonusAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAwardExceedsMaximum" name="CashIncentiveBonusAwardExceedsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_CashIncentiveBonusPlanMember" name="CashIncentiveBonusPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashIncentiveBonusPlanTextBlock" name="CashIncentiveBonusPlanTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" name="ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightRedemptionPricePerShare" name="ClassOfWarrantOrRightRedemptionPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" name="ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CommissionPercentageOfGrossProceeds" name="CommissionPercentageOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" name="DerecognitionOfWarrantLiabilitiesThroughExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EquityOfferingMaximumAmount" name="EquityOfferingMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_EquityOfferingPercentageOfCommission" name="EquityOfferingPercentageOfCommission" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" name="ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sava_GrossProceedsFromIssuanceOfWarrants" name="GrossProceedsFromIssuanceOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IncreaseDecreaseInDevelopmentExpense" name="IncreaseDecreaseInDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_InsuranceSettlementsMaximumRecoveryLimit" name="InsuranceSettlementsMaximumRecoveryLimit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" name="IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_LeasesAndCommitmentsDisclosureTextBlock" name="LeasesAndCommitmentsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_LeasingCommissionsAndOtherMember" name="LeasingCommissionsAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PaymentsForCashIncentiveBonus" name="PaymentsForCashIncentiveBonus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_PaymentsOfWarrantExerciseCosts" name="PaymentsOfWarrantExerciseCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_PercentageOfOccupancy" name="PercentageOfOccupancy" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" name="PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" name="PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PerformancePlanValuationMilestoneAmount" name="PerformancePlanValuationMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" name="PrepaidExpensesAndOtherCurrentAssetsTextBock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" name="ProceedsFromWarrantsExercisedThatObligatedToPayCommission" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_RedemptionPercentageOfWarrants" name="RedemptionPercentageOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsDelawareCourtMember" name="ShareholderDerivativeActionsDelawareCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsMember" name="ShareholderDerivativeActionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasCourtMember" name="ShareholderDerivativeActionsTexasCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasStateCourtMember" name="ShareholderDerivativeActionsTexasStateCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockIssuedDuringPeriodSharesWarrantExercises" name="StockIssuedDuringPeriodSharesWarrantExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockIssuedDuringPeriodValueWarrantExercises" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" name="StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2018EquityIncentivePlanMember" name="The2018EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ViolationsOfFederalSecuritiesLawsMember" name="ViolationsOfFederalSecuritiesLawsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_WarrantDividendDistributionTextBlock" name="WarrantDividendDistributionTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_WarrantRedemptionPrice" name="WarrantRedemptionPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" name="statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-12-warrant-dividend-distribution-tables" name="statement-statement-note-12-warrant-dividend-distribution-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" name="statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" name="statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-significant-accounting-policies-tables" name="statement-statement-note-2-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" name="statement-statement-note-3-prepaid-and-other-current-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" name="statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" name="statement-statement-note-4-real-property-and-other-income-expense-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" name="statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-tables" name="statement-statement-note-5-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" name="statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" name="statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-tables" name="statement-statement-note-6-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sava-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:02PM UTC 2024-08-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20240630.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="sava-20240630.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sava-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:02PM UTC 2024-08-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-9-commitments" xlink:href="sava-20240630.xsd#statement-note-9-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-9-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets" xlink:href="sava-20240630.xsd#statement-note-3-prepaid-and-other-current-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information" xlink:href="sava-20240630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity" xlink:href="sava-20240630.xsd#statement-note-1-general-and-liquidity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes" xlink:href="sava-20240630.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:href="sava-20240630.xsd#statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies" xlink:href="sava-20240630.xsd#statement-note-11-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantDividendDistributionTextBlock" xlink:label="sava_WarrantDividendDistributionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_WarrantDividendDistributionTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies" xlink:href="sava-20240630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:href="sava-20240630.xsd#statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual" xlink:href="sava-20240630.xsd#statement-note-1-general-and-liquidity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual" xlink:href="sava-20240630.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20240630.xsd#statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual" xlink:href="sava-20240630.xsd#statement-note-11-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_GrossProceedsFromIssuanceOfWarrants" xlink:label="sava_GrossProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PaymentsOfWarrantExerciseCosts" xlink:label="sava_PaymentsOfWarrantExerciseCosts" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_RedemptionPercentageOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_WarrantRedemptionPrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_GrossProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CommissionPercentageOfGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsOfWarrantExerciseCosts" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputConversionPriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20240630.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="sava-20240630.xsd#sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DilutiveSecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sava-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:02PM UTC 2024-08-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="sava-20240630.xsd#sava_DocumentAndEntityInformation" xlink:label="sava_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="sava_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DocumentAndEntityInformation" xlink:to="sava_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_RedemptionPercentageOfWarrants</link:label>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption Percentage of Warrants</link:label>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Percent of the cost for redemption of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RedemptionPercentageOfWarrants" xlink:to="sava_RedemptionPercentageOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="sava_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="sava_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="sava_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:to="sava_statement-statement-note-2-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CommissionPercentageOfGrossProceeds</link:label>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission Percentage of Gross Proceeds</link:label>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of commission required to be paid from gross proceeds.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CommissionPercentageOfGrossProceeds" xlink:to="sava_CommissionPercentageOfGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid and Other Current Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:to="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property and Other Income, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:to="sava_statement-statement-note-4-real-property-and-other-income-expense-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_GrossProceedsFromIssuanceOfWarrants" xlink:label="sava_GrossProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_GrossProceedsFromIssuanceOfWarrants</link:label>
    <link:label xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance of Warrants</link:label>
    <link:label xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross proceeds received from the issuance and sale of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_GrossProceedsFromIssuanceOfWarrants" xlink:to="sava_GrossProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-12-warrant-dividend-distribution-tables" xlink:label="sava_statement-statement-note-12-warrant-dividend-distribution-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-12-warrant-dividend-distribution-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Warrant Dividend Distribution</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-12-warrant-dividend-distribution-tables" xlink:to="sava_statement-statement-note-12-warrant-dividend-distribution-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:to="sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain from change in fair value of warrant liabilities</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">gain from change in fair value of warrant liabilities, liability</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">gain from change in fair value of warrant liabilities, liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:to="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed</link:label>
    <link:label xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Redemption of common stock warrants (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants redeemed common stock warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:to="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:label="sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:to="sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatements" xlink:label="sava_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatements" xlink:to="sava_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="sava_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:type="locator"/>
    <link:label xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_InsuranceSettlementsMaximumRecoveryLimit</link:label>
    <link:label xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance Settlements, Maximum Recovery Limit</link:label>
    <link:label xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum amount of monetary recovery for insurance policies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:to="sava_InsuranceSettlementsMaximumRecoveryLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance recoveries</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value of Common Stock Warrants per Warrant (in dollars per share)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of common stock warrants per warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:to="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightRedemptionPricePerShare</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Redemption Price per Share (in dollars per share)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the redemption price per share of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:to="sava_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued development expense, classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AccruedDevelopmentExpenseCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized; 47,976,166 and 42,236,919 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, performance awards (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, performance awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Performance awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Performance awards forfeited/canceled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAssetsCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyNewClaimsFiledNumber</link:label>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInDevelopmentExpense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInDevelopmentExpense" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Bock]</link:label>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Acquired-in-Place [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAcquiredInPlaceMember" xlink:to="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantsToPurchaseCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
    <link:label xlink:label="sava_WarrantsToPurchaseCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants used to purchase common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantsToPurchaseCommonStockMember" xlink:to="sava_WarrantsToPurchaseCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Issued During Period (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, liability</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Adjusted numerator, diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, shares (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants or rights exercised during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:label xlink:label="stpr_TX-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TEXAS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_TX" xlink:to="stpr_TX-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageOfOccupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Occupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of occupancy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfOccupancy" xlink:to="sava_PercentageOfOccupancy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="locator"/>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission</link:label>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Warrants Exercised That Obligated to Pay Commission</link:label>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dollar amount required to be paid for commission from warrants exercised during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DilutiveSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DilutiveSecurities</link:label>
    <link:label xlink:label="us-gaap_DilutiveSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockDividendsAndOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustment for change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNonoperatingExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognition of warrant liabilities upon exercise of warrants</link:label>
    <link:label xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from derecognition of warrant liabilities upon exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:to="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsNet</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositContractsAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract research organization and other deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 9, 10 and 11)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyDisclosures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTextBlock" xlink:to="sava_CashIncentiveBonusPlanTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Violations of Federal Securities Laws [Member]</link:label>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the violations of federal securities laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanValuationMilestoneAmount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Valuation Milestone Amount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of valuation milestone for performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanValuationMilestoneAmount" xlink:to="sava_PerformancePlanValuationMilestoneAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:type="locator"/>
    <link:label xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability</link:label>
    <link:label xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, liability</link:label>
    <link:label xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of decrease in warrant liability from exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:to="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashBonusIncentiveIncrementalAmounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Bonus Incentive, Incremental Amounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of incremental amounts for cash bonus incentive.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashBonusIncentiveIncrementalAmounts" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantDividendDistributionTextBlock" xlink:label="sava_WarrantDividendDistributionTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantDividendDistributionTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Dividend Distribution [Text Block]</link:label>
    <link:label xlink:label="sava_WarrantDividendDistributionTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of warrant dividend distribution.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantDividendDistributionTextBlock" xlink:to="sava_WarrantDividendDistributionTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum number of days valuation milestone must be achieved and maintained in performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanMember" xlink:to="sava_CashIncentiveBonusPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas Court</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsMember" xlink:to="sava_ShareholderDerivativeActionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="locator"/>
    <link:label xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of warrants resulting in recognition of warrant liabilities</link:label>
    <link:label xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of issuance of warrants resulting in recognition of warrant liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:to="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Delaware Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Delaware court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas State Court Member</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas State Court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-market Common Stock Offering [Member]</link:label>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the At-the-Market Common Stock Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AtthemarketCommonStockOfferingMember" xlink:to="sava_AtthemarketCommonStockOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingPercentageOfCommission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Percentage of Commission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commission in equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingPercentageOfCommission" xlink:to="sava_EquityOfferingPercentageOfCommission-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingMaximumAmount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Maximum Amount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount to be issued in the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingMaximumAmount" xlink:to="sava_EquityOfferingMaximumAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAwardExceedsMaximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award, Exceeds Maximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award if the maximum milestone is exceeded.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">the percentage of valuation milestone cash bonus award subject to approval and adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PaymentsForCashIncentiveBonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Cash Incentive Bonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payments for cash incentive bonus.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsForCashIncentiveBonus" xlink:to="sava_PaymentsForCashIncentiveBonus-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAward</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAward" xlink:to="sava_CashIncentiveBonusAward-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing Commissions and Other [Member]</link:label>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents leasing commissions and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasingCommissionsAndOtherMember" xlink:to="sava_LeasingCommissionsAndOtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2018 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2018EquityIncentivePlanMember" xlink:to="sava_The2018EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Net Settled in Satisfaction of the Exercise Price [Member]</link:label>
    <link:label xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options were net settled in satisfaction of the exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfWarrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of common stock warrants, net of exercise costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PaymentsOfWarrantExerciseCosts" xlink:label="sava_PaymentsOfWarrantExerciseCosts" xlink:type="locator"/>
    <link:label xlink:label="sava_PaymentsOfWarrantExerciseCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PaymentsOfWarrantExerciseCosts</link:label>
    <link:label xlink:label="sava_PaymentsOfWarrantExerciseCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Warrant Exercise Costs</link:label>
    <link:label xlink:label="sava_PaymentsOfWarrantExerciseCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of warrant exercise costs during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsOfWarrantExerciseCosts" xlink:to="sava_PaymentsOfWarrantExerciseCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of warrant liabilities upon exercise of warrants</link:label>
    <link:label xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_DerecognitionOfWarrantLiabilitiesThroughExercises</link:label>
    <link:label xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cash flow effect of derecognition of warrant liabilities through exercises.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:to="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants (in shares)</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercises (in shares)</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued attributable to warrant exercises.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares of stock issued attributable to exercises of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RealEstateOwnedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate Owned [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateOwnedTextBlock" xlink:to="us-gaap_RealEstateOwnedTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetRentableArea</link:label>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Rentable Area (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:label xlink:label="srt_OfficeBuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of common stock warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive common stock options excluded from net income (loss) per share, diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average dilutive common shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases And Commitments Disclosure [Text Block]</link:label>
    <link:label xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure regarding leases and commitments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation for stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, basic (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant measurement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options forfeited/canceled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RetainedEarningsAccumulatedDeficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputSharePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputConversionPriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Conversion Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputConversionPriceMember" xlink:to="us-gaap_MeasurementInputConversionPriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_WarrantRedemptionPrice</link:label>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Redemption Price (in dollars per share)</link:label>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price of warrants if they are redeemed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantRedemptionPrice" xlink:to="sava_WarrantRedemptionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sava-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:02PM UTC 2024-08-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-9-commitments" xlink:href="sava-20240630.xsd#statement-note-9-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-9-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets" xlink:href="sava-20240630.xsd#statement-note-3-prepaid-and-other-current-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information" xlink:href="sava-20240630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity" xlink:href="sava-20240630.xsd#statement-note-1-general-and-liquidity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes" xlink:href="sava-20240630.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:href="sava-20240630.xsd#statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies" xlink:href="sava-20240630.xsd#statement-note-11-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantDividendDistributionTextBlock" xlink:label="sava_WarrantDividendDistributionTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_WarrantDividendDistributionTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies" xlink:href="sava-20240630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:href="sava-20240630.xsd#statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-12-warrant-dividend-distribution-tables" xlink:label="sava_statement-statement-note-12-warrant-dividend-distribution-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-12-warrant-dividend-distribution-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual" xlink:href="sava-20240630.xsd#statement-note-1-general-and-liquidity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant" xlink:label="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="sava_ClassOfWarrantOrRightRedemptionPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_InsuranceSettlementsMaximumRecoveryLimit" xlink:label="sava_InsuranceSettlementsMaximumRecoveryLimit-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightRedemptionPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_InsuranceSettlementsMaximumRecoveryLimit-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:label="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual" xlink:href="sava-20240630.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20240630.xsd#statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual" xlink:href="sava-20240630.xsd#statement-note-11-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_GrossProceedsFromIssuanceOfWarrants" xlink:label="sava_GrossProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_PaymentsOfWarrantExerciseCosts" xlink:label="sava_PaymentsOfWarrantExerciseCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_RedemptionPercentageOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_WarrantRedemptionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_GrossProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CommissionPercentageOfGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsOfWarrantExerciseCosts-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputConversionPriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:href="sava-20240630.xsd#statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed" xlink:label="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-n9" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability" xlink:label="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-n9" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:label="sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability-n9" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_DerecognitionOfWarrantLiabilitiesThroughExercises" xlink:label="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-1" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:label="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sava_DerecognitionOfWarrantLiabilitiesThroughExercises-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20240630.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20240630.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20240630.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:href="sava-20240630.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="sava-20240630.xsd#sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:label="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:href="sava-20240630.xsd#statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:href="sava-20240630.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20240630.xsd#statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20240630.xsd#sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DilutiveSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a03.jpg
<TEXT>
begin 644 a03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @  @$2  ,
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAEM>\GP2OQ2N_#FJW.JW=R=.^R)''-;VU]) PE6S#R2LZ1G.V$;<%5!^OO\
M@BUX"/PM^+7Q.T;2?'WPDU[PW]BL+D>'_A[JVHZIH^CSL9 )8Y;H.H,BAMX2
M>1B0-P4!: /LW_A=Q'[0W_" ?\(?XZ^72AJ@\2_V2/\ A'N6*_9OM6_/VCC)
M39T(YYKO(E(+9^F<?R]J^#_CY#$?^"OGB"1ECW?\*"G5B>-R_;+[@GTKX^\)
M? ?0?@O^P!^S;\;]#?7(?B-?^+8;%]2;5)R([-;B[1;5(]VQ(1Y2G"J"2SY)
M#8 !^R7Q6^)V@?!CP!J?BKQ1JEOHV@Z' UU>7<V=L2 <\ $L3T"J"22  2<5
MX'\#_P#@J/X-^._CS0]%L? _Q<T'3_%,S0:)XAUGPR;;1=6< G$5P)&SG! )
M5>1CBL'_ (+;^"=:\9?L >)!HT,]TNEW]EJ=_!%DM-:PW"O*<=P@&\C@84UT
M7P/_ ."@'PA\=?!WPCH?A#QYH%YXHU+18[/3="MI=]_;W,=M@126Z@M#M9<9
M<!>."1@T ?2T*$'G'3KBI*_#6TA^%^J_L:1_$.;Q9J+?M;2>)T+NNM7']N+<
M_:0# MMYG$&W/SA..F[ Q6[^W=HG_"\OVJOB!H/C"V\)ZIXB;3])T_2M7\9^
M.8/#,?@VX>WC>=[>SGE5;U"Q;.Q3R>A(H _:VN)^/GQE/P)\!_VZ/"?C3QH?
MM<-K_9WA;31J&H?O&V^;Y1=/W:=6;/ [&OS]^+/[(7@?Q#^V'^S#\*[IA?>#
M+;X>WUI*NC:E-#!J42R(S)YRN9&@D<DD;\$8Z=O&[I5\,?\ !/\ ^,_@NUDN
M?^$=\$?%NPT_1[2:Y><64!=7\M=V=H#'Z9YZT ?JQI7[27@W6?C?)\-8M4DC
M\<0:6FLS:3+8W"-#:MC#M+L\G<"P!4.6![58^!7QO_X7;:Z[+_PAOCGP?_8>
MI2:9L\3:5_9[ZAL /GVXWMYD#9P'XR0>.*_/74/@?\)-)_X+2VTOCBRTO3;?
M5="L?$6F2:AJDUK]LUUGAV21'S5WRE\CRE&T\_)UKS?Q)XEU'PK^Q?\ %".U
MO]2TCPWK'QS-EXKO-+)2>#3GV>?DJ1A< DY&"0H/!Y /V.HK\K?A-X8^&7PN
M_;JNM!_9OUK[?\/-1^&VIW7BVWTO5)-2TI+@0OY3R2,[@3$^5P#E2SCC+*/'
M=.^ _A_X-_\ !/SX#_'30I-8L_B5-\0;;3AJAU:9EM[(7-TGV.*+=Y<<.VW0
M;0N?G<$E3@ '[ _'_P".OAG]FGX4ZMXV\87PT_P_H<8>XF$9DD8L0B)&BY+.
M[LJ@>_) !->9_LL?M^Z#^U-XUFT"U\$_%+P3JJZ6-=M4\7Z%_9R:I9;XXO/M
MW62177=*G&1G.0,<U;_X* Z?\,O$G[*^L:3\8-8DT'P7KDEM:SZC$KLUE<&1
M7A=65'\O#JOS,NS&0W#'/Q#\,/VF_B=\+-3^*?PF\#_%BQ^/WA70?AGJ&NZ'
MXITH1SW?AJ>.,K%%]HB9A+(%)VJ7E;<8MI7:\5 'ZGP+A,[2F>H./Z4^OR9_
M9DMO@YX!_9%;QO\ "?QIJ5Q^TQJGPYUB_P!7M;769[R_U"]%J)+B2[MRSA&@
M8%K=F$9D.UL2LQ!\\\*Z#\*_"7PU_9M\7?!?Q9>7?[1WB/Q)ID7B5;;6Y;K4
M;PR*S7B7L!D*QQ+,4C!( EC9B1(-SJ ?M317YF_ +]FS1/BE^V-^U5XWEL;[
M5O&7PU\5-JGA""*XE6&TU(PS,LWDJ0LLC&&./#@@ID8YS7RS^R)X4N_%7C/X
M<?$*'XI?!K0?B!>>*(6O)KK7-;F\=ZE-)<8>VN[7][$T4F_EEA2-@5#R ;A0
M!^[%1W#8V_>]>*_(_P 57OA/X:_\%1D\57VK:+\5-0USXA)96%QI'B:ZMO%W
MA.:.;8UE+I[G9+9*5,7^KVNI&V520*_3GX0_M%>#?C?X@\5Z7X7UH:M>^"=3
M.E:R@M9H5L[D;LQAY$59,;2-T991C&: /%_C)_P5'\/?";X^:U\-['X9?&GQ
M]XB\/6\5W>_\(AX>@U*...0 J2/M"N!R!ED R0,FM3]IO_@I9X)_9+^'G@_Q
M!XL\/^.XY/&41N(M&ATZ'^T]-B5 TDEU%).BQK'D!L,Q!/2OF6[^&/Q"^*O_
M  6'^,UE\.?BE)\*=4M_#5A-<ZBGARTUS[9"6C7R?+N2%3YB&W#GC%8'Q:O_
M (B?M-?MF>/H?#?PW3XY:7\/O"O_  K^YNG\06>@0PWUU"#=WBB0,C-(1GRX
MP I7&[@4 ?=?QY_;.\"_L[? ?3_B#X@O+J31=72W.EVUG!]IO=4EG :**&,$
M N0>[!1W(JK^R_\ MFZ/^U!>ZW86_A+XA>!=8\/B-[K2O&&A'2[T129*3*N]
MU9#@]\^U?#'P3\6_#;XV_P#!.#2_AC\<O%5U\.]>^'?B5O#EIK!F^;2K^#=)
M [3 &,  'YI"JG:-K=#7MG_!+G]I/QWXX^,'Q ^'&M>/M-^,GA+P7# ^E^.K
M.) )RY(\AY%^69@HSN!D.>KL"* /MZ#A<>AJ2F0C:",EN>I[T^@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444;J
M"B@'-% !1103B@ HHS10 44$XHS0 449H)Q0 449XH!S0 444%MM !11FC-
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M-_PAL)?V3?C[K?@[Q%JWB]=?MO#UK=6>F^%/[(TMKJ"_B.^"!!EK@0E/-95
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M]OF^\3?%"QU-_!/B+P;!;Z;>0?;/)AO+6X<R02?9OFWE)0Z@_*06QD]/8O\
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M\]-+_P"_4G_Q5&W6O^>FE_\ ?J3_ .*H U:*RMNM?\]-+_[]2?\ Q5&W6O\
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M !5&W6O^>FE_]^I/_BJ -6BLK;K7_/32_P#OU)_\51MUK_GII?\ WZD_^*H
MU:*RMNM?\]-+_P"_4G_Q5&W6O^>FE_\ ?J3_ .*H U:*RMNM?\]-+_[]2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !FD#@GJ*-P_7%?EIXC_P"#@G2=&_X+Y:?^SH+RR;X:_8SX
M9NK]5'R^)9661#Y@SF-<"WZA0TKDC*B@#]3**0NH[TM !1110 4444 %%%%
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M&VBMWOKK;]HNV1 IEDV@+O<C<=H R3@ <#4HHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E
M"%@*^8/$4P'_  64\%?-]_X-:YCW_P")UI->'_\ !=W_ (+8ZM_P1^\/_#^Z
MT7P+I/CB3QE<W4,T=YJ<EG]D$2J1@HC;LEL<^E?D[K'_  =Z^+]5_:UT'XL?
M\*3\+K>:'X4O_"HL!X@G,<\=U=VER9M_DY!4VH4+@YWDY&!0!_3CN -+7P#_
M ,$)/^"R6L?\%@_AAX]\0:UX'TGP3)X-U:UTZ*WLM2DO1=^="\A9BZ)M(V8
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MWQ_TCU\3?^!]W_\ &* /U\HK\@_^'V?[?'_2/7Q-_P"!]W_\8H_X?9_M\?\
M2/7Q-_X'W?\ \8H _7RBOR#_ .'V?[?'_2/7Q-_X'W?_ ,8H_P"'V?[?'_2/
M7Q-_X'W?_P 8H _7RBOR#_X?9_M\?](]?$W_ ('W?_QBC_A]G^WQ_P!(]?$W
M_@?=_P#QB@#]?**_(/\ X?9_M\?](]?$W_@?=_\ QBC_ (?9_M\?](]?$W_@
M?=__ !B@#]?**_(/_A]G^WQ_TCU\3?\ @?=__&*/^'V?[?'_ $CU\3?^!]W_
M /&* /U\HK\@_P#A]G^WQ_TCU\3?^!]W_P#&*/\ A]G^WQ_TCU\3?^!]W_\
M&* /U\HK\@_^'V?[?'_2/7Q-_P"!]W_\8H_X?9_M\?\ 2/7Q-_X'W?\ \8H
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MW_@?=_\ QB@#]?**_(/_ (?9_M\?](]?$W_@?=__ !BC_A]G^WQ_TCU\3?\
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MKNB1DRSZ1N'VH1C!*R0G]W<+QC(&_ KV+]B__@O;X7^(>JP>%/C)IK_#OQ=
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M^)ZLO_!7OX3R+]UOAOXB1O\ P-TXU]15\M_%=V7_ (*Z?!W _=R?#_Q(A/\
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MX"7PXBB^>FU_>M=TWW4M$]$VSW6BF^<O]Z@2*>]>\?E ZBBB@ HHHH ****
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M_P"3B?V3_P#LJM]_Z@_BJOH*OGW]L/\ Y.)_9/\ ^RJWW_J#^*J /H*BBB@
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M_P"&?$G@W43I/B3PSKT$5OJN@W6T.J3+#++"RO&0Z/%+)&RGAB00/B_X _\
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MMTT^@ZBBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(<U]#_L._P#!>7X=_'NZM?#OQ*BA^&?C$D0^;=2'^Q[R3H=LS<VYR#\LV .
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M^K?^"VX_^(H UJ*R?^$RM?\ GWU;_P %MQ_\11_PF5K_ ,^^K?\ @MN/_B*
M-:BLG_A,K7_GWU;_ ,%MQ_\ $4?\)E:_\^^K?^"VX_\ B* -:BLG_A,K7_GW
MU;_P6W'_ ,11_P )E:_\^^K?^"VX_P#B* -:BLG_ (3*U_Y]]6_\%MQ_\11_
MPF5K_P ^^K?^"VX_^(H UJ*R?^$RM?\ GWU;_P %MQ_\11_PF5K_ ,^^K?\
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M1>F#E1V!KD_UAS;*O=SJASTU_P O:2;5N\H;KS:T[(Z?]7\JS1<V2U^2H_\
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M (3*U_Y]]6_\%MQ_\10!K45D_P#"96O_ #[ZM_X+;C_XBC_A,K7_ )]]6_\
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MQJK2;7RS90=:]P_+SU3QE^U?#I7QBG\$^'O".O>--6TM[1=;>PO=/M8=&-R
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MV!G_ -NRC+_(/^(3\'XC_D7\4X=]E5I5:7WMW2/UC,R@]S]!2^:M?DR?"?\
MP4D^&S;VU3_A($7HOVBPNL_]\@'\Z=_PW!_P4"^'_&K?"9=2@AX,A\.LV[_@
M4<F/TH_UJA'^-AZL?6'^38O^( XJM_R+\YR^O_AQ*3^Z44?K)YB_Y[4AN%'>
MOR<_X?K_ ![\!-Y7B;X LTB_*SB&\MN1U_Y9L*W-'_X.3K72RO\ PDWP?U^Q
M[/\ 9[P?*?;S%6JCQEE5[3FX^L9+]#*M]&OCY1YL/A85ET=.M1E?T7/?\#]2
M#,H/7K0K[C7YV^%?^#D+X-ZR5_M+PYXVT?)P=\,4^/\ OAS7I'AC_@O+^S=X
M@F53XHU;3V8#_C[T>>-1_P " (KLI<3954^&O'YNWYV/FL=X(<?83^-E-?\
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M_'7B[2U[!X8;@#\\5^E%%>?4X7RF?Q4(_)6_*Q]E@?'GQ!PG\+-JS_Q24_\
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M3+L4 ?4E%%% !1110 4444 %%%%  3@4U9-_3UIQY%>,VOQG\96_[;UG\/\
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MX_\ XJ@#6HK)_P"$]T7_ *"VE_\ @7'_ /%4?\)[HO\ T%M+_P# N/\ ^*H
MUJ*R?^$]T7_H+:7_ .!<?_Q5'_">Z+_T%M+_ / N/_XJ@#6HK)_X3W1?^@MI
M?_@7'_\ %4?\)[HO_06TO_P+C_\ BJ -:BLG_A/=%_Z"VE_^!<?_ ,51_P )
M[HO_ $%M+_\  N/_ .*H UJ*R?\ A/=%_P"@MI?_ (%Q_P#Q5'_">Z+_ -!;
M2_\ P+C_ /BJ -:BLG_A/=%_Z"VE_P#@7'_\51_PGNB_]!;2_P#P+C_^*H U
MJ*R?^$]T7_H+:7_X%Q__ !5'_">Z+_T%M+_\"X__ (J@#6HK)_X3W1?^@MI?
M_@7'_P#%4?\ ">Z+_P!!;2__  +C_P#BJ -:BLG_ (3W1?\ H+:7_P"!<?\
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M +1I:* $V_[1HV_[1I:* $V_[1HV_P"T:6B@!-O^T:-O^T:6B@!-O^T:-O\
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M[8?_ "<3^R?_ -E5OO\ U!_%5 'T%1110 4444 %%%% !1110 4444 %%%%
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M$XHE#!9M9*&+2M2KO91Q$5I&3V5167>R2@_U2CD\U<BG5\'?\$VO^"TOA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8[74W7@^26^Z_!S&W.>F:^W3<X)^7I[U\._\%(/^"-7AK]JQKKQAX(:'P?\
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M?@C^SSH/P$LM671Y-6OM0\07O]H:KJFK7KWVH:E,(TB0RS2$LP2..-%'150
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MU% &3_P@^D_] ^U_[]BC_A!])_Z!]K_W[%:U% &3_P (/I/_ $#[7_OV*/\
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M:F7B/VB2UFMXCI@P\\<D"$()-BA1LS7V=4:P[3GY=W?Y?SJ2@ HHHH ****
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M'V==^[:N[&,@<X^M "Q?,S-N+;OR_"GTBKM%+0 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cab1ac4300e0img001.jpg
<TEXT>
begin 644 cab1ac4300e0img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %4 FX# 2(  A$! Q$!_\0
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MT(.10%QU%)D>M&1ZT +13!+&S,JNI9>H!Z4[(]: %HHI,CUH 6BDR/6C(]:
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MM_$&CO')+>OY$TT)215.<,A/O6S\-)=<\/:C>>$-9LKAK>V8FROEA_=NOH6
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MJS.BI<5SG_"52_\ 0"U+_OV*/^$JE_Z 6I?]^Q3Y&.QT16C'O7._\)5+_P!
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MC%8'_"3R?] 74/\ O@4?\)/)_P! 74/^^!2YT5]6J]CH,8H-<_\ \)/)_P!
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M#O-/TRZE@EBO%NM.#('$D) ;+'C YZ=:A\0_$"[DLKF^T>XN55K*RNHH#$G
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M[Z"Q&I:>(0"JPOD*K8[J<9^M;GP^US5;O5=6TW5;Z>?[/'!-#]KA$<I#K\S
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MY$6#P0#7?T %%%% !112;A0 'I7%>*-$MYO$NCN;B^C^VW#1SI%=.BL!&2.
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M%22$08&2<G]:GS0 M%)FEH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M57#12#*-D?D1VK$N?AE+J&MW,]_J4#V+?:#$L-HL<V9EP0[C[RC.1^M7="\
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M\1>'TAU_Q!-#)-,)9C/DP#R^"#CC)XYK>_X0.3_H;/$?_@6/_B: .RHKC?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH
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M:NNFBU6$^8VZ(.&W9[$XKG+;6KOQ3J%[-J-Y;71D\/73-:P(5^S,'^XW/+#
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M>UE@M+VX>>$W!A2+#Q1@X+,#CH>U"3"Z.IS1FN"U?QI=1W.H/ISP/:QZ2E[
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MK/SX;F]N;R:=(1;P!2?+8C&,_K5P>.K"2SLY;>TO)KFZE>)+1(QYH9/O9&<
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M\2Z=H3*EWYY+*9"(86?:HZLV.@HN[A96,63P??V=PTFCW]M L]D+2X66$D<
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M;+^UOLBVM['/DQR[3\K @9!KN^*.*?,PLCBU\-Z[.VA3:CJ$-W<6=ZUS.Q&
M%(X1..<>]4YO UW=ZANNEM9K1]7>\DC9B=T13&",=<UZ!Q11S,+(X:+1]6\(
MVNKC14M7LGQ+9QR*=\;D_,IP.1Z<UM^(=+N=8T1;=+>TFE!5WBN<A2>^"O*G
MT-;U'X4KL+(X*#PGK9M]/6YN8G^S:B+A8C*S^5$!C8'898YYYIVG^#]1M8-
M21[8FPU":YEPQY5LXQQR>:[NBGS,+(\_M_".MZ?>07]LUG)<07US,(I78*8Y
M3QR!P1Z4_3/"&JVW]D-<2VK/:ZE->3;&."K@XQQUKO<44<S#E1P%MX,U2&>S
M?SK=3!?W-R65B2%D7"D<=0:HP>!-;#K)<-9&5;2>VDF\YV>8N#AV)''/\(Z5
MZ;BC%',Q<J.*M_">HQWNGS,\&VWTA[%L,<[R.W'3WJ]8:#=VW@2'1)/LLETE
MOY;"0%XF.>_0XKIZ.*7,QV1YS_PAFNS:%J5@9K:&.?RA!:?:'EC0JV2VYAD9
M';I5[6?!EYJ^IWLXGBBCDLX8X3R<2QMN^8?W:[BBGS,7*CAY/"VJ:Q-J%YK#
M6<=Q+8_9((K8DJO.[>Q(]0..U9^G_#W4+>[TF>XN86V$RZD 2?.=6)0CCG']
M*](Q1BCF8<J.'TKPQK-EXB2Y1K.SM!([3BUD?;< ]!Y1X0]R14GBOPSJNLZI
MYL#VTUJ]JT'DW$C*L3G^/"_>/UKM./2BES,=D9F@6,VFZ!8V5P4,UO"L;E#D
M$CTKGET'Q!8:+K$&FS6L=[?7SS12,YPD;=>WWJ[3BBA-A9'-^$=*O-&TYK.Y
ML[2!5.X20S-(TK'[S.6 Y-<AH.DZKKFD262-:QZ9_:TDTLK;O.&U\[0.G)'7
M/2O4Z1411A5 &<\"A2:"QP4?A#5K2<:A;-:O>0:C+=11R.=CQR#!!..&_"K+
M:!XA2XT_65?3I=5MA+&\&#'"R.<X! R"/7'-=K@44^9ARHX72_!FH6&KZ9?/
M-;N\;7$MT5) WR= @]!ZU%;>"=073]"M)Y( ME+<-<%'/*R;L;>.3S7?T8HY
MF'*CA+3PIK1&E65]+9?8=)+-!)%GS)SM(7<,84<\XSFL[_A!-<_LVRM#+9S)
M':20/%)*X2-V8D2 #[W7H:],Q11S,.5'(^&?#5]I.KB[NF@*C3HK7Y&).Y2<
M_A5G6/#LNJ^(K>Z9H_L0LIK:4$_-E^A%=+2TN9A9'"Z?H?C*VDL]/?5K1-*L
MW7$T2GSI8UZ(P(Q]:GN/#VL:EJ5M%=KIL.GVMT;E);92)'X( (Q@=>3GFNRX
MHI\S"R.&T?PEJ=IJ&F)=R6QL-):5K5HR?,E+]-PQ@8%+XL\+:MK6J32P/:S6
MDUH8%BN)'40O_? '#'Z]*[BBES.]PLCB;+PIJ,$]])(T'^D:0EDN&/\ K I!
MSQTJG!X2U[38&6Q>QD:ZTY+.Y$S,!&R@C<N!R#GI7H5&/:GS,7*CDKCPW>R_
M#@>'T>'[8+98MQ8[,@CG/7%9VH>%-:DU-+BP-G;2$1#[9%*Z2*% !W(/EDZ'
M!/K7??A12YF.R.?\4Z1/J^E)!!%:SR)*KE;AF3/^ZR\JWN*YB3P;KUOX=CTN
MQEME2YN&GOE$K)N!QB-6QG'')ZFO1^**%)A9'-_9=5@\*_8;:RM;6[QY,:6T
MF4B0G&[) Y R?K573M*UK3O$$4,3L-(A&U1O&PQ[  -O7?NR2:Z[CTHHN%D<
M-XK\*ZMK6JS2V\EM-:RVODK'<2.H@?\ OA1PQ^O2JUWX0UIC:M:"Q@N4MXHO
MML<KQR1E0 <@<2#TR!UKT+ /:CCTI\SL%D<WXJ\/3Z[HMO;Q3+]IMI4F&XE1
M(5Z@D<KGU'2L6'P7?)86P5+6&X_M..[F59G<;%X^\W+-7?44E)H+(X/4/!=_
M>P:L!+"'GU-+ZW7S& 8!0"K$<J>O(ID'@S4+:U@N[=+2/4H+W[6(C*[QN,;<
M,[9.<=Z[_ HQ3YF+E1Q-QH7B&X?2;^8Z<U]:7KSM$F4C",,8SCEAZ]ZJR^"M
M4/AV>"">"+4EU"2ZMI0QPJOP03CTS7H&*,"CF8[(X'5_ T[#3&TT0R?9+3[(
MT4L[Q YYW;DY/)/'?-;,WAZZC\$'1-/N([6Y$.Q9$R%!SD@=P.HKI>*./2ES
M,+(\[M/!>J1KJC26NE#[9!$HMR[NNY#SN8\Y/7=V/:M_PGI&IZ3%="_F7R9'
M!M[99FE$( YP[<G)KI:./2CF861YW<>$->,5QIT+V)L9-3%^)&9A(1N!*XQ@
M=*M3^$-1DTG5[57M_,N]4%W&=QQL!!P>.O%=UQ1BGS,+(\^N/!^L[KIX);=X
MY=3:[:W,K(LT97 #$#(P>W>H;'P=KVE-IL]K_9S265Q/)L+LJ,LG0#C(KT?'
MM1BCF8N5'F\O@+4VBAOO,MY=0,\TT\*S/%'^\[*Z\\?K5A/ =QBPBW6\,*6=
MQ#/Y;,=KR<_+GJ,UZ!BBCF8<J/-K3X>7DEE=6]Y]FAD-K]GAFCFDE).<Y(;A
M5X'RBMG2M%UW_A*+75M5%BB061M=ML[$DY'/(]J[#%%',Q\J.%O_  $VOZSJ
M5_JUW-$)<16R6LI \H#H_'//.*QVTS6;;7M"TZ5+&ZO(=/GB99B3'+&#A<G'
M!Q]:]2I-BEPY4;AP#CD4<S%RH\\?X>74N@%9=2G.JBW>%%67$(5FSLY&=O0?
MA2WOA3Q#)'I=ENMKW3;*)2T%S<,OG2C^\0O*@]!7HE%',PY44--;4"L@OX+:
M+:0(Q Y8$8YZCCFK](*6I*"D-+2&@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,'7=5O+&_TRRLQ;![UY%+W+$*NU=W;UJ-]>&F
MR(FK75J'\AYSY"L0RA@!CUY.,5/K&@KJ^IZ9/.L,EO:/(TD4BY#[D(&/IFL?
MQ+X:#%+RU3RH+2WVI!!$6;>)%<$*.H^7G'-7%1=DR7<U+3Q5IEU<BV#3QW'G
MBV:*6(JPD*EP#_P$9H'BS2GNH[=))6D<R<+&<*(VVNQ/8 ]ZY[3])UK5+ZZU
MAD@@G6_CGMTD1E215C*$'(W=^#BKFG^#;J$RF\O(V\^VN89?)0@_OGW9'T'%
M/EAU8KOH;NG:]9:K+Y5OYJL4$BB6,IYD9. ZYZKG^=8\'C1/[7O;6ZMIHHXK
MH6=NJQ,TDTFW<?;&*D\.>%IM(O$N+C[,3#;_ &=#$79G&1\Q+?=Z?=''O2IX
M7N5UO[=]IC,?]HM>%,'.TQ>7M^M*T+A[UBV/%ND;Y0991&@D(F,9$<A09=5;
MN1S^1JL/'&C'<2;I0%20EK=@%C;[LA_V3ZU0D\&7\VG1Z4UY +"V,SV[!3YC
M,X8*&[87>>1UJ:Y\'W<UM>Q+=1!KG3(;($J<*R=6^AIV@/WC9O\ 5FL-7TZ!
MD3[+=B16E)Y1E7</S -85EXTN;G3A/+:0PW+7RPI&SG'DL-PD/&1\F3^%:GB
M;0)];T)+.VN%M[F)T:.8J3C'#?FI(JE>>#I)=:2\M;L6\*V1@5 N2LH4JD@^
MBL11'DMJ#YBTWC/1XX9Y9GGA$2))B6%@S(S;591U()J4>*M-,61]I,PF,!MA
M"?-W@;B-OTYS7-CP#?M-YIFL86,,4;^6'8NR2!R[,>22!CVJSJNEW>D:\^N0
M[II)+AFC587=54QA2&V\@Y'! ]J?+#H*\CI+?7M.NM!_MF*<BQ*EO,=2. 2#
MQUSD8K-N_&-M$MH(+2Z>2:[CMI(GB*O$'&0Q'H0.*K:=X<NK[X>+H]^?(N)U
M9V('W&,A<9&?IQ4<7@Z\0I= V<=TES#*%1G92L><@NWS'.XD#&!22@MQ^\=!
MJFN6FE;5G$[NRM)LAC+E47JQ] /6J^DZZ-6U.^AA"-;P1PR0RJ?]8'7=53Q'
MX<O-8NXY8I+=X1 \+07.[8&.,287[Q'H>*7PQX;NM!$IFGBF+VT$(V@CF-<$
MGZTK1MYAK<KW7BC4-(G_ .)M9VZ));37"10R%GC$?9ST(.>H[U+%K6MR32:>
M;*T.HF*.=")"(EC8X);OE<=!US5>W\+ZG<1ZDNKO9S3:A&\<MW&SET0YVHBD
M8"CZ\TEQX=\0RI/<QWUG#J$L,=J'C#A5A4Y;!QD.WKV]Z?NAJ2#Q)J<NG7$R
M16*&SGEANKF64B$;!G*]SG./;FMW2M1.I65M<-;2PM- DQ5AP,]L^M9D6DZO
M9Z;;6UDFF11P[D:U8,\;J1PQ8C=NSDGCFK.A65QI,$.E,#+#! &^T'C<Y8Y4
M#L!2=N@*YE:CXYMM*\2WEA>*L6G65M$\]SDEA+*V$3 ]N:;/\2M BLXYXOMD
MYDNOLJQ);/O$G'!!''!S5<^!;N?7Y=1NKN"1)M56^D0(<F.--L2?@>33(O!&
MJP7MA>I?6CS1:K-?W(DC;$@<;5 _VE7@9J[4["O([>XN$M[26X?A(XS(Q/H!
MFN2/C.YC^&A\5SV4:3M#YD5MO.&);"#/OQ^=2^*/#WB'5[J9--UJ*WT^[MOL
MUS!-&6* GEXR/XB,CGBK6K^%S?:'INCVLB0VEK-"9%<9WQQ_P_4\5$5'2XW?
MH<\GQ'N9KGPU9PV$!N-2C66]W2G;:J<]/4_*QY["MRR\?>']2DNH[2Z=V@A>
M=2\3(LJ+U:,D88#U%<YI/PKELU5;O45DW)<B5T4[LR#:FW/0*N?Q- ^'6N7-
M@8;[5K,R6]@=.L3!"R*D;$;W;U<J,<<5I)4NA*<^IO7'BVYLOAVOBBXL-T[0
M+-]G1CM 8_*2>PP03^-0:7XUE33;J]\0Q6EO:Q;&AO;&;SH+C=QL3N7!XQBM
M?6=&U";1K:TT6^2RFMBFSS(]T<JJ,;'']TCTKDT^&^I):27*7>GPZG_:,=_'
M!# PLT9%QMVYS@YR3US4KDMJ-\R.A3QE9Z@FF'2Y$9[R\-L8[E'C=-H+.-N,
MA@!WK8UB\N=/TFYNK.RDOKF-,QVT9PTC=A7,W.@>(8KBUUB6ZMK_ %&RM)EB
MC6'8C3R$<X'\( QUS6SX@L-<U+PO)9:;>P66IS(JO<%3M3(^;;CG/I4M1NAW
M9RTGQ*N=/\.ZQ=:EI\!U'3[@6T<5I*7BGD*[L!L9^4?>],5UEAX@CNX;8/!/
M]JEL5O2L4;%,$?=#="V>W6N._P"%87=QX>ALY=22RN[:"6"'[ "(G#]6D#@D
ML>YS77:!I6J:-:V.GRWD5U96]HL9=P?.:4>_39C@<9JI\EM!1YNI4T_Q!JFJ
M:1<7,&G16UQ%>/;LES* L**>6<CO["JUMXJO]12SCLK>T-Q+'-*\DCMY3)&P
M7*'J=Q/'I6A!HVIV-I>"RNH!-/J$EUME0E&1CDHW<?45F3^#KV2V!\RQDF>:
M:9T=6"1E\ >61S@ <CHV>:7NA[Q-/XJO_P"RXM;@M+<:64B8AY"992Q"D)CC
M@\#/6K,FJ:Q%XFM=,5+&6.8--)C>'BA'\1[9)(&*IQ>%M3M;RQ2-[*YTW3XT
M6U@F9TVN/O2, ""WIZ5M6VD30:YJFJ,\;R7*1QP*<_(J@\'ZDYXH?+T'J:ZT
MZF1AM@W@!R.0IXS3ZS*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "D-+2&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *"<#-%% "*<@&EHHH **** "BBB@ HHHH **** #O1110 4444 %
M%%% !1FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
JHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>chart_2.jpg
<TEXT>
begin 644 chart_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P =M5^ /Q,^ FK>!=?TW2?#OCJ\\.:G\5/%7Q%\4K8:QX1BTO[)+:+X$O\
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MO%,-_97FF7NL7,%L]E=07,LD43@U]C MDCWQQC _3_ZXZD'I0!)17YV>+O\
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MPG\#_C;\-?C1KGQ ^&NH? [Q1<?%+Q#XJ\,Z590^#[;P[X2N?"\WQ*,,FOW
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M)'B<?#?X<>-?B3:^ _AYJ[*NE^-_B#>>#]%U2V\&^&]01O/M-1UN6U26W4W
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M4U\4_M;ZUY7B?59(V^$VL7$4MG#9R'PQ$;GQ?M0F?1I([>Q1C\NL,.G[P44
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M)&F^,M9UK_A+?B9JOPQU&]N?@]\/!>V'DR:S;:7H^G)+97*VUA=S7HFO8_[
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M@KQ7/X[U'37U*77-?N)XM+FO7GETR_=6CK^AA((HRS1QHA=MSE$53(W'S.0
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MUO4R_CGQ3X9^-VL_&#23X.MSX;CAUFT,.J6OAJ0:@VC*+;2XW,313M&OTO\
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M$;+I"67]JF^V+]HFLE*A?W/HH _"KXW?\$S/C9\7;[]ON>V\1> M"/Q^U/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_;K^(GC2;X"^)?B)\#M \"?"[]HNW\?V_@;Q)H?Q.E\8>)[#6/A_P"']?\
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M2W?BO1(+JXT;0_#9\1VVBZQI=U+J%_J>G:A'#;U[#\'?V4_"?P0U'2/^$/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
MA!+#_H.^,_\ PK]=_P#DRNWHH XC_A!+#_H.^,__  K]=_\ DRC_ (02P_Z#
MOC/_ ,*_7?\ Y,KMZ* .(_X02P_Z#OC/_P *_7?_ ),H_P"$$L/^@[XS_P#"
MOUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\ A!+#_H.^,_\ PK]=_P#D
MRNWHH XC_A!+#_H.^,__  K]=_\ DRC_ (02P_Z#OC/_ ,*_7?\ Y,KMZ* .
M(_X02P_Z#OC/_P *_7?_ ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/
M^@[XS_\ "OUW_P"3*/\ A!+#_H.^,_\ PK]=_P#DRNWHH XC_A!+#_H.^,__
M  K]=_\ DRC_ (02P_Z#OC/_ ,*_7?\ Y,KMZ* .(_X02P_Z#OC/_P *_7?_
M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@%+X6_&WQ!XO\;>._AEX_P#A];_#[X@>!_"?@?QY)INE>,H/'.AZIX3\?_\
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M$1?_ !='VZR_Y_+7_P "(O\ XNN<_P"$!\$?]"CX<_\ !/8?_&*/^$!\$?\
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MMUE_S^6O_@1%_P#%USG_  @/@C_H4?#G_@GL/_C%'_" ^"/^A1\.?^">P_\
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M=<W_ ,(%X'_Z%+PW_P"">P_^,4O_  @7@?I_PB7AS/I_8]A_\8H Z/[=9?\
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ME;1>!?C#\2+SQ5X1@U1[K3-+:T\01Z7/&NLZ=!%=VME>%H;?4;U!YS']=?\
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M>O\ 45]+@N&N'LM26 R/*,)R[2H9?A:<^FO.J7M+Z+[=^MSU,/EF783_ ';
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MD?O+?&XC*74?^"W?[1*'[+I_A']FWP_>,0'E@T#PUJL5G<*=A8W;^,O%L<L
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M4^_X-R=$"BQ_:1_8[(3I]NTG5M6/&#R=5\-7I;G^]G/U))]&TO\ X++_ /!
MS0P/[%_:U_9 TC:<K_9GAD6(!]1]F\%1<X)YS2> \4*R2GG_  I@TWK]5R7'
MXE]$]<7BVEY7;5]UT%[#BN=N;,<FH?\ 7G XBHUMJG5Q&MK76B/4[C_@KM\/
M+H[?#/P1^)VN,3M7?<:#;JS'H!_9LNM/@Y&?W>\'HIK+/_!3OXJ:RYC\)?L?
M>.;QF8"-KG4/$-V7!Z'R;'P-"O/^S='/054M_P#@O!_P1/LL?9/V[_V<+7'W
M?LR:Q"%],"'PNF".Q_2M-?\ @OY_P1J7 7_@H/\  55Y&!J'B4 #Z?\ ".84
M_EZ#BG_JWQY6M[?Q!5#NL#PSET+;:1G5KSEMU<7LA_V;G\]*O$?*NU#+,-#:
MW\\YZ=->9V1 /VUOV]=:.SP[^QA?VL<JYBFU'P_X[=0'/RMY]W_9=J01CJ0.
MYPIX0?&3_@J]X@;.E? ?PEX?AEX5KW3]"A:$'H3_ &OX[CFXP3AK4XR,J1C-
MD_\ !?O_ ((TG'_&P?X"<'.?MWB,G/\ X3G^>]'_  _[_P""-0Q_QL(^ O\
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M5_TD'^ O_@P\2?\ S.T?\/\ [_@C5_TD'^ O_@P\2?\ S.T ?L)17X]_\/\
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M-C'XJEM4MM:^)OB7R]?^(6O8W&0W7B"[C#Z=:R,S$:5H<6FZ9&NU1:N=SO\
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MVU@L+BTU'0[B]\(/_!?S_@C43G_AX1\!?_!AXD],?]"[Z=:/^'_?_!&G)/\
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M WZEX9<=4Y)*#QN:\-4</5X"XIQ"24FL1E63SERJ,*])7O\  OPK_P""7O\
MP0X^.'AN#Q?\(/V*_P!@SXD^&KA$=-7\'?"[X<:[:H9!N6.X^Q64LEE-C.;>
MZCAF'*L@92*]/'_!%7_@D?W_ ."<O['W(Z#X(>!R?UTOOD8QGZ]*_-OXI_\
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M$5/^"1X_YQR_L?\ _ACO _X_\PKKCI49_P""*O\ P20!Q_P[F_8^Y X/P/\
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M>$IY]P'Q?@91C&K@N(^&,<Y8#&0J03IQQ=*&&S+#*3^JXR@TF?Q2_L?^)/\
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M.IX?>,.48?C_ (:6'CI[+ 2S=RSK(G"',J%3(<VRV6'E)U*7+/WC^:7X2?\
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ME0XZX:I5ZC2C#"U\\P6$IM)TVJ?M#^C $>HSZ<>^.Y]*,@]"*_E-_P"&D/\
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MIWEA,E52+?+*I[?%TW[\5![?T3]2^BW]')N69U\!]*WQ>PON_P!F9?6QN6>
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MZ=17T?Z]]?Z]#\8ZWZ_/YZ?+KKYV"BBB@84444 %%%% !1110 4444 %%%%
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ME?#.UU'P=X<T#PMX/FM+KQ<FE:YXUOM5MK*XU"WL*][^%WP=_;>_: _:K_9
M^,_[3O[/_P 'OV7?!W[$7@SXP6=A:^ ?C):_&+5_C-\0_BSX$T3X9R_\(?:Z
M5X,\)6WPW^#^AZ+IFH^(3IGB.:Z\4ZIJ$WA;36TJSCT2[O) #]E,EL'')SQV
M(QD<G\\C!^G=OEC/!R?XNV3['UQQ] 1C'25?<<Y]!_3\>?Z4['M^E%WK9M>E
MM]-=4^BW6H65V^KM^:>OW>JZ-'R!^T;^PA^R7^U=8S6_QO\ @GX.\4ZL\,D5
MIXPM+$:#XXTUI 09;'Q=HC6.M(RMAUAGN[FTE*()[:9%VU^'OCO_ ((4_'C]
MGCQ!>?$G_@FU^UUXX^'FL1237<7@'QKK=UI*7CK\RV7_  E6A6[Z1K-L<)&+
M;Q?X0O(RB@7-[<;OW?\ 4!@>@_*C ]!^5?)YUP1PSGM3ZUC,LIT<Q34J>;9?
M*>79K2FK<LX8_".E7<HVT524X[^ZS^@/#'Z4/C=X38*61\-<:8K,>#ZT72QO
M '&.&PO&? 688>2M4P^)X5XCHYAE=*G67NU9X&EA,0TE:LGJOY7=(_X*U_\
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M;P7'XB\7QA@B7\1+5]K_ +'G_!"3]G_X-:K;_%']IG6+G]J?XWW5W'K5_?\
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MJTY_VB_V)OV1_&^C^+O$7PJ^)5I\'/"WPZ\"? 3Q7HGAGQ!X9U*[L;S4]/\
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M$CXI_P#E/1_PL'P[_P \_$/_ (2/BG_Y3UV]% '$?\+!\._\\_$/_A(^*?\
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M'P[_ ,\_$/\ X2/BG_Y3UV]% '$?\+!\._\ //Q#_P"$CXI_^4]'_"P?#O\
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M_$/_ (2/BG_Y3T?\+!\._P#//Q#_ .$CXI_^4]=O10!Q'_"P?#O_ #S\0_\
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M;4=8U+7)K'1-':ZOCHOAO1Y=3?1O#&C"\N1I/A^PTW3Q-(+?=7N]% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %%%% !2'M]?\X_STS2TA[?48_K^F: /D?\
M8UX\"_%J/DB+]JO]JB,$]2!\<?&;9..,Y8]*^N:^1OV.?^10^-*CHG[6_P"U
M4JC^Z/\ A=GBUL8[<L3CWKZYH **** "BBB@!#U'U_H:_(C_ ((-_P#*)S]D
M?_L%_%O_ -7[\5:_7<]1]?Z&OR(_X(-_\HG/V1_^P7\6_P#U?OQ5H _7BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T
M=Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"
M_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG
M9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)P
MO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )
MV7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17
M#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0
MI^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\
MX_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I
M^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X
M_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\
M"<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./
M_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_
MPG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_
M  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W
M%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_
M -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E
M_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_
M]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9
M?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</
M_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"G
MXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C
M]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GX
MX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C]
M '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )
MPO\ T*?CC_PG9?\ X_1_PG"_]"EXX_\ "<E_^/T =Q16?IFH?VG9QW@L[^P\
MPR#[+J5L;2]C\N1X\S6Y9RF_9YD?S'?$R/QNP-"@ HHHH **** "BBB@ HHH
MH **** "BBB@ K"\3^'-"\8^'->\(^*=(L]?\,>*=&U7PYXCT+4H%N=.UG0M
M;L+C3-7TK4+9\I<6.HZ?=7%I=PN-LL$SH>H!W:* /PH_X(K_ /!%KP#_ ,$D
MT_:NO],U6P\7^*/CG\;-?NO!?B-5EGU/PU^SCX>O[B3X1^ =2NKBVMY#X@ME
MU'5-4\87%L6LM0U-]-*;UT^';^Z]%% !1110 F >HKR#P/\  7X5?#?Q;XD\
M=>#?#,^D^+/%X4>*-9D\2^*]6FUTQB%+>34H=:US4;2YGLH+>&TT^X>W,^G6
M"#3[&2WLBT!]@HH 0]1]?Z&OR(_X(-_\HG/V1_\ L%_%O_U?OQ5K]=SU'U_H
M:_(C_@@W_P HG/V1_P#L%_%O_P!7[\5: /UXHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\76>J7_AG3M1\,>.O"_C.'^V[31F75)+*['AUK*4V!^T1_:5E0'80?F?Q/\
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M<_X)\_$WX.?LU?L$>$8?%FC>.O$W[ MM\<_&&N:;X7T.Y>_^+%[XN^!/QP\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]#7Y$?\ !!O_ )1.?LC_ /8+^+?_ *OWXJT ?KQ1110 4444 %%%% !1110
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MJD2PZ;XDL[6Z2\MHG6^@N5C$D BFD_0TX/7''3/8]?S[T CH,<8X';/3\^U
M'%?VQXY_Z$K3?_"OC_\ E%1_;'CG_H2M-_\ "OC_ /E%7;9I,CU'^<_X'\CZ
M&@#BO[8\<_\ 0E:;_P"%?'_\HJ/[8\<_]"5IO_A7Q_\ RBKMJ* .)_MCQS_T
M)6F_^%?'_P#**C^V/'/_ $)6F_\ A7Q__**NVHH XG^V/'/_ $)6F_\ A7Q_
M_**C^V/'/_0E:;_X5\?_ ,HJ[:B@#B?[8\<_]"5IO_A7Q_\ RBH_MCQS_P!"
M5IO_ (5\?_RBKMJ* .)_MCQS_P!"5IO_ (5\?_RBH_MCQS_T)6F_^%?'_P#*
M*NVHH XG^V/'/_0E:;_X5\?_ ,HJ/[8\<_\ 0E:;_P"%?'_\HJ[:B@#B?[8\
M<_\ 0E:;_P"%?'_\HJ/[8\<_]"5IO_A7Q_\ RBKMJ* .)_MCQS_T)6F_^%?'
M_P#**C^V/'/_ $)6F_\ A7Q__**NVHH XG^V/'/_ $)6F_\ A7Q__**C^V/'
M/_0E:;_X5\?_ ,HJ[:DR!U('3]>GY]J .*_MCQS_ -"5IO\ X5\?_P HJ/[8
M\<_]"5IO_A7Q_P#RBKM20.I [\FC(]1ZT <5_;'CG_H2M-_\*^/_ .45']L>
M.?\ H2M-_P#"OC_^45=MFD) ZD#MSQ0!Q7]L>.?^A*TW_P *^/\ ^45']L>.
M?^A*TW_PKX__ )15VV:* .)_MCQS_P!"5IO_ (5\?_RBH_MCQS_T)6F_^%?'
M_P#**NVHH XG^V/'/_0E:;_X5\?_ ,HJ/[8\<_\ 0E:;_P"%?'_\HJ[:B@#B
M?[8\<_\ 0E:;_P"%?'_\HJ/[8\<_]"5IO_A7Q_\ RBKMJ* .)_MCQS_T)6F_
M^%?'_P#**C^V/'/_ $)6F_\ A7Q__**NVHH XG^V/'/_ $)6F_\ A7Q__**C
M^V/'/_0E:;_X5\?_ ,HJ[:B@#B?[8\<_]"5IO_A7Q_\ RBH_MCQS_P!"5IO_
M (5\?_RBKMJ* .)_MCQS_P!"5IO_ (5\?_RBH_MCQS_T)6F_^%?'_P#**NVH
MH XG^V/'/_0E:;_X5\?_ ,HJ/[8\<_\ 0E:;_P"%?'_\HJ[:B@#B?[8\<_\
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MS_T)6F_^%?'_ /**C^V/'/\ T)6F_P#A7Q__ "BKMJ* .)_MCQS_ -"5IO\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>fig5.jpg
<TEXT>
begin 644 fig5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 X17AI9@  34T *@    @  @$2  ,
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MBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK!\?\ CU?
M.GV]PVD:YK'VB7RO+TNT-S)'P3N89&%XQGU(K#$XFGAZ3K5G:*W9I1HSJS5.
MFKMF]17F_P#PT<G_ $)/Q$_\$A_^*H_X:.3_ *$GXB?^"0__ !5>-_K5E7_/
MY?<_\CT?[$QO\GXK_,](HKS?_AHY/^A)^(G_ ()#_P#%4?\ #1R?]"3\1/\
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M;_XJL)S4':1C4R7&TW:</Q7^9Z%17GO_  T)'_T)OC__ ,$S?_%4?\-"1_\
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M@B9;50DZOYJK*LH5=I7+&)T915V5&I%Z(]L\OZT>7]:=161H-\OZT>6*=10
M4444 %%%% !1139&VK0 ;Z<&S7E>O_MB?#[PU\1=2\)W&L7TVO:'<P6FJP6>
MBW]Y'I#SQQ2PFZFA@>*WCD2:,K)*RH?G ;*.%;K_ .V9\.?#'BF\TF\UZ:-M
M-O!IU]J*Z7>R:/IUT2%\BXU%839P2AF52DDRLK,JD D"@JQZM17E_@W]I.S\
M1_'OQ9\/Y]+UR'4/#VH0VEM=P:1?7-A<1OIUO>EIKM(/LMNX,SH(Y)0S;4(&
M9%4\Y\)OV[_!?Q!U%M,U"ZFTC6%\2:AX9.+*[FTR.[@U">T@MWU#R1:QW4RQ
M1LMNT@DW3HH5BR[@D]S)P* V:\AUC]M7P#X9N+.TU#5+I]5U2\U6TL--TO2K
M_5KV^_LV]>SNC%!;P/*_ERIA]J$+G.67#F_X:_:2TGQW\2/".E^'Y;35M!\6
M>&]5U^+5HK@KY)L;K3[=H3&5!#;KR0.'*M&T!1ESG:#MT/3BV#1OKQK5/VO]
M#U#7OAX/#7E>(M"\=ZG=6 U6)GC@CCA98O/A+)B>)YY(D61"8W$@9&8$$FO?
M'_Q /V;;?X@:5H^AR-'8S:A>V=[J$T02.,/\L+)$YDD9E "D*"6ZUV1P%>48
MSLK3T3NM=6OEK%[_ *H\NIG&%A.I3<O>IIN22;:247T6NDD]._D[>RALTR\O
M(]/M9)YG6.&%#([L>$4#))^@JKH,]Q<:9;/>0QV]Y)$C3Q(^]8I,#<H;C(#9
M&<#.*J_$#_D1M:_Z\)__ $6U<G6QZ/-[MT9\?Q&EU.%9].\.^(K^UD 9)O*A
MM=__  "XEBD'XJ,]LUR_Q^_:/_X4%X)T'5+CPCXF\0:AXDUFVT*PT339+%;V
M2YG$A12\]S%;J,1G),V.1]*]$T*('1;,_P#3!/\ T$5X3^W_ #_9;7X.RYQL
M^)VCG_R'<UTX6G&I7C3:T]68UIN-)SOK8L?\-<^._P#HVKXP?^#SPA_\NJ:W
M[6_CLC_DVOXP?^#SPC_\NJZ/_A*Q_>_6E7Q1O.%);OQ7=]7C_P ^U_Y-_F<7
MUI_SO\/\CPV?0?#=S'XH5OV'?$VWQL5;7]K>"5_MDB83CS\:P/,_>J),'JXW
M')YKH/@[XZE_9[T2[TWP-^R#\0_">GW]S]LN;?2]0\'6T<\VQ4\Q@NL\MM15
MR>R@=J]"OOBA:Z=XIL-&E34OMVI037$+1V%Q);*D6P-YEPJ&&)CYB[4D=6DP
MVP-M;&D?$<B]58=?7MUJG1[P7WR_^2$JZW3_  7^1X_INLVFC^$/#N@6G[&7
MCBWT3PEJZZ]HM@EWX,6WTK4%>21;N%!K.$F#RR,''(+L>]0VMSIEI\0]7\71
M_L4^+4\4:_#+;ZGJ@D\$_:K^.9=LRRO_ &QEQ(H ?/WQPV17J'CCXNZ7\-?!
MFK>(M>OETW1-"M);Z_NW5F6WAC4N[[5!9L*"<*"3V!KDM-_;+\%ZG'HK?;-?
ML4\1ZE9Z1I;:CX:U33Q?75U!-/!&GGVZ=8X)6+?=0J%<JS*I?L/[B^^7_P D
M'UC^]^"_R.7\"QZ1\+[.QM_#?[$_B_08-,U4:Y:)83^"[<6]^(9(%N5VZP/W
MHAEDC#=0CLHX.*I:3X7\+Z%XCT/6+/\ 89\26^K>&51-)O4/@GS].$;%XA$_
M]L97RV8E,?</W<8%>\?\)&V<8;). /?TI&\2LB[FW!>N:7L?[B^^7_R0>W7?
M\%_D<T/VN/'0_P";:OC!_P"#SPA_\NJR?'OQ[\0_%+P?J'A[Q'^RK\4-<T+5
MHO(O;"]U;P?-;W29!VNAUHAAD#@^E:FJ_M(>%M$^+&A^!;G7+5/%WB2WGNM/
MTM=TD\L,"[Y)'V@B)<9VF0J'*L$W%3CC]%_X*%_"GQ#X8U[6;/Q>DNF^&U@D
MO)3IMZC31SS-!!);(T(>[CEF5HHWMA*KN-JDGBA89;JFO_)O\P^M/^9_A_D1
M^/?%"?%+5-4OO$G['/CS7KS6M(70+^>^O?!LTEYIXF\\6DA;6<M")?GV'C=S
MUIOB#7+3Q5\1M'\8:E^QAXSO_%?A](X],U>XG\%27M@L>3&(Y3K!9=A)*8/R
M$DKC-=]\-/CMH?QA\'6NO^'-0_M#2KQY(XY##+;R))&[1R1R12JLD4B2*RLC
MJK*5((%= WB1T&6# >O-'L;?87WR_P#D@^L7UO\ @O\ (X#3OCKX@TGQSJ7B
M>V_95^*,/B+6+6"ROM275_!_VJZ@@,C0Q._]LY*(99"%Z NQ[FN6TF?3M!\-
M7NC67[%WC:UTG4M%;PW=6<5YX-6&?3&DFE-DR_VS@P&2XG;R_NYE?CDU[0_B
M5HQEMP^M8/@KXY:+\1;GQ!#HM\UY)X7U670]4'D2Q"UO(TCD>++JH?"RQG>A
M9#NX.00#ZNOY%]\O_D@^L7^T_N7^1P=UXL%]K,VHS?L=^/I+^XOK#4Y;AK_P
M:9'NK!0ME,3_ &SDO H C;J@'%5_A/JEA\!]=U#4_!/[%OC#PEJ&K#9=W&D3
M>"K.2X7=NVL8]8'R[OFV],\XS7I\/Q2LY_%-QHR_VA]MM;6.\D=K"X6U,<CN
MBA;@H(7D!1MT:N74%2R@,I-3Q#\<-%\*>,_#?A[4+YK?6/%[72Z1;^1*XNS;
M0^?/\ZJ43;'\WSLN[HN3Q1['3X%]\O\ Y(/K']Y_<O\ (A_X:Y\=?]&U?&#_
M ,'GA#_Y=4#]KCQX3_R;3\8.>!_Q._"//_E:KH?^$K'][]:DL_%N+N/#?Q#O
M[U/U=?\ /M?^3?YA]:?\[_#_ "-O]G3XZ6?[1OP>TGQE8:7JFBVVJ/<1?8=2
M\G[5:O!<RV\B.89)(R0\3<H[ C')KNJ^?O\ @F6_F?L7^&6_O:EK1_\ *Q>U
M] UY^*IJG6G".R;7W,]*C)RIQD^J3_ *Q/B-X;O?&'@36-*T^^M]+O=2M)+:
M&[GLUO8X"ZE=S0L0LB\\J2 1Q6W6+\1O'FE_"[P#K7B76[C[)H_AZQFU*^GQ
MN\J&%#(YP.20JG@<GI7.:'R'X6_X)$1^!WU%M&U?X3Z2VKZ?/I-ZUK\(],B-
MW:3KMF@<B7YHY%X93P1P:ZVY_8#\9WE]=W4WQ%\$RW%]-IUS<RM\,; M/+IY
M#6#L?.Y:W(!B/\';%>1ZS\=O'/@OX7:EH/Q8NO&GP^O/$^O^&O%!O-5U^"PD
ML["[UW3[76K"UN[*[=H;*U\^)5=Y(I5COL%5"Y/1Z]\7=9\0:%KW@#X8^(O'
M'C30?%'B."V\/:UHNMPWVK6FGP6<-SJSV=_>7"+<01RF"W\^2X9DEU!XU=C"
M(U['*HW=O\O(YUR6V?XG177_  3"U2_UGQ)J,WBCX7S:AXP1X]=N7^$>EF76
M%>197$[&3,FZ1$D;/WG16.6 -0W?_!+"\OO A\+S>(OA;)X:^VC4AI;?"/3#
M9K=>4D/GB/S=JR&)$0L "5&"2,UQ'Q;_ &JM1\3>'-%\0:YXHO/#.O:?X7,=
M]X9@\3S>&KRUU^TNKNWOQIA1)K36KL3V_E+87 >(!;5QE+K)]Q^/WQ>OKOQ#
MX8M/%%MXL^%_P[EU>YMM9UN[U2VTY=0VVTCVB_:[2Z>6RMI)5)+R-;R-(D$7
M25D9>TJJUW^"':']-G+Z-_P3S^(6@?&>Q\>6WQHT^'6](T#_ (1?2HT^']A%
M9Z1IV^-S!!%'(NT%HE.6+%065=JG;5KXO_\ !/[QA^T)%81^//B!X#\:)I;-
M)9KK?PLTZ^^REL;C'YDIV[MJY X.T9S@5CZG^UQ>?#R&+3_"?BF/6-#M+#[;
MX:?Q-!)>:C\19WU2[MVTS3KGS(FE$$<,*1W!6X>5+RVF=I%#/-N_!O\ :3\6
M?'CXIR>$%\8^&]+O=1\/ZK?WEEI>E;M8\$W5OJ%K;I;SF:66)Y1%-(/WD(!D
MC,FPQLJ5/-4^*Z^[_@!:%[:_?_P3,^(O_!-?7OB]:Z7;^*O&7PW\1P:'9MIV
MFQZC\)]-N%T^V90IAA#2GRX]H VK@# QC IWBO\ X)O>(/'E[KUQK7C3X=ZM
M<>*H[:+69+OX4Z;,^J);@"W$Q:7+^5@;">5VK@C QQ4'Q[M-1^'G[.^GW_Q8
MU#2/B1XF\&^&M6_XFGBF/3+&UB?RFNK^YC9D.HW%WA[=+>02AG7*K /.FKZ?
M_:J\4:AX8^$<*Z;<7-E-KGB#1= EN[=RD]I!?ZI:V<TD;CE)!%.^Q^JN5;G&
M*;JU$TK_ ((:C%K_ (+/"]1_X)A:IJ^G>';.Z\3_  NN+/PB"NAP2?"+2VCT
MA2_F$0#S,1@O\Y"X!;YNO-;UI^PGXZL=;CU*'XF>#8]0BUJ7Q&EROPTL1*FI
MRP&WEO0WG9$[PL8VDZE3CI6?H'Q1T]?'NI7&O^-O&0^+5IXRU*SLO!NGZFX:
MZTV.\G2QA_LLAH?LDUBL$[WK1;E,COYZ;0J\_P"$_P!N[Q9KT>BQS>+?ARFC
M:JNE2:OXM739(M,\'7%U:ZG--IUTLET )UEL[6$"62-T:]02('>(/+E4?_#?
M\ +0_IO_ #-";_@EYJ5S_P (SYWBCX8S'P5$D'A\R?"73'_L6-'\Q$M\RGRU
M5_G4#A6^88/-4]1_X)2ZC=Z1XPM;7QE\/='D\>Z=<Z5KMYIGPITNUNM0M[G/
MGHTBR<[R=S9SE@&.2 :;\/OVU?B'XT\):+KUY>>$6TNZC\-6UY:VNDW,,ES+
MJUB))98YC<[H4CD=&12C-M5E9MQ#IQ?@/]L;QMH,$U])JUCJUTMO;7L5G<2W
MLT>@6TWAO0IS<RQBY+W%M&]S=SL9BSM]FN"LBNS,NG-5[K[O^ 3[EKZ_?_P3
MUCXL?\$^O%_QXT#3])\;?$+P/XNTS26WV5KK'PRL;R*U;;LR@DF.#MXSZ5DW
M?_!+[4]0^&MGX,F\3_#&7PCIMR;VTT9_A)IAL;:<C!E2/S=JR$$@L.2"020:
MS_&'[;OQ M=)\47/AW6O NN:7X1\.^*?$=OKL6DRS67BR'2;?1IHQ;[+K;&I
MEU"ZM9)5>4%[0E0IW(OT-\#_ !7?:G\3/B;HUQ>37UAHNLVTEB\CF1K-;JPM
M[B2U+'D[)'>102=J7,: !445'M*D5H_P12C!_P##L\7\3?\ !.'Q)XSO+6XU
M?QM\.]2N+'2XM$MY)_A5IKM!812++%:(?-^6%)$5UC'RJ1D <UU/AS]E+XL>
M$-1UB\TKXR>']-NO$-Y_:&J36WP[LXWU"Y\J.'SI2)_G?RXHTW'G"*.U?1=%
M9RK3>C_)%^SC_39\OWG["WCS4+JZFN/B9X/FFOM:M_$EQ(_PSL2T^IP)$D%Z
MQ\[F>-88@LA^8"-0#Q63XP_X)L^(/B%<S3>(/&7PYUR6XU1M;E:_^%&FW)DO
MFAB@:Y.^4YE:*"%"W4K$@.=HKZVHH5::=U^2#V<>OYL^/]8_X)?:IXB\/MI.
MH>*OAKJ&FO%8P-:W/PHTZ:/98Q/!9C#2G'D1221QD<HCLHP"17>? 7]B[7/@
MS\3-!UZX\4^#]0M?#^D3:#;6FF^ ;+1YH;"1A+]EBGBD+10B9(Y3&HVLT8SS
MS7T)12E6DU9_D@5-+7]6%%%%9EA1110 4444 %%%% !391N2G44 >%?"WX6:
M]-XJ^-4*Z]XI\+2ZSXTM[JTUBVLK,7%Y$N@:/$98_M%M)"Z[XI(MPC(!A9?O
M*U> >&OA_P"+OAI\";CX7ZIKOQZU3Q):VUQHW]@:=X0T:XT'Q*)2RF?^U)-'
MDM8X+D.993=W!F0R2"0/)@/]Y851_"*"Z>JTDK#W=SYQ^'FHM^R!X^\5:+J^
MD_$#Q%8>(6TN[T35=/T:[UY]0,&EVFG20W,MO$1#<![,2-).(HG6X5E;Y)1'
MFW_PZU>+_@G]X[T1=#U+^V)M<\27EK8K9O\ :)6D\17MS#+''C<2P9)48#)!
M5P>0:^H-R^U'R_[-,#Y@_9@^'NL:)\?;?4-0T/4K*&-?'J+=7%D\:HMUXP:Y
MA =AP)H0LJ\_.@5QD &O//&7[(NN?'/XLWNDSKKWAO2O.\;W<4[V!;2KV6;4
M]!GM8+V-E"W%E<21S226X91<I',"2-]?<0VG^[2E1Z"@=SY,\;R^-/B_J?AW
MQ%_PB%]X9N/!.GVC:GH]QILTY:YBUJ!YX+&5=BR)_P 2U72548202QG8AD&V
MUIGB[[-\#? WA>^T#QQ'#IFMV_\ ;X3PGJ<AAAMY)KQ0H6 ^:LDT%O&3'N7;
M*<XS7U0 I_NT;%Q]U?RKUZ>:6HQHRCI%W5G9[6[/JV_4^9K</N6(GB*=5IS3
M335U9M/356T23[J_7:GHM\FJ64%U&LRI<1K(HFB:*10P! 9& 96YY5@"#P1F
MJOQ _P"1'UC_ *\)_P#T6U:V%C&?E7WK'^(DBQ> M;D9E5$T^X9F8X"CRFY)
MKR8[H^BE?EU-#0O^0)9_]<$_]!%?/'_!2.Y^R>&/A3)_<^)6D'_QRYKZ'T+_
M ) EG_UP3_T$5\W_ /!4&0V/PQ^'^H26NJ7%EI/C_2[V]:PTZXOY;>!4N TA
MB@1Y"HR,[5/6N_*[?7*=^YRXR_U:5NQ3_P"$L_VOUKS/]L'PG)\;O@!JWAR&
MQU#5I+J>UG%I97EK;R3^5<1RX(NT>VE0;,M#,-DBY4D$@BC_ ,-(>!O^?CQE
M_P"$'K__ ,@T?\-(>!O^?CQE_P"$'K__ ,@U]A[*/9_<?)^UJ'S3XX_9)^)?
MBGX(Z9HJ^%?#=K<Z?X5\6:-;V>G/8Z?'#]NNK"6TCDCCD^SI*X@F9_(/DKA1
MD$\]QIO['<G@?X_KXB\-^$]+TNQTSXEZ'K.EW%O=PHUGHZZ2(M3,8,FY!+=[
MC+& 'F8!B' !'KW_  TAX&_Y^/&7_A!Z_P#_ "#1_P -'^!?^?CQE_X0>O\
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M\J][7T-7S[_P3%T^XTW]B+P='=6E]92M<:G,(;NUDMI@CZI=NA:.15==RLK
M,H.".*^@J^+S"SQ55K^:7YGV&$_@0]%^04UH]WK3JQ?B)XENO!G@/6M7L])O
MM>N]+L9[N#3;-<W&H21QLRP1YXWNP"C.!EAGBN,Z#1FO(8H6=I52.,D%B^T
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M_P""AO@+2_C9J'@O5M=TS1Y([72;K2M1GO5:UUT:@CM%Y+*"%48C&]FVL9D
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MOXM>^VFY#^5N\Q;0M&LGWE#&,;8R:YSX.?L7^*?$GPNTG4(?"/A7P_;M"O\
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M^9"9/M"V;LYB'(VLV[ACD#'2MO\ X0'XW?\ 1%_#?_APX_\ Y!H_X0+XW?\
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M4444 &,T;:** #%)M!I:* $* C':EHHH **** "BBB@ HHHH **** "BBB@
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MY<SQD@@2%V9BZ\DL3G)I\T5]D2B^YO"B@#%%8FH4444 %%%% !1110 4444
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MW9/566FFK/B<E>-_=TL;S\T9N[?-9QY$E=K1WEKKIOWU].K'^('_ "(^L?\
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M&@CQ)IGF6?@CQ7X2\T6C[3+K-[]I2<#.=L8)5AU8G((KV[9\5O\ HW7XB?\
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M&@Z!!IDVEZ.GA^T:.21O(L$D,J6XW,05$C%LG+9/6N=_X6%\%_\ H_>/_O\
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MCB?<&//'_"SQGXK\$_M1:Y;Z'?>/H9=7^+VL76JZ-)H\G_"/SZ"]N3-?^>8
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MAZU%OI]G:V-N#D16\2Q(#ZX4 =J%9 TV6Z***DH**** "BBB@ HHHH ****
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M_A_F']AR_G_,\3_M>U_Z#.F_^!T?_P 52#5K51C^V=,Q_P!?T?\ \57MO_#
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4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>figure01.jpg
<TEXT>
begin 644 figure01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, E8# 2(  A$! Q$!_\0
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M /':BT/PJFC7%O*UZ]P;6V>U@!C"[49PYSZG@?ETKI,B@# \GQ=_T$-$_P#
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M>! D<8LIB%4=!S-73Y'K1F@# \GQ=_T$-$_\ 9?_ ([1Y/B[_H(:)_X R_\
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M^N: .OM4>.UB5UVL$ (SG''K5BJ>FRR3:?!)*29&0%B5V\_3 _E5R@ HHHH
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M%WE]BX QDDDY()_X%6U69H\U_-:RG4559DN)$&Q"@9 QVD D]L<UIT %%%%
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M?,.U7XM/LHHVCBM+=$92K*L0 (/4=.E &9>>*+*SG@B;<QD9@YQ@18XY/NQ
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MUC#;!K^(2Q;LA3"9>0"<X /0 G-1R:AI:26D3&(O=;I+=5CR7^4DD8'IGZT
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M"& )(;>5V\#O3F\2Z7'Q+<;) 5#1[&9E)4L!\H/\()^@--NK+0K:QMUN#'%
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M6=(D1KV5F50"Q5><#KTI_P!GF_Y_)?\ OE?\* %^Q6O_ #[0_P#? H^Q6O\
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M ->@"U150WAQ_P >UQ_W[K'\.^+8/$EG-<V^EZI;+%*8BMW;>6Q. <@9Z<T
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M]I,LSJ %SZ@  ?A0!8M]8L+N39!<I(1*T/RYQO49*Y]<'-7JS/[*MUNA.)&
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M\)%88C68,=[8!<Y##)))7D<GN>:?I6I:'IEW;L/%%J8(=W[L.W()8[>3C'S
MGC.5]*Z+4)]334_-M;9FLK<J)$VC,N?O$#&3M&",=3D56FOM6,<3I 0WS^9"
MMJV0<':-V>>>XI7D:*%-K9_>O\CG);C0YTG\S7]'5Y)"1Y<9";2& RN?O#?D
M-US^&+5U?>&I)KB:+7[ M*(-RSY=9#'O'S\\Y##\5K<GU'64=E734VI(8VD\
MLG/!(8 <E<;1]2?2M^V+26T;S1*DC("ZCL<<BA.3)E&G'H_O7^1R>C^(O#^F
M>:KZ_:2*4B13YG+;$"EF]SC]!6K_ ,)OX;_Z#-I_WW6]L3T7\A1L3T7\J?O=
MR;TNS^__ (!A?\)MX;_Z#-I_WW2'QMX;_P"@S:?]]UO;4]%_*C:GHOY4>]W"
M]+L_O_X!YS?7GAV5KH6^MZ4([JY\Z1)@6('EA#M;/!..O8=,=:2YO/#\]S<3
M+KVDIO*XBV$HV-W+#/)^?.?4 UVFMI??V<6TPJMRKH0/+5BR[AD<].,\UDW<
MFL";41 +SR@!]G80ID/D\#CE/N\\FCW@O2[/[_\ @&=IVL^'K'5!='Q!8,$M
MQ!D</+C'S.>[<=?>MS_A-O#?_09M/^^ZU[0.UI";A%68HOF# X;'/3WJ?:GH
MOY4>]W"]+L_O_P" 8/\ PFWAO_H,VG_?='_";^&O^@S:?]]UO;4]%_*C:GHO
MY4>]W"]+L_O_ . <?K?B3P[JNG/:KK6G?/P3*=VW(QD>AYZUFWFH:%>ZA:3O
MXEL0L$8C(&<D#=SG/&<_I77ZN;U+5OL, 8X&74C>HW#.U2,$[<XYZU0,>K7.
MF6:!I[>[,V))%1.(\D[F!!&=H' _B:CWNX7I=G]__ ,SP]KOAW1;&2&37[*5
MI)-YVD*J_*%P!^&?J36O_P )MX;_ .@S:?\ ?RI=,-\VIWRW"2FT&WR3-&JD
M-D[@,#D=,=?K6SLC]%_*CWNX7I=G]_\ P#!_X3;PW_T&;3_ONC_A-O#?_09M
M/^^ZWMJ>B_E2;4_NK^5&O<+TNS^__@'(:EXET"\N+>1-:TYDC216CF;<I+
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M_P#KI#_Z*%;-<]IYD_MS6-LT0??%O)7(/[L=!GC]:ULW/_/S;_\ ?O\ ^RH
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M%W_T,VL?]]Q?_&ZZ*BCE0>UF<[_PC%W_ -#-K'_?<7_QNC_A&+O_ *&;6/\
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MF!/W644 =.!\N?Q-7?[#TG_H%V7_ (#I_A5B"S@MF)AB6/*A<+TP,X'ZU8H
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MZ!=E_P" Z?X5CP^,X)KR2!+.5L!#$5=29=XCQWXYE Y/:B7QO806IGG@N(@
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M5I8^9(BQS)"JL&W @ XZ\5T JK>6%O?HJ7";@C;A@D?RJT!0 M%%% !1110
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>figure03.jpg
<TEXT>
begin 644 figure03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #- G$# 2(  A$! Q$!_\0
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MS8+;4TO?,FU&*2WR3Y0M=IQV^;=].U)-;:H][YD.HQ1V^X'RC:[CCN-V[O\
M2M*BGS,+(S[ZWU&:139ZA';(!@J]MYF3ZYW"G74-_);QK;7L<,J_?D:#>&X]
M-PQ5^DI<S"Q1\F__ +-\K[;']K_Y[^1\O7^YN]..M%K#?1V\JW%['-*WW'6#
M8$XXXR<U2\0B]7^SI+2>=%6]B$J1+G>A89W<9V@9KGA=:G=:!X@EM);^('$=
MFLA<SK@X,G(R-W4 = ,]ZK5H1UEC!J,,C&\OXKE2,*J6_EX/KG<:;!;ZFE[Y
MDVI126^XGRA:[3CL-V[^E<;IVJ^(X=2N);M+A8758LS1.\<.S>I?:.I=D_\
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MKG_09MO_  !_^SJS>637&H:=<*X"VLKNP/5LQLO'_?57ZN=5NST^XB,+&/\
M8]=_Z"]K^-D?_BZ7[+KW_04L_P ;,_\ Q=;%%3SO^D5RHQOLVO?]!*R/_;HW
M_P 71]GU\?\ +_8'_MU;_P"+K9HHYV'*C&\GQ!_S^Z?_ . S_P#Q='E^(?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&UB&E&Z-BMT"=QG";L>F,\5CZ;X=U[3M1T?4VL&ENHK2ZEN?G3/GR%BJGGW
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M[L;N_I3W\.V,LZ(WB" Z<EU+<K;;%W9E5@R[]W3YR1Q^=/GI]PY*G8W5\9:
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MU0[_ 'HW^]%@N3;J-U0[_>C?[T6"Y,6KP'Q5SXNU@_\ 3W)_.O=R]>#^*/\
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MCO;F)$57'R#:"5!./3-1K=3QF':P'D@A..F:V?[!'_/P?^^*:= !_P"7@_\
M?'_UZ?L:PO;4/Z1BB]N(_+VN!Y8(4;1T/6F/J%T?XUX0H $ PI[5MGPZ#_R\
MG_OC_P"O3#X9!_Y>S_WQ_P#7J71K_P!,M5\/U_(P!?W,;1E7 ,2%$^4<*:H'
MY2".QKJSX5!_Y>S_ -^__KU&?"(/_+Z?^_?_ ->L986N^AM#%X>/7\#G#J5V
MMZUX)<3,,,=HP1Z8Z5'_ &O?+=O="?\ >LNULJ""/3'2ND/@U3_R_-_W[_\
MKTP^"5/_ "_M_P!^O_KU#PV*Z?F6L5A.OY''W5S-=7+7$S[Y6.2QHGU6\F^U
M[Y ?M0 F^0?-CI]*ZP^!0?\ F(-_WZ_^O3#X!4_\Q%O^_(_QK+ZGBKW2_$U^
MNX2R5_P.=M]:=YKB2\NI%:6)8_D@21& Z;E/6J7B#4DU6^21-^Q(5B#.,,V.
MI('3K76'X>J?^8DW_?D?XU&?ARI_YBC?]^!_C6CPV*<>5K\3)8G"*?.G^'_
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M11V^IV21(L:"";"H, ?-'VJMX0T >&[*YL!<FXQ-NWE-O55[9-6=6.-6LO\
MKA-_Z%'7M8.+C!19X>+DI3E)#]U&ZH-](TH1&=B%51EF)X KML<=QFIRM'I5
MVZ7*VS+"Q6=AD1G'WC]*Y!+^YMHI;8W%RLVZT?*WOVB-E,ZJ65_O+NSRIXQ7
M57&I65O;+/<74$<$@&V21P%;(X^O%5GDT33[-9&%A;6TS!E.U%1V'(/H3W_6
MBP7,)_M++#<C4KY7GUN6T(6X(58M\@V@=!TZ]15BRO9;;6K:UEO93;1:A=0
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MFP7;&<#WP#4F^BP7+"O\Z\]Z?H'_ "!;?_@7_H1JLK_.OUJSX>_Y =M]&_\
M0C436A<'J:E%%%8FIQOC;C5?"_\ V$C_ .BGJV'XJGXX.-3\,?\ 81/_ **>
MI0W%=<%>".:;]YD^ZC=4.^C?56(N3;J-]0[Z-]%@N9ODQQ>+(C#$L9DL9F<J
MN-S&1.3[UCV;^?8Z'I461>VDY-Q'M(,857!)]CD8]<UU6[W-&_WHL%SF--G2
MX3PY91;OM%B2;J/:1Y6V,H=WU)_&K.KVD%[KLXN8O-5-*9E5LX#;S@_7TK>W
M^]&^BP7.*:"6#3[.2Q287-UI+/.R$EY2"A)/JV"V.]:FCMI7_"4/_9&T6_\
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M'^-[>]>;0[JSL+B]%I>F62. #=M\MAW([D5G?VQJ>/\ D4M:_*+_ .*KT"C
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M?E%_\57H&/:C'M1[?R#V2[GG_P#;&I_]"EK7Y1?_ !5']L:G_P!"EK7Y1?\
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M1RGF-_SYWW_@,U'F-_SYWW_@,U=7CVHQ[4>U8>R1RGF-_P ^=]_X#-1YC?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!"L$:S/*J*)' #-CDXZ?SJ4444E;H&KW%HHHI@%%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>figure04.jpg
<TEXT>
begin 644 figure04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "R ?,# 2(  A$! Q$!_\0
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MMI&G/+M9F3[(H*;3M(;C@Y[&@#7_ .$@T;_H+6/_ ($+_C1_PD&C?]!:Q_\
M A?\:A_X17P]_P! /3O_  %3_"C_ (17P]_T ]._\!4_PH F_P"$@T;_ *"U
MC_X$+_C1_P )!HW_ $%K'_P(7_&H?^$5\/?] /3?_ 5/\*/^$5\/?] /3?\
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M * >F_\ @*G^%0W.@>%;*WDN+K2M)AAB&YY)((P%'J3B@"Y_PD&C?]!:Q_\
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M*C;Q!I"112-?PA)20AW>G7Z8]ZFMM5L;RYDM[>Y266,G>J\XP<'F@"[1110
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MA=P>RQC  ]SQ6[6?;ZWIEU=/:PWL3SQD*\8;D$]*T* "BBB@ K'UG_C^T?\
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M*T7=8UW.RJOJQP*4$$ CD'O0!EZ-X=TO0=-MK#3[81V]L,1 DL1SGJ:U:**
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MI'+<,EO$L:EI3DA1@9K3HH 04M%% "4444 +65XDT^;5?#M]8VY4331[4W'
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M2P\6I/,5%RK3(5"B13%@D9SDY'&<8[UW/GZC_P ^2?\ ?W_ZU'GZC_SY1_\
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MQ5H\A@TQYKE3(K"1F4KCGY<-R%&?7M77^?J/_/E'_P!_?_K4?:-1_P"?*/\
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M.MM:3W<I( AADV$\]SD<#KC-8>E6&N6^I)(%G<JA#RW,F%DC(&U=H)PRG/\
MB:[6BJ$>:RZ9K\Y,MM;:A;#[46$+S;NG1B=W?J3VXXKTA<XYZ]Z=10 4444
M%9'B.'4[C1+B'2"BW3J5!9RA P<[3@X/I6O10!PVHV6O3IHVR*Y22VB59O+E
MR"^!GG([9^;GGM6OX2ANHK.Z>ZM[JV,DY9;>=]^P>S9.<]37144 %%%% '$Z
MW#X@O+J^BTX_,MS"Q4RF,F(8(VG&,=<UI:I:7UWJ"7,<5P]N;.:-[9I-JE^-
MO /4GOZ5T?>EH YJWL9K7PO)H\0O/M"6P+2!LDLW4*S'J.:RI[/Q)_PB,=AI
MUN8ID;/[R79(T>X8&[G#>M=U10!QHTV[L;V6\B66*>XOHDCC$C,I0#YB1G S
MR?RKLJ2EH **** "L?6?^/[1_P#K[_\ 9&K8K'UG_C^T?_K[_P#9&H V****
M "BBB@ HHHH **** "BBB@"M+'=-(3'/&J]@4S_6LS7K37KC0KR'2-0@@U!T
MQ!*T> K9Z]^WM6Y10!AZ#::_;:%9PZMJ$$^H(F)Y5CR&;U[?RK3B2Z60&2='
M3N F#_.K-% !1110 E%%% %+2O\ D%6W_7,5D>((=9N=5LX-,F>&,P2LTF\J
MBOE=I. <]^.,U?M3?VMK%!]B5MB@;O-'-3?:M0_Y\%_[^BN>E-*"33V-)QO)
MM'.%-:M=3NFCFOIT%["B*WW6C*@OCT&[//:GZU=ZK;R7<[_;TMVM$*06L89D
MDWX(# 'J.I["NA^U:A_SX#_OZ/\ "C[5J'_/@/\ OZ/\*T]JO,GE9R^DW6NI
MJRM(;F_5K9<JT9A1#M'S?-P23GT/%4Y+_P 5);D6MM?3YEC-P[*JM&V\[T0'
MJA&.1G S7:?:=0_Y\!_W]'^%'VK4/^? ?]_1_A1[5>8<K+W:N2\2W6IV^MV9
MM#=/%M'[F%2 [;N2&P03CJ&QQT-;_P!IU#_GP'_?T?X4?:=0_P"? ?\ ?T4>
MU7F'*SE(=7\5E/,^QJ%7.(FMVW-@J/O9[[B?^ U!>:KXFOGCGM[>Y@CC3:8E
M@9=SG9D\^A+8[<5V7VK4/^? ?]_1_A1]IU#_ )\!_P!_1_A1[5>8<K.0@U_Q
M3-+<01V+HL:[EDEM6SD _+UYR0.?>K4EYXFEABE D65/M"-''#A7(3*,<].>
M!ZFNE^TZA_SX#_OZ/\*/M.H?\^ _[^C_  H]JO,.5G&+?^((Y5>#^T944@VJ
MS0G$J?QF7C@CMTJ>XU_Q%81,UZ(HX26'VC[*WR8Q@[<_-G)'X5UGVG4/^? ?
M]_1_A4<S75Q'Y<VF1R(3G:\@(_E1[5>8<K.8U/5=9N-/TR[2&X@WQAS' #B8
MD C! )4]<!A@]Z<FJ^*6>79:^7&C, LEN69L MUSWP!^-=0+B_ P-/4 =/WH
M_P *7[3J'_/@/^_H_P */:KS#E9Q]]K/B6]2)H+2XMS 29HT@8>8V&XR>PPO
M3UI;?7/%#77V-;.0#8%,\UJ?E.1D]<'()_*NO^U:A_SX#_OZ/\*/M.H?\^ _
M[^C_  H]JO,.5G-1WOB:YBM6D1HI$N4WK'!@2(R9P<YP >]9R7WB$>64.I.
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M^7*@=<^A&: )**** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ();2VGD626WBD=1A69
M 2!2BUMUZ01#Z(*FHH K_8K7G_1H>3D_(.M3_2EHH **** "BBB@ HHHH **
M** $HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>figure4b02.jpg
<TEXT>
begin 644 figure4b02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> <<# 2(  A$! Q$!_\0
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M=.+Q8YX3<J#;-N$ QF8CJ$^8<U<\3^(DT/P^]];1B[N94Q9PJ<^<^TL/^ @
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M,R-\T?\ =(_O?I71:GX/DOO'\7B*2:-K--,DLI+;!WONW9P>G0T/V6J7G_P
M7,<?=?$CQDO@R;Q=#I&E+I,K[;9&=S-&-^T.XR P)R,#![]*T-?^)-_;:_\
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MN(TATIY7DC8'=)O  Q],=ZX^#X/SVOAOQ1I<-];>;J\T9MY"C8AB23>%/O\
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M/F *-DC(&TU;M/%6B7M[-:P7\9DB!)+ JIP0#AB K8++T)^\*$[!RH/L6O\
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MW,45+BAJM)*UE]R,3[#K_P#T&(/_  &'^-'V'7_^@Q!_X"C_ !K;S_G-&?\
M.:.1>?WL?MY=E]R_R,,V6O?]!>'_ ,!?_KU);VFM).C3:G"\0^\@M\$_CFMB
MBCD7G][!UI-6LON17\NX_P">R_\ ?%'EW'_/5?\ OBK-%1[)=W][,KE<1S]Y
M5/\ P"BK%%'L5W?WL+A1116P@HHHH **** "BBB@ HHHH ***YCQE9:MJ.BW
M%G8KF"6+$OD/BXSN!Q'NPO3/4B@#IZ*XS31KUAIF@63M9VDLRM%+&\)D*%5=
M@<A\9P!D<@'.#6[]FU[_ *"=C_X!-_\ '* -:L+4_"^DZQJ"WEY!(TH54?9,
MZ),JMN42*" X!Y .>M3_ &;7O^@G8_\ @$W_ ,<H^S:]_P!!.Q_\ F_^.4 8
MEM\/-'CM1'=>?=3B0NL[2,K1Y=VP@SA1\[9 ZYK57PKHRS>8UDDO,IV2_.F9
M&5F^4\=44CTQQ4WV;7O^@G8_^ 3?_'*/LVO?]!.Q_P# )O\ XY0!DR_#WPZY
M.ZUGP8FBP+E\8;(/?@X8\U*/ VA+,9O(E:9DD265IF+3!\YWDGYCR<'M6C]F
MU[_H)V/_ (!-_P#'*/LVO?\ 03L?_ )O_CE %:]\)Z5J'V-;B*8QVB)&D:SN
MJ.BD%5=0<. 0#S40\#Z$('A%M($<,"/.;^*-HSW_ +KL*O?9M>_Z"=C_ . 3
M?_'*/LVO?]!.Q_\  )O_ (Y0!23P9HL=ZUXL,OF,XD ,[E5(D67Y5S@9= QQ
MUJ"3X?>'9%1#;RA5*D;;AQG P,\\]!^5:GV;7O\ H)V/_@$W_P <H^S:]_T$
M['_P";_XY0!!!X3TBVG@EB@</ R/&3*QP5\S'?\ Z:O^?M6[63]FU[_H)V/_
M (!-_P#'*/LVO?\ 03L?_ )O_CE &M163]FU[_H)V/\ X!-_\<J&%==F$A&H
MV2['9.;)N<=_]90!E>-?"]YXDDL([6;RH'+VU\0Y5OL[X8[??=&GYFN=MO"7
MBGR+6>\DW73217%VL%ULWR>9)O&>X"&/@\<&N]^S:]_T$['_ , F_P#CE'V;
M7O\ H)V/_@$W_P <H X&?PMXQ3PY_9*74TUN;18A']L",)#;A3EL<QAPWR]\
MBM&31_&"O8^3=SX-[))<.;L8CA\T!5"XP1Y6?Q_.NM^S:]_T$['_ , F_P#C
ME'V;7O\ H)V/_@$W_P <H XB/1_B'LN/M.H"92@\M(;CRVSO5.N/^>:>9V^:
M0CM72^#M.U>PM[V36V#7=R\+LP<-N801HQXZ?,K5I?9M>_Z"=C_X!-_\<H^S
M:]_T$['_ , F_P#CE &M7.:CX+T349+V=K)8KJ\A>)[A#R-Z;"X4_*&V\;L9
MJ?;KGVLV_P#:-ED1[]WV)L=<8_UE3?9M>_Z"=C_X!-_\<H K6WA#0[4P&*Q
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ME!P2<<#UK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 5_WOVT_O%\KR_N=]V>OTQ5BLH>;_PDSG<OD_8UPO?=O;GZ8K5H:L 4444
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M]'/6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M43*8US"O  YQM)[C!Z]<UKP7D,XPI(=?O(PPR_44D<3K?S3$CRV1%'U!;/\
M,47%I%<;2P*NOW74X9?H?Z5-.G*"?+W>C*G-2:OV6WH.N9A!"9""0"!Q[D#^
MM6*Y_6;R;3K'_2@98S(@62,<_>!PR_@>1^E;4%Q%<PB2)PRGN#50JIU''JDM
M"94W&"ET;>OW$]%%%;F9!^^^V'A?)\OKWW9_EBIZJ#R?[5/+>=Y X[;=Q_7-
M6Z "BBB@ HHHH 2JUU TWD[2!LE5SGT%6J2A-IW$U=6%HHHH&9'AS_D%R_\
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MO_7Y<_\ HYZUZR/#G_(+E_Z_+G_T<]:] !1110 4444 %%%% !1110 4444
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MW9!Z'W]#3AM_MAOF.[[./E[8W'FKE0XJ2L4I-,KVMRERA(RKJ<.AZJ?0U/\
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MCC4@C><DDDGBO7Z\K^%\\DFLZBIUB/48UMHSYB,""Q.3M C3@'(SDYXQ7JE
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M?LNN_P#05L__  !/_P <H^RZ[_T%;/\ \ 3_ /'*UJ* ,62+688FEEUBR2-
M69FLR H'4D^9TJAITVJ7$LUO_:NFPW(D=O(6UR[)N(63'F9PPP<^]:7B72$U
M[PWJ&F.D;_:('2/S<[0^#M)]@<'\*Q=.\.WEOXOCU*ZMM.^S06HAAEA<B8N4
M179QM^8G:%'S< #C)H V_LNN_P#05L__  !/_P <H^RZ[_T%;/\ \ 3_ /'*
MUJ* .:U*;7+&#<FIV,DQ(VQ&T()7< S#]YT4')^E36C:E?VXGL]>TZXA)($D
M-KO4D>XDQ5/Q#X6.KZO#?P^2D@L;FTE=RP8B1 %''8').,59\(:/>:%H0L;R
M2,LLK-&D3EUA0]$#L 6QZD=\=J +GV77?^@K9_\ @"?_ (Y1]EUW_H*V?_@"
M?_CE:U(1D$'O0!RC76I)K'DOJ^F(K((UN#;8W2[B#$/WGWAUQUYK6^RZ[_T%
M;/\ \ 3_ /'*XJ]^'5\RQQ6,EG%#'?W%PB$L J2/&PR,?-C8<KQDD'=Q7I=
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MX&3@<^M:%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M698>-M/O[F*(0W$*RPSS+)*H"[8G*GH>I +#V%7]6\/V^LB,SS3HT<31J\3
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MW5O$EM/)%<$)%<# 1V*E@!DY/"G)Q@5,==T]-/MKUYBD-P,Q_*68\9(P,G@
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M3SY)(D;<K*709(#*2#QD@C^Z?2MRN?CT!H[B%DNW.)I+F68JN]I3'Y:D #:
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M0>8C 2*N4=7(<8;D':<X]Z[ Z=9;]YM("W][RAG[^_\ ]"^;Z\U%_8FE?O\
M_B6VG^D<3?N5_>#.?FXYYYI\\>P<K[D.FSW\NER/)N>ZRWEB>'R.W&0"W&>]
M<Y'XLU)X=/>585#6\<]U(L19/FE\L@?-D#CL&.2.,9KL+.RL[&)HK.VB@0G)
M6- H)]>*C.G:>?)S90'[,<Q?NE_=_P"[Z4E*-]4#3,:YUY[FYLSH]S!.LLFT
M0>4Q=\,!(23C8JKWQU('L30];O[V>-9D29;BWBN5\L;/)5V<%3D_-C:/?K6S
M/IFGW=\EQ/9P2W,8&R5XP64 Y !Z]>::-)T_<&CM(HV$PG)C0+N<9P3CKU-'
M-&UK!9W*T^LM'KL.F&U,:O\ \O$[%5DXSMCP#N;U!(_&L[6=?U#2K^^00P-;
MQ6)N(0-Q=GWJI+=!@;N@].HKJJKO;6\K,\D,;L4,9+("2AZK]/:DFD]ANYBV
MVMS1Z+=7%T8WGM;@P.&'E?-E< XW#/S#[N<]N>*RV\:R@K<&W"VRJ?,C&=VY
M?/! )QQF)>H&!G-=4-.L5LOL(M(1;'K"(QLZYZ?7FD72M/C&U+&V51P%$2@8
M.<]O]IO^^CZTU*/5"LSG[OQHNG2-#>V.V6.3RWV3!EXV%R#@9"QOO/ Z$>])
M_P )M@R2'2I_(B3=)(K9VDQ^8.V,%<=\Y/3 S6\ND:;Y*0BPM?*3<%3R5P-P
MPW&.X)!]:<=.T\W"SFRMS,%\L2&(;@N.F?3'%%X=@M+N8ESKNI)H6N70@MDN
M[%]L4?F;T'[M&Y8#G[Q[#T]Z3_A*IHQ#&;(2R3.886$P7>RRK$Y88^0;FR.O
M'H>*W8=+L(+5[6&SMT@D.YHEB 5C[COV_*@:=8K/).MI")9&5G<1C+$'()/J
M" :.:/8+,PM>U;6+?58[/34+2&U,PC2W\T,^[ #,67:OO3(O%%W"9EO;: 8D
MF2%A-@,4D5-I&">KC&,DXZ<BNI\F/SO.\M?-V[-V.<=<9]*K2:=83*R26D+J
MQ8D,@.<D%OS(!_"A2C:S069SR>-$VPO-9/' ^_?+O) 96=2H^7J=G ;:3GC)
M!J]I^N7&IZ3=7'V06+Q1AT>Z8^7@KN#$\' [_H>]:*:/IL4B21V%LC19V,L2
M@KDDG''J3^9H72]-CLIK9+"V6VFSYD0B4*^?4=#0W'H@29S:>)]1ME2:>!+B
MT\F:?S"/)>2)&C <*<]=S8'&0 >,XK5U/7VT[4?LXM!)"D<4DLOF@%1)(8QA
M<?-SSU%7%T/2D\O;IMH/*8F/]ROR$XR1QQT'Y"E?2;*?5%U*2!)+A$6.,NH.
MP DY'H?F_04-Q;V"S,:V\6R7=RMM!8H\KR1JI\\A"KK(P;=LY_U9Z @Y&#4&
MG^*[R6.)9;2!KB2W6<KYX2-5V!F.XCKR.,>O.!FNBM]-TZW??;6-M$V=V4B"
MG//I_O'\S0='TPH(SI]J4#;PODK@-Z]/>CFCV"TNYAQ>+&W$RVJFW1E$L_G!
M2N^62-<+W V#)R.#GM44?C625'$6G(TJ,21YY"E1%YF02@)Z8Z8[YQ6XFB:<
M-1DOOLD33,BQC<BD(,L3MXXR7;/K4D.F:9;AA#86\8/7;$HSQC^7'THO#L%I
M=S!3Q;<19DGLD-LUTT:S+(0(X_DP7X.#\_LO'4<9T=0UF>TU"2"&!91&D *E
MMNYYI=B\\X VDG@]:NG2M,>1)&L+8N'R&,0R"  #^0'Y#TJ233[:6_%TR9DV
M!,'E3M;<"1Z@Y(/N:+Q[!9F/!XI\VYLX&L]C3G:W[W.Q@[(>W(RIYXIL6M:@
MJ7LEVMM_HNI);%8LG]TXCQR?X@9 3QVQ[UT,4<<,>R-%1<D[5&!DG)_4U6GT
M^VGVLR;1YZ3L$ &]QC:6]<87_OD4KKL%F7OI2U%#%'#&L44:HB# 51@ >PJ3
M-24+129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)
1FC- "T4F:,T +129HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>figure5b02.jpg
<TEXT>
begin 644 figure5b02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #\ A<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N'\5>.9_#_B*#2H+733YEI]I,VH:B+1/OE=H)4@GO7;USMS
MX7@O?&":W=>1/$M@;06TL(?GS-^_)_+I50:3U$[]"K#XTM8I[]-2\BW^R_94
M @=IFDDF3<$4!?FYZ;<Y'/%7;'QAH>HSV\-K>%Y+B::",&)UR\0W2#D<8![U
MSGB+PE=PW]YK=@9+BZ>^M+J""&)3Y7E(T9W!G7>I#'@$'TJOH?@[672#5)KA
M;'4H]4O+Q4GA#AHYQM.Y5;Y6P,@!CCOFM.6#5[_U8B\KV.FA\;Z!<O9I!>/*
MUW$9X=L$AS&&*ES\ORJ"#DG&*NZ5XCTO7))(]/N3(Z(LF&C9"T;9VNNX#<IP
M<,,BN<T+X??V7';Q7%^+B./2I=-?;%L+!Y2Y8<G'!QBK'A#P0/#-P\\ES%/(
MMLEI$T<+(=BG.6+,V2>.!A1C@<U+5.SLQIRZCM,\:?VGXPO=%2.SACM9W@!E
MN&$TQ506*)LVD G'WL\$UV%<G=>&-3OM<MKR\U>*6VLKF2ZLXA:A71V0JH9@
M<,J[CV!/<UT5C'=1V,*7LT<]TJ 2RQQ[%=NY"Y.![9J96TL.-^I;HHHJ2@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-_%7B_6-)^*?AW0
M+26)=/OD0SJT8+'+L#@]N *J>-?B%J7_  D5OX6\&QQW6KM)^_D9=R1>J^G'
M4GM]>G,?& :B?BAH*Z/N&HM:*ML5(!#F1P,9X'UJMX;6Z^$OQ#CL-;:*6SU:
M% UZ%^ZQ/7<><!LAO8@UV1IQY5*UW;;N8N;NT>VV,EQIFB)+KFH0231)NN;D
M@11@]\>@'3FH])\4:%KLKQZ7JUI=R(,LD4P+ >N.N/>O-/CI=W#KX>TM5DDM
M;NY9I8HVV^<05"KG_@1Q[X-8U_H.M'Q#HFJ>'? -UHDMC,OG%)HR)4R." ?3
M<">X-91HJ4>9NU_0IS:=D>WVVJZ==W,UM;7]M/<0'$L44RL\?./F .1SZTO]
MJ6']HC3C>VXOB-PMO-7S",9SMSG&*\HUA%\$_'.QU48BT_78S%,W10YP#G_@
M01OQ-3_#*$^)/'7B7QI,N8S,;2S)[*,9Q_P$(/Q-)TDH\U]+?B-3UL>C^([V
M?3?#.J7UL56>WM)98RPR RJ2,CO7D7A_Q)\6?$VCC5-,;2Y;8LR#>B(Q*]1@
MUZMXR_Y$G7/^O";_ - ->*_#VT^(UQX17_A&+ZPM]-:9P!,J[PW\1Y4UI12Y
M&]-^I,V^:QVW@SXBZGKVA>((=1MH[?6M(@D<E5PK$!NJGH0RX(SBG^ OB1%>
M^#AJ7BO5K&VN'NGBC+8CW* O1>_4\U'X;\ S^#_"?B6]U*[6[U2_M)3,Z9VJ
M C'&3R2222:Y?X6^#M"UGX<ZI?ZA817-TSRQ))(,F(*@(V^AR2<BFXTVI-;7
M0)S5CW&"]M;JR6\@N(I;5UWK,C@H5]<],5BP^.O"MS>BSB\0:>]PS;519UY/
MH#T->4>!-1TR#X':L-?EN#IHNGB*6[$2-N"'8OU)^G)S7+^*[>-O!%I<:?X&
M_LG35=/+U.XE!GFR#C/0D'KGD>E*.'3DXOO8'4=KH^D]4UC3=%M?M.IWMO:0
MYP'FD"@GT&>IJ#2?$FBZ\'_LK5+6\*??6&0,5^HZUY7XZ\.ZQK,?A/6;&"VU
M4VUDGF:=<R#]Z2H8MM)&[/?'/ JGX-U+0X/B+9IJ'A2[\.ZW*ABB6)V2!R0>
ML9 QG\1D#ZU'L8\ET]1\[O8]?U?Q-HF@LBZKJMK9O)RBS2 $CUQUQ5^TO+;4
M+6.YL[B*XMY!E)8G#*P]B*^>]+>;6OB!XHOK[PI-XEE2=H1%YJJMNH9E'#>R
MX'I@^M=O\)-(UW0[W6[6]TJYT_29I!/9PSR*_EDD@KD'KC;GUQ1.BHQO?4(S
M;9WGB;5WT#P[>ZG%:2W<L"9C@B4EG8G ''.,GGVKR9_B+X]\/KIVM^(].L_[
M'U"0!847;(BGGUR#CD9S^%>R:GJ^GZ)9->ZE=Q6MLI"F64X )Z"O'_BCI\MO
M)9^.UU./5=.6>)K?3+@'R K*,%<'G.,GCO[44.5OEDMPG?=,]L5@Z*PZ$9%>
M2^-O%_B^U^(]MX:\-RV@-Q;J\:3Q Y;#$_,?9:]0TR^34M*L[]%*+<PI,JMU
M 8 X_6O$O'VGWNJ?'+3;'3M0?3[R:T01W29S&0LA/0@\@$?C10BG-\W9A-NV
MAT$7_"Y_-C\TZ/Y>\;\;/NYY_2M#Q%XPUC3?BUH7AZVEA&G7D:M,C1 L22^<
M-V^Z*@TSX?\ C2TU6SN;KQ_=W-O#.DDL#!\2*""5/S=QQ65XP_Y.!\+?]<D_
MG)6BY92Z/1[(3ND=?9:IX@?XE7EA-?Z6VBI&3%;)*AN5.U>67.[&2?S%;FH>
M*M TJ^CLK_6+.VNGQMBEF"MSTSZ?C7F.D';^TAK3 <BU8@>O[N.J?PH\/Z5X
MO?Q%JWB"TBU"]DN]A%P-VP$$DCT/.,]MO%*5)6YGLDMO,%-[(]B&J65W]KAL
M+^UFNH$.]$F5C&><;@#QSZUY_;^*?%%I\--=U>_U#2;G4K1@8)+)TEC4?+PV
MTXSR:YOX4VD5AXD\<6=NQ:&!6BC8G)*J[@<]^!63X0X^ _C#_KL/Y1TU146U
MOJOQ%SM_B>H>%OB!ILWA72+GQ#K-A;ZE>0EV1Y%CS\Q ..PXK3\;:AJUGX9^
MU:%>Z?;W1D3;->RJD10]>6XR>U>=^&_ _AN^^"LFI7%E"U]+:3W#7;??C=-V
M,'L!M'%<_<7D]Y^SA"+EF;R-1$,1;GY Q('X9(_"DZ47/W>]A\[MKV.W\>>-
M?$'AOP_X7GM;FT-W>D+=NJ"2-SM4DH>F,D\BNAUS4]?M_'FCV=E?:5%I<RJ;
MF">5%N'.YL[%)R>,=/>O-?B5_P B#\/O^N<?_HM*V?'&/^%[^#N/^6<?_H;T
M_9JRT[BYG?[CH+KXEP1_$N#PXLUE%IR1LUS>R3#!?:2$!SA<'@YYSQQ7;V>K
M:=J$DB6-_:W+Q<2+#,KE/J >.AKQ6Y\+:)<?M ?V3+I\36$T!GD@).&D,98M
MUSG=S6IB+P'\=&<E8-+UVW+$GA5?J?\ QY?_ !^IG2BTE'>UQJ36_<]874]/
M;46T];VV-XHW-;"5?, ZY*YSW%)JVIV^CZ3=:E=MMM[:)I9".N .WO7F?PBM
MGUK6?$7C6Y3Y[^Y:&W)[1@Y./_'!_P !KI_BM#-/\,M;6#)98E=@!U574M^@
M-9^S2FH>A2DW&YP^FZ[\3?'D<VIZ#-9:3I8=A DJJ3)CMDJQ)]3P,UTOP[\:
MZOK.HZAX>\26@AU?3^6D1<+( <'..,C(Z<$&KGPCNK>Y^&NDK RDPJ\4J@\J
MX<DY_,'\:V-.\8:'JGB"^T*SN=^HVF?.01G'& 2&Z'!('7K53:NXJ.Q*6SN3
M7'B[PY:VPN)]<T]8C+Y(?[0I&_KMX/6L.WUC7#\1[JTFU+23H*P>8D"S)]H7
MY%.XKG=C))SZ8KR_X5>!M'\5SZS=:O')-':7(2&)9"J@DDDG'7H!6_8PQS?M
M'ZK#(H:-[-D8>H,2#'Y53I1BY16MD"FVDSI/#_Q*AUSQ]J>CM+906%J/+M9/
M/!-S)NQE3G!R.@&:ZO5/%>@:+<K;:GJ]G:S,,B.64!L>N.U>0^ O#>C-\6_$
MMLVGQF'2Y#)91Y.(663@CG^=8?@_?K=UKVHZAX-F\37-S<%9)O.1?(SDX ;H
M>G(Z #%5*A%WMLDOQ!3D?1+:A9+8?;FNX!9[-_GF0>7M]=W3%4AXGT)]0MK%
M=7LFN;I=\$2SJ3*/5<'GH:\?TS2]>T7X.^+M.UFQGM8$'F6:3,K85B,@8)Z$
M#\2:V_A'X$T@:!I/BBXBDFU1C(\;M(=L8RR !>G0?K6;I1C%MOR&IMM*QU/@
M'4]?U!-3_MZ_TN[,<JB#[!,C[%YR'V]#TZUI-XZ\*I>?8V\0Z<+C=MV_:%Z^
MF>E>2_"RYTZS\)^-Y]4D>*Q60"=H20^TAQA2.<G.!]:Y_6(+*?P%+-HG@1[3
M2D(<:Q>3 S$%\<>H/W>XJ_8IS:8O:-*Y]-@A@"""#R"*6N9^'DCR_#S07D8L
MQLH\DGGI735RR5FT:)W0M%%% PHHHH **** "BBB@ HHHH 3-&:SGNM1#L$T
M\,HZ'S@,TGVK4_\ H'+_ -_A7/\ 6(=G]S-/92[K[T:6:,UF_:M3_P"@</\
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M]7]/O7^95\+Z/)X?\-6&DRW*W)M(O*$JILW 'CC)[8[UM9%9QNM1P<:>"?\
MKL*I_P!HZY_T!!_X$K63G=W?Y%JC+HU]Z-W'^<48_P XK#_M+7?^@&/_  )6
MC^TM=_Z 8_\  E:7M%Y_<ROJ\NZ^]?YFYC_.*,?YQ6'_ &EKO_0#'_@2M']I
M:[_T Q_X$K1[1>?W,/J\NZ^]?YFY161:WVJRS;;C2A%'C.\3JW/IBK_F3_\
M/O\ ^/BI=9+H_N9FZ;3L[?>BS15;SI_^>'_CXH\Z?_GA_P"/BE[:/9_<R>5E
MCBBJXEG[P8_X&**/;+L_N86+-%%%;""BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG'3%220E6MSC*D=SQUKH:*.:7<+(PM!\*Z?X=:0V3WK[U5 +B[DE"(.BJ&)
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M:(25506Y) QF@(JEBJ@%NI ZT^B@!GEH P"+AOO<=?K08T9-A12O]TCBGT4
M%,"(,X51NY.!UI]5+2_M+[S_ ++<1S?9Y3!+L.=D@QE3[C(H LJH50J@ #H
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MU/<>$-;7Q<=1TLQ::DEZL\\\%[)LGB&-PD@*[2Y QN! KT>BG[60<J/,-'\
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MJ?2O0J*6HE)R=V-*P4444AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %34-0M-*L9;Z^N([>UA7=)+(<!13K2[M[^
MTAN[29)K>9 \<B'*LIZ$4V_T^TU2QELKZWCN+69=LD4@RK"GVMI;V-I%:VL*
M0V\*!(XT&%51T %&EO,-3B)/%?B/4KG5IO#VDV,^GZ7.]O(UW.R2W,B#YQ&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>slide05.jpg
<TEXT>
begin 644 slide05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F K<# 2(  A$! Q$!_\0
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M>-;GQAXKN+<Z@Z%(H+<Y"Y 7)/3 7@#GUKB_AGX0TCQ5XA\4'68&N8+>Z8)
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M\5TGC+X>V_BKPU8Z3'?36KV#*T$[YE/ Q\V3DY]<UV'GP_\ /5/^^A1Y\/\
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M?F@NIK&QC:2"W&,N(P &;_:(/O79?#[Q"==MK[/B&/5O*D&P-:_9YX5/:1>
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MQ\;]:FGFM)OLFG+,@EM Y5/X54D_*P)^]W]*UI/@[HCHT*ZGJZ6@N1=0VHN
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MV=C+<YA@8_W1C/X$TY_AGI36DL27M]',VJ-JL5PCJ'AF/]WY<8]B#3YZ=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+(Y>/5]7-]#I^FRV=FUWKE[;R2"V!PB*6W8&,OQU/7O3+GQ?K5G;C2I)O-U
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MW=/:K';S.TL!"EE+G&WM@@<C/>B\>P6EW.O\K_II-_W^?_&CRA_STF_[_/\
MXUP-IK6MS>#YKW6/L\H&IK!&;69XW_X^=F"<#Y1V]0.:FNOB'LU:[C@2T>VM
M+\63P%G^TRG<%9T &T $]#U /2B\>P>_W.X\H?\ /2;_ +_/_C1Y0_YZ3?\
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M,VDS)97YL60,,LPD6/</;+9K*N/"FL:G<W&IW\EE'?SSV>(H68QQ0P2%R-Q
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M %%%% !1110 4444 (0""",@]0:%544*H"J!@ #@4M% !1110 4444 %%%%
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M$'KFN@_X1>X_=_\ %2ZK^Z_U?[NW^3_=_=<?A4UIX?N+6Z@F;7]2G6$\12)
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MK45%:)I2=YFC1116!TA1110 4444 <WKGC;2] \1Z3H=XEP;K4VVQ-&F57G
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MU\2ZG'I&GZG! +RXU[46C@BFF*)!'A]G8X 5 3QR2:ZCPUHG_"/>&[/2#/\
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MUVOB.#[>P_MFWC@#-'N,6V/9D\_,3U[4NI^#8-6GS<W3B$Z6VGE47# ET82
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M'B'69-&LH&M[87-W=7"6MM$S[5,C9QN/90 2>.U<Q+\.;AX9[5-7A6UDO1>
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M-J/Q&C1117.=04444 %%%% !1110!335M-DGD@34+5IHE+R1K,I9%!P21G@
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M 59TG[EU_P!=S_Z"M5JLZ3]RZ_Z[G_T%:RJ_";4?B-&BBBN<Z@HHHH ****
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M<+*A8X^@)-8?C30-2U75=9%C:R,)=)ME5UPHE:.X9VC#'C=M]?45$(1:U?\
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MI56E8AT4W<P?-'_/.;_OR_\ A2^;_P!,Y_\ OR_^%;M%'MF'L(F%YW.=D_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092526370400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CASSAVA SCIENCES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6801 N. Capital of Texas Highway, Building 1; Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,976,166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520908800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 207,291<span></span>
</td>
<td class="nump">$ 121,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,831<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">222,122<span></span>
</td>
<td class="nump">129,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,364<span></span>
</td>
<td class="nump">21,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">243,568<span></span>
</td>
<td class="nump">151,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">52,552<span></span>
</td>
<td class="nump">10,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_AccruedDevelopmentExpenseCurrent', window );">Accrued development expense</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">54,594<span></span>
</td>
<td class="nump">14,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 9, 10 and 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized; 47,976,166 and 42,236,919 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">538,497<span></span>
</td>
<td class="nump">518,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">(349,571)<span></span>
</td>
<td class="num">(380,769)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">188,974<span></span>
</td>
<td class="nump">137,468<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 243,568<span></span>
</td>
<td class="nump">$ 151,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_AccruedDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued development expense, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_AccruedDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092523435744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">47,976,166<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">47,976,166<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521700480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 15,198<span></span>
</td>
<td class="nump">$ 24,969<span></span>
</td>
<td class="nump">$ 31,431<span></span>
</td>
<td class="nump">$ 47,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">46,204<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
<td class="nump">49,905<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">61,402<span></span>
</td>
<td class="nump">28,777<span></span>
</td>
<td class="nump">81,336<span></span>
</td>
<td class="nump">55,289<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(61,402)<span></span>
</td>
<td class="num">(28,777)<span></span>
</td>
<td class="num">(81,336)<span></span>
</td>
<td class="num">(55,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">2,316<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
<td class="nump">4,092<span></span>
</td>
<td class="nump">4,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="nump">65,142<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,183<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 6,155<span></span>
</td>
<td class="num">$ (26,376)<span></span>
</td>
<td class="nump">$ 31,198<span></span>
</td>
<td class="num">$ (50,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net income (loss) per share, basic (in shares)</a></td>
<td class="nump">46,202<span></span>
</td>
<td class="nump">41,793<span></span>
</td>
<td class="nump">44,601<span></span>
</td>
<td class="nump">41,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 6,155<span></span>
</td>
<td class="num">$ (26,376)<span></span>
</td>
<td class="nump">$ 31,198<span></span>
</td>
<td class="num">$ (50,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Adjustment for change in fair value of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(43,793)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Adjusted numerator, diluted</a></td>
<td class="nump">$ 6,155<span></span>
</td>
<td class="num">$ (26,376)<span></span>
</td>
<td class="num">$ (12,595)<span></span>
</td>
<td class="num">$ (50,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net income (loss) per share, diluted (in shares)</a></td>
<td class="nump">46,202<span></span>
</td>
<td class="nump">41,793<span></span>
</td>
<td class="nump">45,152<span></span>
</td>
<td class="nump">41,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092518593024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Employee [Member]</div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Nonemployee [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 511,049<span></span>
</td>
<td class="num">$ (283,552)<span></span>
</td>
<td class="nump">$ 227,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,271)<span></span>
</td>
<td class="num">(24,271)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,749,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,786<span></span>
</td>
<td class="num">(307,823)<span></span>
</td>
<td class="nump">204,005<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
<td class="nump">$ 227,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,647)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,919,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">513,510<span></span>
</td>
<td class="num">(334,199)<span></span>
</td>
<td class="nump">179,353<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,749,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,786<span></span>
</td>
<td class="num">(307,823)<span></span>
</td>
<td class="nump">$ 204,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,376)<span></span>
</td>
<td class="num">(26,376)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,919,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">513,510<span></span>
</td>
<td class="num">(334,199)<span></span>
</td>
<td class="nump">179,353<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">518,195<span></span>
</td>
<td class="num">(380,769)<span></span>
</td>
<td class="nump">137,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,043<span></span>
</td>
<td class="nump">25,043<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,248,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">434,280<span></span>
</td>
<td class="num">(355,726)<span></span>
</td>
<td class="nump">78,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(113,363)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(113,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance of common stock pursuant to exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodValueWarrantExercises', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">22,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants', window );">Derecognition of warrant liabilities upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">518,195<span></span>
</td>
<td class="num">(380,769)<span></span>
</td>
<td class="nump">$ 137,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,198<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,976,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">538,497<span></span>
</td>
<td class="num">(349,571)<span></span>
</td>
<td class="nump">188,974<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,248,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">434,280<span></span>
</td>
<td class="num">(355,726)<span></span>
</td>
<td class="nump">$ 78,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,581<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,581<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,155<span></span>
</td>
<td class="nump">$ 6,155<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,976,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">538,497<span></span>
</td>
<td class="num">(349,571)<span></span>
</td>
<td class="nump">188,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance of common stock pursuant to exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,727,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodValueWarrantExercises', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">101,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">101,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants', window );">Derecognition of warrant liabilities upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from derecognition of warrant liabilities upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to exercises of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092522547904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 6,155,000<span></span>
</td>
<td class="num">$ (26,376,000)<span></span>
</td>
<td class="nump">$ 31,198,000<span></span>
</td>
<td class="num">$ (50,647,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,939,000<span></span>
</td>
<td class="nump">1,508,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liabilities</a></td>
<td class="num">(65,142,000)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(108,183,000)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">244,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,334,000)<span></span>
</td>
<td class="nump">4,116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,979,000<span></span>
</td>
<td class="nump">6,661,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInDevelopmentExpense', window );">Accrued development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,441,000)<span></span>
</td>
<td class="nump">4,764,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157,000)<span></span>
</td>
<td class="num">(396,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,368,000)<span></span>
</td>
<td class="num">(33,179,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,000)<span></span>
</td>
<td class="num">(351,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,000)<span></span>
</td>
<td class="num">(351,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants, net of exercise costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,552,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">953,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,552,000<span></span>
</td>
<td class="nump">953,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,155,000<span></span>
</td>
<td class="num">(32,577,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,136,000<span></span>
</td>
<td class="nump">201,015,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 207,291,000<span></span>
</td>
<td class="nump">$ 168,438,000<span></span>
</td>
<td class="nump">207,291,000<span></span>
</td>
<td class="nump">168,438,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities', window );">Issuance of warrants resulting in recognition of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,363,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_DerecognitionOfWarrantLiabilitiesThroughExercises', window );">Derecognition of warrant liabilities upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,180,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_DerecognitionOfWarrantLiabilitiesThroughExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cash flow effect of derecognition of warrant liabilities through exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_DerecognitionOfWarrantLiabilitiesThroughExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance of warrants resulting in recognition of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527244176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - General and Liquidity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">1.</em> General and Liquidity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> All intercompany transactions and balances have been eliminated in consolidation. Accordingly, the condensed consolidated financial statements do <em style="font: inherit;">not</em> include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em> are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>be expected for any other interim period or for the year <em style="font: inherit;">2024.</em> For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form&#160;<em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $349.6&#160;million at <em style="font: inherit;"> June 30, 2024</em>. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092528371456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">2.</em></b>&#160;&#160;<b>Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> June 30, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The fair value of common stock warrants of $6.71 per warrant was determined at distribution on <em style="font: inherit;"> January 3, 2024 </em>using a Monte Carlo valuation model since the warrants were&#160;<em style="font: inherit;">not</em> traded on the open market on <em style="font: inherit;"> January 3, 2024. </em>Warrant trading on Nasdaq began on <em style="font: inherit;"> January 4, 2024. </em>Quantitative information regarding Level <em style="font: inherit;">3</em> fair value measurements for common stock warrants are as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c115657898">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The common stock warrants stopped&#160;trading on Nasdaq after <em style="font: inherit;"> May 2, 2024 </em>and subsequently had little or <em style="font: inherit;">no</em> market activity. As of <em style="font: inherit;"> May 7, 2024,&#160;</em>the warrants were presumed to have <em style="font: inherit;">no</em> value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Segments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c115657804">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Income (Loss) per Share </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be antidilutive. A net loss&#160;causes all potentially dilutive securities to be antidilutive. Potentially dilutive securities consist of outstanding common stock options,&#160;warrants and Performance Awards.&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net income (loss) and comprehensive net income (loss). The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">44,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net income (loss) per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">0.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(1.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">31,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(43,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(12,595</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">551</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">45,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Dilutive common stock options excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em> from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti<b>-</b>dilutive. The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em> from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti<b>-</b>dilutive. Warrants were included for&#160;the calculation of net loss per share, diluted, for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>assuming each warrant was&#160;exercisable for <span style="-sec-ix-hidden:c115657815">one</span> and <em style="font: inherit;">one</em>-half shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><b><i>Warrant Liabilities</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8220;) Accounting Standards Codification (&#8220;ASC&#8220;) <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC <em style="font: inherit;">480&#8220;</em>), and ASC <em style="font: inherit;">815,</em> &#8220;Derivatives and Hedging&#8221; (&#8220;ASC <em style="font: inherit;">815&#8220;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b>&#160; &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses, accrued development expense and other&#160;liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense and other liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research Contracts, Prepaids&#160;and Accruals </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;CIB Plan&#8221;) to incentivize Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">10</em> for further discussion of the CIB Plan.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities. As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements. Intangible assets also include&#160;leasing commissions which are amortized over the life of the lease agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i></i></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Insurance Recoveries</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense. There was approximately $5.8&#160;million&#160;of insurance recoveries recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024. </em>There were&#160;no insurance recoveries recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2023. </em>There was approximately $8.8&#160;million&#160;and $0.1 million of insurance recoveries recorded during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. The applicable policy has a $10.0 million recovery limit.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s condensed consolidated financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b></b></i></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b>Recently Issued Accounting Pronouncements</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> November 2023, </em>the&#160;FASB&#160;issued Accounting Standards Update, or ASU, <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses and other segment items by reportable segment. The ASU becomes effective for annual periods beginning in <em style="font: inherit;">2024</em> and interim periods in <em style="font: inherit;">2025.</em> The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. This standard enhances disclosures related to income taxes, including the rate reconciliation and information on income taxes paid. The ASU becomes effective <em style="font: inherit;"> January 1, 2025.&#160;</em>The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.</p>

   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527080528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock', window );">Prepaid Expenses and Other Current Assets [Text Bock]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid expenses and other current assets at <em style="font: inherit;"> June 30, 2024</em> and&#160;<em style="font: inherit;"> December 31, 2023</em> consisted of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,432</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,433</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Insurance recoveries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,831</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PrepaidExpensesAndOtherCurrentAssetsTextBock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521672304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstateOwnedTextBlock', window );">Real Estate Owned [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">4.</em> Real Property&#160;and Other Income, Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s potential growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex has&#160;approximately 90,000 square feet of rentable space. At <em style="font: inherit;"> June 30, 2024</em>, the Company occupied&#160;approximately 25% of the property with the remainder&#160;either leased or available for lease to <em style="font: inherit;">third</em> parties.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#8217;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is&#160;allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">314</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">559</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">717</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(356</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(723</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">203</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateOwnedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateOwnedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527168320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">5.</em> Property and equipment</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of <em style="font: inherit;"> June 30, 2024</em>&#160;and&#160;<em style="font: inherit;"> December 31, 2023</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">873</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,138</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,779</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#160;$244,000&#160;and&#160;$272,000&#160;for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em>, respectively.&#160;Depreciation expense for property and equipment was $496,000 and $544,000 for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024&#160;</em>and <em style="font: inherit;">2023,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092645945504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">6.</em> Intangible assets</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#160;<em style="font: inherit;"> June 30, 2024</em> and&#160;<em style="font: inherit;"> December 31, 2023</em> were as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">317</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,370</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,288</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was $56,000 and $119,000 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2024</em> and <em style="font: inherit;">2023,</em> respectively.&#160;Amortization expense for intangible assets was&#160;$117,000 and $238,000 for the <em style="font: inherit;">six</em> months ended&#160;<em style="font: inherit;"> June 30, 2024&#160;</em>and <em style="font: inherit;">2023,</em> respectively.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets as of <em style="font: inherit;"> June 30, 2024</em> is expected to be as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092528286832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity and Share-Based Payments [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">7.</em> Stockholders</b>&#8217;<b> Equity and Stock-Based Compensation Expense</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Common Stock Warrant Distribution</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">See Notes <em style="font: inherit;">2</em> and <em style="font: inherit;">12</em> regarding the distribution of common stock warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>At-the-Market Common Stock Offering </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock in the offering. The Company is <em style="font: inherit;">not</em> obligated to sell any shares in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were <span style="-sec-ix-hidden:c115658082"><span style="-sec-ix-hidden:c115659235">no</span></span> common stock sales under the ATM during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> March 2020, </em>the Company entered into an at-the-market offering program (<em style="font: inherit;">&#8220;2020</em> Program&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on <em style="font: inherit;"> May 5, 2020. </em>The Company gave notice of termination for the <em style="font: inherit;">2020</em> Program on <em style="font: inherit;"> April 26, 2023, </em>which was effective <em style="font: inherit;"> May 1, 2023. </em>There were <em style="font: inherit;">no</em> common stock sales under the <em style="font: inherit;">2020</em> Program through its termination.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock Option and Performance Award Activity in <em style="font: inherit;">2024</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>, stock options and unvested Performance Awards outstanding under the Company&#8217;s stock option plans changed as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">193,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(154,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of June 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,077,329</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The weighted average exercise price per share of options outstanding at <em style="font: inherit;"> June 30, 2024</em> was $14.57. As outstanding options vest over the current remaining vesting period of 2.4&#160;years, the Company expects to recognize stock-based compensation expense of $22.6&#160;million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $0.1 million over the implicit service period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>, there were <span style="-sec-ix-hidden:c115658098"><span style="-sec-ix-hidden:c115659238">no</span></span> stock options exercised.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2023, </em>there were 262,158 stock options exercised. Of the stock options exercised, 92,066 stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $889,000 during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023, </em>there were 281,175 stock options exercised. Of the stock options exercised, 97,205 stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options <em style="font: inherit;">not</em> net settled totaled $953,000 during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock-based Compensation Expense in <em style="font: inherit;">2024</em></i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em>, the Company&#8217;s stock-based compensation expense was as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">972</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">443</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,994</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">727</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">835</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a designated committee of the Board is responsible for administration of the Company&#8217;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan, as amended (the <em style="font: inherit;">&#8220;2018</em> Plan&#8221;) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and Performance Awards. Share-based awards generally expire <span style="-sec-ix-hidden:c115658124">10</span> years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended in <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">2022,</em> provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520013184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">8.</em> Income Taxes</b><b><i> </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <span style="-sec-ix-hidden:c115658171"><span style="-sec-ix-hidden:c115659233">not</span></span> provide for income taxes during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>, because it has projected a taxable net loss for the full year <em style="font: inherit;">2024</em>&#160;for which any benefit will be offset by an increase in the valuation allowance. There was also <span style="-sec-ix-hidden:c115658175"><span style="-sec-ix-hidden:c115659234">no</span></span> provision for income taxes for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520059600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsDisclosureTextBlock', window );">Leases And Commitments Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">9.</em> Commitments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure regarding leases and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527292544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - 2020 Cash Incentive Bonus Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanTextBlock', window );">Cash Incentive Bonus Plan [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note</b>&#160;<b><em style="font: inherit;">10.</em></b>&#160;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the CIB Plan. The CIB Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;CIB Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The CIB Plan is considered &#8220;at-risk&#8221; because CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em> receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the CIB Plan&#160;are met.&#160;Specifically, CIB Plan participants&#160;will&#160;<em style="font: inherit;">not</em>&#160;be paid&#160;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#160;(the "Compensation Committee") determines the Company has sufficient cash on hand, as defined in the CIB Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;CIB Plan&#160;grant date has <em style="font: inherit;">not</em> occurred&#160;as of <em style="font: inherit;"> June 30, 2024</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">CIB Plan participants will be paid all earned cash bonuses allocated under the CIB&#160;Plan in the event of a Merger Transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company&#8217;s independent directors were participants in the CIB Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#160;amended the CIB Plan to remove all independent directors as participants in the CIB Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the CIB Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the CIB Plan. The Company&#8217;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the CIB Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization for purposes of the CIB Plan&#160;is&#160;determined based on either (<em style="font: inherit;">1</em>) the closing price&#160;of <em style="font: inherit;">one</em> share&#160;of the Company&#8217;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;Any warrants outstanding are excluded from the determination of market capitalization. This constitutes a market condition under applicable accounting guidance.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;<em style="font: inherit;">$5</em>&#160;billion in market capitalization. The CIB Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the CIB Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for <em style="font: inherit;">no</em> less than 20 consecutive trading days for&#160;CIB Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#160;are&#160;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $5&#160;billion market capitalization&#160;for <em style="font: inherit;">no</em> less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(<em style="font: inherit;">1</em>)&#160;the Company completes a Merger Transaction, or&#160;(<em style="font: inherit;">2</em>)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#160;CIB Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the CIB Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The CIB Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#160;achieved&#160;the <em style="font: inherit;">first</em>&#160;Valuation&#160;Milestone.&#160;Subsequently in <em style="font: inherit;">2020,</em> the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all CIB Plan participants (after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment), subject to future satisfaction of a Performance Condition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all CIB Plan participants from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million (after taking into account the <em style="font: inherit;"> March 2023 </em>CIB Plan amendment), to be determined, approved and allocated by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense was recorded&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.&#160;There is <em style="font: inherit;">no</em> continuing service requirement for CIB Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during the years ended <em style="font: inherit;"> December 31, 2023&#160;</em>and <em style="font: inherit;">2022</em> or the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024</em>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the CIB Plan through the date of filing of this Form <em style="font: inherit;">10</em>-Q.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the cash incentive bonus plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520002896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em> Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Company is, and from time to time, the Company <em style="font: inherit;"> may </em>become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time <em style="font: inherit;"> may </em>receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company other than as disclosed below. The Company believes that its total provisions for legal matters are adequate based upon currently available information.</p>
   <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><i>Update on Government Investigations</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">Beginning in <em style="font: inherit;"> August 2021, </em>the Company has received subpoenas, a Civil Investigative Demand (&#8220;CID&#8221;) and other requests for documents and information from the Department of Justice and document requests from the Securities and Exchange Commission, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, CID and requests for information and intends to continue to cooperate with these&#160;government&#160;inquiries. The Company cannot predict the outcome or impact of these ongoing matters, including whether a government authority <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">The Company is in the advanced stages of discussions with the SEC staff to resolve the SEC&#8217;s nearly <em style="font: inherit;">three</em>-year investigation of the Company's disclosures regarding its Phase <em style="font: inherit;">2b</em> study of simufilam for the treatment of Alzheimer&#8217;s disease (the &#8220;Phase <em style="font: inherit;">2b</em> Study&#8221;). The Company has reserved a loss contingency of <em style="font: inherit;">$40</em>&#160;million&#160;on its consolidated balance sheet as of <em style="font: inherit;"> June 30, 2024 </em>relating to this potential settlement with the SEC.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">The Company continues to cooperate with the DOJ related to conduct alleged in the indictment of Dr. Hoau-Yan Wang announced by the Department of Justice on <em style="font: inherit;"> June 28, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><span style="-sec-ix-hidden:c115658255">four</span> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <span style="-sec-ix-hidden:c115658256">four</span> class action lawsuits into <span style="-sec-ix-hidden:c115658257">one</span> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>On <em style="font: inherit;"> February 22, 2024, </em>plaintiffs filed a motion to supplement their complaint to extend the putative class period through <em style="font: inherit;"> October 12, 2023.&#160; </em>The court granted that Motion on <em style="font: inherit;"> June 12, 2024, </em>and plaintiffs filed a supplemental complaint on <em style="font: inherit;"> June 13, 2023.&#160; </em>On <em style="font: inherit;"> March 13, 2024, </em>plaintiffs filed a Motion for Class Certification.&#160; The Company has opposed that Motion.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendants&#8217; alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between <em style="font: inherit;"> November 4, 2021 </em>and <em style="font: inherit;"> June 20, 2023, </em>four additional shareholder derivative actions were filed alleging substantially similar claims, <span style="-sec-ix-hidden:c115658262">two</span> in the U.S. District Court for the Western District of Texas, <span style="-sec-ix-hidden:c115658263">one</span> in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <span style="-sec-ix-hidden:c115658266">three</span> actions in the Western District of Texas were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On <em style="font: inherit;"> November 9, 2023, </em>another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> February 2, 2024, </em>a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> August 18, 2022 </em>and <em style="font: inherit;"> October 12, 2023. </em>On <em style="font: inherit;"> May 28, 2024, </em>the Northern District of Illinois transferred this action to the Western District of Texas.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Beginning on <em style="font: inherit;"> March 18, 2024, </em>two related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. The complaints rely on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaints allege, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative cases seek, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiffs in these derivative cases do <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The Company believes the foregoing claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> May 28, 2024, </em>the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the &#8220;Stipulation&#8221;) to resolve the Action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the &#8220;Notice&#8221;) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the &#8220;Scheduling Order&#8221;), were filed in the Delaware Court of Chancery on <em style="font: inherit;"> May 28, 2024.&#160; </em>The Stipulation is subject to final approval by the Delaware Court of Chancery. The Stipulation, if finally approved, will cause the dismissal with prejudice of the Action.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> June 26, 2024, </em>the Delaware Court of Chancery entered the Scheduling Order, which includes approval of the Notice.&#160; Resolution of the Action is subject to approval from the Delaware Court of Chancery. The Delaware Court of Chancery set a final settlement hearing for <em style="font: inherit;"> September 9, 2024, </em>at <em style="font: inherit;">3:15</em> p.m. ET in the Delaware Court of Chancery, Leonard L. Williams Justice Center, <em style="font: inherit;">500</em> North King Street, Wilmington, Delaware <em style="font: inherit;">19801.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Anti-SLAPP Lawsuit</i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">On <em style="font: inherit;"> August 6, 2024, </em>a lawsuit was filed in the District Court for the Southern District of New York asserting claims under the New York Anti-SLAPP Law.&#160; The complaint seeks costs and damages relating to a defamation action filed by the Company against the plaintiffs and subsequently dismissed voluntarily and without prejudice by the Company.&#160;The Company will defend the lawsuit vigorously.&#160;The Company is unable to estimate the possible loss or range of loss, if any, associated with this lawsuit.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527155728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Warrant Dividend Distribution<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_WarrantDividendDistributionTextBlock', window );">Warrant Dividend Distribution [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -11pt; text-indent: 9pt;"><b>Note <em style="font: inherit;">12.</em> Warrant Dividend Distribution</b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;"> January 3, 2024, </em>the Company&#160;made a distribution&#160;to the holders of record of the Company&#8217;s&#160;common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on <em style="font: inherit;"> December 22, 2023 </em>received <span style="-sec-ix-hidden:c115658348">four</span> warrants for every 10&#160;shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately <span style="-sec-ix-hidden:c115658350">16.9</span> million&#160;warrants.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Each warrant entitled&#160;the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, <span style="-sec-ix-hidden:c115658352">one</span> and <em style="font: inherit;">one</em>-half shares of common stock (rounded down&#160;for any fractional shares). Payment for shares of common stock upon exercise of warrants was required to&#160;be in cash.</p>
   <p style="margin: 0pt 0pt 0pt -9pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;"> April 15, 2024, </em>the Company announced&#160;that all outstanding warrants would&#160;be redeemed on <em style="font: inherit;"> May 7, 2024&#160;(</em>the &#8220;Redemption Date&#8221;). The redemption price was equal to <span style="-sec-ix-hidden:c115658354">1/10</span> of $0.01 per warrant. The warrants were exercisable at any time starting on <em style="font: inherit;"> January 3, 2024&#160;</em>until the business day prior to the Redemption Date. There are <span style="-sec-ix-hidden:c115658356">no</span> remaining warrants currently outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The warrants were subject to the terms and conditions of the Warrant Agreement (including Form of Warrant), dated <em style="font: inherit;"> January 3, 2024, </em>between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A. as filed in a Current Report on&#160;Form <em style="font: inherit;">8</em>-K with the SEC on <em style="font: inherit;"> January 3, 2024. </em>The warrants were&#160;listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#8220;SAVAW&#8221;.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">From <em style="font: inherit;"> January 3, 2024 </em>to <em style="font: inherit;"> March 31, 2024, </em>a total of approximately 674,000&#160;warrants were exercised resulting in net proceeds to the Company of approximately $22.3&#160;million. The Company issued approximately 1.0 million&#160;shares of common stock&#160;from the exercise of warrants through <em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Subsequent to <em style="font: inherit;"> March 31, 2024 </em>and through the Redemption Date, a total of approximately <em style="font: inherit;">3.15</em> million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately <em style="font: inherit;">$104.0</em>&#160;million. The Company issued approximately 4.7 million shares of common stock&#160;from the exercise of warrants from <em style="font: inherit;"> March 31, 2024 </em>through the Redemption Date.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Gross proceeds in <em style="font: inherit;">2024</em> from the warrant distribution totaled approximately $126.3&#160;million from the issuance of approximately 5.7 million common shares at $22.00 per share. Total net proceeds of the warrant distribution were approximately $123.6&#160;million&#160;after deducting estimated exercise&#160;expenses.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">After the <em style="font: inherit;">first</em> $20 million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock from&#160;warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $2.7&#160;million.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">Costs of the warrant distribution totaling&#160;approximately $537,000 were recorded&#160;as general and administrative expenses in the statements of operations upon distribution of the warrants on <em style="font: inherit;"> January 3, 2024.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">The outstanding warrants are classified as liabilities in accordance with ASC <em style="font: inherit;">480</em> and ASC <em style="font: inherit;">815,</em> which requires&#160;the warrants to be measured at initial fair value&#160;on <em style="font: inherit;"> January 3, 2024&#160;</em>and at each reporting period thereafter, with the changes in fair value recognized as a non-cash gain or loss&#160;in our consolidated statements of operations.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;During the period from common stock warrant distribution on <em style="font: inherit;"> January 3, 2024 </em>to the Redemption Date, changes in the Company's common stock warrants liability and&#160;warrants outstanding were as follows (in thousands):</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Common Stock Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Common Stock Warrant Liability</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Distribution of common stock warrants on January 3, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,895</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balance at March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,152</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(226</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(65,142</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Redemption of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(13,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">See Note <em style="font: inherit;">2</em> for additional information regarding common stock warrants and associated warrant liability.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_WarrantDividendDistributionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of warrant dividend distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_WarrantDividendDistributionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092645895040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arr Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="other" title="other"></a>Item <em style="font: inherit;">5.</em> </b><b><i>Other Information</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the quarter ended <em style="font: inherit;"> June 30, 2024</em>, <span style="-sec-ix-hidden:c115658401"><span style="-sec-ix-hidden:c115659230"><span style="-sec-ix-hidden:c115659231"><span style="-sec-ix-hidden:c115659232">none</span></span></span></span> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) of the Exchange Act) informed us of the adoption or termination of a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item <em style="font: inherit;">408.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092523460448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> June 30, 2024</em> and <em style="font: inherit;"> December 31, 2023</em>.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">The fair value of common stock warrants of $6.71 per warrant was determined at distribution on <em style="font: inherit;"> January 3, 2024 </em>using a Monte Carlo valuation model since the warrants were&#160;<em style="font: inherit;">not</em> traded on the open market on <em style="font: inherit;"> January 3, 2024. </em>Warrant trading on Nasdaq began on <em style="font: inherit;"> January 4, 2024. </em>Quantitative information regarding Level <em style="font: inherit;">3</em> fair value measurements for common stock warrants are as follows:</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c115657898">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The common stock warrants stopped&#160;trading on Nasdaq after <em style="font: inherit;"> May 2, 2024 </em>and subsequently had little or <em style="font: inherit;">no</em> market activity. As of <em style="font: inherit;"> May 7, 2024,&#160;</em>the warrants were presumed to have <em style="font: inherit;">no</em> value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Segments</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b>&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c115657804">four</span> years.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;">&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#65279;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Income (Loss) per Share </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#65279;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be antidilutive. A net loss&#160;causes all potentially dilutive securities to be antidilutive. Potentially dilutive securities consist of outstanding common stock options,&#160;warrants and Performance Awards.&#160;There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net income (loss) and comprehensive net income (loss). The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">44,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net income (loss) per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">0.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(1.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">31,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(43,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(12,595</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">551</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">45,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Dilutive common stock options excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em> from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti<b>-</b>dilutive. The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023</em> from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti<b>-</b>dilutive. Warrants were included for&#160;the calculation of net loss per share, diluted, for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>assuming each warrant was&#160;exercisable for <span style="-sec-ix-hidden:c115657815">one</span> and <em style="font: inherit;">one</em>-half shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><b><i>Warrant Liabilities</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8220;) Accounting Standards Codification (&#8220;ASC&#8220;) <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC <em style="font: inherit;">480&#8220;</em>), and ASC <em style="font: inherit;">815,</em> &#8220;Derivatives and Hedging&#8221; (&#8220;ASC <em style="font: inherit;">815&#8220;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-align: justify;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b>&#160; &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses, accrued development expense and other&#160;liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense and other liabilities are at cost, which approximates fair value due to the short maturity of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research Contracts, Prepaids&#160;and Accruals </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;CIB Plan&#8221;) to incentivize Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">10</em> for further discussion of the CIB Plan.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities. As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible Assets</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements. Intangible assets also include&#160;leasing commissions which are amortized over the life of the lease agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Insurance Recoveries</i></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense. There was approximately $5.8&#160;million&#160;of insurance recoveries recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024. </em>There were&#160;no insurance recoveries recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2023. </em>There was approximately $8.8&#160;million&#160;and $0.1 million of insurance recoveries recorded during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2024 </em>and <em style="font: inherit;">2023,</em> respectively. The applicable policy has a $10.0 million recovery limit.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s condensed consolidated financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i><b>Recently Issued Accounting Pronouncements</b></i></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> November 2023, </em>the&#160;FASB&#160;issued Accounting Standards Update, or ASU, <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses and other segment items by reportable segment. The ASU becomes effective for annual periods beginning in <em style="font: inherit;">2024</em> and interim periods in <em style="font: inherit;">2025.</em> The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> December 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. This standard enhances disclosures related to income taxes, including the rate reconciliation and information on income taxes paid. The ASU becomes effective <em style="font: inherit;"> January 1, 2025.&#160;</em>The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.</p>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092519959104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercise price per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Conversion rate - common shares per warrant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Closing price of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c115657898">zero</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">44,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Net income (loss) per share, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">0.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(1.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">31,198</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(43,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0pt;">Adjusted numerator, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">6,155</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(26,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(12,595</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">(50,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator, diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Dilutive effect of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">551</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Weighted average dilutive common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">46,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">45,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">41,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Dilutive common stock options excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive Performance Awards excluded from net income (loss) per share, diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520023824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,432</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,433</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Insurance recoveries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,831</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527274864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">314</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">559</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">717</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(356</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(723</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">203</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092524393088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">873</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,138</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,779</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092519918528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">June 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">317</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,370</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,288</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527326080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Stock Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Performance Awards</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">193,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(154,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding as of June 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,077,329</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six months ended</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;"><em style="font: inherit;">June 30,</em></em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">972</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">443</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,994</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">727</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">835</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521672304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Warrant Dividend Distribution (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Number of Common Stock Warrants</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><em style="font: inherit;">Common Stock Warrant Liability</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Distribution of common stock warrants on January 3, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,895</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,363</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(674</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Balance at March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,152</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(226</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 9pt;">Gain from change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(65,142</td><td style="width: 1%; padding-left: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Redemption of common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(13,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527287840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - General and Liquidity (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (349,571)<span></span>
</td>
<td class="num">$ (380,769)<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521684672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 07, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 03, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant', window );">Class of Warrant or Right, Fair Value of Common Stock Warrants per Warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightRedemptionPricePerShare', window );">Class of Warrant or Right, Redemption Price per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from Insurance Settlement, Operating Activities | $</a></td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_InsuranceSettlementsMaximumRecoveryLimit', window );">Insurance Settlements, Maximum Recovery Limit | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of common stock warrants per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption price per share of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_InsuranceSettlementsMaximumRecoveryLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of monetary recovery for insurance policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_InsuranceSettlementsMaximumRecoveryLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092513285872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details) - Warrants to Purchase Common Stock [Member]<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">23.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0.054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092522831584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 6,155<span></span>
</td>
<td class="nump">$ 25,043<span></span>
</td>
<td class="num">$ (26,376)<span></span>
</td>
<td class="num">$ (24,271)<span></span>
</td>
<td class="nump">$ 31,198<span></span>
</td>
<td class="num">$ (50,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">46,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,601<span></span>
</td>
<td class="nump">41,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Adjustment for change in fair value of warrant liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43,793)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Adjusted numerator, diluted</a></td>
<td class="nump">$ 6,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,595)<span></span>
</td>
<td class="num">$ (50,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of common stock warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average dilutive common shares (in shares)</a></td>
<td class="nump">46,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,152<span></span>
</td>
<td class="nump">41,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common stock options excluded from net income (loss) per share, diluted (in shares)</a></td>
<td class="nump">2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
<td class="nump">2,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common stock options excluded from net income (loss) per share, diluted (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520355632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 759,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsAssets', window );">Contract research organization and other deposits</a></td>
<td class="nump">7,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">1,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">962,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance recoveries</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 14,831,000<span></span>
</td>
<td class="nump">$ 8,497,000<span></span>
</td>
<td class="nump">$ 8,497,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483081/340-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483054/340-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527103232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense (Details Textual) - Office Building [Member] - TEXAS - ft&#178;<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area (Square Foot)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfOccupancy', window );">Percentage of Occupancy</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092519894128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Lease revenue</a></td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">$ 1,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Property operating expenses</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092620079616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 244,000<span></span>
</td>
<td class="nump">$ 272,000<span></span>
</td>
<td class="nump">$ 496,000<span></span>
</td>
<td class="nump">$ 544,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521238688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 24,143<span></span>
</td>
<td class="nump">$ 24,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(2,779)<span></span>
</td>
<td class="num">(2,284)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,364<span></span>
</td>
<td class="nump">21,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">15,980<span></span>
</td>
<td class="nump">15,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,062<span></span>
</td>
<td class="nump">3,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092527244176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 117,000<span></span>
</td>
<td class="nump">$ 238,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092632027168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">$ 1,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,288)<span></span>
</td>
<td class="num">(1,170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Leases, Acquired-in-Place [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember', window );">Leasing Commissions and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520079232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521216608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">262,158<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">281,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 889,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 953,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember', window );">The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember', window );">Stock Options Net Settled in Satisfaction of the Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember', window );">At-the-market Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingPercentageOfCommission', window );">Equity Offering, Percentage of Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount to be issued in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingPercentageOfCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission in equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingPercentageOfCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092520927168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,039,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(262,158)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(281,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="nump">3,077,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,077,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, performance awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Performance awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Performance awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Performance awards forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, performance awards (in shares)</a></td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092626563200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,604<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 4,939<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,632<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 2,994<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092522320096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092518379280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual) - Cash Incentive Bonus Plan [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashBonusIncentiveIncrementalAmounts', window );">Cash Bonus Incentive, Incremental Amounts</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained', window );">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment', window );">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash Incentive Bonus Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-Based Payment Arrangement, Expense, after Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsForCashIncentiveBonus', window );">Payments for Cash Incentive Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">111,400<span></span>
</td>
<td class="nump">111,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">$ 289,700<span></span>
</td>
<td class="nump">$ 289,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashBonusIncentiveIncrementalAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of incremental amounts for cash bonus incentive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashBonusIncentiveIncrementalAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAwardExceedsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award if the maximum milestone is exceeded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAwardExceedsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsForCashIncentiveBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments for cash incentive bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsForCashIncentiveBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>the percentage of valuation milestone cash bonus award subject to approval and adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum number of days valuation milestone must be achieved and maintained in performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanValuationMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation milestone for performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanValuationMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521187888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">20 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 18, 2024</div></th>
<th class="th"><div>Jul. 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Oct. 26, 2021</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember', window );">Violations of Federal Securities Laws [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember', window );">Shareholder Derivative Actions, Texas Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember', window );">Shareholder Derivative Actions, Texas State Court Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember', window );">Shareholder Derivative Actions, Delaware Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember', window );">Shareholder Derivative Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092518424048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Warrant Dividend Distribution (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2024</div></th>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>May 02, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 07, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,552,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class Of Warrant Or Right Issued During Period (in shares)</a></td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_RedemptionPercentageOfWarrants', window );">Redemption Percentage of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_WarrantRedemptionPrice', window );">Warrant Redemption Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65,368,000<span></span>
</td>
<td class="nump">$ 65,368,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,152,000<span></span>
</td>
<td class="nump">674,000<span></span>
</td>
<td class="nump">674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodSharesWarrantExercises', window );">Stock Issued During Period, Shares, Warrant Exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_GrossProceedsFromIssuanceOfWarrants', window );">Gross Proceeds From Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission', window );">Proceeds From Warrants Exercised That Obligated to Pay Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CommissionPercentageOfGrossProceeds', window );">Commission Percentage of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsOfWarrantExerciseCosts', window );">Payments of Warrant Exercise Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">$ 537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CommissionPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of commission required to be paid from gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CommissionPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_GrossProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds received from the issuance and sale of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_GrossProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsOfWarrantExerciseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of warrant exercise costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsOfWarrantExerciseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dollar amount required to be paid for commission from warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_RedemptionPercentageOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Percent of the cost for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_RedemptionPercentageOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_WarrantRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of warrants if they are redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_WarrantRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140092521345824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="nump">$ 65,142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,183,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="nump">$ 65,142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,183,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="nump">16,221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="nump">$ 65,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Warrants exercised, shares (in shares)</a></td>
<td class="num">(3,152,000)<span></span>
</td>
<td class="num">(674,000)<span></span>
</td>
<td class="num">(674,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability', window );">Warrants exercised, liability</a></td>
<td class="num">$ (226,000)<span></span>
</td>
<td class="num">$ (4,954,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="num">(65,142,000)<span></span>
</td>
<td class="num">(43,041,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">gain from change in fair value of warrant liabilities, liability</a></td>
<td class="num">$ (65,142,000)<span></span>
</td>
<td class="num">$ (43,041,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed', window );">Redemption of common stock warrants (in shares)</a></td>
<td class="num">(13,069,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,221,000<span></span>
</td>
<td class="nump">16,221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance, liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65,368,000<span></span>
</td>
<td class="nump">$ 65,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants redeemed common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in warrant liability from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@3,KJ4IJL*O6KJX4T+P1E=P-/"]V2\J$,Y\V8TLUG\K:<"9@J8BNRY*J/S?
MY7;F^,[SP!U;%\8.N/-I1==P#^:A6BKLN7V6G)4@-)."*%C-G$_^]2*U\4W
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M2C"':B_XMF-DU=R1C]+@C=LT"WPG F4#<'XEI7GNV&NW?\N:_P-02P,$%
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ML_W5C,R4SUE99MOCCP]ILDKS0X/J[W=95KX\F%?^4Y9_.8YQ_3=02P,$%
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MJP;823WH5"AF2K'%O8U6-^ZEM'I%RUJT;])JLW/2V@DS""[*)BM2H[HX(YM
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M6,^O1%Q6_"RC"P)\O[7<FOTF&!@>^L7?4$L#!!0    ( ):)"%G$*RZ")1
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M2C@]3T"3FHZ2BU<3-9TFY\,1OYV?]U#5"#Z@ B7#P6A"! T'YQ.F<3BX&-+
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M+*(8]7M4)NH.IL8@9'.LHJ:R;19LXEV7N%M!P+; D=RE<N$B"8H60'$3A96
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M&G1NF=.7!95U(/M24N<U&QN@_59-?P-02P,$%     @ EHD(6<U29C'A @
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M<Y%G><8LFTVT6H-VUH3F!!^J]R9R7+JB7%M-IYS\[.R;L@A#.(0+:9E<\85
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MU_/D.($25ZR5_L:L/V"?ST'@XT:Z^ _KSG=ZE !OG3>J!Y,")73W9(_].6P
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M<N2R+7$?F#*Z N-KM(XL:YFNNDNC/O$UM)K U@DOD/9)K[=L4R--*Z;%[ZC
M=6'I- 0G#8,/H=&]3+QF;B!K@][_ I,BA__01^F,KH=3B2$E)_$%[=Z;XWQ\
M=.K +*6H>E!+'6-[NN>0+K)(9BN43W'HE$ G&&Y*<*J,!FT8QUB.8%NYI1OC
M0"&1A*$7$FJU[R;#\':8JV?=./GKW@WE*](@2*7$%4&ST=%! K8;=)WA31.'
MR])X&E5Q6=.W 6UPH/V5H;KJC1!@^-H4?P!02P,$%     @ EHD(6?GY'[U?
M!   M0D  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULC59M;]LV$/XK
M!W4H]B'SB^RD06H;B),5\X!T09-U'X9]H*FS1(0B-9**[?[ZW9&*[;2.,2".
M2.E>GGONA9RLK7OR%6* 3:V-GV95",U5O^]EA;7P/=N@H2\KZVH1:.O*OF\<
MBB(JU;J?#P87_5HHD\TF\=V]FTUL&[0R>._ MW4MW':.VJZGV3![>?%%E57@
M%_W9I!$E/F#XL[EWM.OOK!2J1N.5->!P-<VNAU?S,<M'@:\*U_Y@#1S)TMHG
MWBR*:39@0*A1!K8@Z/&,-Z@U&R(8_W8VLYU+5CQ<OUC_%&.G6);"XXW5?ZDB
M5-/L,H,"5Z+5X8M=_X9=/.=L3UKMXW]8)]DQ>92M#[;NE&E?*Y.>8M/Q<*!P
M.7A#(>\4\H@[.8HH;T40LXFS:W L3=9X$4.-V@1.&4[*0W#T59%>F'VV 6$X
M@%\@'^0#N!&^@H61:)@LF%O3>KC7PDSZ@;RQ3E]VEN?)<OZ&Y0NXLR94'GXU
M!1:O]?N$<@<U?X$ZST\:_+TU/1@-SACI^(2]T2[T4;0W.A&ZAV#ADS+"2"4T
M/ 01D$HN^&/Q)G/CX^:X>ZY\(R1.,VH/C^X9L]G[=\.+P<<38,<[L.-3UF=O
M)@;^?L1-@+FV\NF?8ZA/VCV.NBN*7JJ)A8'KMJ12C-LS,#;$WQ#R^*2\X"XO
M<+.8)UR-<$%)U0ABDXI::U@BO50%"%JC< 8+D!S6DH.A5-![*RD!!;14,@Y"
MA7MSRL0]/A,#8%<@X Y=25*/3A@O8H_WX-KSMUN46"_IVV@84>5G<"><K&!X
M$?>C?1"/[,/6A'+[_MUE/OSPT5-[N2<:AU(T*@BMOHDX/V@ 0M.ZQC)4<O(:
MG:=1$-!1AQ)\'A,%D XJDG+P,W%EB:0\N7M1"DZ5% $%#@TQ3IFE$MPS0AP1
MY$ C,/GZ7RB5D32;&:)7I5$K)8E_O3V#MN%2%SP[5-W6\-,YQ=_1 (O5H0M8
MHT.6QHU$"D2P\)(RR [>)H?L<$G48LO+Q^_H$5+:UG!R659PT%H)LJK"%L1:
MN*(7=59".7@6ND4F.5+PE7;)S9W22".1J(P:N[(ZX-Y2CY#MDJHB0$'5!%;*
MEDDV>WE'32Y\ZT@^>G#86*I64T*#3EF"PE30T9/<XH;79-9[2W."@UA39E^7
MP-ZVM,3\-\;RW%4Q&Y"L1LX4E3"/F,Y5I"."Z&IJ.#X6L#^#=85TBL$]NG@6
M<YPWUA0JY=V#M'144M^0F\;9I5CJ2.$2.:X:0X\[^0\9+'=&:N65<KNV3AW"
MW0&WK6,=1K.E1@7D"?Y#5PU?Z<1BXK_/]@?)46Q"JLC-=\."9*ESVY>R;\0V
M#M]4@*(-E76)2$=E5<2:?#56CLR)4#G;EBDW*?TK"E-S/)%@(HJ/<S[SCHWE
M_L%16O. X0L#<TNUFT[5W=O=G>0Z'<5[\72A(7)*93QH7)'JH/?A/ .7+@EI
M$VP3#^:E#73,QV5%]RIT+$#?5Y:F0K=A![N;VNP_4$L#!!0    ( ):)"%FE
M01&:AP0  $(*   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;'U6VV[;
M.!#]E8&ZZ)-C2[+C.*EMP$Z:;8.F">IVB\5B'VAI+!&A2"U)V?'?[Y"ZQ+D9
M:&IQ.'-XYDI.=TH_F!S1PF,AI)D%N;7EQ6!@DAP+9OJJ1$D[&Z4+9FFILX$I
M-;+4&Q5B$(?A>% P+H/YU,ON]7RJ*BNXQ'L-IBH*IO=+%&HW"Z*@%?S@66Z=
M8#"?EBS#%=I?Y;VFU:!#27F!TG E0>-F%BRBB^7(Z7N%OSCNS,$W.$_62CVX
MQ==T%H2.$ I,K$-@]+/%2Q3" 1&-_QK,H#O2&1Y^M^C7WG?R9<T,7BKQFZ<V
MGP63 %+<L$K8'VKW!1M_3AU>HH3Q_\.NUAV2<E(9JXK&F!@47-:_[+&)PX'!
M)'S'(&X,8L^[/LBSO&*6S:=:[4 [;4)S']Y5;TWDN'1)65E-NYSL[/R[L@A1
M!"=PJ:3E,D.9<#33@25PIS)(&J!E#12_ S2&6P+(#7R6*:;/[0=$JF,6M\R6
M\5' FTKV81CV( [CT1&\8>?IT.,-CWAJP"JXYI*1DTS RC*+5&'V37]KN-';
M<*Y9+DS)$IP%U T&]1:#^<</T3C\=(3LJ",[.H8^?Y8,N.(F$<I4&N&?G_AH
M82E4\O#O6Z2/PKY-NBF!/OS,D:J@*)G< S<]8#*%C58%6&I#%SGWVP-[H%:P
M^D\J^%6F%$V@3OM3;5%+%U?X*K=H+,^8:T$#2\RXE.08< F+*J/Z=NF->A[D
M^?E.Q1W%TBVE"U,PEJ:$ ;6!E.)1&>,A=]SF7F_U^=*I;#:.*3FGQ!;;C8\?
M)G%T]LF 1*;%GL0:$>*U^_?'* 2J->QJ[1F/Q">BJBLG430,M?.R._7J[H8.
M$R1+:PV95HD%)@1F)&I\X#+EB?41(?I7N@]?%*M._F82?C.*!I-25=[)];Z&
MQ9+ISN"&XL03'UO/-)[43/NPPJ32W+HBN13,&%@D=:1=[E8YTY@KD:(F0,VW
MS$W 3F6)=H?XE(<S#QK!76+5FDSB<:])SD95&N[DLS#%C5B1J$&(:EHQL2JI
MKQQ&-/(B%V$*>X,8]^&6TAU%?C7LU9O#>M6':USKBBX(<&<X-WL=I2ANE3R5
MJ%.HEQW$+=-)WJZ=O83O5)2>TJCU2BK[2MK$-VR9V9WR'GJ&IZWC=?ETMN>M
M-AWS1/X][J^B]=HY%YTVQ[V#IJ'\-YY-WD5W7AT6\!H%QZVK7Q+2)8Z9<E")
M8+R@,M%U+=-U#065B/6%PZ5%F?J2IPN./H%E=+\3:0(Q"(+M3,6M@2W/E%:5
M$?N7TP,JR=;"3PTW  K7-(Y!J:AOW0;-,^IE#9KJ'UV1.T$/^(88[&GV&*-H
M1KNV:GOMX."^"W4;Q_,V+;[0GJ9*2%7"I$_&N,U0$[[PQ7K41OY.O@C^X:K?
M]4!3R+3_5.KGK6AX$9W":1@2LTE(8W5!$^1D]6UQ?P_?:OX'[#N@MRZ-P<&]
M3MG)_.O%T)"II*VO^$[:/9 6];O@2;U^79&C5$4&!&[(-.R?G0:@ZQ=+O;"J
M]*^$M;+TYO"?.3WR4#L%VM\HNB::A3N@>S;._P=02P,$%     @ EHD(66(4
M,QB!!   @ H  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULI59M<^(V
M$/XK.[[,36Z&@E^ D 28@>1R[4USS81K\Z'3#\)>L!I9\DER(/^^*]DX).'X
MT@\)>ME]]#RK77G'&Z4?38YH85L(:29!;FUYT>N9-,>"F:XJ4=+.2NF"69KJ
M=<^4&EGFG0K1B\-PV"L8E\%T[-?N]'2L*BNXQ#L-IBH*II_G*-1F$D3!;N&>
MKW/K%GK3<<G6N$#[9WFG:=9K43)>H#1<2="XF@2SZ&+>=_;>X"^.&[,W!J=D
MJ=2CF_R638+0$4*!J74(C'Z>\ J%<$!$XT>#&;1'.L?]\0[]QFLG+4MF\$J)
M!Y[9?!*, LAPQ2IA[]7F5VST#!Q>JH3Q_V%3V_:3 -+*6%4TSL2@X++^9=LF
M#GL.H_ G#G'C$'O>]4&>Y36S;#K6:@/:61.:&WBIWIO(<>DN96$U[7+RL]-O
MRB)$,?P"#TQK)BU<\R>>H<QH8*SFR\I%;]RS=)ASZ:4-\+P&CG\"/(1;)6UN
MX+/,,'OMWR.2+=-XQW0>'P7\6LDN)&$'XC#N'\%+6N6)QTN.*#=@%=QPR63*
MF8"%918IXZPYI+>&ZQ^&<\5S84J6XB2@ZC"HGS"8?OP0#</+(V3[+=G^,?3I
MT<N!O[_CUL)<J/3QGT/,CV(?9M[D11?^D/"5R8H*%I(Z]AVXQA2+)6J(8[^4
MP$I5&J)A]QP^LS2'34.70LFMP QLCI KD9$/1;RL=)I3*76 V;VMCQ]&<71V
M:< H@8!;>G@, B.UN$U%9:A\85?.WI5)VD&=<C(K-4\1U I.DJ0;AE#240V-
M#BB)_H_$S,A00#38:;EESW!63^ 4HEX4OM4+4L%W(MF@&=B@1GK%EO\2%2?'
M*;"H"^.YIDIFW%$TCHW;VUW>;*W1IQ><<DF",B[7X-X69]@8?>I 1DF8O0_Z
MZ.U2%VZT*MZQO6447$BB%X'[\RXLJJ7!'Y6C0=Q?[T+2C09P$H7];OAVZXM6
MQE"858J8&>"R7IZMK+M4DKGBVEBX4L:VRG=YD.UGJU66"2>=E82VY?2THGB&
MDT%RU@GIYGQX-:9*T\,!S, :)6HJ3Q==EM$CZ-"8]>E0)XFGXPXT;04["O3I
M<G;N*JJ23GY%XS5%LG^7Z%U_[?0E(U3I+ZLU9D0Q%<P8ON(U2<'9D@NZ^)H,
M2QU_>E?H!&YSF"VNH#\*8>0R[^V575?:H3LZQ)BK#%;N9E-5%,2*O@'IX^%0
MON<,WRI?F:3NJG9?>/>''?-#J_![0_[Y];M"((<X'(H5%7]G=$ZY U&4=))A
M\G+BKD0S.!V>]>$3G/8[YP,W^$)-0R,U9W*-+G KQC4\,5'Y8MZIWH^N?R;B
M2X)).F$_(IPY$S[2]"2\25IB%<<1# =$:7204M*)!K$C%<?#_T^)#HKZ#NX>
M,RS*XU$\I4B%PW.RWOFW0GSZTA</VR]>:W/2CA:(X-_I& Y]8GI[74&!>NU[
M'T-<*FGK!J%=;=NK6=U5O)C7O1E%=<VIB@2NR#7LG@T"T'6_4T^L*GV/L526
M.A8_S*E%1.T,:'^EB&<S<0>T3>?T/U!+ P04    " "6B0A9>6$[)\X"   U
M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RM5EUOFS 4_2L6D_:T
M!D(^&G4)4I*N6J9UJ]IN>ZCVX, -H!J;VJ;I_OVN34+3B5@MVDOP-?<<WW-L
MASO="GFO,@!-G@K&U<S+M"[/?%_%&114]40)'-]LA"RHQE"FOBHET,2""N:'
M03#V"YIS+YK:N2L9346E6<[A2A)5%065?Q; Q';F];W]Q'6>9MI,^-&TI"G<
M@/Y17DF,_(8ER0O@*A><2-C,O'G_;#DQ^3;A9PY;=3 F1LE:B'L3K)*9%YB"
M@$&L#0/%QR,L@3%#A&4\[#B]9DD#/!SOV2^L=M2RI@J6@OW*$YW-O(E'$MC0
MBNEKL?T,.STCPQ<+INPOV=:Y(UPQKI06Q0Z,<9'S^DF?=CX< )"G'1#N .$_
M@$EP!##8 096:%V9E75.-8VF4FR)--G(9@;6&XM&-3DWNWBC);[-$:>C%>Y'
M I+<2IKD/"5S*2E/ ?=)JZFO<063Y\<[MD7-%AYA&Y!+P76FR">>0-*"7[KQ
M8P?>1V6-O' O;Q$Z";]4O$<&P0<2!N&PK9[.\!?E#!JW!Y9O\'JWR5?,(2L-
M1:O?-=^PG<]<\3-5TAAF'MYA!?(1O.C]N_XX^-@F]C^1O9 ^;*0/7>S1)=4@
M<\K(+<A"$;%I.W+D[A:>-%DP$=__;K/#N<9;[>A -NJ1[SK#'5SQ^A_4_!6=
M5]+HP'GR4%&).@F8\TOP^$!S? @7&/7'E/1)/UB/GA_#8-(C#HM'C<4CI\77
M%0/+>=)_8>H\$:7&<NXN&$U;;77S;BA3T&:@$];Q/(T;L6-G4=\$/^DNV,U]
M5+ 3UE'P:2/XM-/NFON4<^K6ZZ8^JM<)ZZAWTNB==-[@5VEVTQ_5[(2]5;-_
M\&4N0*:V85$D%A77]4>ZF6UZHKEM!?SG]+JANJ0RS;DB##8(#7JG>/MDW:34
M@1:E_<ZOA<:NP0XS[.M F@1\OQ%"[P.S0-,I1G\!4$L#!!0    ( ):)"%FT
MF>OVIA$  #@Y   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;-4[:7/;
MN))_!>7)SB95M*S#DNP<KO*1[/I5)NN*Y\U\>+4?(!*2,*$(#DA:5G[]]@&
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MG?@,[C 5H[W[,:S2-A&9*>&Z_6X"3^G%1-PN<8L=<A(5N].\ B:6:XGDIKC
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M\E0[=F4590J Y2D L=AUF :7_8V YK(A7S33-G]D7TVMNRU;9:#0FQP;-Z7
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M4AF*KX4%F24W>"SZ_1E;[=I@"ZRK/ZS"\5J"B:809LTL$F:X5O'N@4Y4%&+
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M_QBN7LZ_*?Q-VA6$4,@BE_#I<#"'JMGRS_3XIC0Y_31N8<K2;.ARK22$"%P
M[Y?&E/X&$80?2U[\#U!+ P04    " "6B0A96>=1"DX$  "V"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6RM5FU/(S<0_BNCO>L)I"79]P0NB42
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MR1$5EL1*]47=2[534KLQ<N$FDSMI:,YQRSD-EJCL!3HO);W,ZXU5T(VJDW\
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M -U.T79AU<I/KKFR- >]6=&/![5SH/.%HMO?+5R _E<V_0-02P,$%     @
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M.ZCK<\;D\XD>H/SF9/@?4$L#!!0    ( ):)"%GLB:CH'P,  -H+   9
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M$-5\\IIW.9 @KA4I? R&I0KVGT'TNIT=%#?% 1]0'3+=6$"$OH-(F]F]1G7
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M.Q1^TLT-SN:%DX6Z0'@CG)-,/<X13!"5 N+[E!"^?9$ Y3W:X%]02P,$%
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M-4?@D+:HOYR1VU_-T>RGJNMS>I/XZ&K&K<1X5.)W)G&!JN8,@VX#J#=RVC0
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M:%NG=8OZV#Y,^^# 3;!J;&J;I-NOGTTHRH.DFY0O8)M[CL^Y%WSI+[EXE!F
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MZH'2?"A:6=&;K)[Y@])Z>FYM+8(F]LRC*3L;U*%SW*$+ZM #I?E0M+(&-PE
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M'JY?V+]Z[5;+DFJ<2/Z+Y:88!5<!Y+BB%3?W<O<-&ST#QY=)KOT3=G7L<!!
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M+L#NKZ1MPL9P"=J?1/H'4$L#!!0    ( ):)"%EJ&@N+R@0  * :   9
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M9%U;$.$ERA/^F>Q^QV6#>I(7DH2I_[ KRSH6A#GC)"V-A0=IG!6_:%\&XLC
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M(7^DQL%Y7;XVY8;SEGQM;Y_BL,-OGV1RYZ7+(&8DI OA2KH<B\E]NGTXR/:
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M*^JM!'H;ZFT$>AOJ;01Z&^IM!'I;[["$0&]#O8U ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U ;^\==A/H[:BW$^CMJ+<3
MZ.VHMS]2[Y1/NYAN/=<UOO^15.?SL_'V^LORNMECYX)S@)^([[]02P,$%
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M;"ORZ?D2)WHT\WF946ZR51V7I-XZTKDOB$)=I;NB_?/)(>XP[:[\ZORNS+G
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ E8D(69E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "5B0A9U:H B>\%   +'P  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ E8D(6?=Y(!)%!0
MLA,  !@              ("!,@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( )6)"%F&M_FWPP(  '$)   8              " @:T3
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "5B0A9&=1%
M2SL%   >%@  &               @(&F%@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ EHD(6>AN/TFO#0  >;8  !@
M ("!%QP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ):)
M"%EW+V6V5P<  $PK   8              " @?PI  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " "6B0A937&_Z,D#  #T!P  &
M        @(&),0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ EHD(6<0K+H(E$   0RX  !@              ("!B#4  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ):)"%E/0IE)\0(  +<&   8
M              " @>-%  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " "6B0A9S5)F,>$"  !'!@  &0              @($*20  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ):)"%E4XDKW! ,
M ,T&   9              " @2),  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ EHD(64?$>AX5 P  )P<  !D              ("!
M74\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "6B0A9
MF,<9W  %   )#   &0              @(&I4@  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( ):)"%F3POZT-P(   L%   9
M      " @>!7  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ EHD(6>$GNIKL @  >08  !D              ("!3EH  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "6B0A9^?D?O5\$  "U"0
M&0              @(%Q70  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( ):)"%FE01&:AP0  $(*   9              " @0=B  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ EHD(66(4,QB!
M!   @ H  !D              ("!Q68  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " "6B0A9>6$[)\X"   U"@  &0
M@(%]:P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ):)
M"%FTF>OVIA$  #@Y   9              " @8)N  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ EHD(65GG40I.!   M@H  !D
M         ("!7X   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " "6B0A9_>HYN\X"  #_!0  &0              @('DA   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ):)"%GS$,^/G (  +T%
M   9              " @>F'  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ EHD(6?3U-ZRR @  ]@4  !D              ("!O(H
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "6B0A9GYY,
M$^4"  #U!@  &0              @(&EC0  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( ):)"%FO'_%#4P,  +H'   9
M  " @<&0  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MEHD(65&5R>7Z @  U@8  !D              ("!2Y0  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " "6B0A9IMEWI T"   P!   &0
M            @(%\EP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( ):)"%G.12@?AP4  '\B   9              " @<"9  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ EHD(6>R)J.@? P
MV@L  !D              ("!?I\  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " "6B0A90C7\BU0%  !3&P  &0              @('4
MH@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ):)"%F\
M@G%V\0(  +@)   9              " @5^H  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ EHD(6:$Q6P9A @  /P4  !D
M     ("!AZL  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ):)"%D*PFPWU (  +L(   9              "
M@:ZY  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ EHD(
M6=I.W45Q @  &@<  !D              ("!N;P  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " "6B0A9QBX!94$'  "-.P  &0
M        @(%AOP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( ):)"%G_*U2:Z ,  /T4   9              " @=G&  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ EHD(6<3&2NHT P  Q L
M !D              ("!^,H  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " "6B0A9J!8/04D"   P!@  &0              @(%CS@
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ):)"%EJ&@N+
MR@0  * :   9              " @>/0  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ EHD(64Z'/J;\ P  ,!L  !D
M ("!Y-4  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "6
MB0A9.BFFBUD'  "N10  &0              @($7V@  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ):)"%E#;SX\[@0  #4A   9
M          " @:?A  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#
M%     @ EHD(66&.TNE/ P  K!4   T              ( !S.8  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "6B0A9EXJ[',     3 @  "P
M    @ %&Z@  7W)E;',O+G)E;'-02P$"% ,4    " "6B0A9>]N=,0P$   (
M(   #P              @ $OZP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ EHD(6;DCVC>R 0  5!P  !H              ( !:.\  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ EHD(667AF;6W 0  91P
M !,              ( !4O$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ #< -P#X#@  .O,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>159</ContextCount>
  <ElementCount>212</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - General and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity</Role>
      <ShortName>Note 1 - General and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies</Role>
      <ShortName>Note 2 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Prepaid and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets</Role>
      <ShortName>Note 3 - Prepaid and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Real Property and Other Income, Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment</Role>
      <ShortName>Note 5 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets</Role>
      <ShortName>Note 6 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-9-commitments</Role>
      <ShortName>Note 9 - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan</Role>
      <ShortName>Note 10 - 2020 Cash Incentive Bonus Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies</Role>
      <ShortName>Note 11 - Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Warrant Dividend Distribution</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution</Role>
      <ShortName>Note 12 - Warrant Dividend Distribution</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995464 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Note 2 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995466 - Disclosure - Note 3 - Prepaid and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables</Role>
      <ShortName>Note 3 - Prepaid and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995468 - Disclosure - Note 5 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables</Role>
      <ShortName>Note 5 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995469 - Disclosure - Note 6 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables</Role>
      <ShortName>Note 6 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995470 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995471 - Disclosure - Note 12 - Warrant Dividend Distribution (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables</Role>
      <ShortName>Note 12 - Warrant Dividend Distribution (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995472 - Disclosure - Note 1 - General and Liquidity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual</Role>
      <ShortName>Note 1 - General and Liquidity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995474 - Disclosure - Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details</Role>
      <ShortName>Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details</Role>
      <ShortName>Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995476 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995478 - Disclosure - Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995479 - Disclosure - Note 5 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual</Role>
      <ShortName>Note 5 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995480 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details</Role>
      <ShortName>Note 5 - Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995481 - Disclosure - Note 6 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual</Role>
      <ShortName>Note 6 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995482 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995484 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995486 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Note 8 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual</Role>
      <ShortName>Note 8 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995488 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual</Role>
      <ShortName>Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995489 - Disclosure - Note 11 - Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual</Role>
      <ShortName>Note 11 - Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995490 - Disclosure - Note 12 - Warrant Dividend Distribution (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual</Role>
      <ShortName>Note 12 - Warrant Dividend Distribution (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sava20240630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995491 - Disclosure - Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details</Role>
      <ShortName>Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sava-20240630.xsd</File>
    <File>sava-20240630_cal.xml</File>
    <File>sava-20240630_def.xml</File>
    <File>sava-20240630_lab.xml</File>
    <File>sava-20240630_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sava20240630_10q.htm">sava20240630_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a03.jpg</File>
    <File>cab1ac4300e0img001.jpg</File>
    <File>chart_2.jpg</File>
    <File>fig5.jpg</File>
    <File>figure01.jpg</File>
    <File>figure03.jpg</File>
    <File>figure04.jpg</File>
    <File>figure4b02.jpg</File>
    <File>figure5b02.jpg</File>
    <File>slide05.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="473">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sava20240630_10q.htm": {
   "nsprefix": "sava",
   "nsuri": "http://www.cassavasciences.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "sava-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sava-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sava-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sava-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sava-20240630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sava20240630_10q.htm"
     ]
    }
   },
   "keyStandard": 177,
   "keyCustom": 35,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 11,
   "hidden": {
    "total": 51,
    "http://fasb.org/us-gaap/2024": 38,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://www.cassavasciences.com/20240630": 3
   },
   "contextCount": 159,
   "entityCount": 1,
   "segmentCount": 39,
   "elementCount": 326,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 473,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
     "longName": "004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
     "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity",
     "longName": "006 - Disclosure - Note 1 - General and Liquidity",
     "shortName": "Note 1 - General and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
     "longName": "007 - Disclosure - Note 2 - Significant Accounting Policies",
     "shortName": "Note 2 - Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets",
     "longName": "008 - Disclosure - Note 3 - Prepaid and Other Current Assets",
     "shortName": "Note 3 - Prepaid and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
     "longName": "009 - Disclosure - Note 4 - Real Property and Other Income, Expense",
     "shortName": "Note 4 - Real Property and Other Income, Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment",
     "longName": "010 - Disclosure - Note 5 - Property and Equipment",
     "shortName": "Note 5 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets",
     "longName": "011 - Disclosure - Note 6 - Intangible Assets",
     "shortName": "Note 6 - Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
     "longName": "012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes",
     "longName": "013 - Disclosure - Note 8 - Income Taxes",
     "shortName": "Note 8 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-9-commitments",
     "longName": "014 - Disclosure - Note 9 - Commitments",
     "shortName": "Note 9 - Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
     "longName": "015 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan",
     "shortName": "Note 10 - 2020 Cash Incentive Bonus Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
     "longName": "016 - Disclosure - Note 11 - Contingencies",
     "shortName": "Note 11 - Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
     "longName": "017 - Disclosure - Note 12 - Warrant Dividend Distribution",
     "shortName": "Note 12 - Warrant Dividend Distribution",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:WarrantDividendDistributionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "sava:WarrantDividendDistributionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies",
     "longName": "995464 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables",
     "longName": "995465 - Disclosure - Note 2 - Significant Accounting Policies (Tables)",
     "shortName": "Note 2 - Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables",
     "longName": "995466 - Disclosure - Note 3 - Prepaid and Other Current Assets (Tables)",
     "shortName": "Note 3 - Prepaid and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables",
     "longName": "995467 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)",
     "shortName": "Note 4 - Real Property and Other Income, Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables",
     "longName": "995468 - Disclosure - Note 5 - Property and Equipment (Tables)",
     "shortName": "Note 5 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables",
     "longName": "995469 - Disclosure - Note 6 - Intangible Assets (Tables)",
     "shortName": "Note 6 - Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
     "longName": "995470 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables",
     "longName": "995471 - Disclosure - Note 12 - Warrant Dividend Distribution (Tables)",
     "shortName": "Note 12 - Warrant Dividend Distribution (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual",
     "longName": "995472 - Disclosure - Note 1 - General and Liquidity (Details Textual)",
     "shortName": "Note 1 - General and Liquidity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
     "longName": "995473 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual)",
     "shortName": "Note 2 - Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "i_2024-01-03",
      "name": "sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-01-03",
      "name": "sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details",
     "longName": "995474 - Disclosure - Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details)",
     "shortName": "Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "longName": "995475 - Disclosure - Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "shortName": "Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "longName": "995476 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual",
     "longName": "995477 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)",
     "shortName": "Note 4 - Real Property and Other Income, Expense (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX",
      "name": "us-gaap:NetRentableArea",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX",
      "name": "us-gaap:NetRentableArea",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
     "longName": "995478 - Disclosure - Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)",
     "shortName": "Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
     "longName": "995479 - Disclosure - Note 5 - Property and Equipment (Details Textual)",
     "shortName": "Note 5 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "longName": "995480 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "shortName": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual",
     "longName": "995481 - Disclosure - Note 6 - Intangible Assets (Details Textual)",
     "shortName": "Note 6 - Intangible Assets (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "longName": "995482 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "longName": "995483 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
     "longName": "995484 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "i_2024-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
     "longName": "995485 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
     "longName": "995486 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2024-06-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual",
     "longName": "995487 - Disclosure - Note 8 - Income Taxes (Details Textual)",
     "shortName": "Note 8 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
     "longName": "995488 - Disclosure - Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "shortName": "Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual",
     "longName": "995489 - Disclosure - Note 11 - Contingencies (Details Textual)",
     "shortName": "Note 11 - Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
     "longName": "995490 - Disclosure - Note 12 - Warrant Dividend Distribution (Details Textual)",
     "shortName": "Note 12 - Warrant Dividend Distribution (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "i_2024-01-02",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
     "longName": "995491 - Disclosure - Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)",
     "shortName": "Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2024-01-02",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-01-02",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "sava:WarrantDividendDistributionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20240630_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "sava_AccruedDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "AccruedDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued development expense",
        "documentation": "Amount of accrued development expense, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r88",
      "r350"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r480",
      "r621"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r515",
      "r516",
      "r517",
      "r518",
      "r577",
      "r622"
     ]
    },
    "sava_AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derecognition of warrant liabilities upon exercise of warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from derecognition of warrant liabilities upon exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation for stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
        "negatedLabel": "Issuance of warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r57"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r240"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
        "terseLabel": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "terseLabel": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r163",
      "r169",
      "r467"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Dilutive common stock options excluded from net income (loss) per share, diluted (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r72",
      "r90",
      "r106",
      "r138",
      "r140",
      "r149",
      "r150",
      "r155",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r271",
      "r273",
      "r290",
      "r343",
      "r399",
      "r462",
      "r463",
      "r480",
      "r500",
      "r545",
      "r546",
      "r582"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r92",
      "r106",
      "r155",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r271",
      "r273",
      "r290",
      "r480",
      "r545",
      "r546",
      "r582"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_AtthemarketCommonStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "AtthemarketCommonStockOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-market Common Stock Offering [Member]",
        "documentation": "Represents the At-the-Market Common Stock Offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r86",
      "r455"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "sava_CashBonusIncentiveIncrementalAmounts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "CashBonusIncentiveIncrementalAmounts",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashBonusIncentiveIncrementalAmounts",
        "terseLabel": "Cash Bonus Incentive, Incremental Amounts",
        "documentation": "The number of incremental amounts for cash bonus incentive."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r49",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r49"
     ]
    },
    "sava_CashIncentiveBonusAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "CashIncentiveBonusAward",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAward",
        "terseLabel": "Cash Incentive Bonus Award",
        "documentation": "Amount of cash incentive bonus award."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusAwardExceedsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "CashIncentiveBonusAwardExceedsMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAwardExceedsMaximum",
        "terseLabel": "Cash Incentive Bonus Award, Exceeds Maximum",
        "documentation": "Amount of cash incentive bonus award if the maximum milestone is exceeded."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "CashIncentiveBonusPlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Member]",
        "documentation": "Represents the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "CashIncentiveBonusPlanTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Text Block]",
        "documentation": "The entire disclosure for the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "sava_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)",
        "negatedTerseLabel": "Warrants exercised, shares (in shares)",
        "documentation": "Represents the warrants or rights exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant",
        "terseLabel": "Class of Warrant or Right, Fair Value of Common Stock Warrants per Warrant (in dollars per share)",
        "documentation": "Represents the fair value of common stock warrants per warrant."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Class Of Warrant Or Right Issued During Period (in shares)",
        "documentation": "The number of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "periodStartLabel": "Balance, shares (in shares)",
        "periodEndLabel": "Balance, shares (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantOrRightRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ClassOfWarrantOrRightRedemptionPricePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightRedemptionPricePerShare",
        "terseLabel": "Class of Warrant or Right, Redemption Price per Share (in dollars per share)",
        "documentation": "Represents the redemption price per share of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed",
        "negatedTerseLabel": "Redemption of common stock warrants (in shares)",
        "documentation": "Represents the warrants redeemed common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CommissionPercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "CommissionPercentageOfGrossProceeds",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CommissionPercentageOfGrossProceeds",
        "terseLabel": "Commission Percentage of Gross Proceeds",
        "documentation": "Represents the percentage of commission required to be paid from gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Notes 9, 10 and 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r68",
      "r344",
      "r386"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r439"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r515",
      "r516",
      "r518",
      "r577",
      "r620",
      "r622"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r387"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r387",
      "r405",
      "r622",
      "r623"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 120,000,000 shares authorized; 47,976,166 and 42,236,919 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r346",
      "r480"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositContractsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositContractsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract research organization and other deposits",
        "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24"
     ]
    },
    "sava_DerecognitionOfWarrantLiabilitiesThroughExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "DerecognitionOfWarrantLiabilitiesThroughExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derecognition of warrant liabilities upon exercise of warrants",
        "label": "sava_DerecognitionOfWarrantLiabilitiesThroughExercises",
        "documentation": "Represents the cash flow effect of derecognition of warrant liabilities through exercises."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30",
      "r31",
      "r32",
      "r33",
      "r108",
      "r122"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DilutiveSecurities",
        "terseLabel": "Adjustment for change in fair value of warrant liabilities",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20240630/role/statement-note-9-commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) per share, basic (in dollars per share)",
        "terseLabel": "Net income (loss) per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r123",
      "r125",
      "r132",
      "r133",
      "r134",
      "r137",
      "r267",
      "r270",
      "r282",
      "r283",
      "r341",
      "r354",
      "r458"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) per share, diluted (in dollars per share)",
        "terseLabel": "Net income (loss) per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r125",
      "r132",
      "r133",
      "r134",
      "r137",
      "r267",
      "r270",
      "r282",
      "r283",
      "r341",
      "r354",
      "r458"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r136"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82",
      "r96",
      "r97",
      "r98",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r122",
      "r139",
      "r156",
      "r157",
      "r175",
      "r200",
      "r257",
      "r258",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r353",
      "r360",
      "r361",
      "r362",
      "r373",
      "r425"
     ]
    },
    "sava_EquityOfferingMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "EquityOfferingMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingMaximumAmount",
        "terseLabel": "Equity Offering, Maximum Amount",
        "documentation": "The maximum amount to be issued in the equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "sava_EquityOfferingPercentageOfCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "EquityOfferingPercentageOfCommission",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingPercentageOfCommission",
        "terseLabel": "Equity Offering, Percentage of Commission",
        "documentation": "Percentage of commission in equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ExerciseOfWarrantsResultingInDecreaseInWarrantLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ExerciseOfWarrantsResultingInDecreaseInWarrantLiability",
        "negatedTerseLabel": "Warrants exercised, liability",
        "documentation": "Amount of decrease in warrant liability from exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain from change in fair value of warrant liabilities",
        "negatedLabel": "gain from change in fair value of warrant liabilities, liability",
        "negatedTerseLabel": "gain from change in fair value of warrant liabilities, liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r476"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r160",
      "r168",
      "r467"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r452",
      "r467"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
        "terseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r452",
      "r467"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r452",
      "r467"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r309",
      "r310",
      "r452"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r168",
      "r310",
      "r467"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r452"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsNet",
        "totalLabel": "Total amortization",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r537"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r409"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "sava_GrossProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "GrossProceedsFromIssuanceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_GrossProceedsFromIssuanceOfWarrants",
        "terseLabel": "Gross Proceeds From Issuance of Warrants",
        "documentation": "Gross proceeds received from the issuance and sale of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r287",
      "r288",
      "r289",
      "r357",
      "r359",
      "r410",
      "r452",
      "r475",
      "r592"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r287",
      "r288",
      "r289",
      "r357",
      "r359",
      "r410",
      "r452",
      "r475",
      "r592"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r259",
      "r261",
      "r262",
      "r263",
      "r372",
      "r474"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "terseLabel": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r81",
      "r121",
      "r122",
      "r138",
      "r141",
      "r150",
      "r247",
      "r248",
      "r260",
      "r355",
      "r474"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r245",
      "r246",
      "r252",
      "r253",
      "r254",
      "r256",
      "r369"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sava_IncreaseDecreaseInDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "IncreaseDecreaseInDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInDevelopmentExpense",
        "terseLabel": "Accrued development expense",
        "documentation": "Amount of increase (decrease) in development expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities",
        "terseLabel": "Accrued compensation and benefits",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
        "negatedLabel": "Operating lease right-of-use assets and liabilities",
        "documentation": "Amount of increase (decrease) in operating lease right of use assets and liabilities, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r506"
     ]
    },
    "sava_InsuranceSettlementsMaximumRecoveryLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "InsuranceSettlementsMaximumRecoveryLimit",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_InsuranceSettlementsMaximumRecoveryLimit",
        "terseLabel": "Insurance Settlements, Maximum Recovery Limit",
        "documentation": "Represents the maximum amount of monetary recovery for insurance policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceSettlementsReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance recoveries",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r173",
      "r174",
      "r451",
      "r452"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r309",
      "r457",
      "r530"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r537",
      "r539"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r512",
      "r523"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "sava_IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants resulting in recognition of warrant liabilities",
        "documentation": "Amount of issuance of warrants resulting in recognition of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r300"
     ]
    },
    "us-gaap_LeasesAcquiredInPlaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAcquiredInPlaceMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Acquired-in-Place [Member]",
        "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r540",
      "r541"
     ]
    },
    "sava_LeasesAndCommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "LeasesAndCommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-9-commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases And Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure regarding leases and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sava_LeasingCommissionsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "LeasingCommissionsAndOtherMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasing Commissions and Other [Member]",
        "documentation": "Represents leasing commissions and other."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r69",
      "r348",
      "r480",
      "r514",
      "r528",
      "r581"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r85",
      "r106",
      "r155",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r272",
      "r273",
      "r274",
      "r290",
      "r480",
      "r545",
      "r582",
      "r583"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r241"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LossContingencyNewClaimsFiledNumber",
        "terseLabel": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r186",
      "r202",
      "r241",
      "r286",
      "r304",
      "r356",
      "r358",
      "r365",
      "r378",
      "r379",
      "r428",
      "r430",
      "r432",
      "r433",
      "r435",
      "r449",
      "r450",
      "r465",
      "r468",
      "r470",
      "r476",
      "r477",
      "r478",
      "r479",
      "r489",
      "r547",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ]
    },
    "us-gaap_MeasurementInputConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputConversionPriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Conversion Price [Member]",
        "documentation": "Measurement input using price per share at which convertible share can be converted into common stock."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r476"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r476"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r186",
      "r202",
      "r241",
      "r286",
      "r304",
      "r356",
      "r358",
      "r365",
      "r378",
      "r379",
      "r428",
      "r430",
      "r432",
      "r433",
      "r435",
      "r449",
      "r450",
      "r465",
      "r468",
      "r470",
      "r476",
      "r477",
      "r478",
      "r489",
      "r547",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r51",
      "r70",
      "r83",
      "r93",
      "r94",
      "r98",
      "r106",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r130",
      "r155",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r267",
      "r270",
      "r283",
      "r290",
      "r352",
      "r407",
      "r423",
      "r424",
      "r499",
      "r545"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
        "totalLabel": "Adjusted numerator, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r131",
      "r134"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetRentableArea",
        "terseLabel": "Net Rentable Area (Square Foot)",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "sava_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "sava_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r522"
     ]
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r625"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r459",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r66",
      "r366",
      "r367"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherAssetsCurrent",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r480"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r480"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherNonoperatingExpense",
        "negatedLabel": "Property operating expenses",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease revenue",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "totalLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "sava_PaymentsForCashIncentiveBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "PaymentsForCashIncentiveBonus",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PaymentsForCashIncentiveBonus",
        "terseLabel": "Payments for Cash Incentive Bonus",
        "documentation": "Amount of payments for cash incentive bonus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "sava_PaymentsOfWarrantExerciseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "PaymentsOfWarrantExerciseCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PaymentsOfWarrantExerciseCosts",
        "terseLabel": "Payments of Warrant Exercise Costs",
        "documentation": "Represents the amount of warrant exercise costs during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "sava_PercentageOfOccupancy": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "PercentageOfOccupancy",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageOfOccupancy",
        "terseLabel": "Percentage of Occupancy",
        "documentation": "Percentage of occupancy."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
        "terseLabel": "Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment",
        "documentation": "the percentage of valuation milestone cash bonus award subject to approval and adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
        "terseLabel": "Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)",
        "documentation": "The minimum number of days valuation milestone must be achieved and maintained in performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PerformancePlanValuationMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "PerformancePlanValuationMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanValuationMilestoneAmount",
        "terseLabel": "Performance Plan, Valuation Milestone Amount",
        "documentation": "Amount of valuation milestone for performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PreferredStockDividendsAndOtherAdjustments",
        "negatedLabel": "Adjustment for change in fair value of warrant liabilities",
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r509",
      "r520"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r198"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r387"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r198"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r387",
      "r405",
      "r622",
      "r623"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r345",
      "r480"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "sava_PrepaidExpensesAndOtherCurrentAssetsTextBock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Text Bock]",
        "documentation": "The entire disclosure of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r466",
      "r529"
     ]
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities",
        "terseLabel": "Proceeds from Insurance Settlement, Operating Activities",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r453"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfWarrants",
        "terseLabel": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock upon exercise of stock options",
        "terseLabel": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of common stock warrants, net of exercise costs",
        "terseLabel": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ProceedsFromWarrantsExercisedThatObligatedToPayCommission",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission",
        "terseLabel": "Proceeds From Warrants Exercised That Obligated to Pay Commission",
        "documentation": "Dollar amount required to be paid for commission from warrants exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r300"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r76",
      "r79",
      "r80"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r87",
      "r351"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r300",
      "r342",
      "r351",
      "r480"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r76",
      "r79",
      "r349"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r300"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r186",
      "r201",
      "r202",
      "r231",
      "r232",
      "r233",
      "r241",
      "r286",
      "r302",
      "r303",
      "r304",
      "r356",
      "r358",
      "r365",
      "r378",
      "r379",
      "r428",
      "r430",
      "r432",
      "r433",
      "r435",
      "r449",
      "r450",
      "r465",
      "r468",
      "r470",
      "r476",
      "r477",
      "r478",
      "r479",
      "r489",
      "r493",
      "r542",
      "r547",
      "r579",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r186",
      "r201",
      "r202",
      "r231",
      "r232",
      "r233",
      "r241",
      "r286",
      "r302",
      "r303",
      "r304",
      "r356",
      "r358",
      "r365",
      "r378",
      "r379",
      "r428",
      "r430",
      "r432",
      "r433",
      "r435",
      "r449",
      "r450",
      "r465",
      "r468",
      "r470",
      "r476",
      "r477",
      "r478",
      "r479",
      "r489",
      "r493",
      "r542",
      "r547",
      "r579",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ]
    },
    "us-gaap_RealEstateOwnedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealEstateOwnedTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate Owned [Text Block]",
        "documentation": "The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "sava_RedemptionPercentageOfWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "RedemptionPercentageOfWarrants",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_RedemptionPercentageOfWarrants",
        "terseLabel": "Redemption Percentage of Warrants",
        "documentation": "The Percent of the cost for redemption of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r452",
      "r462",
      "r590"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RetainedEarningsAccumulatedDeficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r57",
      "r347",
      "r363",
      "r364",
      "r371",
      "r388",
      "r480"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r122",
      "r156",
      "r157",
      "r175",
      "r257",
      "r258",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r275",
      "r277",
      "r278",
      "r280",
      "r281",
      "r297",
      "r298",
      "r360",
      "r362",
      "r373",
      "r622"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r536"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r538"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r375",
      "r376",
      "r377",
      "r429",
      "r431",
      "r434",
      "r436",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r454",
      "r469",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r493",
      "r548",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r460",
      "r461",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
        "negatedLabel": "Performance awards exercised (in shares)",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
        "negatedLabel": "Performance awards forfeited/canceled (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance awards granted (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
        "periodStartLabel": "Outstanding, performance awards (in shares)",
        "periodEndLabel": "Outstanding, performance awards (in shares)",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Options forfeited/canceled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodStartLabel": "Outstanding, options (in shares)",
        "periodEndLabel": "Outstanding, options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r209",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "sava_ShareholderDerivativeActionsDelawareCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ShareholderDerivativeActionsDelawareCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Delaware Court [Member]",
        "documentation": "Represents shareholder derivative actions in Delaware court."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ShareholderDerivativeActionsMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions [Member]",
        "documentation": "Represents shareholder derivative actions."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsTexasCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ShareholderDerivativeActionsTexasCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas Court [Member]",
        "documentation": "Represents shareholder derivative actions in Texas Court"
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsTexasStateCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ShareholderDerivativeActionsTexasStateCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas State Court Member",
        "documentation": "Represents shareholder derivative actions in Texas State Court."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r105"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r42",
      "r43",
      "r82",
      "r96",
      "r97",
      "r98",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r122",
      "r139",
      "r156",
      "r157",
      "r175",
      "r200",
      "r257",
      "r258",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r353",
      "r360",
      "r361",
      "r362",
      "r373",
      "r425"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r375",
      "r376",
      "r377",
      "r429",
      "r431",
      "r434",
      "r436",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r454",
      "r469",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r493",
      "r548",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r139",
      "r298",
      "r308",
      "r368",
      "r374",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r494"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity",
      "http://www.cassavasciences.com/20240630/role/statement-note-1-general-and-liquidity-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20240630/role/statement-note-10-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes",
      "http://www.cassavasciences.com/20240630/role/statement-note-8-income-taxes-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-9-commitments",
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r139",
      "r154",
      "r298",
      "r308",
      "r368",
      "r374",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r494"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r39",
      "r57",
      "r370",
      "r425",
      "r437"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r39",
      "r57",
      "r215"
     ]
    },
    "sava_StockIssuedDuringPeriodSharesWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercises",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of warrants (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Warrant Exercises (in shares)",
        "documentation": "Number of shares of stock issued attributable to warrant exercises."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r42",
      "r43",
      "r57"
     ]
    },
    "sava_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of warrants",
        "documentation": "Value of shares of stock issued attributable to exercises of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "sava_StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Net Settled in Satisfaction of the Exercise Price [Member]",
        "documentation": "Represents stock options were net settled in satisfaction of the exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r42",
      "r43",
      "r53",
      "r389",
      "r405",
      "r426",
      "r427",
      "r480",
      "r500",
      "r514",
      "r528",
      "r581",
      "r622"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "TX",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "sava_The2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "The2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20240630/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2018 Equity Incentive Plan [Member]",
        "documentation": "Represents the 2018 Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r74",
      "r75",
      "r77",
      "r78"
     ]
    },
    "sava_ViolationsOfFederalSecuritiesLawsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "ViolationsOfFederalSecuritiesLawsMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies",
      "http://www.cassavasciences.com/20240630/role/statement-note-11-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Violations of Federal Securities Laws [Member]",
        "documentation": "Represents the violations of federal securities laws."
       }
      }
     },
     "auth_ref": []
    },
    "sava_WarrantDividendDistributionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "WarrantDividendDistributionTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Dividend Distribution [Text Block]",
        "documentation": "The entire disclosure of warrant dividend distribution."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r495",
      "r496",
      "r497",
      "r498"
     ]
    },
    "sava_WarrantRedemptionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "WarrantRedemptionPrice",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_WarrantRedemptionPrice",
        "terseLabel": "Warrant Redemption Price (in dollars per share)",
        "documentation": "Price of warrants if they are redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding",
        "periodStartLabel": "Balance, liability",
        "periodEndLabel": "Balance, liability",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580"
     ]
    },
    "sava_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
      "http://www.cassavasciences.com/20240630/role/statement-note-12-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock [Member]",
        "documentation": "Represents the warrants used to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
        "terseLabel": "Dilutive effect of common stock warrants (in shares)",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net income (loss) per share, diluted (in shares)",
        "totalLabel": "Weighted average dilutive common shares (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r134"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20240630/role/statement-condensed-consolidated-statements-of-operations-unaudited",
      "http://www.cassavasciences.com/20240630/role/statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net income (loss) per share, basic (in shares)",
        "terseLabel": "Weighted average common shares outstanding (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r134"
     ]
    },
    "sava_statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-12-warrant-dividend-distribution-changes-in-warrants-outstanding-and-warrant-liability-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-12-warrant-dividend-distribution-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-12-warrant-dividend-distribution-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Warrant Dividend Distribution"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-2-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-2-significant-accounting-policies-quantitative-information-of-warrants-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Significant Accounting Policies - Quantitative Information of Warrants (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-2-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-and-other-current-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-3-prepaid-and-other-current-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-4-real-property-and-other-income-expense-components-of-other-income-net-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-4-real-property-and-other-income-expense-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-4-real-property-and-other-income-expense-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property and Other Income, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-5-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-5-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-6-intangible-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20240630",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21B"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483081/340-30-45-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483054/340-30-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001437749-24-025611-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-025611-xbrl.zip
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MKK2GJ=?EZIS*NFR!-K>#:AA+X1RB4X7X9'D.P5K?&"=/C?Y[O3[.VCB/:KW
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M1=E-0C2U*RUM:W3E)@L#V#[%6;S )57?.'U%JJ9$KC_37M7_\"%3?NY!L&N
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MD#B#,;#23M+Z/B-T:4.*BP^VW\QK-9(?O_M0$YC7(\JRQ*8;*$Y(W4LAP+O
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M%:^VX_1?5=P5@]Y?]?8\-41&G=K?M#*)H@.8I7VEN8TG8?R^;8//H6W3OF(
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M.N $5WA+H*[@.B],851,24D@_D$6P8$.*/%;;J(S1"Y)0VO:2A07%G'ML:?
M0&ZG].C,,ELNHG2%0")\32;9N_6#Q^&GW"$M@T0Y\-I/020=H-L#S)WPKRK]
M!![^>2'-OPM+!R0^ (+0B3"#><; H=&\JE<6:1Q 1+)"./*%EOQ2*3.UW#.R
M%+[P 5F]V3:,.$-QI(V?120HKV,4J72 T>$PM>G]7=(W?L:/5!Z-_@+&<1)@
MHC1UBE%88**YL6/@QISH;G1_YC[XCLYR">P!\A2C&BV0H,+>.!A[7OT'VJ&L
M?HBZ=82RBB', @D/9<(H3IA3R89!(JQA[<4SZ 6#'L0(8K>0@Z8@4ASXE*8;
M13O/=K6&$K6=UHPFN4N ZPTTU\3?HU>J+M0:S*/%P=A#.D"$<FS>-*(94'$?
M+7DK=&LF;I)F5E8R *2QZ56-]#*PKTN 0SZOTP'VC4")O6UNIZPN,^,-I=K#
M+IT=V9(=Y\4ED><@'NYD3;TJ?LBP)X8 -F3M9;>NE/PI?S"#A9"46!;FRTW)
M.NT9"L-;+WS:N4@,^ A-9OO:T%CZR(J^079&N!@+_6=,--".WZ(!'7 4$+F>
MTS%EK!_:"'/%I"-2NGTO='_37[23IP,VOBFAFH6^D&4C#S;;D01CY!2F8Q4X
M1;OFJ\?[=D'3\\43MYY7* U"S88!0P?DE^3X[K<I?@S53"Z\.[0\_L.P_WH5
M.,Q09CCO$"D<BV4E'R^]>=P<22H8!*<98 S,ZGVBY=(M\RO'Y<@E<ZJI[Z T
MC4K5X1^81.\"\<_;VWE70&:YR/=XB=R'@D(KJ_='KW*D;3^(VWD$=["T7UZ+
M?;<;.-_X*WF<KM]1[ZQ^_K^$^!;(%<Z$ *1^+9IH7OP,16@S],Q"LP1LL)F7
MU.Z*F9ZV=/:)EOI^9FE6IAF[CUXP0QV;8&AF=#BZ8C[[,+F=ZK'RL&)PI?(W
M[F_P*HX#01K3-M#I$)<5QY\:>0"=>>-!\:)][ET=M]!C3])9KCG(#50PZJP+
M/2K2JO4H>__-I!RD9V/+X0"%[=XX8%6,RB%MZM0.HQ:Q*Z&7K]R_I9)%[ANM
MOKV+RFR46!2^V25PSZ?>BEK]T?D\:WGK^1>:V,=H#MHI7Q_< #*YU-%DTI"]
M[D66+9$JY-G]\0L*2=$E"Y#Z%N:K+G\FK'3P<AY))HOV+#$T?X=6%[.H_"+5
M)MP#L=CY^X_2SY95AMNQ(P=.0Q \!9P*/PIY5$CK1\HK4'(:8?[2W>.YWL?1
M4VMZ)K.22ZBCL+GIL#>[QL,T40=3'EZ#-/FQL^\VHROMD=:/,JIV-%^#Q'X%
MU.0T#GOK6&GPK-RXSR+S6?B.R.Z.$IC3[B#IO5/&X;R,ELSC)M@&.],M;&/[
MM4EN_;D +6?>U4MYF((F=<V]*C5%8&9>UJ:0:;/OQ>'_P%9*D<1M]@W_#-.-
M-;(H@\,8\8;C&)S##;&#RHMH024SG$W>%MH5/B7,4&FD"HA^9Z-2OLV! . P
MZ)=O#5W2Y7K(+$RT6! /IBD[!.L1$:$[< [S'0,?5_Y/=( WC4&26NZCN C=
M%,Y2MR @=PG%F(#NGK](V.IW<?%6$S>!;SBKS%S)M;\N>A_ZI:S\/B?KRZ2A
MJD"E_SM$AGM[<R.,#A#G)(O3 5/&S73 &+#3>(?[S_9: @*/_U<=<Z#K-8=P
M8O"&LV',/TL$^42""?)27$<$-0:5 \[J>3Y6[FY#GR&]J=D+"_,27)B##3_E
MJF/8@'>3ZNH/LOBAVLN5SF,YTDZ&[H&CSENJR$YTV5 K'2 H>D8'BPPJ5=SM
M2N2"' *X5T"_@O^4:(.@RS&)S7P.>]>F^J:&Y*3H@(^+C#'(+U6NLV;+(TJH
M'W;"XW9J191Q#[B3V*^C]#!])HZ!O28@82([17"1K.J,$&W-(Q4]>"D4B'S\
M>R%\SDY^!72%X00=0/QXPQLC%&_<AE0 <ZC@*["JZ:HZ]\H8%IH+YSY)241+
M NU>$U<ZA,0)%4Y#%$,C.F!D#-%;HD,[TT,4#V60^9/(KCGM(?M#M/+\8_=?
MN<=IQK?AK<)@9_90)#@4IAI8AIJ#;#A_(Y*T:D]3;3_58DXL19'<WP5>NG28
ML0.*3W._U!==I%V/+WR8(WDX?8HF_KT/-@@A&"#"PJCLW3K%%NV]^>,;N;/,
ME>&"N[GH#8:+.,Y'\GIIZ<OG')??ZIG5[L&FLB0$[)Y&FV7K=CPRO/VSF48'
MK*P=C- !QG7PX,@B(!E&!Z3(T0'A.VNK[[^;!4+ 15OH9EG-;10YD#8)%VZ$
M$TL'MW%"_BOMF+,SJQSFZ<J]9CL_ED/L/B39\,&*^]>0>Y([[+0SB]222C '
ME'N2PH23X;.$^!Y"SNH7SI@[^;B)[2NXN+GP;67\YN/B,/N.6?2E^P LB)2U
M0 >$JGH67MJKPB+9\/L19T/LFT<_UB;:'']_><7P9>BS6ZM)H"H"@L*E2#OY
MX2F1W3@!I]BJQ-L*/EN<38;LN62C[2K'Q(0VPTM5(YJ1$C^9S8F\[,M*KA++
MC\0W]ANMXQTW[2O@HCL]ODVM:<YOC1:*ATZ75X[Y2?XVDG.JDURHE7-)=WY@
M6\5U6GME'%Z#Z-BPQ^:MDR\-A>XRCWC'V%N,-*KP9,9%B(UV[E)X$+(G%CVN
MY;Q6 KPV Y9/-.#866'#0&Z8(!YV?E+5-(>D)R5J/%(E;#7A_"U^3^6U5&-\
M8;ZW2?4L6OIVW&N&AA&BIOXZU/DZY<[P+G!J9:]Z9/<,[Z.W+$RH0?,1VT0^
MOI27UC8?+$]HC4;GBT\TDPCH]8"%*D)'B#R"RVD4?]B9'"'M7>!=DT0V2AHK
MJ#$3?^#V^C93'_""R=/@!(ACXO(W:*",XQU\C;X&\ADZ&RY/G RK&SJU:,(I
M'[245(E7WS8J$(E_,Q&C)C=<5)3]PA_S1GY#9N\' 1Y* 1-%<5+?KR1;2Q+5
M$G\6<.WQ[*E$O]S[!!;C/J>W<&7N;1S8TG3LK805QC+R>R,WP4V=X-.AS^U;
M/N":/=%H.X&9YK2TY+^MXV4;>:N5'-Z0MB'\+6-W\EZ.CNOF?),H3O/_:58?
M>5QXMOKK9=X*U(?0<)?T(5>^M"YGVNEA6<LVYXK^OD4^*@/J3699$V$>GS$C
M>:.LS.8T[D8Y/ILZ+YQH^Z,]-EK-&1\9>^_W X8A/NAF69I*1H?G;9;D"5]N
M$JL:'?RQ7PZ[W.^!\60WF@UH,V_=KP^D%$-+L) 9G4[@Z=V089J8@^+IWJ.I
MM;BM)=>6#3+J*W4TY9 =B^H"GJ$8CO(LWAV7VKS5=X_O5-:M'SUC E^)IJ\K
M,8*.+O9%CM7^(47N2X.I92H+N\RK$#!4@_J:5[_)1:<EI:H+$< _GS32>\^6
M#J@X_SV03=U7I#N\'(&5C\JN![\LM-9WA.[:-VW4PA5&"GVU487[!8K+-8B^
MNZNOE>,P6WF2F]Q;)J_)IM#;)/;\[AS*O6%IF9+))?)#JW*.T1?N6VA8K?PF
MA@7L(',::EYIE(6/TW*/3C4#^RB37=3@K),5[]Q=(0AD6?1?<T%=V@J@E/H>
MU)Q:YCL9X->IEZS5NJU.F<"H"'=R=:6;*@V)C"VY+$8>VBQW_EOA6J[J#(7M
MW%]-!U2CUD,'D*E=_B.L;"OM*>&H_*(ES ST"O4SVC8=X^L[8SRSRW!Y\(=_
MU]Y_N/[7Z=7_V2NK-FR :>S1NX?,@_ :%(73D\'L-^:P/ CKSX@'1-W& #G,
M6?,NT.CS $DZ8.C^]BMC]%');0P6LG&3V$ [&4=4F&R!<WF14;S0J_6I+C&S
M*MFQ?$/$:6V,5VP)$WEQ FTK'I-MU^VT!+M!.4>8[-X,FZ3Q$E\B[$M^^,>O
MITQC/8.GQG9-A.\(!4-44FQ!$ZC)ZX9[WI/3%F )Z2+B+MAV <)S*?D)DLW]
M$K!TR=-_)&%_%;SR40U[J:AJS+K!JARQODM6)RGNI9&\G7&H8VLFTQ,)ODH.
M@V(U4$^A@G$A'V;"E^6&[!>+D90 $IG,!GW&\)T@J&X]Z2-!T6BL\2YA'9Q>
MX%C.>=/B;H9-?3B\)/IEHL;20MJ3%#*"=FJ1X54>_(J5QE955<6#V4FX>;7)
M^N,=+5^^ >62UMV7-3&(#P&QNTK/H"NF^,<DLO)<O<Z@#"IW.<T%J_JBEGTW
M]<U:H,^UI&V=_7>0+=.@"2FX?)WUH14$KWQ5OL[TU@IH,4=9PL0@$94-YA7^
M(Z%X$,<B#XH$#$RJWK##!2I;J&D,SN]-/ V-M&4K(0D0]"/!93P)^7-:^22-
M0S=VO#;T"W;6'#!7';<MGLO,O>.B04Q*$#V8C$HET" ?VA/X=74JIGZE ?!;
MMU/:>YJDCSQNW/V7A"C 66B"#7$?E[P^[">,B)&KDQ^0T!OVP"@RD2O8P">X
M?\)/T@%.^LP4JQ#1LC&3>>KG5!7D7"][YM 9$LQX;F[5'<]P<^ZLBF=[]D?4
M6;,#)=MAUVBMS8)$KR$_[ &RW3]C\6)XA,)@][@RBG(L\@"UWK\OL5]^R'#.
MS9V:CCG4J=T#I!8U)^Y9_3,N&LJ86N]$<"-_G8,BH)P28&V._5(_H/G!B9EN
M#"_83H+GC,>(/@?IY<U*;:T4.9$1]@^@:(7)2LIY:IDJD*AW"\NKF^VD/S&Q
M\V8VD)NV!D-J[W@,RK;@G*BF'/[RZ/A/2W#Q"BNTZ&!_+5@X-&>W6*W(@.8/
MVSHHF4S?^^G?Q#6DI+^4MI=S[BA8^W!QB?G/:+!I'[+FF@4=X(R84O[M1=]B
MTSU$]V]H[EUAAKWPR6=X]SQJHL7;OD5R&5A88.<A\]@_[<OZ_X^H_@>N8XK5
M47[\,8M:HB^,QT/O,HUQS I0&-,A* 3>RCE8AS,#78$RU4*82;@N_1JM;'.M
M/>> 'M-EC&N[R(.\4DQM]ZC8Y"JWINIS.L"G]$;:#DI%MI= .K3N.]LD,@!:
MW8&/@OJ";I&5L*KPR2W_QI+56VI/#=5L;C6)(>=K=-7T!R#?F&@L5C=)Z2!>
MVM>)+9)1UX1L%-]N:@.\0O,%]:C594#$$+"1R<:6,S9O)WYP2\EEXIY=G-B1
M\;@:R:.R)T'I:\L8TA5>"B=+"[@F.=0VT)#C(VEDXF@*/%Q*5,2#8]_0;G$
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M7MHIE'T@=C.2#A!I5 .&J8(9TN/,#X'E5#>W3PX"'2FY<;F0ZE2NY+B[DJT
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MLVJKNP14V^;T]EX9:01VW8+DW (^@JJ"!-/$D6WEWW10^+<*-3X\2'NH:H0
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MSAFRB@FI^6E@P0J/<F9VQOOK_=,V=AUB<;Z:.I)S<92:/Y!W[GF8&C6>)FI
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M[SN@T"-X%40L>4*OSXL[;D8F1=7NIB, 8 GCPOQ<GYRT()HGK4;.LR0)V@5
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M?RI!P<3$Q,'&(</%)>-Y1O6,Y[_\W+<#!(]0-!_8HZ(\!QX0H* 2H-QW [0
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M[V@G%K13C,W^>YPDU&TU6B&W!/SI>G4VLM3M'L"UGEC8/B^M.AM<XMB44,_
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M8#;_IX#!4#;0_ET38C;"HC99.,O:K@)182[1>$H\/X8B(SR,=/ -';HY7MF
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MZ-]NB*O];^C[9O.LUH5'[MR',\''BL6R#^/>6J3RHT=R$%>M1[7S.H6=E$3
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M,,M1=J,($]KGL(BT15;J$:;*ZU*W>5G%C#K)+>]OZ(X4UG?LU]]DI?T[&O?
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M,^_=A"B<1(>E3"#^7G9 G)*+GW)[QS2\45-DBT<(2S49=,X/BY<B9$0S%ZU
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MZ"&\W(.XLGQ/5;@WV/\;:HW@XT&A34MO/8<+SKZW]>*-QTC@V_9PI1"R'9H
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ML5*9GD41#<>E#:IIML$"&7/>*6,/DNU'<['/_4@L0;+K4O"C2T6QB8-Y@+)
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ME^3A[6EON&$035 Z=;<NFB$1*WFXI9>UX&PN?^8Y9G9!^3F;F#U\6I8F))
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MY U]K-IV7'<Q%^F50FEN6Y643WG21?)M;%:DMRNV_Z!EF8':V,!YDTK'KS!
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MP?:JTUR3555 DXVZ[+G2"1&YR>$*X=J!WVKG"$UYACUU1\YAL]WCO1",\/+
M@Q<OZE55^A=;QLD\M4VG$6 GB5%8I*RM_3>N3.\6BOS3XWG:0YUU;PRQY'Q\
M%)Y?58+5Z;;VE*LK_*"XLR5!E*G!GI3=EVIT88?Y>>S:K&'Z'N8OGDY=0Y95
M@N5<@FR$5^@-*XG/F/-E6*_I=+L09WI.X,/T,A&^CNZWC2+R+LW;\FD"JCM^
M]@+<?95Y+WM;?Z!+RK[[,,FOF("HBDO6\I7::ACH_H"6SG_XI#.SP@X9+(ZU
M<>7.^N=PG=K7%+^5O07R%R&POWB1EGX>JSO.F],IPX>81Q;1!WB?<E_J)TER
MU!YZF?F&ECAEBU7!"@0V#/3U<7%T?H3CCJ NS<P5C^SR4Q-%4$[Y6^T3@O(*
M1QJ:%XZ3)J8J_KB##)&/-5_SC0:/#O@:D;'5%Y3UL.&EGPM@QJGV%!GHZ^0:
MT\(]OV<#)0Z*14Z^XAEAPWOW@%<1&2:V2CK), T)CPNJK)?AU39-A*.U*?;9
MCGE,AARVQX3I($D\3VEQ:,EA=+OFR]CJOWAU:^B5!B2]D5IF=%*6+;]24N9Z
M^/<)XWJN<KC*&L1,6+??<(L4F+G$S ,Z8?[%$1I;1A/9*&,R0IEP@/!>E >:
M&'+9:R+DS^/Q6)%E)2XFCL\4$4[91;)NG,,@QL=>IWSAW5>I^3Q!'83EB(8]
M&\LFTA5"]J2R>-2^2-C_6F?ZOY8H<N,#=12(RECIC?^_5^%W_+_E['3_/Y60
M_^/\>Y3E[Z__ U!+ P04    " "6B0A9><]B($OH  #Y%@$ "P   &-H87)T
M7S(N:G!G[+MI4%-9V"X:1$5 C,P*0E1 5(2TRJ 8$A4!E<:(*%$0T@X( 2&-
M@$0(B<H,AK322 LM$1!1&0(R*<9$2(!6U,@8"4I(HB+SW@IA2Z:3ON>K[_ZX
MY\>YY]2M6W7OMU-O5:KVRLI^W_6LYWV>VGNK/ZA'8:L/>Q_RAFEI:<%^TWQ@
M:C%LFQ>)< $&\_.#;87!8"LTY[;#EFB^Z6G"0A,PGTMA83%Q$<1XF'H8YOGO
M;_^WCG\G^=^=0TO]$F:X0FM@R:BVUD;8$D,M;4,M-0^&@,&TEOWW ;#_.+26
M:"]=MEQGA:Z>OF9 TVK8$BUM[25+M9<M6[I4<S9%<QZVU'"9T8;M^Y8;^Y_1
MV1AKLN/:S=(5-OOKVTR/]0"V.\]>NJZK9V:^9JV%W2;[S5NV.KNXNNW:[>YY
MP,O;Y^"APP''3P3B3IX*.G<^[$)X!"$R+C[A<B+I2E)J6GI&9E9VSJW\/PMN
M%_YUIZBL_'[%@\J'CQX_:6AL:FYY^JRUG<OKZ.SZY]7KWK[^@4'!AR&A6"+]
M_.7KV+?Q"?#[C[EYV0+T<_'?O+1@VO^9^O\P+T--7DN6+M5>JO-O7EI+$O\=
M8+ATV8;MRXWV^>N<B37>N./:"I/]-TOKVW1M=AX#3,]>ZM$SLW46VX'_IO9_
M9/8_E]CU_Z7,_C.Q_S,O(6REMI9F\;0-81B82K6Y+ ?V_XNHU9<4\OQTQ/9<
MJC7Y*.C[*]L*2A8C5Y.Z@LS:@B;\,-S%D'>5L<N>[-83X/1C?FL.W$I#U2]/
M".EDZRK_1&]3?1(UXC(HII3W0J'J+5L7V@)Z2Q!&GD#Z'#PKD6/B3$Q?3&NH
MS:]B9/\"W<8;B$CL[Z\<Y^W>,UXV!^$*+MU\6Q/4_74?3&?\KBE$+Z.V'6)O
M$5';=JIVJ@;-F4 .(@^M!?KPE.;<$5,S00\I::*O'6&*:"O:5CBRIK!#!/PQ
M<II?AA3&O*UMN%AH?ECPN]>R.OFN&6HT=;A2.M:.S&0TS-R1[X'P+ZV1T#BX
M1XS)I:"@+F\PM+!FPMTZ&W@N9G!WD<.DEI...P\)&G,AI,O=2)G@ -#]<:)E
M>TK9EFF[O"M6,38P);6,8\N)X \_E]AQVD0? B3V4^./%=M[NJ:S0>.7;,-6
MT)PG@D=9;P74L-1JU!GQHP3+Y]G.2D2'2N_.C&)/]?WFH!QL58>A&>Z7F(S]
M]NNZVK%"CJP#>OM -<A>!BSD<,+U,0C*/R.[&I[TH[>/,PQ8L9+9-(P9V2UQ
M='8U='W24S-UQC3;8=R=GJ$(*\43 B\O?E;#@"+2[?8VI-% ==C=]%<PY9]E
M'&?.:#%F'2<2(\P<Y:>I81%4&GHKY*32AU++)LOW _9<?D:H$]"5-6=%] %/
MO,M!NN#-HAC&Y.#*R,7XP:2026JXD!3E=S?\>1-UVLRLMP.CI88M,U0^QD1Q
M/O3MH^:56&(:6K(HJSPUR8_H]E#,)EKMZ>%0DS2*:A2\O_7&('MK"[CISCU"
MR7KZB=1 ^I'W\;-ZDP";9M!<@:Z453SK>ZDS&69ZK/-+[;1C3-"F]%K'Z!F+
MM;MN;2JR+2C[??\?/84?]AW=%U!"LD;*?R4?%*A64_@,"]46*,C15<JCPM%K
M25V=%J;LAFB/D7S7JGL1B4FT/Y-H34T#Z6\[\ODKSTH<DH=/!>UXG>_-^P6V
MX.X ZAQ2/N5<Q*=Q=-2P"T0A0_JIY24Q2]3 Z2J>S0CRN3%-64/"=([ H&P@
M0RIY[ADM5OY&)4*S7>Z(&W,I&/^GU[L#5A09]/=VKW/MV7#''M]"IFJ* E?^
MA;8@[Q6H$%!Q1^@6Y"C?.(*B!Z5*[YJ+!33%/J!<S+G!\I:-EY-P76J8<7R*
MT6R[M:F@5C@S@/?KG]\UXQ@DV35S>VW@B:/PIQ%,.ME/'J?BL]= ;Q.!37[G
M.M$;P<[<QU"P)WBWZYK*$A)UCJR&XJJA=Q.6> ,"U1!%$-<8^P.SJ4R74S'1
M[5[5HKW1@V%NT3%MO9AWU%1\,Z.3:0&YM26U\/#"C7RQC/E8#6L[S$J6[R'4
M#RM6]9#/<PQ1NF6?AKON*;8@RSL>#$.;@K,^4W=*/-[@<  M8X)P\L95RK0_
M_FXOM>T8YOP*LE^LN)AA3AI\/RXRC5'IDU)Y+0A],JED.5#(.YGP3($)OP<Q
M.Z7[J081QR:#:(VB#]')#YDR6C4RV2+WM&\(LX,.;<9,\8%S7=8V .(&RU<R
M-,M:3D:A[2%Z.\- 090BM!3V1--&*D"OY*EAEE#<@7[R[M$["6N^Y)#*!XGB
MF[_=##WX_FZCENR+*<B8[@ ILV*?*:Z$F6-M"0U' [M.A4)VU2J'#N UAN8J
M3+C-D81L;-].'(U%;9_\?;(NTG#(*V5=IX>'4T99Q6VSX3;R 37L^E^4;LP*
M\B&I2)LTS%-YM(*8]ET*)\VR!7,9NJ@K$@>X_CC%MJ=1&=C7:3%2>B^B-:.P
M'#K^H)Q@.L),3#2M*%"V$W[>"MMX%;,_@LF@.%-Z2I9#N^6[2")9\=.G:E@:
MXV6H,92 Y(6X^UD<M^FP2'E[PRW4NJ4O)F3M4>BZ9,&OL?GI+8\_4IK"BE ;
M@GXR99>@3'DL2<3%P]%H\L4!Z@6X#MD,Y*0Q)(@LE34A",'31ZPCNP/>5>*?
M*$^Q?!QM&VF]I5^Q76)PI+<]V))I%!1*\N5>-G-EDLX,V-W^8'.5DNN/UU7\
MHLF7INJFFJ,T! ,CX7BJ7QI>0'><ZHD @\=VA,*E'!V2CN13Y_5>*H$+"#I5
M&]]/H3"2H?4G'VQM39#^?&N89VP[]<>K=/$LM(4Y]4(RF\U>!@6+?3DY[(T#
M%'L2_QB Y/*-"?CEZ(U\X$=G46?J(P,DKR74 NS[YD^BGGQ/=OP]"&L<)</%
M$9),;YA;9)3'&OQ][ CLW^J]$^EK@'J,>AYN!N6VCUCU*H*E$8(.CF$,VXB@
MVMS/-B/)_0"[2MY3E^"WUJ(VBQ;:3*,S\.ZNQ/'8Q.M#SB_0T0??)A(<7XS8
M7#]QYCNC@P%MT<FFAL.U5/W6N^D="XS&K\Q1O)#-'Y7EBC>K]";5L%7D/4!D
MN\3/0>[91MD(WDZ/?FR?8]_TY,5M+)ST_)C9(PGMRC1Y3_C7D#>&>S'$A\QW
M5O:RNKYYAC"J/7:"NK:)GZ&&&<QCABPUH+5JPE_%&*.71(XL$\Q]LN>RW5G
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M>^[MJLD#&L&2F6"U?VRJ*+3E86A'],/N:%)S-G+H_AF1XJR2S0GG7TMZ5_J
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MM@(N/SI18@<0ISHD>,L(M#-H72-.)J9JMPMI4]8K0/.,61=+!-RUI7I%T7=
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ME9]KOJAN5GU+=&N^?;ONXRL;[_,Q8P>5MU"F8D:6.R</A9!JZL)>V8ORDC:
M.WE4/052.M9',9MDNQ4%^]9@@UGO\PI=&RX6S<__::[:T-/(-"2,( 9G5WZ?
ML#@NF1C?!(/DHSB>/LU>PDA'>5"1N?-;_KWKN$Q;R69M"7-ATN>5B'U]%Q68
M,%"?]YXK0>IY6@W>D=:@A8ZPDQ#UT,#]A@;@A>)5S7CXM&MLFQL1H,HF-2[M
M$'L)5"BQ?SFM_9*ASXEX3D4,0Y:\(@1OG'Q&DFQP3J/1,^?5,--?579  VF/
MYY/Z'I17.>E<,./@LR>">:O#O;[)$0DTU\[@TG48; 3F"8,+7P4QN=8[^L9
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M?71R9Y:GXE^!CW76;MH$CGG/'1F!>RI;-=LV$VJ2A_MLD3B:).H2F;OO _H
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M148,2XPQ!Y2S!$4!Z LI(UQ4[JDK'^45F'\Q-,7:\]3!DVJ6GIG[F*-MAZO
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M>L8)D!0*,U"W3:#M(\9+ U#A3GRH-[NF]0+ H$/5LAN#O"\$"$))TM38IOG
M] 90,-P/PQ'_ZX"B'5,),J?!XC<P88,^K4'^T4D^8HKLVE;K,8J3W\H:,E/*
M]/0TTC7KX&IE@R4;5![LD5/??Z9W.Q0]<K92AE&F$HYI.X'[(K+=23L(!ZY#
M[S(]N+"G?'98VJ--_*CF+3CXIP%FY)2Q;) ]6ID3(FO4A7$#W7*^V:F@#L-3
M-.Y)%^<S,)I\?H7 WI^LDV8(P4*UQ:2ZZ:>'P[CV-\9)>=3[&'0F4C^&8P',
M#D.XG)4!IDJP00?D.9"R\. ?GGR%%J6&>-^,4Q1XYN9L&O1J/F$@2&_8:7G
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M@PE.]!!)LVD7>H5Q3?4%=@'614D6XJ6'))2C#*_XFKKTA-NSZLJV4B@AO<
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M![JFC,7G9F=-LPB-ZFM0+IBF47]1F4M[)NPYBT J.,2<%QRK[&6<$Y#M??=
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M*TV*C7_R;E>1QLU+FZP@&7_W00H&T8[^+3;3N!V%B3.GQ \X)YMK%>@ QE^
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M*A",]BF'E<VGVR@B/4A>NA+0V.;/H)QAVZB:?8^.I9Y #$:\; [)_.%H3FY
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M84B75/OD3O%$X\>[C L4UF:OLU=3044I?"1$.JO0+UCW5UD_]JLF[1,'=)X
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M)0@4G";)UX_D?N'QH]H6G$ATERUZX15:,>6^YK3@YZ$A(.?_<1F7^5V6=8C
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M$+%4)),&O/Z:*]OLBY0;N.!CZ*F42=_8A(R%H9##!M2$A-IN7<@F!+DV2C>
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M%)=N'CJDF.?6Q?RL><(< @M*.D=1N<C=U"DPSZ(N1B4B=">R)A\8$0JT#&U
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M%:W&JXU$*^#JX\7GW^>KH03]ZNF.#]2B2K^".FU5W6^Y_@)02P,$%     @
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MSQ)F$%DR8QF#6>[I>__NY[<]Q_'<S_W7_9YYSW'->6WG]GZ=KW.N8^@_Z O
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M=H3<TR7<(+9BK9U4^6O9:=4H6GUF)[>/#@3L5/1CHQD,YR$L&BS8S+:($D+
M36"<B)>HL%8>HD!:OO5@OU^AS9Q;DM5 [=*5L_=(.SD)Y<+S7QVT'!/ &*PC
M-B9(DOIA%QUE*T2T5T&%(S47T*=G$;8!\Z=^?AU6Z75P]SK7R77=0Y?[RGB0
MPT6D]:NV:8ZW#JR^5'?:4^'*Y"KUIG_ID=LG2@>R@CS(OEU8;JSC$!@Q?:3/
MZ/68\9(Y# H6E0%KIX+UB06-22XWM(JF7$:HY:L:SZN$<E/7[BLXF)QG?OI$
M_V7V-6HKTIW@.HGWJ9''N6MV61G&*G)>@']Z[.IKI,\:'Z[0?Q1?:6W=(YO8
M\6OV29IW&*O7Q:8;[O)KV]BFH@#G/9V?<P_I@-O.!VV@8F@ 1-HF%Q>3JWOF
M+A'2PGS _!J?7()8QBY\IP.H8AV<:J"^?G-C8WW4]"S[GTJQ.S$)KS;K(5??
MF(_0@:HM!HWE#AJVDGJ#-(+[+*A6G%BW!=>G[NW.9!*1BLYP@>,6.0W!DM:F
M["K8C)++??PO4_K/9 EIV:0()_I?G%'[5[W)TK)W5NX_'%Z.\N$#C+3^UU32
MGJX!X(7'!_QLL4?/D!!&$;;1;_<5[MJ=)H5[L1:4L&9'H_Q$$W9Z^#YG%N>\
MQM?%W<VX7J77%[["5!7'WT@'-M,9#$)4NGD$KO@[UUV)X#(Y'?7;M\KYT&?X
M C(Z5NNITC]Z0BEZNM>KJB\GL!\++O7'\"_3N*AY&Q0=XE87&K0RLO?5!P1R
M/3UM;=.6!WO\X['VH4_+;Y?R$5#53/T-E1-+;V^XWSEN;ZJVT@Z?P;:A3OL(
MC"IR%M?$/D7J%B'L\7U_W*^KUBNR;YZO"]3L%:C\>;]2N]]CA%WY011_])6%
MY-G>+Q^4W+[ZQ,^8?X$(U5?7C"GJ%X[[Z ^8C708C.R64*U(1T=*>QM_8AY:
M?]G&IEU^2LKA?+^<=@I.=B,EC2!]B1?;56#ARS7C-6 !!-QT$C_^L5YF*5.D
M#/(SYUH*B])Z+W/XY>$:5B&OK ^;WW?Q/Q3@%<+C4#<JZ.%DJRB(R\]6['NS
M;_%/"RXS2<1"W$W+9SLXV7?94MGW$NWOV'F>MW=DX7&;!U-N0QUG4!'"9O$Y
M7X=_#!393LVM\=[EN=E!^5QU]Y>NT%L@[Y)$XZ3]/_S+9P;[1H=5RWS<EDMM
MZ< GM<;T;@'>8H/^N8+,)-W:)*- @49===4#U8!+ST?EY2^.;MIG.UG@0D_&
M;2"TF,71'SXUGMP7%':HGM,\U[*4>-&0![(7=9^K3R3FU930E\'+%9V@ VY,
MQ2$!30>T,"]\*E=W NJTD2CN_#&<Y>[6*7(4;>*VD.1V#F:>P?WK4Z79\+GJ
MU8^Q/5O34!J?8+#W.>/%=H@D\7@.WL!QYL[G884I63.2?GIG*%_S_C7KHDXG
M\8$XG9$6WCL1YP08G<XH"QWXKH4PW*0#T"GWH%/][Y^3LW+1E' OFYM6GL6V
M"M.CX^\F,F.E5->?]5 4A^+HP.ITZU74PDX[F-)84+<)7ZR"+DW3_B6!4AK+
MXVD\E=2MB12D43-.UX-B[CN^R.B+)FD&-"?!"?0.MH,2SX76(/S\%G3)C!J.
M-*CK[K*&3<^QPS:3)'GCH<)?=J#^'^^+EBN?S7;[0%9=+$8YM?!L&1"4-T*(
MH';_0.K0S!7WW1;-MHGA(:4NPVO!ZVJU8Z:]&Q]>5MQI)>>X%2(*.K13%.7K
M7!\:>'+J//64J,JS9O9+XP@[\^X@&B/NXW)UAMG]N0N8^VN+:3C,]J=KEB@!
MAL0>7+B\[LVH*32=^-^- P7Q.-"I50%T95J<W*XAN^MZA7,MN^]"5]T(AM5/
MW+K^H=M-W9#^BVQG@S<"QI3J5!P*.]5A7<.T+HB<(9\;H1]>O!9LR$+]1+N5
M]KQ?A@X\=^B, I!48H>]>1%B$?\GC3#9EE$7@5E?'O4VX!BQ7C^J,W.H"U.\
MLH71<&P/_N=#\@_AI9KY&?DV__?^,H'5L$I#[C4S?^W4Z?@PC($:S,9&0X&@
MG1W8Z!/';E'W\T[.XY+KQ4$=1]%;C#Y0'&Q!VU_ ?EVF<(HF$EH'N^<[4)70
MZ-TS"@,F;JF13Z'!FUTMY+![ LLOUYGW/PK9QR@_C.N[>?.3E6$H13X'$:\Y
M(4L'GJ)YK-?FA$P,)/= P4CJ3>TN/#>4U&W>[RAQ;1_TLYLUH(<B[O[^:=4#
M8'\W#\Y3=>77K&"Y2P#XCWPKC)(0X#-/@"UY:9+JB0RDS70E,WK3D*$3J.VU
M*F0 <:L3RM<,+D($=**J*KJXO.Z,?]R6?R[O V<;@'NGL[GE3$0\3;@)22G^
M1!L1%1B&R#H'L39,RCWJFA.ORUXW')GT3NX_R=FJ"W86D^A^F<X1?KE-F?_F
MXBZ,? G6CCY-MK.=>$ZQ3?K=*F(AWOSV=UW1J([:  N/]<4[HG]N.9I%*=?R
ME-1/YV5?LG!H+,!NPW= 9=!?J/ #;O)^%SM1WV1<OEGWZ"QYQ[9YHB;TN_Q*
M:POA^8BM"QZN9G7/VK+_CL0!2539:R(3S_5BM(O!HU!G7&&5X3%;%'/<;ISZ
M#?-Z=)NQ[0]9OVL1RRIM#C]TI4.V>?06%>>1"N3-',I3@D\Y%C>@>:2IU^QW
M,4[S9.VV>&*3CO@+K<NEB?>29&0N?JI*.?_:AAF1^-TAA&E]0+1[_FG@-AU8
M"ED7G&#P)SIP\=5HJPHY1)<XF(\/@$^9XV,@8A-R3ZI:Q]+,":CI\@^OOG[O
MW*)6)T4X)(2N<E;^<4L=<1JM 7/9KD[ *GUCR[RS]+7@7#\MN_P6QL,"K^5E
M/++OIU:',"7A7V[3_C@$W5+<!.'-8ASJ0&5/R#*+J=%$@97.TZMU WY2H7N6
MWNH/_7@ZY> 7[RTAJM9R"%7=OCGVJO6W6)C7U@\$Y^5I]R"5J!K:,DV'S0??
M%E@Z4#1P=(Y\J'\4O<[UP#H,2W!)_%/*)_>6T4X\7VKF &(;/YPU1;TYS __
M$NC[<(S">R1 [FBW"BM5LIEUX45<'M0/_=GD=F;O]?:?@]K=H9L#_D@H7^D*
MT: [!CL-=L=@XK9UW#A#,=>^_HD26/@0NL0JXNVZ/,8O^^%Z\J-.Z%D%& =B
MJ"-(=$P^8]Z"&&!S)1&^I(??F-%<&=KY]-:@DC*O>N5/='*7:(_AZW]S-'@.
M]8(.B(');NASJ&$,\@D=:%MY SWPN4TM5T,84C(-NT\AP$150CSTP*H\_'_"
M7EXUT>/*8@?J]-;6HSV??P.^IWN%E"T&O[T()WF3?SL=:5-$1Y .3_/7,N1J
MB_:Y \.-MX/&70F/^^%BM\)T+XJK&?2I'KO66[[6&L2(M0,V_4B0[(!M*7;3
MH0,R@IA=+C_R)]<LEW95R<G9(;V8]\7=AI\,"1R=Y%A<T_P9!*_%2,W1>N"5
M?>.:I&F1AHT)TDW.8IL!SM-5\FK%Y[F[W"?D.^&B+BC.9N8R1)IU_9%D/&Y=
M""/SF]C4%\9W_=:7I81/B+/9*8/.R' <G"Q^-X@M4*O&'8:#)$VWHB')_A/8
M$[M?8W_FK=<ZGXT,<EZR%3)D^<>MK('ZBN+D%^CKH]P)8^GW#%3*\O*205[[
M+*?6Z,?U9 /YQVKVU3-HVPS_DO]0#_PL61[W,O\#Q:*16-BQ/L2[3A,F:C2/
M^Y!EQ:L_-TUZ']FXMD_\Z=N<%I&!023,_<12[%K;3#F3A]?G!7W0IYVM]E]!
MSI"C>T05OB.-\#?EFM7+G!MGE:<Q!6C6]\HJU5/S<X_%9C7.%G"B(/IA]FD/
M$>,_VB_:]ER._8GM_[KR.'6*)J7%B!!+^[C\'IK']08B%X><#H_A7IST@.%$
M4QTF^)<L'S_HOM_;>%=7!.HW;+'\2I%KGL+3OGWT);Q]!Q&->YXM?.0\%I8Z
M?V*WP['.UEAS)8+RL^1")#<GP&X4?&_ $RQ !US+=#KGS@XC-<H1'W<Z5$AH
MG->Y_; G1+4YX6;,Y.:5\LVM[G=&DC43Y9TDFO&/QVP1K!C/MXV]^^#X><&*
M<HHF+MJ0SQI1C4-U-/@$9+H[63>-R]4LCRG-W"-%DYKT"U/[IG5-DK85FV/%
M- 1U+84"]#Y-HH+/Y5"57APJ4WB'\ *OB=D]/:GSP@IDGY:+M^G &YA>+ 3\
M0\LISV5FT8N%6T=LD_7CHU19$P'3Z4)W*S*6X14:,7R3G?]-D!KY]0)46#)U
M0")C'<6IL+Y5E=J]"$Z7GFER73IU:OC]@AFD\.BQ+5(M3 [:'B0=;_%]4Q8R
M@RLD*O#8ND*YG0*-__RL&5!9^1:9?UKGI/2Y-NOP%'FY@I>)FFHSV.-TP 4J
M@$20"Z7>"'9#1$:V?,"@M;K]5"O;E"8+@L%X:XZ;1^I.>GZJU%LMA9#]A%?V
M,;V?N_M2U,8A,A5--,!*L!:+HO#>P,M3>&&VY!:W_!ER23>,BZ)S/-QQ^F6F
M:"X!;5!O YEZ*QUV>@1]1?T#5\FKJ]=B.'RCZ,!"YMQYXO*?%L\RQ"ANKLP3
M7[3Y<<*^B?RHX-OA1^M7<IU=^?T'%B+LRR_+3WSIX6?K:3+0P:UL;!7.4RS&
M%.(C124)\# ,G)R!*%"_WCTAM9VQ1ONE9*\2VS4G^E-NB2?,IZ^4>3"C%4W]
MU&Q4A+##G94IF'T\95"."-'Z+M%4]R)Y6@/UR6IJ0-SCEB[+H]:>M7+3AF[I
M1@SOW^?8PC%6C,\ASC'4PCNK@HI"Q,O!=09:<I;+4L0X5O_1)43K.^^&RO_B
M!G:NG9'?2:AG;?5HGM@KW)!:+#GGH:X'CLSFBG\8;976Z?("RR5[M[BXGZDN
M=5<Y*U&UO5LIN?A17 KZ ])H=+*G,:4;NP@7 D6;95\?*]UH%BE<\Q!>-XC;
M]JX,/Y(-"]](MBCE;5G7:K@?1_-WYVAF)! =\-@2<!M>K1S SX=+Y[J6Y.N6
MD#'>4V*C:N<\?=R*!Y2RO*ML "G+YYM/CUE>]'8;XSGO&Z'68((BS!..?:=E
MTH$;=^!DB5_Y?Q\R#67AX\-N@%GO)B"0O82T^Z@-BV%*ISZR#XDQ/Q@[Q=_Z
M-&3@$<,/;QMCYQ(7.:UA0DCUX27BGRRO?+>Z#*?VK"L3ZP_K&H:R8\5Z![=]
ME;Q2F>+N'<\D')'&R>&+ANS.C7O+*V^L]1OC.\PF4VL;#;Y=?]Q?8A$ID7HK
M=G#5^-8Y(;Y<I7$'QUG-0L$%Z(Q(]_1)7IANB<7:I#[</8 _J[.N6N>#M0&N
MA</+2_;94DM7#=S+5U4H6C4P8Z$T:N-;HY?IG]8M,LM1:NO?;)R R*+:(,TP
MXN+MT5VT"/(. 1I=,R!1-V6U#CY9"A?#N#==#]:-.S5WX[>E,HJ@OVGXD.SF
MM-#;;$CHAIWX72=)&M5&O<EX6EG[/D;(&*KL^E7C_.>E8 UQX2'&HFPB'IO4
M)6H-A?M4'%O/@+U!JN+1W#/KE2[7!QSP7[TS X6=NUK[RRJ+TQXV8I),_30"
M[IA(ST;O*G^A _SSKBA>B.3JI& RS,*Y<: F5?YBNO" 1ZG<'W&,K)^JN&^B
MAI3KX^Y7K%K\HB-Y9O$$K4L,VM91W44Q8& "CB@5LR7GH8@20:J.E<MZU]?H
M^TF130N:-)[R1<N:12#G4_D2^2>N;1<+ 5XVAN%0!_EHT=-C/M$#,HM2X;LS
M%:?G4,ZNR=9(U>K8/4[TY9O(W_?0*Z@KET8]5T[D8@(%M9PNC_I#>P4W%JE*
M2*S?$2=BYV%C8\8BWBGD5\:151U1HC.>,-A9<_B>G4?#OV?P%V+B3/#7H"<7
M'X+XDQ=!9,FA",B%QP/*$6H.! ;"+YJX>YAAR48%L^GR&6<^N"6W/DJWNG3A
MSD^]SE<KSA5E13EF&;ZP))"3*#83 IV +J1-%T8T0Z8?Y. KPAK#,H@67R;J
MH!P*OW.G['C;'*^.O/?CUA7W3.R[6!5S3,L7S81ZMNFU,-0YP&9;3S0,V>.$
M@7[S.BM-9,!?/:_QR_F<^ ;K$(7(D^,3LX][)!Q;.ARS,Q#(KB5MEFR&2F(U
MD$.9\1EI.5K\^T\"?, C!Y&D+"T 8=X^'YJQ.W>9/,ZQ/B=-J&D<BI7[4Z88
M[29SS=./9U583=N"-NPN?J4)GR37?ITI-&U+QOP5P@U'!Z);A9'L]638)S>L
M*,:0QVKFL?/\#V'?-PINL6R='XW[G&ACR3I)$S>O:*8[*/L>M[]^3QPDR4Q=
M#C6BB 7_7JM)^KSO"_$D^Q75;;Q>W.)W;FQ-)C)WFHE><+^R=7?<FRJ\91MX
MNRU_VF5$TTNN^:[F/Z+?[HT\$(N<P%E:+[W5R401ULVC:>S4Q19N;W7]HV?N
M7IUIJ;4RCG3 .26/R+_Y[7J/J#)/6Y+)D^L:YFP);FM<_9LZ_;2!JY GU'<0
MT75AJ9Z90,V'W_=D+MG!1#_^?&RIYAKMLWB\X0W;TR\9IZLJH"JLG@E,%6K$
MM(WH<J07N3H@;[!Q/VRW0K5[W_,!B;6F9,IQ;%=H\TE+[%NYKI3.Q 'Q5-S;
MQWE>Q^[-PSRY"H]J\G4^?/"%W"<VMRJ0L<5DWTX8(0*&<%QL4PG,=?57[\Y4
M6"Y_-O'!;Z$RY:5L)!W@&?=.,7J3H"_T(TRC=B(=OU6-Y"(HAV[5@,[JG$HO
MFZ$#\#>$[,(+82)^DLT/<YY 7'L5!(C)HLLSTH,W8"8 XY;/'P>.4THF"S.L
M8IS[5+1^6DYM>@R5P,<.,F8ARQ'98EEF[T<-%'T<1T=-W7D,&[$VQ:MUO9\L
M-7R$OQ5["G_]Z)PAS7>5Y;@V4TK#LL4Q$(OC)PJCD">"+>A !3L=V+4VJQ6X
MADX)7 ?CQ:,%7V$:A%*,%(["'.U>Y?9YZ%9(JN:NY@?9&'!QTFZGHO;:H+O<
M,#54V[T_0;VX^-#K*"^\60**V)]Q"+Y#!Q(DT-1_#*DLY@-T@& BQ!7? 0X_
M?)/:F-^5FKQ(O4+:*U58CSYP7S"IY[H0Q>+'$1.S^6BB:;LI\$76T?OZ?JJ5
MV<8C1HVHIE9,- ^1V@COT2*M@.O<V;">A^-YC=D3GBX.?FYP<9IIYXN%Z)H
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MB1:!A+KAZU.8O8-Z?3LE'+?#?8$G,[X";3<'O%YB*S%#P30E+M_V;/Y1;]5
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MS=M[V/DJX!7(_S?M/.IK?"EJ\@T=.)3[=.%6VY12J\.#:TE-6E11L_J1S:7
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M(#4*H2A-Z0H2%&DB(D4Z1)J44%1:@$ 4I#<! 0'I3;K4 -*[("(=0@]5()"
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MDJ+P-+0'NS.) 8O!5Y5:"L6E%:G^,?&5QO'5:=$IQP3<_ S*>G-.CST7(D(
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MA;W% .A-34SR?.%K\%V./_9#T.LH3N);<3)@)QBQ)=!"1[IL(Y6 I>U.1(R
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M9I25R-$]F[A>:^/#,G3&[: ]MM;O@1^9+R]@P7VH@IZEM4-U _ ?L=EA1ZW
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M@*3$Z*%7_=N7>#L^%+'E3S@B \(M>H#$9$WB[=3_2K$,W_US^IB0CP;V+G'
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MJ:8$YS*/6!K1V-7QT*(\DP!&I]%X@N*JS'E1^<BAKHN*H1=;IRG]2-IUM?!
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MFYZ_OF?.N$I(H+^@M?B;H9!1Y?]@Q?0]+HSO?Y"A\C^_X36[%O\;Z\3 *4I
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MW^?#'/Q"^])>ATROI"-D!M$#_P7!$;V& I%^NE"@- (*[&3H<H?F@GO;2J#
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M\)@-\&N?J<HX%"D*.5Y[1$1Q/+.50LKH>1#Z,(K0)\2>RZ^XV)^DUXPM#C/
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MW^=U G4]4U_))LU/KCA:*7X3NY^& BVA#UQ_&8"T*8F4?E>(^:_NM#<U#S_
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MXD)D>,2QYP.)7>AFN"CP\8\DG[U'SIT?03[BH=HHG6*6Z1'"O6=,G[QC,UE
MCWP)JT>V  4&>-'4Z]_#M.A48G[A^N$1G)"EC5>*+_%FBQA8%0-<;_W@(.I0
MX!.OU'=-T^]4=C<3K1T B)8+4WPF*8,HZ:KG>R,4H(>LJ.O/\Y/QDX7K%.'U
M?$XX?&.X?_R=S *;7L7;IH5G=81I>;P8W,YK)/*](7?>!>>54@MR3C!)UOT6
M;69T^YQ'[WAC=& V=67QUSZ:X*?"E]]NGL.+G @)([3)-<BQG7U>&K)%^?9
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M,L_IUMU?CGW^2HA_.URIMOY[MO[[O[+^C7J<0]\+(B@O)*.$'[BVG)U@WE^
MNG/)V=H(+RB3-O,N-4_3D1]F;:" \&^)?)=R^0EI<,&0$WI<@;E0W%"%2YC1
M:_-(O]W1!_6<1^YGIX4:.JSQN0,.+&%IUC8T W8I:P$,D76;Y9.G8 &@\F+
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MLPLZ1ZUX#'K.4 #%<NQ?(RPF9 \)A'?@L"=>CF&?7N-/#VOK*%-'?L6YU)8
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M,O<\;.KI^;HR,P/'44.HF/__30!02P,$%     @ EHD(6>[QR_]P2@  9%
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M#]IB"=>X7.KZ_)Q7?3V7\'0$*M]\^97"_\>-SC6SOQ )6#6SIEMI00+:_9
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MB)?+A"-$X/#Y7@+^S :=9SG%L&$K.%@J[:V4_>\2C_YZDHC2;4EG[8IJ R3
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M-TD]!=/OH0HS>6R<XG_)N+LP\ .]7J'/M>:<YK6SD9O.\;"KLST5),GAG9+
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M-12UQ7<PJI6[OJN[%\Z_5<#-4N7)<//1MAYM]@ZS]?D&1P(,02L3&J*%!4C
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M"Y*$2'V7BA(EN1@I5@8H@XQ#[SQX5CE^:-9L'J"-\?^2S.]O_P)02P,$%
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M2>",&E+1Q'VX*IG#)5DV?#5/XM\J<-3:(N"TXLU'S)A8=E04DK-S7F?]>72
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M8R>!"^K0>>>B7%K+E..351LJ=E2U,HC,^IBGSY=G=L %RC+XGP;>%3ZZRW@
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M]VNZ-^,=9"KEU-R55YAR5^6.WOQO'];]:7#_#QS\KPSVX?O_ 5!+ P04
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M?];AKM)%<43S2I5;T?NUNVL(A.Q(LS[)T]>^T(SVSI+ 1G>>QL3\&_UDQUB
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M?[[NP[1M:>O>/TRA:@I8$TEWVX;;)"!B].6%EQ<3O?OA-<$T+OOL>KK*UK!
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M<";2TOB@G=;GX2R 8"&M'-<@*^!*J-AXC@82;V^[)#=KCEC^L-K 66%O*YC
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M2QR2)>+LCQN)1AU) (R.1E2,CCBH3H"V^F65I:R,6M+E9XS*>OS$D<#@89@
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M2&0R6D<D@586,@=B"%))R/XLCMTHTSPW<6]_I]U>2+(UK',6</DR222%AD8
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M7#3F%2Y&-N"V,]./I6G/3O>Q/++N<O;>/WG\L-I)BVQ7$URTLY18HX=F6&Y
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MNZ#TZBNJJN]M;RLSR0QNQ0QDL@)*'JOT]J2:3V&[F+;:W-'HMU<71C>>UN#
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M; Z[CNQ\43%0[N@.Q=@FY^_+C4PT3IW P\"W4R?N+=6U;(6S.0Q^Z;DW=)[
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M[K:B*M'1UFX__[L^*R!Q4"KTM1?!T*>]CTAW; RR"L7B[KYL^'L2F ^*2<\
MAT.!-O@\H>K'#J5MB:PV^@]&CL\ J^"' <L'"=BWVT V,&'F1J>R)U,)P9>
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M;DL2GCG(1_:Q003$1MRO>-Q-6L@JA^/5WLIOY<D \'Y%\82KMZ<&S^=ILW%
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M]CSB$SENMW'$GPI>NK 2V18"P/)<3, Q7-)5@<&_O9MKR?M)4(+9:04@_L[
MN-IR"*1QNA?Z-AC[$QGR?HJ(9P5?-Q9J(!:0T,M I*="?\")3.>XXR_5G];W
MW('F'2D^Q-2=Z3%B#3/*H<EDZXG(Y6MO9P=C]P-:!OE]*(_Y3TF;@YK GBQ_
M',V? =&4,8D1[^=2I805,<#4:LI[3YXH?QO 9Q9Q"ZWJFB39568MJRL[!=/0
MJZ!(W62#XN2SGRE M-]_QFCDTLWU]H5J.<^/>)8@PT5RE1'BE-G'&!*9ZBL#
M]Z"2%@8Q_F< AA]HKD/7,]7@3WMA)G_\@N!(<N@=2:+J3_ ,[[$=FMZ(X?+'
MNH\ET9!*3F15AICRN?I <Y?675_';W>>D1NH;$7MA(2Z=6.^QCOF$SN<?R\G
M,9$%\97ZN$R#'&T"M0QZX=DF\AX++3A_9;&RA!AV:$Y/EDV69"B6E@[(RG(?
M&*8U%GJ'R\?P?\VR6Z;1^:P.+];_5,-/1*0([72%:-=4</3CWAQG907HV=83
M\SBY;MFI./] &<%.&\12LX,<%$&ZOMQ'LD=3:&XZB&@] \(ZW6.+6TB"(E[W
M@--&S3?^!'E,P!RD^A87!,H&UY?$B5ZF1)!;776?+/6CV=.O<(CN#6YDGR['
MMVYU'L4$+MT0OK^<;.HVQ8";L\DX%DP/9C&7G3J2CK9=&J;\W 1#!U=7/&HB
M=:8</=C4S69WN]KL@E!_^,]=FEU:ZXCH?_M\=M9XF3MWDJTN77W[\R\63KN9
M\"&N=XV8HQW#)-4]<0/.&6'0T*W$;NTG@JT?6V_XF!Z,!5M:9NWW+!N?AG+E
MV:U2N!H=?\6=K+:+W"ZTJ$N!K'^ZDIGV6W4Y84+>A"_K/S930M];M8_Q+XG<
M0/?)>1)<C%[?Y"X$XL^ECZRK"[^9JQ[/(-M3V_1B_%;NE/5%8=#7U6[E8*N4
MST>[&E/ 2U B&LWSB:CI_";#B?;RR*VD7 /:KW0IOB\T*+7-,-]*3#/G#N49
M,J#;2[VAZYI95VL$@]UX;15//'3>"M$B@O&A6N91L_5-$=M>;B-F7;']D/V0
M&7EP&Y W;\UD9=B.5@G'QU#1\3.WW@UQ12!U<]Y+5P1'INH1UI9F*16)>G9]
M4>'_G$SY1S:HQ#?>VLCF1E=XK+2*]>.:@2RL]_[WV]KX/G(LR?EP=9/'T SI
MH7V'CW!5R?HY>\?5M37H9N:!RCWR]N[[>/&K$I?&NNUCC4.=X ?)30Q-C>87
M2C5R,!H)RP]!E7YA)422=MU2-$&_%U8M W^V8F&>IV?XE3P#>BG%,S.234R!
MX%B7/9YO[)6?)+^=YPNHO#8\MW>+#Y+D5[=CJGA3^E(D\;5([<3-V=9>(X9!
MJ\N0SLP8\B]W0:8SK]$H,$H_T)P_ R(R^CTA90\TQU:NHNU:W[ ]]IM7-\7M
MH?>MVWQ^P[/AW1%8L5OSQ?6&J,UH09R_P>+6IQUCV6<7L!"_?;%CR#&NP7E7
MVA9R_-G6]PY;;1/2Z/<.994I<=QB\1*V67-H*;]AQR+QFK+G<I%\HY2-RF[E
M!BM =K04_R4Z-[0\YZ6]3MS^.XD;W5X,:85F+![)TN\9@ 81A.%KVNS,15.4
M P67TD_I[X/J9QRRS64OMJY$W$)6<N49,@^8K;3Y,\]<!OGEHH$D5/-6G3.\
M\M=V=@KN'S)*+\?4P+\JXN*? ?U<XVM<QJ9]=EG=V,KEWI77M/'[\M4%T8FK
MV!QG6&7<! ]5X%E6JMD3^OI6S,\_/"4R:&@LEKZ%2+S]\J*##R#NP@%A:*^K
MT9H%%T2QABHF?.ET#O/5&T3W5#&/(&?Q_G9V#I5=65:N;$79I%Q,.9\$1?2C
M!I'EB(_UVQK5X6Y#$4M\\:KRC:&RS<TA?H8TSE9O]!R<DB,17\@UJU99=T'A
MLNW3W?B$_E)T+A[E/LF]2!..&OHNS"$#_"%8*#]K^DQ)(A^H[Z*FATFB&X,:
M+&I_-$*'NNQ,8A("<#"-';T3$G&W@DX$/:*V2,A_S0?.T_VM:?9O69]77NXZ
MLST+I#R +7H3],KW3ZV90.38^E-%>'Z\Q539'A1#%M:U4-)FCH^6'4J$^ZE%
M*IR7)(:==7!Y!(&D/9J5%-A4TZ%[!)</TR4N"6[9,&U1-4.5!8_]F8@J8(61
M(ND]OR%6L_Y1)*(=5@9:;B1#G&Z3NK*V;F=HAA*%,69JU5$>]C7Q^UGV*P6)
M>A!ZGG4XN9+_TJ>VY(L\Q:L=C;K*=-8/@+JC@,.K)IRT$<4>&3RM.,;"&, _
MILC"8S)-O7 ETLD.W L1^;8X_6'9V._<UH%%59E%H7&F*!V8 J'[']6;5S@<
M4)3'1T@0+:)$&271HD<9G9!$BTX,9I0DNC%Z+XD6H@U&$&U$'5V4T8E>@FB#
M&-WHC!HE2K+9_?9Q'W8?]^'_?+]SOO\YYW>^>V^T37J#/$ ,&>PPT8E=KU+B
M_@G1*^$?QZ17_)K-8"UKA*?DQ552 /=_ #A_52;N9AC&6DD88.(6'K52<'^/
M?X3ZH"(+6I/[%BFZT7JDK;<R$A"8N;MM4X/"$:SK.4/KFM, <7%9):L5?@TJ
M1^!\>W^'2_5,^>WIF%K33FJ^)#)Q<C;$^EU/C ES990N];2/Q 92T0YNI-?0
M&O,C<-=A_U^1FA /EQ[\,O2 *?7WLMB>]OYZI%>+R3[Z:NUF3()<!O(I;#ZU
M<EIU^:4UT&I6.N*]0D.H+EZ SD,66C_FD1CK&W^^'JP+4P9LE)GY02&3?S@7
M_.+W[!KKY7IBZ@OX*>@_DN*,4%]":(+L"I])+7WYG3VJ+?<CM4''R9M5Q:VR
MND[->Y&Y?0<O.[CW. HRL>G/%658EX0W/!;0+<@+#].E ;!+6/+<;H;LO&.;
M+)@D6.G']J"<,\J-^A\V&7%)LVJ^R_8%W,$M1G6RQ/J1@AL27JIBT5.6*ZL>
MQ3-NY.'^MC?,ZH L(Z^\AM<%L]O;Y=O(V>!V1;7QO:GZS _9VJ\WF1:R[+EI
M^G)$T&](4;564#5X5WK#</YWJG-?FR/4[*ZEL?\*W-IH0L'8&WT1M.V^Q(.>
MK>NS44M:291HIR<8*G><]K+T)53M3K^3;E+B:*D/UET<%(:OV8A<L6YLN9'M
MQDV\PB]=CNFZ5N\D.C5[#QOIW+ZIJU;62,>GFUES5:[2<,0;3 ;I%>W@IJ;3
MK4519V/J\GJL@B^^KX5B0F6?\H_XGV&6*U0*C^#UR07E4FE/3"7O%?W$-QTC
M;.*L<[D0,/M.B,6\$FCZ5&*E?US(I4)XFLF4<X@?/O^0DSVGD(^L8*%_^, Z
MT.2H/B7O MG]O(DN,W.DT4O9.L$3;K&I8!-VFQ>#UPKF@%CP>&4;_MF;"RZN
MB*/@_7G.,#A$O=H8#.UB%SRB;^=O!V-J'R0+0#O=B1QCH"=T7'>Z7)Q1*KN0
M]TXS! 7HFU7F5E#Q@N0E"W24X5O:9_2)]!/YS^[]K@9Z2*7<$:[&L=,Y45I'
M@QWP?0GEM1+J%C,FH/A713))T8^2)M0F)E_?L/@C5+^SE4RZ;X8>F+83CQ_4
MQ=_9QC"E4@Q=S1Y8+IA*)V\ (P:6$P$_!&,/ST,*XEOI75L5[SW!G#A9VFCX
M._]^9W_>8ETIX&_M6]DY(BRI: BWUJFO0^SC]>MB<-K^GIKBI4H!;Z(["]JG
M]B2WP%HM X\6"WJJ!$K2B&7,47H3K>X*')7=N7Z.^Y*Q):NU#2T-&3]D5I :
MZ>L\ID)-Y@P= VO@^/Z(JE^_G2G\?/ 0C!S?69"8N2:=IKW(ZCOKQ,9.8H]C
MJ:FKQW\!3SS;^W.WV?EKII/UD#A^8]$*G7D[M7@-<_QM7Y?11I+ Z0B6OG1O
MX,2<DY2G.NGE)L+[#<=5#_M3EN/8IZ2[QXZ7ML5U2-R;%<<][<H.,K0=DZ$*
M_E%%?^$.QR'"2AT=I%1?W0IE@B]4*A1=J9BPAL0!90",MS\.]CG*N6]UIV<O
M%J[>4&B/9YHD&S2DCMC0^B=J5#4-KJC16/X%:&<TW&FP=??T9M'B2"/1%&L\
MR7\\@.>,$^-\[<U)/ =:-[HP@K:.*T#0&LVI6F5E\BW&31HI&^3Q%Q3'9:]I
M$3(R91G]D:!L0WS/ \9F^6Y73_9T;A]#<<[L1X-(:NH[I.R?;K+D_P(@I)(M
M[!D9/]*%T^;RL7#V8:E)MUK^."">M39N+>;5M&13A5USK$%=H)_F_>^U)1H#
M>_TR'/'^X-R58!.#L58S4$[4OY(_E;!+O;0?8/H\[X]D,,)X*-+(E%TFA&>[
MMIK1LX"&?>C:(NICT;_=D>/A34G0=7E=<M(*47OVOX#IT.$K]C3[8/MBZ.\S
M7WUSU2S72.7=G.+B---)EM.]-(,Z:0UR/Y*A-O<9P:R8305B>#D$Y\1E7*\Q
MM>_;+89!+#IV&C2MO^!V&67><3=?3/L"8V07#S%SK+T))YSHR#D]Z7STK"I[
MXKEX]F_GA$^(ZXFU>%Q[Y_ >8D[K"!%:NCWSX.PRNP;7*1:CR9.B?XN::.V0
M6F84HO47\,"1Q?M/.ERQRQEK:!*Y)?=;H+IRU>PD1%%N!K5]R=Y4N'UDRA>)
M$[M3+5EKH>I*4L,TYQ^_0NG>]PRI_IV& 3+4#>G-3HC G72=6!5E*GV9 3M;
M<Y,ZYS++FYXDRKGCJF;[KF(SU$L6_)!=N+\ C;K;:+AQ-GPMBC)'8)\[ZU=_
MD1.AOO"-K\(89'%N5)+T?C]]Z0CS7X #<=+%3-HV.]V,L$DWYZQBL=;",T^6
M)V^L@<5=(!G%:#;^=QQ^NG\!6M/.-M\F70DBDE>.#U/=A*?)ASB,?Z\-_@YU
MB2R<#-,I O$%(RXW>QG!?_CJ#R_[)6<F53=IV1>JB]Q3>:+6B)2FWE%9Z31+
M4 2K3;O6;OXXW@ ?5\_X_.N%[AGGD:X@&K;%!1RN_*TKS1"<X<CX9F'P+?UF
M\6MT5:'GI=Z'T^>@3)65Y/R_ 'N'<T9?;;:GDX4VN%R?G,\NMQND*WC(,(%1
MDE75._4!V9%YP)^+T 6RHV\#*58N:FIN?@/EF4^9MV9P/PJ+H.:_$]#/-\VU
M&\4X!P?F:0P03AQ1EZ)G#\*\6LR$#"?VH&B<_F-*FWZ>CSLPI4GU3,VC_8KW
ML$*&R;^ &BX$PP<&L";#0@S1CH?<)7;6(G=ARW),P;?P(MQ Z['P :$@E=C=
M>4;?&?HYM--+5A:(: 0UB92A._A.JBKR&?=*Q/P_^3LO>4GID:Q9*WJ:BX:E
M@5N/)'$-'[UTU)8,4QEC9+EI8V&F*@,Q"F)O]4BJ@7B,T=&W,&\VS]Z*V^7:
MDO&0V[#?KT)K3!FNOPW7)%Q0F7#[5P222F!&U3+!DX0/G3GZF(]0^,EPLL!O
M:/O^7DZ:8NUT- 8NAQL1Y<,*OZT+@J,T4PQJ)REUJ?SI_+1Z&BPYODZ=4BF9
M>9.#)'R+S?)ZCNEI?QLDU@3%O:)<_@OPPZ8I44\)UU7<6F63UL^8GH:5\$ZN
M:3G:?AR*+[1^VL)5Q6;B2W_SZ>EGE._/7[/7FN@Y6"K.'-&Y+VS3:G:LD,MB
MS5WOMYOSLIJWI>!9/8&WS):I47_L0:/*1OA8E4)"H;](X>&Y:1MF;*\\KS5,
M4$<$_V@]Z7A#>=OUH>&=R4E$5YV">O[.S*1ZR78SVVD;83J;WA RY$IR5OD*
M^3"):>,)^B**";V'+_S\.\<:NU\E7/Y%8GZ4GO86D;^Y0)@N*1]VRFO:JP$3
M6(>M8,%)_SP1VC& RG0Z+P-1*0-!^F9Z7;/(U<?7J]-=&HDKTO[1*>RSJTUP
MDZ[+^OP"OQHM#JKV3(9CL^X[&45/;!S6;J]U97^QCCOOU794+6N8N0X=1.?N
M^%P2/BQ<^Z36JKLAGTV2KV9(:0O"N2(7LL[[%$^,>LNW3>[IN%.C';FE_@)V
M"S2QY>\/[KD]95ENU5MAO:IP6:6Z/PX7SNFNG>WF5N:&";XLIT.D TX.3*M6
MLL%G,\:HH2Y"OEHS988_YH[BC&?6ZQ T"250;&TC(P+2UIV.JF8L0^O!0,/2
MTQ-SG3E2INM@TT-Q#Q7\K=I?HXQ; 441&5BY^%8?RE[MVH%J@O,OYYQ/YYV;
M) 9?ML9,_9Y-ZD ?Y_*.,SH$?27R")%:&<LZK9*8N :5F6[]80D<O:OES8XX
MI[5T_ MHYO5UD_KQ);L*D75BQ-2[I._A</8"Q<])UR\@J=T27G:K(&!SHN3?
M:+<+,YL!5S_I;1A.-"_"+IQ[>(:B%C&ARR.,?P&:A\:]V0N-868%C1F"(+<E
M>W7N<K/MOD#W$8]F^RB0#E?'.Z:&\&<OFK7B+\/5X?1I8L$WE;E_#.=#D[.(
M>^_2MIB0\@98[\J9@\?--4L@W'2WWB:A]:M"D^LV28DG4D[CQ>7IOP4_FW*>
MCT^CDOLXI_ADMK-*:$*!HZ0]>T5+45TML=>^S$++&]C)) 1O+ ,"[VFR\2?Z
M&;VJKI[@S>P>?6^/WIF9T"RB2G=8XWZQ4^Z3V.9^8+R'GY?-L9Z07&+8AJ"R
MO=_Q06%0:(FP3>IZR@,/X'UJ]_"?4]N@>'$*OTI>K+!UV)O/!?Z?!)?MUV4[
M\2C!06<%_G*(8X#W2']D!@RJ^'9_PX))3DQL !#_B0Y3[W.G8M9/PL!V#'RB
M9EPCM]Y[8GJ_,M5-CNUC-]K235S<P0L?W/G2(D$ORG32Q2Z&"<1J9IOQ5)P;
MX6WG]><0<*S8:Z!'O[5*DK%_-CT4V/QH?N$%Q9[S_2<][,''\JNMNR\.C4\_
M]$=MZK .H-A\=AP+C/4'77PC!O_LBX5>@H,WHS#=7TRW:B_>[L#,7"O1K1ED
MJX[3=&*V"/$>^$(GGR)_J7M;)7#XC!G4)L#EPHW=&YL/&;N339I!\ZSUNGO;
M+ $OS"8*@G(W:AY(-O:DT0I]1),6W_[\;^S), .R9E!^M2^F3[58YRR>=AOA
M<(-H7&&6V'/JXWMK_1)(,Q_K=6.%RZFV]]T!63-_I!EQ=(,W56_H(.9YZ,57
M1'B%-0EII2C@6$E_V9\Z:OO@!-U@*[U(!T[4V2)K; BE_J!X5- EY<F%D0LH
M6V0"OW<NEY(E$59JC?0&#WDQ\2F<50G-! F6C7A706FHJ=2"(?+NUL4/E(7.
M\DHH-><S-82D3DN"U)<KGALT'GG5.+Z'-Z9I8R*_KZ1H(HTY9+51U,J_"O[[
M[)^GEP*8&#E3*'=(-",/)8V^FP08]C_\-0M;W:#0\N=KRI!Y$^?BS_VZ-!^;
MW%$8X[#Y@2=2%2E-E#)>P\0>08O5)\&:H#BBQV*K&'"@R+DV<FZDS'"KQ2-O
M3OPZ)YX+E5=?V>K[Q='-C U\(VS?W*"5( A[FEI.*O2*K0PE[B:P("L2<<)5
MG-?D=PU##^%=+]2XS"">SGQF7<@XC0% :!Q\T\=]KN*IR=%H5!WK63460WO[
M^Z.! 6N?KNJ.M\I<[&B,B*;E--MX">.' I7B^GSJ-'NVDTWO[\IYSU%-SG9U
M,%3U44Z4]^UV*5RY4"K_AKG$K=+HFV4-0!6;FNIS.'Z)<L'Q?.;(*6;Z3(/=
M8URNAG]K3F->Y9287D9G_[,%FR+#D-81:?<]T^Y@7G0]^4(JUYIFVES\\ ,7
MG[B$3*;S,EQ_M%!= L4\;#U^),O-?^#U[]:.=_LT[>J*MT7,?"CR76*6$WJ%
M'PFV/24X3)^9!+BWT=4TV;Z^H@R\M8;?D&]^;8\&M03B%8EU(YG16")$X'L,
MERK= (G"NT,"J=.QK S]/'<S1;JOW%W!SU,*@2O9[&LJP27E'DR&;B2ZRWT+
MK )D_6R!X-22TINH9YE&]769^G-,R,?":AN9,GU+HU5HR2;;HDS$UE1AI56W
M)5_3-$A82POK]6WOYKD>;5UUP:J-(">/6P>UW]K;XHOD5;6$7$U0P?W"C4+*
M\6=G'34A%B%<[R9:0F3GLHYTGNG,/O04-"<X5 8<]+6S?9U62_(LZ67;MGWV
MP;14(GC*GM@I^>=]?L(J@<';:N^@GLY]\^9S$MWGGI^CJ>94N=5SLH5#(MT;
M:J<,H31Q7A05WG6FWDRX&[/D(=R<5O'08V>XD'R(!S_.-];+ OQ;6*B*1=,&
M[!?]88K'6.8M0AD,N*13%VJY/=ZB^A:&$AP/DGG#@CGN.+'I"V7^&8HEZ.N2
M>D[45%W[.C[XAR*/.E2\O%^<I'J*O3*]Z&0R:LS*HB8%)NFHZ=E0:[)]8(@O
MO\C4&,LV,FAV6,AW]"G0>V@Z<R![EYK>ER^FL,3OI!OR(JG_7Z;A/,WS13^S
MSU\L .&DB*=W7XH'<FZHZZAZB%^<:^G1J^=R^G.G]BRJNS'$O; 6$"=:KM3=
MSV[. O](*G]><O%N#KQTMUM2R=W+[O$#9F[&N^ZGMZ*8>7Q")4<@@AFQ_99L
M*-S&BNL  C='\& ,4^5E1[T-:[(]-Y\R.I+O[.)+W-7$D%%=I4N$CU<WR+_'
M;1_H(8/#_]GA4O"N*^-6ZMEEUL220'\1B;2]=5!HQV-UCB><<=:RI5IX*!.(
M+8!-W3:[*/G,P\7&\VH4)$W4P$Q:+\N+C,M1WE WUC(O:)<>7QO+,:YNBW3
M-R(659X@Q>.&[S#[,)*BQ+\E!)2L6D6S*$5,0CH%+)V>C-#K.5,\OOWSEC1!
ML)$XNVF4'LN]@*1#JL-4[7<R>A&QKL"92:9I31*#TGQYC<V\TF)NE!R1F='%
M9G?]I6UEOLB7^[@=<"3?\1*OZ@_]2G&FUW&T,S'_\OEP@4V8H=?J6FL,SCDA
M E]+W5\R:GHBE*3V%] R=QY+:<^Y#._S_U6,X?@XW6S1<\LF=#D8;*%DEI\T
MFEPM;1.6+CS Q P\U#%$2X^9#^P75WI=+'6'/].QOS)\^K45];*^;][FS\:P
MRP(A;NR/U.%:P'V8<*GZ&3/WL<&4:77R529@H66.N60][<T)5WY>8[#\*E5]
M$5+G?E?J7\ <>=%SKH&_@/9Y(DK L^>>Y[K_3 0Y0TD<WIQ5\R;?*:1;5#.G
MQW6:HA?O]L#?RH?H\C=J>MU'VK6M9U=<WUG<)T-')&I[?+'E!H:';ZDYC;QQ
M?"<TCHG%8+ZV.'+[#8_O?QBW578S8PZAE)BG@V(S8&H@^Z\&JO21] :J@/^+
M['<N=5*;"N<=FR-NP;0^S'';)"5EG0(1RB5>5Q1P4=VPKA\/&3#-9*MQ0(+!
MF"=X*V^_PU^JY7#4<,IK)*A;N!62W5<"FOJ4^X.%F<$8[XD@ AR-<AK/?2/U
MB\%M'/W*V9LU>37Y\&O+ ]V.N9J'.H,AOB+D> 1L\G&%8ET]7Q*0-WE%4>O9
MD5VFM_/9.8NSW N(\ZA@2DI0C<;K)RJ#_>XQ43V6-%,@"Z.>\W\0:3];XK!M
MZ]HV\$C9-.NH8\WDR[@63GY>UKC<OZCP\$H?NV04\0^1I2'"F#AG<GG;Z',/
ML?. N^%&A_;1H%VXTXF^A3CN#_ZEA12.PI&I3]EM?2$FSD.&:=FDQ$#'&$G]
MRG\F6H&US,*)1;<0[2\^ G_M;-<0V 0/)25U\_O-Q96R+^BA1]EP+9C>"G+^
M.J=Q1N,<:K$H:6<H(WS",'CP0[ D+[F$%[D'+#XI<[T+J[6<6UA2M4&JK_SV
MZDK2-O<OC)P@-^@T&"T*G(;_!80&Z;FOS+$]Y LEY(^#![]<07N2YJEKV,JN
M.A$ !9J7IP'\I37:LK0;M7Y<X,].\7]B6':[DQR3PA^NVI+*XO>/96\$BS(F
M(36'"F"(1OV?F<@?,ESBU<=371^$LSP1&O\(K*"@8&-Q.2^IW^^!ZI0D%%KL
M+<]J6I024;.@[C,YY,U_-;Q6BJ\'+)O(EUUP]-2HEVZG<FDEZ[9-I;VB&^$2
MZD@#V_1-R/23*LI4O<K[8/C2O/-[A?6PM]ZMW0;1BFVIXW]T_/-R:JLU8^?9
MDD-XBE!I8S='6GA2'/:<_=[T3&^_P<0PQ$DSH'94X4&-,^IA?)?&78*(<M^R
M<I5Z7@XFT2-_6/(]P$G.YQM38PQN4Z?A6^H9.>[2;<<428I4TNGFIILW3J"\
M> X=;U4E&9<,>/<9Y8H3YFQ#^O$MG <U+KSW#A]<NS3)'W]>QM?HP15S=">\
M(H%!?96*W-F%%\;X-95BT];8<"Z\!'"^(Q^#_G+!?OX">RW2Y5?4,%%>^:8Q
M*$68NYQUW3QX?O.P-X"*OFFA'%AZ+O.4Y<+3:F8_6V@S_M=V.7>#U('7(<EG
M%#<\Y'<X$,['7.I^(6@B+/AM]OG3#VF:Q,-\='&;#0OG-X+C6[FO',V(8UPV
ML^<NM*!UV%_I>$978 #IF<Z8^-?'W=F#_</B@$T&5XU#NWS[E6P1#@*LQ<*P
M7^]*O)^J4ZI(IYQ8W)HJ[+V*Q8@P=?YM>G^F0YIHOE@C6+Z+BZ@D[^0PTDI3
M0N$J=%%+]#L:]8_[ZS"BQ$X->A62:MC@6N58W2@1-1[S306WMG_6F"@1:*L+
M5657+7;XYG(1GK\U?;QO8._B/9#":B=\>&1;'=Z8%7P;MLM^9PI#!37'"J_7
M:?*T5K=5FVD^)MQ*!"N3 C;K8>-;A00;X,<3BB42&"X[M=;?Q]D:>ZHU)*M-
MJ]'W.#\TZH@V]:W$W$3NM +5JIGU5-W<PR)-M-5.64GT1E*J+<]4NE@=0NK0
M<S+F%/+8V"8\"3@:Z[5@;XBI9GG1"99/"2R.(!#K,5*_TOB2LDF*P'S?9B>9
M%B)X,:$9WV^Q8&<F]E(^,V5)22'%-827)F6K]/.0)8_+.-UUYD^(EBL"IB>F
MM0QLSGT6.3.-3 M24MCYY@%"#R([MV,0KB07,?)3;34LGCH//HJ )#77X!6L
M?0PJ76M2*I=N,.P6^K\"([NFJ>H&LC0KH7 XI^.=>">S]A\OHK]^<;;G!/A:
M5XA><U[N^50[N0^BV^N;AW9&G<P^?!O.I'Q3G14:WL(&FW3(QPW(&FPP+I+/
M?/^=]OXU-%I!A[V",TSMYR.*$Z*D[-GKR_&5 X 3Q+($SH"52@-+2>B!,$-+
M>BVB+1Q-5R'7/=+%_Z)*@ N:RM)NHN@.4QMR=ZLUV(0D"Z*G84Q5!8V1:D^]
M^BJ_])#RE?RJ>I:7FF?HX6O]GQ<TADS_]1SK?R\B(WVLL&09LVM5)5<#YH.O
MIE 4D:K<Q/[BGPG6%DTDS#]1P>/A]QI4A)'KKRL=PSZHX*[?OK"=18TJY_>O
M:!P.^A.G"H/=?>YZEP0AR61L,$:DEGI"I?M(C^$BP;!IJNCP+-E:*:?PQ]DQ
M:'X/.3\0ODD;0L:T1>&--KO6"#>8]J*0UY':7IDJCY_)NM?PR3,>S19*ZD[H
MKY#2(_>+U6V:RCO<K[9U13O5*O9$>[N,\M0EG _;W*,.6&E^E;I(DJ.!;966
M2O(F:Y@@6/[P:GP&>>%!(9XT7D-C*5OQS==UM\'HJ9]K>#NWF5\8!9GK6^2,
M?@O"A.39*JE8<B,7BOPN$2A@<I4WW$\$(HHI?0[GP7IHN@PTB*F?9SQZ=\&0
M5A2DU%)7<XBIZ%VCSM#V=9]WIE3H%$^4NK16W$E-.?Q^KE?;7)MJ(: *)=_;
MVP<SO_CM+< \Z)$?/F P(F\(;XF6_4EH55P5U+MO&MS\G:*1$,T.G5>VOG]+
MHLD3ZSG==/7^(\XF )RI.(ISL<>2$.Z:F36)KLN"B<0U%-Y%'%F(1OW:ELRA
M=LQPKA%"0B#]Q'((IM+0)$*O!X0FY, K_5J6.RU19B*_35-*,&C#5ZCE7?I&
M[F.81XY49,%?P+U?,K]&Y"YYFULLGDFEDL'A.,V7HDMO\[\8=8Z8-!X16N5:
M55\I(7!"&67:M!&-8&(B77D?A8V:/06BBJU4.:%+<.';YLH<.*@@TB\]%RG+
M+9H41L:)WS4Y:*4MWFFP@]T8\J,L[L)%_%/9XB;D[?T,.H@G2K&3\Z)<$'P?
M#E3VM3'5-,5KO%2BSO[6+>5_^%.CS@ YZ$M$1V$45>$'0K@^GD^9<U(XXV;:
M\$@.M8$#4]S[,-"1/T\?^GVAN?29])FY02S8X9#IGH7F[]#.42Y<6>_AC+X.
ML<4DOJ6^-D&_WO1-[8?U0+\L8+J2AP9?$2GQ(@("*Z[BRFV_",_=]BV:V-XW
MRS,=P1Y!6Y[#6ZG:K:D?R!9,O>-R@$BAO:V]S[K.4&:-2$$[OU4S@,!P=T@K
M L;QZO!.E;M(F:-U*:Z["&9IUF[&*2S H%^Q#L1O4"P5ZI1>W-H_XV#H=O4E
M<2R'XE1<6\6.(P3#6V:4L!Z3.W\!%4^7PSU!&!HFZ'9 >R[;F 'ZYYSR_A:%
MQN3+X?L@ VPB*?MJAL+[O/@G._<I&A\B"' 1,,PCP8DP]AV=8JFN*%M^8]5A
M!&.QJP+.& BO+US[)FK6?3*X7]H7)\/]1M?]9E^@ZII3[E,[6^,$2D<$NR/]
MV)M<*"^1L<%JV7"OIVF[$0\82Y%WZCJ6RNF_?#+Q&IOD:ANSLU)!N,_J<6S!
M\$/;25:P<S.F_(]BF(Z6RA50]=>-&FN3K;\!TO3ZPR"17M :<(KIFK82ZM@L
M/8O14OLVMOG)5%/2V5#+QR*7AYC4S5)<46"^G78:1''#>&(\);R)FA!LK+24
M\7$Y27:*8(\]F(XULOIHJ9:E)#V.9H&ZIM 9U"+/'O@=,G(#JEUUJ9Z3QI<?
M_&H9&@H,_&G(RMN&@,6":0>92"(-:125]E7*V>@Z(*?Q?Q)G+E'9H/HT:\5/
MY&PMMBD=1%ETD5OB,L# "<<E:F\*'FR*B%!Y7LOD1IU4O9K5(S/SUR\'>B+Z
M\RY/\U,S=AXD54GWZ+!TX4;V41O^MK6(8VM'A_VO+Y;O[=_QX3_GQC9_ZU&D
M46N^]U)4A&FVXA &]4D)"M-82AJCM$G&55MUR!'*A3+ 9?8T<W4#DH3GHZ$Y
M[!#GDT>=P&44#8-[ZVTA(POA0NS;A5;YFWBRQ/N=D7OR@9ZJ)><4 SLNH!&Y
M&16YM1F!9K<0<_\>H#,7)[Y*%@BFN18*IO7*'%'SPU X[.$>2GKB:C1(HL@Z
M]?2#2P._D;,]7\'Y6:ZN<8?]D/>4$U&VH8@$G#(;]-KLH.B/K#XJR >^*=NY
M]!P42B7<ZB3F=N!R&^[)JA9&9-]^W,=F9=4!'\KE+3FB$GK4U(CXL?6QKOX;
M5+;"4K8Q^;609E>5K((]$/L7<%@CV1(LUQ<X%[BU@<):Z-'[(#9P"LN#O$H[
M-D ZK*?>T8-P%U ;3+_U@8'Z[<5HWL]$AF86.6ZNVN#;2]W!;S>TM/ISU#,.
M?Q;&SWMV\T>4TF'&!&_I3H:QAK]*D<(\:/46Q<.%=FL<SG:]%2=>U-0E*5MR
MJ^E\W^L.:?SCK?OTHUP0.T<-MC*_.9L7<V5>@YO]ED;OW[<Q**]>KXDOU"J\
M> F7MIAV-32]CSO[L3A-EF^H\$WX[A_SH\%*"'[E7:U2N'UAMNZ$QMN)/[TU
M;QYJV,[K9;*$$;TE8WZ3E-"%?'50MB<_<*IAAU@EVX@.5W\4I<;6R7RGL!1B
M6XMS!/M,,C@^#.7R:/O7__L;&'RJ U/_KVO2_P>]_SO['U!+ P04    " "6
MB0A9G>/(2K /   AO@  $0   '-A=F$M,C R-# V,S N>'-D[5W=<Z,X$G^_
MJOL?='ZYN:HCMI/)S"0UF:U,/K92E4QRB6=OW[9DD&WM8O @D8_[ZZ\E/@P&
MC  YP6.J\N! 2]VM_JG5ZA;P^9?GN8T>B<>HZYSTAGN#'B*.Z5K4F9[TOC\8
MIP]G5U<]Q#AV+&R[#CGI.6[OER]__]OG?QC&K\0A'N;$0N,7-)KYCD6\<W=.
MT.]?[Z^1@09'QX/]NQOT?72&]@?[[XW!)_%G?/G\S*QC9L[('".0P&''<.&D
M-^-\<=SO/ST][3T=[+G>M+\_& S[O]]</TC:7DALNK[#O9>XP?/8L_<8,?>F
M[F,_O-D7#.,&ON>!7D4MPKNI)A:A^=1P(TW(/8._+ A+R2^;" W@=E_<%FT&
MQF!H[ ^CEL2T\EG C10+XOCS_31I,#C[@SYYYL1A=&P30Y )>X MF;$O;!DV
M?S9G!8S@3HJ339V_\O4 2QSTQ>TQ9B0B=S U67[7\E:J;X8?<:IO$S-QC9D4
M1I^P/=.=RP:##P>Q[(R:^?W#C73O'H\))YB-I=!P<95HQ59)TN!6N@%?> 7\
MX4Z*U&?&%.-%MN?PQBIQ@1S1G12YX&SQ/ 0,#OO!S20I76-"ZHC);,8F?,Z8
M/)QZPZ.CH[Z\VT.8<X^.?4XN76]^3B;8MT$:W_GA8YM.*+' ;=AD3AR>(DC<
MYMB;$OX-SPE;8).HXP!<#4+27]#YPO4X<G+[*%(R<#+7KBFGQ9HFXC\C:F>(
M2\9PWS@8[@'K7E]!BC5.*$\(MJY)](\A_JDG07+^*?%?-@A^-N"=<"M*K&-Z
M^:L!XZ5O5N(;D8L?U;CF>)BU'#/T?6)S)IU.?6U7UBTUE"7;Q/_5$"+C?A1G
M6M1 3+'#>GHG7*^2SC&]_%7?T"G'7-?<LH]J,I3'$T7"E+64_[,ZAB^+/)0D
M*NNF)CSBR$ -'2&Y^-'$Y\4QFYK+"\G%CYJ(7(D4U "9#$8"4$;=U)<B$=TT
M$$)<:3 OP)T<]3W7)GV'3,6>1,TCV9Z7:B7<TI%8^8<?5N7 CN-RV96\%EU=
M+*@S<<-+<%%$3,=1H'Q/)DC&4,?8,P6?]9%6?^&Y"^)Q"E9-Q-JR@YE')B<]
M$2@947#TAXW'>Q#&1209!ND01^H)38A]O10O:BLP -W#8-LDU/K5U3&Q754=
M:&+ZMK1*2Y6RR*2J4M"$.K3%.BT\4E4G:,)@?U#+4J*#$1 @"AMFB-"YW&H8
MEFOZ\@=V+%@[..4OAIB+WEQRZ2'1[OO]E?)F(Y!4G4$L9B3HTG#![DIE*_UE
M,!@@ YV'O)(_3QT+74BVZ&K)]G-_A5=&#)\1Z];Y(G^O3)"P<4BQKF$:A.KM
M5@V=WS*\&EE6S>"FZU@0*X"7AE_,M:DE7?88VW+3QF:$<&8$02TW -#4M0S?
MP;Y%Y8+0% \-^>N"RQ P\A )!;_/(K'$KU@L]#40"SU(L="[LT N="?E0M\C
MN?[5 :J>08T%%M=GA%,8%/;6^%H51Q?<]C7##;V[2PG:X6_5X#$!,]R)(5;F
M<$^T>5^FP%H7K@[4<!63,.1.T&TL$7K7>3!%,S+NFG_-7-LB'C/(#U_$,:\-
MI?4RZ,+4^SJ8>DB(]D]T(67KT*5L68#*S)C8[M/K^Z=<UKJP=%@'2V<@$;H4
M$G4($F9T7$Z,H3&5E6);;J1L"C,,QN6E.4C6]JX+!Q_$EHPRTW:9[Q'XYQMP
M12((#^K?-@*^Z#KBN^.VWC<8G3IT J&=V#B;LI)%G:FQ@!D#-M40)BORT67_
MC[GVEU'Q4@)T&DN [D()=AP)!P9P6&!JR7GI0KSOQ7L7L#9L$C1!08&1+BQ\
MRL6"B&3O A&D+[@5(J!H W0J1=AQ,+PW/ (>.LPSOB0L11TP,#'(\T(LKIH@
MH<Q.%S".<H$APM%[$ 30$0B2@,>5%.3?Z"*09,?Q<9BVE=@@+,1=37@H[%Z3
M_8>#7/L?2L>0,/U%Q'C'S?T!YB''SE26?;4N!GD]ZS+R,-?((CZ\BGEV[EY8
MX6/N?E],/7E=#*C8V,V%ZY-":/;_]?GKPLI^+E8^RCUE3KI!. =YPY"RP19S
M*5NW1$B;?HK6;HZ?M6TC5CK59?V#7.M_DIY"L$,CP6['#7HD9N"<<ID\T63/
M=)^ZS/D^UYQ',BD4<]MQ:PX'ACQ8)G-R,*E$O?R1&&/7\9FQL+&&>KPB'UU6
M/\Q/_(A03T@0Y/JN(@G05R$!N@,)=AT)0Y&S%:D0,*F^C$^F6UUV+DCP#8.<
M[Y+AKIMUWWC"GB?2;19]I!:!:,JB+'@R0,MY&S4VNLR>G]>3@=M_ P'@=B"
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M%0C*$X.AU/)Y]A256,4[CU=2:=F,AU-FIQ%.^2G^=16>SH&I&2WM&M9;=M,
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M^1P/#DPVXGBG4Y/%?I3-W1G;"W>UVK@]3+BQU28O VSLMS%7))MVXQ9KA&J
MVDC8;5:ONB!3FA!6!LE,[99SX]'.]A8,;(K5[9>EBW7-5ZN9@^2"2/E,^6.V
ML[*$^UIMW:(2DXG@V5X((X 2,J>\EN_8->N.=3O7RV2OXXSE(OAG(:(Y965.
MI4Y3IYA61(OJGJG+6#",XI16^^2Y!(]ML[:PF-7+$WW*IDIKIBNH72_XY5LS
M*]V0@?+'HNN?K9RZ=PQWNMC#(;HBDJ,G5&O%P9B&M R)?4.W1]-L_6<SC]E>
M.;MR$;%!O.13-<%VL=O>"_BT$_55IB!VB4O\&[6MJPR[#XR+C0GE .Q=M4^*
M9@A/Q+Z*!CXIH!EO@^J/3\II-Y@U4S6?]LO8 ;2*NWTR0D-LL6J$-F4NGVS-
M#E9EON&3A=E!,E=R?#(H.SQU8W>?;,NZ[B&LW(QW1M8$7U4NX\]*VOH%FR(_
M!H4$![MPU/0(#];/ZC+K:AO&=W$I8/YM'DSO9XHFE%.5:.G.8/O=JC5;M7(\
M)+^28''1M.!B<8ZPO.)4I^F/R[7,7 YFA#*=,#V(E9"@<+R7E*5)Z654C?MQ
M6P]?*$6A)V7C4DK7#K>5>F2@=+_>L&I\:U9I6G:H;-3BZL,EU0=*>:26=83E
M#%"^.;IN!XZKX@HP:-+UU,H[N6NU\;.V7&[.HN&\Z%-$;86NQNAY=:.'R;,)
M:X?M4X*W?<[?AF77"YJ<[,ZOA'. &\8<7:17,4PUIBV?2BB5P.I'U-Z:5ZU
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M]!S([.^))^<S7?-LI[/*%]2,94MY2D^@TE>!;VCMEO)U'21=_=V:)H/0J*]
M.WSI3 LZARZ*NSU-N[^$-@I$I(( [>?6F4>V-U^*^>6J4$:XS)!ZD;X,*;CC
MH> 9MDBJ;0F#[:E^*3,G9;%@F9#^JFGHZSGCF*WUFIR615Z05"1D_TY%O0.^
ML=[3C)L]S\R$KN?0[NFX9A9WH6,_9V,K#BV(O6M>2W<O\9P^KN),-JX*M^@F
MK,OQQS$[C9+FFHI7S[\_9FF1\6VP),DMS9:?NY[']I3X8*W[8&T/='+%ZSS/
M2QJ=E-FVW%*E35S2!_F3>JY-.N/!96(^V _D%F]YE\=13+*G/85:8R8WMO<I
M [YL_( W"=1Y<1C,?X(13_-R8_8F_NA280R%$)KSF!8OB%F'0E&E _7$QP=R
MMA@0@,/'PXYN=P"%#U#R^IN]VP$!]W2<0S"Z$^+-T2QT J7A99IE5: 4"&9*
M::N5["OD^[1EG[9<=ZX?G+4WQJ(%YDE_;N5)=Y7A+3R'0*@'4P2_3502.%?8
MZN,/'LT SANVBOH#Y*H!9PI;37XD^9/ V<-2VK^K8 @0]H_(8!NFD$'5*H?.
MGGZEKSXF#YT.+&JFHY0LZ+1@45"M,_4'.CGXP^:VBH(\TK;E'6"#N3[C9T*5
M/[AWR ?W6N</G$M&NB6/I]4IT".:<IY]>6X.V-IG!ODR#DJ?VY!N;.\/]?[0
MP_&'&DGC@;2P3Q^%!/P8\(X+H:U489_@CJ6<^E5"TI:*F?7XKG6UEH1Z]>V0
MU3?%Z?5CSBM'@D&V\5+^(9-,19(JYO'J%B#3?AV1N7V2?*XT@U64:9KV1\SI
MH_3@K.-%!J35=^R%4'U9 DC[#LA:.S+R,Y:]?F(=7: .71"VC88)7X/TQ7R)
M$YH7+*5;AI>O[*:\^S<-BULV68GKZCG+I]$D^G>9%_L*1_UMA-V,W0W<3=Z4
M?,]\3^+\MW$MG9"G_#6I7S@91W02+F)Z3R-.V1<B2C]RW:%V,?;TB.[!OR9#
M7=7%L&M[TZ_IHL)*<"CO[ZO]O7^JJG>MIJKN]]ZINA:>5<75=J]^<T.-<H9J
M?L5#T:!'!R>)?-!^2&S?@;XV4BYI,9UQFT7A +$;Q!>C\,4HO-/1.QU1.1V;
MKS1\O;>QADT&$X+QG=GR"=HU"=IP^Q*5AWN Y&P\!X\TBC$:]E/),=9H::#B
M,ZB<QL!9+=Z&VAIUFT_M(W4^4G<XD3I+K_P8CS!8^=]&=HJA?^_IR,XZ].A$
M']E)!MM0TL@.'L"#>2,])]#&_SBRY'[3*-Y0F22? J&8Q%QW37FGMAF]T.&<
MYXD8T>730MY@6H@42=7%+B<TB^^)6*@360XA/Z$)X4*8'K,R*S37,]@-T3/Q
M=O0Z)?&6/I*\Q>2J^KL@6VX#;6E7#=(!@-]BEI#J'.?LC'(*2')#PS+C0I;F
M%^1!PQ^&77N/U%[P!\^KLX)<=5"$M-6-'-,GRK'4"EA(TS'0.FBL\(+E^?%V
M2W^ZI _'"8F7^1DWCM9GQ5Y L>CIHY\^^JET%@X:&6B,?FK$(#,10:.+(4+V
M %1AG,;WP-ILQZC<\>T8<P1!(/"[M-=FT;BON\6KUX#1N+([ ]UH#Z)Q5G<&
M>7CQY..?/OYY./%/:X-F*%_SYX!+O(SPOZ/X/HYH&O$/>9'%=V51L7 KW[/E
M\,Y]T:WH]+[I-^B;YNLYYTK_[Q7;3+-K485M6R=IOVA4G1O/O'=?)+\N<@6F
M5]VU"V*W=2#WJT/^DG'!NJE254LHO%L'1#X;5Q3-$E,B$B6V4U5+I$&W#@\Z
M;@??\)FH[J8]Z:COT05I>W.P0;Y=!;<+4DSO$J'D\C\8)TI_D7CKP3H =$TC
MNEP5+]A/QPNP'EU$370E[5Z\YUI*K0;H@/#UT'L357,U(J!E=Z3DG('*+%P0
ML2*V1<+401N#;D[=Q;5277/*J[']\-1KSU4!>HP7P:"A'ZT^(U?A3J:M?\T_
MF6"$CC4\ZFU1Q*T?^)C;QS0Z>CHEX>)Y6Y,9L!D7\VR\?(7=S(5J5+>'/+?Z
MTW;/%-I=G;YETL4M!A.MUJS38#@:M!R3+CX,?0!W@FX8<Y)&E;38*ZNNH!K2
MQ8?2G1S#;=9&F87J-[K@NJ%RCB;.;O)FF*TAA2KRTS7C8@B^^_"=#]\=3OC.
MWM>-)@7$[-UU:EVAR0CI8 [,_ UH$D-Z??M-?H8QGF T<;^/\>@BQ"4^TI.+
M<%-LC.<4;2/$0*R8;Q[2^UR@*@662X?:QLZ@>%'I4,81;BA*; I4'QBQ*$A=
M1M6AV+&H2';))%"4J%0@DVP/*$ L.I!Y>&6@1,S/01[/TW@6AR()D82AJ!W#
M]XE@Q9)8'H__BU-<Q(7,W@[B5)9DD;F);+9)7MR>H=]  J9I]O-PUTF<?:+P
M*9YO,,739_OX;!^L" ;-]OE"25Y6!=W.TU59'(MKA+-\XUVH71I6?0=%]<P%
M:(1)TW-@1"L:<DW]9'W&X9KOGX; F@9 @4_<=VZ%ZW7'0?%(_OE-GC!.^/9F
M!$G;=U!4UW'^YUE&Z7E:T(SFA3$7-@\P*#[IU#$7&JIN@V(1QTHU*D)3\\%I
MUVZOS1W&2K^_,N*-9:N]9 4%"ILA?#:;SV;K%&GCIL',1;3/VO-9>SYK;P@&
MAJF Z/@7(%@T(!L-?)0<W(W@Q<"_O;]@@%<*7<9?.\1Z\Q-=:E\[L #G"+J4
MOG:(H3X3=#E\;06UWK&'+J6O&[A-_EFWLLN?$?!G! [GC$![7\I *2:-1:ZX
M:9;.:1[PZ=EF0[ =J(#_LQTAB<F=W#LM4T[<$(.NCEB'J'Q*RAM,21E]U;'M
M"9H]%]#F)W%(@2\F .DFHW0 83-%N^=?TYPS&Y^N\_2$AAD7]URS7O]XL5FW
M=3A:#N6SFGQ6D\]J<HBDN2($M)M3+&<DSL3EA'1WVV!C\190'Q])/O!(LH)J
M7_=D<""'%"GV$50?07WK$53OT_0^360^33-=%ET$=*"Z :C.Z_9<-P#5^=Q.
MG"GH(IXP+C:PUM %.8W9V-S?-U",Y;N 3P=)YS'?$0+>F19Y0)8L*^*_JY.F
MM+I//9BQ+) $T22^IU%--[NX2G\$N(ZE](W$QT\..7[2WH,F.>I"<-3YEJ$F
MDI\F>UQX6C'A)>>FVP>:W-,O7#E=*%ULG0R*>!ZNJ6"F2-0/.XOSD"3_HD1U
M *K#D1'/B"#SEC]9Y0YL.1IVY ^L.]R[L;"@OJ2JDS:P3MZ;[B^S1NF)]NXM
M[]XZ//=6YQK'2#U@7:JA(_.1=:A^C,QCUJG".5:GF8%6-I 'Z?L@%]ZMZK[N
M/*!_E2(#5.2%RN_O")_&@(\BWLYS/XC\/6"RRJ_LP+=P6>*,/S@0%YM' 0F+
M^-X^:7<0VES[G08$Z5U2WB6E,8@F@H4:*K+4MG%*Y=6.Z:ORQMHJ. VMW1J<
M@H CL;Z/]Y;W1(09YE) '#WMFJPKBLKYOF3I5*[Z4RDLSM.<;W/BUUVE7)7Y
MZN"18Y_#,Y;-:%R4F?+"-C</'?L\_B+"92XY\<4#QSY_>VD"U1T9[F92^>AQ
MS&F%:G]-G:>UIU0</&E4,R97T!:"+#S>TXQIGC2J&>M]D38]!]=LY2H8.STQ
MC:X2DEZ2I;[87)^/\G,&?Y0O[3=\"*D'.C77P\@?UV*GT9ZP'LB'S)P<WJBW
MSYE+.3NZ2"+ MX'N=$>OKY$9^D]015H'70G^Z(B/K?O8>A^AM9X-JI%&VMW[
M@D8:C^_=?S'2:+TKM^Q( _IM[9V1'8UQ'S8"3A"VNX%[=R #YP7+E<)#1,K<
M)]!P[2X2F1@B/R/-61)'XE[28-L@%Q?]\0$7P2QA#WE0IJ2,XCU9V)P'T_H1
M#M-9.J+59Z4<<E:*HDK8"<UHR.850V[/86Z.T,8TOUUDK)PO7EU:O5\SS'J0
M#@"<I]7QW]TQX!-Z3Q.V$IR_3FZLH]FD7R]D3E<T(^((\X7XNSJ!/_LUWZ1H
MIM'>_+T^?]+MH%T ?'4I]MX9[6L]>]1BZV \MUE;V_/9^2T3!*9AG% ^R?PM
ML26]X);*+3OF4O@J8Z)D:'3TQ%],M/?.)E72( <PN>/;+@E5AX[Z?)3;.=M+
M1)[.7J;JJM"#.KDM*<?G6OQ?*$WW)*$5MQ99+(ITBQ]$#8IG7^RUY"\M*869
M?Q+G*Y:3A%NUY8KWX'\+/U:<<JMG_>;X_JZ8E2%(&,\<5ZK]2WEY^KB&S3_(
M@KVBCOKI;$:5*V\8(IS.\PE=\=T\EF]:,0MU37S90V,4K[?O2769><XM,N$P
MYLS$O^&&9*3>++L9;&#<I]Q*8D^4&X>),%ULT#8/,3#&[=Y[3%9Q09*&/=Y\
M@*'Q%0N:[?1/BU?8.,+ "*\RNB)Q=$)G-,MHM#82^+J2A&MUEG:#.<7-U<@Z
MU?$L3KDZ_DQU5& U'P IOH85:C\0!KSGZ3W74UJ\3\T 2/'9O4_ 0!CPUIAV
M9C@U R#%9_<^L=G S\QV-937;=Q2R5+A0=XMAC3:"CH9A6AZ&:;]W9YEJR(@
M^2V;A-Q>$Q?D,<XFQ9/(*BHXK<**6^UGD+P\WF8\@%M\&0LIC?*SC"U-TDS!
M_09#LS;@5.YIDRX(LM,5U.L;^\SP0\@,+U>K*EF-)&+7.DO8PWDJ4SYEY%8O
M70U[^QQPG]KI4SM]:N<+2&T59G3)^2T ,9#R/=)LU?[CA^A8H5?(C8E7R,6#
MJ\GIOI:YNY7E:H[4L35T&=^NIL0DX(]NDF 2V3;:@T[.6@#13H-YF 2==+6;
MDCX2O- )U:ZYQ3SDC4Y>=,HM32F-Z [+=,T0T*P =,=BNIX(8&P=W3F9=O-@
M&^I"MRY:&?#@""8Z;:(%H/VS\Y;!&72:1#?381O/1R<C6RT*<)K&6!8%!-#^
MH@!'Q,:R#%I,0'<G2-WISMW,@FVR%CJ]N9OI&#*_&YW2@6!*6QU,0*?, B-+
M-L'<D9[?MDP+PK<G&^-@G9]SP[=/6T]*RP.E[D^DRQL%O@Y6E;=R<U- +F\'
M8,+T#L(RRT3+]565\)9V5S@XH<7UE0T.0?G#\(=\&+Z+0W(LCXMCKH(( 99K
M#W_H&SL^U)*7F2PB2(NB4C+X?A-2KF_=)?2X6A@*&$9]':,J^(:1%W D#>V=
M4K\7R=*3K6[H./U62M;:4)P>@$'/(1!M&5Q/_JMF/@'7W^ZYU5]]FJI/4_5I
MJGWZ#/1B&)V?%@8*HB.B\[E"<YM VA8Z]R<4G;%6/-) 6I.R-E)WJ[%2.I!W
MZ=M@M0Y;2U<&W<2LY1V5+-W4^5,TLO,B=?I,U]ZB'HCW7B'O%=*5,PO#<EG*
M3+/]-&[^.:%2"J;1?BZSZ2'CKH=W.C='99R(0-[YDB^X^VJ?U-X8VMQA$/I!
M- ](YUF9I;)*KXRV/,IZO5J:FSLXI?^"BV$MO:\;N*5/Q/3%I=%@1@;T<'U\
MOEXN'#V]O*;E]2EZ:$\<B'0W*<(ZX<#QNOZK21<<& 2':&_1,^AY.(C\-7_>
MESP*7S+LVCN3'8*U6/JC\Z-;;Z'H4IU,WA5K5MM0Q0_Z9V,,%]/U]Y)U]@\Z
MQWQ+C$W:/#IOO>W"A9HOZ!SXEH"A!K';1>MCN3Z6>XBQ7+@1CFX# 1;;Z<5K
MBVYW:?F^-;4*G$;9O@OB;7V138+P\WC1Z]_M8FL=/,EU1*TSDGT<[9#C:(H;
MHH0B*8[ML^4RSL6^GV^"[;7N<Z,^;D,L8FW1B_A>G(9[7HQH3]CO"W55Z,5Z
M("QXCYZ^D'^S[#CAJUT3.+ 8 0M"70@!V@T+EMU,7Y*EWG5M.<KA(QW48:^A
M51TB@G5R'T3-U]4X.%5<'0QI<Q!5W\.'3GSH1.D>P!\ZL=DC64<">[3A%&O%
M EU8Q?;]O?340F0D*C_?,/P_DCA,"ZZPL)^\1]M[M+U'NYV'T\PF'*E/NZWC
M8J3>:Q-+RKW_FJ_I2!QAB<2GG"5Q)%Y"<$<2<3PIR!=4^FO7Q2]6LEA54*:D
MC#BH;;6S9N]U-\]QZ+ONDF#ON7Z#GNMU$>G7U93KRQT8]7%]0.5%?>SJL-NK
M(MGZ.@ZVP[C%&D52BI#D2IX67I<+5D'2MW9+N:Z8S(#%8R E/H8OYO&,@H9[
MT[1MG5*]+H3XHOSAI#@F6?;$+3AY;8H"A5%?MZB$W5G=$"((E 4;YWS#5E].
M"^CA' %+97U8[2M0-'-*J[K8O7[-@ONY+NKT4L/>EE+]A;'H(4Y4PMRDJ]NX
MQVYJ.7=+=A&9E33+Q<(MGE3!#V"WH;#HV0L)/[TFHV%S:.[@ODP8>-(;6KLN
MKU7=WM,H1C4M?8FS-W^T\%JDDJ4T.B59RB5Y_BRS<A:'L0H)O*./(1_"7<K0
M?17)3OJ:C*;KGAL[^)B]#T[YX)0/3KV !/!WH$N,T-/,6KE!T+U&,-@65<N0
M1!K!4-N#<G@E+OS]F1^$07*L$HS1W T#Q.JN,J(ADR)?<K!- NKW0+=3  A_
M?BZO11 +W<X! V\1FD3'Q6:OV="YC6Y',4,+<ONAVU',,'8$S]TF8@8/' %#
MQZI0LPKFO$"WO0 (?ZZ@ZUW9Z'80,WSZB">Z3<,,'"@;!.'Z,\%HZA1'MVN8
MP6WR]:+;-<S@F86(T22G;AO(Z@%L>Y%GAWFI\$<,GY)J2JO/1CWD;-3V"4%K
MT7Y%LYL%R>@1R>/P!:V@MH-2?1(GY1[G-]#]HK7;X]DDSJ0R-(G^7>92A]]=
MZZJ@']3'*8I?:,KE3B+J$D5++O?$IE/$]W3M)%#@ /9RG4(F;YXY3[DLWE!R
MR=*U8$WGZN0'DZY.,?'G5C1=J.M2U+89CLK)/8D3X6.[97M6PUH]T:]NZW'<
MIF9MF&+-)ZKWHFPW++4-V0:-[8>AOG$5:%JZ3]S;%QW/9(J*>%"G =/X3N+[
MF*NPT?9 \6[_4E?<-QW <7I93KEA)&+(KUWC"DB@/CZI[ "2RGZG\7PA#K7>
M\P4YIY>EL-RGL_6V(U7/?%H6W()+17Q3 <1R% Q(7Q&GLR:LQO!):SYIS2>M
M^:2U%Y" ^B>Z>%$SW<Q*D4#W&HV &OD)T(61C* VF'OHXD=VX%36%;IXD1$\
M<_\/N@"2V>LTL#>!2-U=]&N$U,#A"@3Z/4Z@&B\@$-@/.(&U,"Z P'_$"1P0
MHX$J!TC5(%L7$10V4J6HI9L;BAZIGM3**0+%CE2- H4OD:9KY'M\*6].+YYZ
MR]L /0M; H<!T;!,#E5]JIU8O&6*W+43KLZ&;%[-PE;AV4L;^G7%TM-'FH5Q
M3I51:U>/ZZ!HEY2:YWDN,MW+C*^Q*UG8K1(GZ^=M"*B%:35 ?X1+G;4%W=K^
M&"IS:>N_@_HX1M&\"C9:&HWX3BXV YG.)5_0="4SNZZ%6,BY/+BAV7T<TNI=
M7>_6CG(^G#X=W<RN&;EB\Q9S5#O.4!6FM"M V<YM<I;<Q8XWESYI;];0MAT7
MU8/>^O&+X%!*A;>\U-VRHVPW'+7:F=:T' _%@W+&.)+!7IXTT(HY?6.WJ0G;
M_?.*/(EM9"+VBKG4[S?'"K58S = @^^2"[^V$)5CN$<)2,W D7RQ#8F^V(9T
M<A_4QR<A'4 2DM8DW5?L-P:>2C6V'P@#7FG*=@"W>9Q#JEN&//,(J,6B2_/0
M:;&LO2[@&"_LKB;U.U*]R%'=NM3!*VW0?=Q"[G!U&N@:Z%:JWA]1?[9]-$L2
M]F*8E9\#W0(%OTD#MS&Z7#,P2(C)/%C:KN;&RVY8%C].V]VR6ZGCTY1[KFO3
M29X"MF)P'97-P%:$:)#P&;J,6 ,6:.$K0)<8VPHVU&> +DD6AKI]TJB[;-CN
MEKHF"HPN55:/NFWF"KH$67NX@(07?-FR +C.TJ_<IQVFK*#!-T%&21*LUA62
M ZY-!4QD_P:QE$P!K?(J@W!K,,AJ2?M-4EIP4Y:;1<D64W,B8I]/=YB:V#\,
M7W;*EYTR*7AA6.IBR/()BG-04-*?M\9 ^>C*C/C8L85SITNWE2]X@,.CZ L>
MO%%/(FA7&:D_$;;9C]2K:'>(VJEQ]7WMH21A'<CO[TAUI&GG[]P:"DV_VYE;
MSNAQ;8 Y!N9-,F^2Z8[4)/)!Z].TKX(:>B/!K#.F6K7:U&6COH[KUHIM8[?G
MB*>*G4^= @SH@0&!]G %J,^X40QZ6$1;8JKA3 :XIW<5>%<!2E<!+%4'(D>9
ME<@:G6/$>&M!E^\)>SO0(GRHLNITF:!=\O!(\D&-W[2%[C>ZE&WOV?2>360.
M,AM+<B!'V><@C^=I/(M#PK\BU66Q<3H/5BR)Q66,04B24-R7)EB:S62TG$]R
M'O"%&^0"GZ5+K(<GNW9^]0;!N[F\FTOGYN*/CT0%-;Z5W]"PS&2N4W7I.(W.
MN,02XJ8L2)46];+XVF0I^%3E!>MR[#'-RM%3_0 :=Y2#)R*8P4NRI%I?$+3;
M(6 9U+5U\HHP!0IU0[?UB/S%?&XI7Q_%W<O;USH\&]O[*C]Z*@_^RC?O>NZ'
MSG4FNG9UUK89_HHD5;WB7;Z^"D^[T89'[J_!,L/IK\%"$.IQ8:,P6UM@M-$B
M9Y8?NF@3^ 4S8ST3E:,>Z?H92:3*ADLT^HX/2OF@E!EB'Y1Z":G]D7=L2?;]
M7Y"$+?.^NYN1L%7?:/)8 F%AJZ[AYL8C;-4U.K'T@=BQU>%P<<L3EBH<1CYP
M(#8L)3=ZC(<VIWJLOQ?_$2=D^#?_"U!+ P04    " "6B0A9VJ&\7*E'   S
M 00 %0   '-A=F$M,C R-# V,S!?;&%B+GAM;.5]:W/DN)'@]XNX_X";NPBW
M(TK3C[''.[/V7J@E]83NNB6M6N/'=5Q,4"1*HLTB:DB6NN5??WCQ454$"21>
M;%_$KD<M@<A$(C.12.3CC__SRZ9 3[BJ<U+^Z9O7W[[Z!N$R)5E>/OSIFY\_
MGIQ^/+N\_ ;535)F24%*_*=O2O+-__R/__I?_OC?3DY^PB6ND@9GZ/X9W3WN
MR@Q7YV2#T5_?WKY')^C5#S^^>G/S ?U\=X;>O'KSNY-7_\;^[^0__ECDY3]^
M9/]SG]08423*FO_S3]\\-LWVQY<O/W_^_.V7^ZKXEE0/+]^\>O7=RW;T-W(X
M^VO6=!\,!__^I?AC-_1HZL_?\;&O?_CAAY?\K]W0.A\;2"=]_?*O']Y_3!_Q
M)CG)2T:1E.%2YS_6_)?O29HTG(RS2T#*$>Q?)^VP$_:KD]=O3KY[_>V7.ON&
M4ATA0;J*%/@6KQ'[[\^WETJ8/[QD(UZ6^(%MT_OD'A<49S[%8X77X]\55;7W
M&</C!X;'Z^\9'O]];+;F>4MYH\XWVP)_\](:TQM<Y22[*!VC/#ZM%]P_-DG5
M^,#^>&+'^-^1)BG<8GX\I6N<J0K#CG$^FM(QSE?8,7\<3N@.7P"BS3&2FM@5
M;-1[^I,<R":<4*H<GE3A@XGQEP;3\TAJS6YNDNXMHDZ>DA-V-+WZ_KM7'$WV
MFU_.2;K;X+(Y+:FR:/+F^;)<DVK#]7L+AJ,I9M :+] JV"E!*KG@O24;SGM2
M#*FI1:1C\E>X)KLJ%8<J!<V.?5R>_/SQF_]H82,*' GH: #^CR][;(_7<EJU
M=$ZJ= 8W.>)E2NB)NFWVU[6NR,:$R,28<H(0%(G#/3E@%89_W1H:ZZ2^YRO8
MU2</2;)]R7CH)2Z:NOT-YRK.4?(7O[Q+\NK/2;'#'W!2[RK,T+LA19X^B_^]
MHRS[ED+]QP&'@;\WY#AC.+XYD"&"."9H@,H*"330)_E?A@_B"/W?H$P)WQ=B
M3>QP3)N7>8/?YT\XNRRIS?N0WQ?XM*YQ4Y]N2-7D_^0B=?%EB\L:_PTGU=UG
MHF)@F[F@S R!Z9NQK9";YO&H5&@4)M,$*2C#?1]':JV8D3BE;?@CZ'I-T:8W
MV#PI+NE=MN)G92U4SMSQH_.M[=$S!2/@L4/6J,,##1!9[AFDM3ECYX\^Q76Y
M56%;W^(,;[9,).A]-J5 D@<*_"])5244X)AUK?<%Q+Z>GMDWHVF@8*+LO:P(
MH-)[%%"/ Q.EQ2PJDY>#D?O9Q+KN'G&[(+::AOXS)76#Z+T"5?V:Z9\^2\R^
M#7])TI05 J"LI=Q?D0;?D4[)?*34Y];N.6Z2O*B9!MTEQ9C\FWT)T0-Z$'SK
M X8%NB.#(Z=#!$E,D$0E/&,9;@*QH.R2+S<4,G9WO1G.%NZ"PZ N^(K#T MT
MR8%1 G;-^</7<LW98TJ[B\XQ?2T/D;K5'R>#G_*',E_G*3VQ3I(T);NRR<N'
MDRTS77-<=S^,'2TNYH,<.#9P?8ONQQX/=-KA(6X\%'SXH\?))A'GE/? RB4]
M+4_>S.+3)%3RM/D9-*DKIC8"'L3 >H-.T%?!XK!]F^)SB\VP9/8SLMGD=7UP
MS_BI(G5]4Y$4XVR4G0T^@S"LQO1!?  :>!C?F;VL#6#Y]'@<> ,X*FA9ZX,Y
M!F[QEOZ5N<NX4V"[M\RT7W^%?]WE%<Y00] ]'9?D&6(Z #UP4FPEVA&\!B9R
M1J ;X.N\_.Z$DI\1\R0ILQ-"MZ Z27=5Q08DW#R%')C&LSH],;6A!SDROZ-'
MYHW !U%\T#7#!YT)?)"X BSHS#3?NME#$[@?OEC^=R<53@J*$Z'*IGD>()67
M5.'@$RPN81#&!\[ME/T-<0@B!+^C0G!+L6)'%L=J( J7'*L5DG??!<D"=#=G
M)<)JBX)Y^%B\;K8K,%E/>"_>[9I=A4=\&'<,];FP'!\@@+Y EZAX]S)(7.4;
M*\7VA*.+>GSER;)" F4TQ+D5-?2)HQW] =8+%Y 06QM.%O$#4Q_46F;XE0\F
ML6]&WT*E1P>&=[$02* .B\6%&IAM!;&BKR_[Z??[YQ:[EVWY7P'VDN9<3NVC
M&9A![*'?\TO!P!2Z:+%8D/FCNSFSYHX1Q2W9=N\._8ZN\K*N=RS=:#I,QN S
M"#-J3!_$6::!A[$SR<O: ,ZR?9\88IB@%A6K"!HO"X1YRW[:<W:A"J>8VWW<
M$\;\9WF[8*94ZD28B!%#:DSDBD#I[>ND^YY>QUHCT<(;-C^-T_--#2[(T?8]
M/=J.KB$+.M4T=F/V0-,E\4*#<:ZHP7CW&1=/^ ,IF\=#;G8[:9#0G$/@RXS0
M.<32?Z"./5U@\3J__PKB=90,"P[;F::VKU/J#_07]/+W2(J,[A6WKJ6AS7_/
MDN&SDY1L&(HBA<_"P>T*F-,3SQ:I(.?B'UCHQ #-W_ [G[S^\3^<<$31V0#1
M!3K%G7' ["GK=EM]B=_K-R?2OC[)\J<\PQ2_+*^;*K_?<:0 4F8XIU-ATH0=
M1&9>LW@C:?.C<XD-_:''9D&"8;IIL_P/VHEX@76_TCM:D[,+[1.F]G&?,4[6
M[3KJDTR$KCL.OX. #ARD9X+B4D+YZ(C_'* ]K& P=*B@%S(AX;<+DD9/3.,@
M0A#.">%>FQZ3"K]EY^M-\LPK03"T'O@R+S;;@CQC_ %O[G&E>G(RG@#Z[J0-
MR/OC$\/DA*.")"YH@,P*M>B@3P*A2"]0YCM#[,D=C'-%,,E=\H4:"6E!6%6(
MN>=1G4^ W#DUM6]^%+ 1!8YZZ.A3[!=0+6H3" G#%P(XS?Z^JQO&^\K'):-O
M;!/_Q^;VS68_)7DIGA_21Z8)$/LG*P+PU!8!D&<:*O+D/B_R9C9'P.\J)ZKZ
MS2[V ;+85?>/Y^6L6U6@+=KB?==VF)2[L9H.\^2.=]5*DR+=%9W5R K&4=58
MGVSIN5MS.\3//<L8;N!+EC9^"[IAG?4X,QFZP@UZSQ^R<86XN?657J_,><7!
MW0K( /ZS*Z1GLE:'P.N/A,AV$$P\97%XP#AXYH?TX]?*%!"CL4O4"&$XS"#9
MQ#O;1$]086\?I,3,,*'*;F\(TWP0/>$)=IP$%ST<EY8 PVR"#G%F$NR/8@;"
M$N7?%^>X2Z:!L$,$E^OP_7?6O3HVV-J5.IPT5"3-.'3(A=G5.@"1+\-G_%1[
M&=X]O:-,,NK555,L>#;!OK0J!D&..*<0PV0FF& 6.7_AZ/12#%OB$>:6,^!I
M$?#M#G9<O<?4,,;O,54:M5X6FL87P(-K8F;?PB! KY  OI@T,QU:$P !;0O9
M%/0ZU7M3KZO;_.&QJ5DQ#%+RL[/]$RNM224E&U/L\%E 96Z,H86I>F.,EGF1
M&)\KMWZ-N-TK&IMRI!"/"^S27="+G/Z*V39SITRD?7=2,:=;;27Q&"=&C,(X
M<$$ECG8A9&;0_JE]_'>(K>H CO?<(DU\XB4?'9FDQR.6:(VZV'M0)A-H0\-9
MGOWCLO2*JPQ.Y4"HG7DT82CGR#%DB&/$!?Z-HAG=5.EW]@F2#G7]*!!?IK&:
M*X@^J181B7E%A=0V&%,YAX=XS"-8T4,R!Q@M-RI3O46:@9DS= ]I(R6#I+G.
M+[\FU<F:)]H5+-'.H^GD!KQWB\H.S:B&UFB9*=;D0Y:I*L;+5'TU!I@C#@+9
M92[98GG)J/SO)X1?Z?D'6USQW BZ>R<)O<9F)TG:Y$]L/H@^B(+90M)< 2M8
M?DYL^RVZ%FX@]LU-ORYTRM:%3N6Z%JEAXO"DQ\1;:T9;J%Z:^'L$7:2/S9+T
MSSS67X_.F1KR+ZAH#!C.MW(QY:)H:?\B2:*F!EF?U4EV#9VFS%C,,EMQ.T.7
M(P'2)F%0"5MDP KEA=0F8'YGL0R6*M-E2U_WR^ ZIYVC]3DMTU0)Q&3V11$<
M<DXP+Q^/\-1V;,^,!GKN%+/ZEB41W+H4[_ <:8DAO8)QT$52E92[:WH!XJY
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MJZ<=K=Q:6>^[+SI,HJOL:<Y3Z&T-H@83/UZ.-:EQ7]:9^\.OVS9ZZF(0%C,
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M)4!3H*,G-*I9FFB3R9.:E[F/SQ=?TD<607Z5;,;N-%/# &I];#KO'A0)$[5
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MTI7:BM*YEHRG(MWHQXC*<;F*44\K>E>)>OQ^FI$MI94&PX^,M.3XP8RA67X
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M7Y*^UMBS>76MNQ'A&'VTGM/ QGC[W ^1]@4W+R3^/_%>!Y>E6-Y/%3EJ7!L
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M UBO6&M#]H>.F44CND>Q[-X?._.2Y8\!8@88@J.Q0@ ]ZEU9#!!Y K<1]K9
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M(H%$)!B"$?GD!B("?Q08BN_=@ +F<0*C\H,;J  =7&!8/KL("\>C!@;E1[=
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M4%$JA#RP?9C%=/:OPX5X\??Y*>\ \0X0[P#Q#A!]<[>*L &J0LBYT5W!J]F
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M4?&@'F"F3CNK\ &EUZC[0>T%ZQP%$29T$5TA(YW:!I=#A[,0BJ-$F8^\.;@
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MTK Y'9>]Q[RJYCU;A^/9,J&@85U%R!60Y49K8WJR*ZX0P^L6J-6XXF4QC*Y
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M?C&?I.?$5FA.H9&;AI8P<OH-_K)7;X@A\EKVS(S'"WX3@<L*(Z)HP:^?)"M
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ML:F[>"">1/C>:$>H@'LP9XICSB'<!S!M$]CWQ3A1R 1"&P4IKG$8,_ST=OQ
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M;Z;MXJ/D%&=PZ\9^G)&1=5,YR\OT4'>HK?KI@_IV9A++@-$2"YB*[R=$4NB
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MK]>)"I\L--P2S;:-Y(J>69*#X6GON=A\HG*ZO8/1.1FZZ;("S9>M"?_7.&V
MLSV33.%%TIR5):J,D<:81"<1VI-S5^:VIW(7#.WH]U&YM&0-M)>>?*+0KBZS
MHO3NN,+:[)V )K 4Z<_XS6 _BL3D-&*OJ && O8\W:AK7<$E$'">YH(\(?(/
M_/X':$J":X+4RPOMGKP3WPL3"+C'J@;^H:1I\"7NY*/;^*>CHM,(ON(3\1Z
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MV.TN]8VV)U4C*>UC&^Q>NUEKMKJU@3B(GVB\V1,D6XC45:4/K-3TK G0Q(R
M<+X0;7X$*X"MG6VB*S^;E>*&1:(VWVS.GJD[&[NLF%IBPNC1A6XGPY&WC"AI
M M9+ DLGR-),M27M"#18>V<-MB#;'5#M6C]W:;;K1D8K[Z)21ZK-VCMKLXP9
M+/8KL9]Q.'X[S1!TI@Y-? )NC%59Y14IXD;W;JT [9PO<T]L2=6)<BF9.CC1
M5H@=%RXW=I,E 2\V@U<GPU9[4.OT"JV:FU!K_SW'U#:8VCF'I@!,]1NU7G?
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M: [98SE@.*VS)BEWQ3.-/D$17=,[LK^"-JJ*6\/EX2CD(>46>&X!+I<-AN*
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MQ7BD-XN#?W>.RIKZ=])"%P48B.!AH7T.5 \!V]"64>US(MBJC5UZ[SQ^PD-
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M#=XK<0F+E%OSI*6^N<]-X8N)A2<FR-H?"/]T="*T&C4!O1BO#W/M: (F^Q0
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MC=L+3L)WL[:9X<(_BHP2FS+!M.H.S!+<6?P";QT%YU"GBYR^XZY0?RC4!%U
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MQ%\C@W&GY47Z-'0S27@U>:7<C;^"#KV1>2@N=PT=78.$L!.5,"8WHW]LNY.
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MAK)-N&SL/.2U9]@Z>5[ N9]P,' %9UHI*>+()A>0<@0DS\LOLQ.09CEU?+F
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M"MO.Y5@$(Z FV"X*>L 13P0JQ?Q#,GO%,JT+JQ^$HP"H3QT.R+>#@8C'SDC
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M1Q&J%QG$)<>HL2TU0HLRLW$\.\)/"X28PU[-^.EW:MX.QM)-?91JN ^?P\#
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MU.I246&+\+A!)']69SLOUAM\\FW7OUQ;>I/[U4H&\>QU0<PC@>94UJQT>O7
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M@1,39\PJ#'4;VI.X;()]0[D*;,%&%BY_F/H^68FUL!:9%O"W]V./^OIF\-1
M#KV$9_OTT6(;QO 4$DJX:Y$4#.:(CT/[@QT<@6!^*"%).D8*Y<^/PWKG>ESS
M7(]*9I_0L<:XB+F#U=NR!Z?*W:[/66C'XD[\]!')([X(T* &5YG&$"X3WD=[
M+[S/E?"V7NKE"FN,"*0X@PUM'6 ^_ /C'Z6]P7@!N*<3M'RB,!W!!>C']+W
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M882I6IO'SGV8^BYJ$E>"I>(:C8Z=0*I&<H ^=E$6JE^J5!N2'#FNVB"9\(:
M/*UA*'8?RXZ>OQVIFW?$KK%BGW6LZ&/P/CJ=]B('9&*;BN3VZ7T;SZ88!214
M'NT(UMS$Q[*VM[F)W;/S]KR:SFVBTHBJ58F:ANQ4A4<Y9XGI6 ?C'3[',]%[
M=X12GC6B:'-E%'8%0$EN Z-/RV_>+=P\"R.4I.CS&?=<Q*$L[:YB=IQ[5T_
ML#P%@E2PUO)50%AHY\3N;;G4$23MGBA/)N  I D,LJ2H2B9,Q(P3"!0ZIA1Y
MV[D8#$+*WF/\(Z$JZH' +I Z8A\,L32B568I_,H2(2T-<07:U]<78K;+%G)<
M?AD;HVD^JMVB[);CE4=%5Z^N>4%F4K%L2@4CE>-(^0??$V @8+S5=E_PAT/A
MZ3; G+5>[;%:!KQ*<1:#ZYIA=(!<S-5_$-'&F=V>NQ$Z^@(KOEV.#T9R&D84
M7YU*''3?+F%NA3WF%%V*^5Q X5&#$ CG3TP%W"FJQ%MQJP0K<*Y$IB?3IF;[
MI#N4JW3)^;.,^RVT@EH@OW3$3S@+Y)]RZ*P2/_#:^KIJH"_QJ+&BS7F98?0E
M5:C7@R3$]':A#-6(3=IZ97MFRK;BCD,OBNTROT6'JRL,TWXL_T@EU3%6-W_3
M$EG%+/635?UL51QN3O[4,N=ZW1(6/#SH'![T.FNQ8$VS;4U#[:2]R,W+V;H8
M< Q-V-V$N;!*H+P<Y;48)BCAQ#=D+W"70JTLEG4YJ>H%%%Q,;EEE@<YE_Y!K
MGQZF"4@I!P\Z'JH3H<J54GGP@K3U5=8K2'UVR[O =#&+?H5J"(5>1W%;-4]V
M"CQ))1<Z_ES)2F6>4>>@TUV7E7:KS4KZ_ZU"]Y+8(QBOG!X@X\-()%-3;#7=
M(#LMY#U*1-NN?'7XJG>RB6W>KVP82+;3H_8\IEH^':83MPN<]R7;5@;]\:!M
MVU+4;T7/_;#;G@?ZS^_;MH4[IT@R"[^5];M0G9.IOZJ,B&O8';3ET:A.IUB]
MLYJR,)5W2B)6T4,9S& GBUL^1'"MC;;V62;7PZ_B^P)BH @E$,0]./.Q#(J@
M:^BPEQ)"&1 S]1NAAX-NMW:3<3>71P1*"_9U,?ZR7N?</4I/48%B++/_C:<*
M%WM+&@98HS%QI53IQ*V-CM6\0.Y;N83.G-4J\F6:CU5\0P4^K,S@R[%D*L[B
MLSJ+4GU*>1QC:[AY>ZA.6WRQNK=G649+Z!)K@55;R=+._DV@,+PD<J@0PT=E
M PY*QH9LPA53L>OX?1C-WV$]D?MY7N0ZJH>;/%-3K<ND;="\D,@FPI4,YF.)
MFI+":-W>;N.R#3T?>8-B3"#\X(TFE<TWW,E[\#]-P]/N&IY.FH:GIN'IL1J>
M'@-3ZV,8QY?:@!_,,G"6.(>;<+(7N F5K-LQJ"SZ;3RY1[@L5019>WJ+S55Z
MH^R1+N:_!QV\B:W7G1+L%D\!IW)9/:9]L6T'_C??$UPK==F7B+2$I1%WH7_'
M!90^,.9(E>A'JH7'ER-0M&!V8PH<SDDCK@AO$ML0J[^U;]O."',X 5GZ7H!6
M/T&XP"/ ^C2!&OS])3SI3QF BYGH'ONT3T8^=1"]O[IH.Q\"$QR:[WG.M_G,
M;4B]/3!-/V:Q?"?K-6STOTCZ#/T #P';):&R^LBC;A33Z4 Y8!%A4CV-8O:G
MTAA3W;&5^ O3A("N.(%%>(K9!GNQ:1?W9UF'>-OY0@WBO@*F4/=HE1P1)IZI
M8PJC""ZBZ8#_!ILW2'17BT&T4" .<#^L+: ,'FQH+)/$9Y=M$,8)8?<2*(_N
MW@@$0^=@<Q6\Z$ JTF2BP3!"&,5MYR)AXXF)M%XB'%Z/'\S9<S+A1*PZU#R@
M2.\;%GR:+43\,TF/3:R=U<V?6!X:>1FDI D=JE_@#L74E0]R%.,GT@_O\\A!
M\!%Z2SJ13@6K">\X0Y<Q5!D?0T88L&H7T2Q!#G*O$T5;R(-G! I39>@%; TO
MB,67"HQS(W46VE15$FR74K!T_5WEMKSY;<H&=^#\DK'=AYS(8'C%1UKH^=[J
MC.Z<SN@>TV+?2K@XX$!D33R=SGPB,R=G43Y/0QD(Y',0WW>>;Q\2B)HK.4$!
M\%I5WEQ^N,I!E#._82P(?L,,XX:#E#TWO,!B@DR:7DGTW'0UU-]P.Q3LK/ZQ
M=4O]HUMN;_-4F]V[[X,Q%?51'"F.29]074,L)85K!V$T1="R'"?FGL(@&T"=
M.EJR$#$-NTR]20K.HYC@ES_"B]X"JU]]GX<CZTM0@8QK286."_<#CE%!U$LE
MQ[!5,#L1V&SZ36Y[B^^"2&V!2X)41>DD_SN<2GKY# 1-11\-/^J,I]*2^3<!
M.1V$"!4'RF>0Y(0PKD*I':WHPF 44GB1Y:1M0F@Q+LH4<$VS9@I*-R6])_'U
M!ZRD5%!$C$"-QDD1EH:AZ):Y[8V$L21,WBK5S3=@:F"8&6>/@'E 1@HJUC1F
M)6GJ@6[?7>(EPR%WU\=H@.HO3-59 /SE5YYZ!OYY0,G<G)U9Z&G]3Z/CT5?*
MH'9(G=]0ZVU5X+*O.HB3U)WE65R#E":("Z8EP(7_)Y@J$\P:J[>!AQ/TJCVM
MHO9C;_&Q65-548R@+(HH$\1PLB;!,Y@M@6KXR]&AE2G(E3>@U&&Q1P-5.;<D
M?$HCQ&,I"9A]%3 @;7)G-C19AEE2U[(Y;4II^')-OM1"/BZ7\L[5]=_8I6&?
M2P&#8BI1CK*&.G@ 2'5-V%<1YO]$>O!/D+"_"X+!"\(TL!#=RU5V6&V($*5T
MSYA2-(AB<^R+;&;+PKG$<)]S,<A\:\I^<F<_'$;DW;%]IBYI;.F:'*7B+V^Y
MA;J6&7U*]-MQZN3"LBI"QJ31!G@-P.WN\?&K-T/PN@V&=IKP&5/L5UL[OKB/
M4T_G14!;29>9&\7OG1?ZP@P&0KX=2H2*\#4X!-(6WL$N*-#(,"H@0:%)G,8T
M! Z/E%5(O038#$3QDIG#Z.)2!W]0* G=L+L\"J2+&T BL?>-1QRF,9H/B<+N
MI0"!6B7%,%S!3]<J/E/6M!/<-R!=$QI (!SAJ\@'> B^I,8CI6CGULAI)A^[
M+ZPZ3#@?!0%"P:NO9.R*@?43/@$E5BE<=D6=A2!S+^$P$V-*_ Y6#)B_V==P
M0E_E=S&_P^C .&F0X5.:*@2<2N&*"9EAMOOE>W*8'TXA&+HEH@E91#\()Z3P
M2!JS>"5A<5U#RRE[2(-B"<-X_T[=D<P;7)0CKR,03O("H5P.4%52K=N=*M0<
M=3>A>$-,IZ$7\! #9!*'Z= #0YZ^Y@^QZBF6?MOYF+]$2:#\&VK,+4/4RRP%
M)6L[;"MT>1/G"#HG#W/TO&B8FR7V^C5$_JV<)EP&T3FBE1S6D_I_2T%6*)'?
M;?-OEE#-)_!M.YTYX+(!R0SP*S"FH;LMP D',D*#R^R[P0KCF+UV@G7+B)*7
MSF?ABCOG/;CW+K!.T *GZ*KE?+I295[P,$K9PPM?CE&&?$)O'ZCVFJ6_(H!L
M) @#=V$W0FCZ#8+P'G/[Z BY+:>?)BR6[G&@D)*?F0#7RYZ$##D;ZG<%N9E)
M>454&.&([S&@RU'>A]$8'5*/=[S>&;V7_2C%J#_R-=JPZJ"R4S#DG[U/G$ZG
MRN'AR':V0&JTQG -O4V!GE4KC*Y9J&-D=+KJ;516DA;WU5"1&@;(*O83+[".
MQ=[)ORW20,D;9^^))1OU#P$?T"M9]U)^(:B_WK*#4.]))6FTKY=@UE +FX5S
M->=LA],IY0FLK=J)BMQ *K$I&]&YY].F;*0I&]DSG-PG8L-^#N_8[CG*N:W"
MA))B*_S@9N$'98QB130)X%;F=K"7F!^79Y /'^(OM2B=S)VKROK):O_HCD5G
MEW+?Z%K"(MUTX*%*=]-DIKY5^8-R_]? O$YH@Q9:FH0X:Z .M38DURS6Z7G;
M92;_MM1;)AU$OF7.;WY-;U'JG/Y@O%/KT>Q?Q[G)/!B<#48$-B\2$PB\@TT!
M'6YYV?*[5H?64,4PYY/:;FA^OZW.:)RL(=*8(_)<8/%-+O/0K2@ $8H):NBM
M7WC&<'$_XG'(0V5\Y0[<DW&A8( WS2)H\HK0 5^T<33$F)J:EWKHB\C?E)>$
MJ1G!67H.VEC6P=O["!8T3'T=U6T[%WXR-B6NF5-&[$7 $OD7<T-9;T  A2!4
M7*$DOU8RK4 Q#XJ=26#LK6(OU\)7Q?D*R_VSHIBJZYUA&/HPYVM555:?=$H;
M7#J=@\,CU6=^<M ]_-='4UAU"9M+]=56E#8+TJH8+0DODG&5_7H+:@)!=UR2
ML'N/<I9Q?!9T[%547E/#'L<4*EKV*H5]>>01!1/._&:VCCU0?B(R!65UPA,G
MW5=ODGL]2/"!&J+6 WNY> @\D'ZL- 6[4*^_1N(.&.D2>[YFA85P"40E)975
MZ#,E=1Y 25>@E._AZWT@)MK!(BVIP]/K5.>&)MD84XT1R-VE034@H^,YH/E:
MYWIBDLA\LIINU:H6DHT&4K>"#-SRYZ"T]C4#H-3U37P]C"27/NBG4 N6*0<#
M8IIA(Y9D'.4A[,.8N,K4EIAUY1YLJ3=%5ZZ,!Y'71Z;K@QA4GFQ=N^X\)_U$
MP%JMVJJKQ=R9[?>P('A614E='5I3BX0U%Z.'Z%H]4P<X?U@,-0*WYQ(@ZVL=
MD67.KGSU/?/]%UKUSRF,G@7;\M&GZCS8RJZ'P7-8+6.V=L+,<@%$/0 2'=53
M[X\M3K[*DVD9$.?R.V W?Y.NPO.A6+FR%V,"VT)C#,UK70J 8X-5VVKV?3;C
M,XSFS-4$O929\YL>X4D%*$A)_PRC;PO\CITG]OB>B-7$.\;K*CJH=834YY"$
M=%Y*??!]+PB]N>,E7V'+V;H-93=*DRQU$]HFUEP[NZ$+/RSU7;FS/(M.(>'Q
M20YT4+U:=S3)S%4J'W05\9)(O0JXYP^QTM@MPP4X(DRN,_N?*QJ[CVS?DDM2
MM&]K1<5L1VF#<;%*'MKSV%AY(<E+4(NQ>GH3CELY',<%,8\?CC/DO&HX3GMX
M<<FKN6$%\>OTS2_O__;/HX.K#Y\/X,4.(G=TD(R)K=UP(@\&/I+K@6G9.KB,
MXR_JCX-Q,O$/).=IP5$>C7W,T4CW46-]C;ZNKZ\7M*S9D0== A)Q&3"2,78B
M)\7^$#X!^XQCF=41W7FC, );W9_E:]$]5"%ZQA16XJ.\8 ('I4NC':@^'00D
MHVP#"^$'+02>)?HI 0^U'MQ0P^9\:&WAGQ>*T;:3O5L<WEMHACS(TEC#RGA0
M%HR5%^O=,MV%%@-!%^GVL260G:HS'M%-#(**0Q JCAY)6J^M[[!ME_H\L&YT
M>2A6!!27F9^R.5]^$\R79945=G&,#W8[7]^U<DF7\E$."\%-(!7"4-,0,63;
MJ#JS!SWH2/G ^]C*\ SJ?JI;FVO5 )TU-4!-#5!3 [2.\; @9J?3,<3!64KL
M-O&FJ9_U(5^,(BEU?]BM:?IKD9J.0A"]DK$DOH W4NR9M&YFVLL+3:07*O>&
M.J_X;/E][/4)P0'Q-9+0;C^F5XA"=J _A]RV-G1N:!8QMU)FJR6*X2P#W':N
MS2JW9KY7KAO^_[U1#_K_G%LT'%*"&KM&R<&6+[AE4P7FK)9"K5W9\W^5@J#[
M<IM3N)49=%'2@++8)%NNX;+3GZLGMC<\-S(,GHX% WH^6-8MN#CQ6[@?N0ET
M%W]FT$];G.!C$!-*%+#RAB<4"N*5+7BQN[3="W$EN&CF9$X<5%"8EA!X69%H
M6VH "S,FFJ&:9-0),C]HRL/XA9_:42;%@7GJ,S>QH"6J*:]B^31^4A&TU;4\
M5BRY9-27U3MRGD]@)E4_Z_W4X2&YSK0]:3OOOM9QKC[*,,#)F1_;SN_8W2W
MO](MN9=T"I6H/,>'RA6A4++S=WR[VP3$-TAKN-\$_DZ0,<T2J@RN\[/#SN[L
MX2>5,U]8QT_=OA?@.1W<?KRXN7$^<BCD137Q+FER*)[Q^L&0DT(YP5SA@.&X
M\GS+;9C.YUMTE+\JW6*NR9^TW8)23",3*A>#SRAOW496$!B<$!K[A>4AOT&Q
M.,&*XEH^^GP!L6DSNP-I&R1P1CZ7-N@X8J9H\X^PRG7,*$G4V"K$B%?J?;;B
MBO,_VD9PT8OULXT]L$M,1P+,_5U$V'QUA5$EV) K:]CH5[C/6_2Q<M".IRM
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MKO0?J:'> J@KC'(M*M:U@!8+2K,6-L5_%F[UGS]GSZ?'Y]2STL[J.2L\9M.
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M,_AO,/IH,I*U1 $F=Q3C-AV0;M7V/-,KDBA-,UN'C=7L7N&4_5!;L\1J%*W
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MX3$3 X6P0#OEF*0YZ+H'_=76?^9(E!"SI"1#NTM*F2$>!>K@RZR>P*C&G#'
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M;]$BCO!<<R-342KUS9E0+2K7%_=(5V5.ZQ#,^5=<AB2/XT+4+8M!M5C 3;"
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M+R =^K54;6@4/4"&$CI2W'Z5(I8>1.PR5P6FB8C""A7^)QC]:5(":8'FR1I
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M,^'J<\C5.L9M63J=-_C"/(M?[%9_>_E[]\@2&P -3-^^>_6BRVJ&OZ K^L.
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M+9, FUNQ7>ET  .KJM,$X/#LJV@"<-C4!.#PFVP"L/%N/U[8[*J82&G^(:0
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M5\FY;]]C?+YVTF44>)2@'?8+M-0MLC"FS=QQ$C!\MC!?1DQ[AC0T_27 ,S<
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MX2M*?+9>6[V21O (P*7M-Y[*$WY4I&G :';KQTB82 L:YUVIA%.;"((SS_)
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M.#EJQ:L5K\\E7B='7]*";,7KB8G7X<&7!*=]M'A]=<&_)[!!U@K=/@G=."E
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MGRW!>Y9W2=5UM;--)2+\6A.2WE/+\KZ6>(KEU;X#;TT>2"\" /IB$]3@N5-
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MH@-T5\A[WEE>]T;OG!9YU1L-RAHS^Q9E1SG+LQV$0K4H>1GDARR"&"<O?[Y
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MO^XI;:+V2E['035I@R+BP@5#4J;0>$/I%QH7RAO&F?'AW"FD^'Y0[U*H7>Z
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M9\),=MP<#2;A_F=@:)P8B^#TJK$]I82H@HW)S$(+9.[*A:0QC=%9AJQ_AZ9
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M&(&+S'O#/6,'0^\J+\;S,M(%(E?3V>"O LXA5^^V77\W7\,F=KC:= N%N8G
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M()CLT3@2:5;($K[@JTB0I\DE%"!?IL6TJFVE#I5 LR+IPF@X?6<L1]81N8/
M;+K+M\UVV*BHNJGJFF8<3P-OAP?'N(10*NJ'B*#L$%4@_*97U9'OX((.GPVM
M.B5P^F,E/)V!3@JO@NY#XNN\^54+?QT/O!IJ584N=3S-*]%U?70M'3"ZFH"N
MR%2!^ ?0M8KT$J+H6I+HFHKW>D3P6F+>*S*/IX&W0XOCQ-?RX>*K7@)\+5<$
MOI+/)O=>RQNO!ER_PE[-*&-;&ZA:J<H* =<C@]2C<EA-%1%0I13NQ]*^V^%#
M;A#5=T=Q."V#)[XYY&V#366SA Q=+\/$6C-5/"T75II+_T,3IGVE!BQZU,T[
M#7<14QX!@DG\H@]G"A,7^M,:3H"2HB2H@CO8?X$TN63P.J,[O"? :P 4(OP<
M5?B*G7_T)F,_Y &Y+]8X[NVJE\0W>-(D:)YM%R7,2LBDYA"V*_1*+A)2*<Z4
M=UV?L^7:V&K6+U+48E-# :2E!P/.]'?;[7Y:#@>E2J5L$CA 54UG4T%H>LW0
MT8_J?ZL 0VR##&TW&\2=Z0SO@E/,.)")?W+5I,P,C"<B@!%+S!L%:'P![OQ
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M-G=]W]P[]\[,6G?WVFMUO[MVO56U:]?SU(]^FGM:!1 HRRO) Y"0D "?GC^
MIP6 +  ##0T=#14#'1T=$Q,#"X<$%P<;&X>2B!B?A):*GHZ6BH:&@8F;E>$5
M)R,-#9OP:\XWO (" O2LHI(B?!+<_ )\?RM!PL3$Q,'&H<#%I>![2?.2[__U
M>/H%(,1 LGK1B(ST"O""$ F9$.FI&T / ""A(OTS /\ZD%X@HZ"BH6-@8F$_
M"T ( "^0D)%?H""CHJ*@/*_Z/:\#4 A1B5[RRJ 1:YJBOW(FX0N*S\5@?%?3
M2?IA L[$;^82C(E%1DY!2<7,PLKVFEU 4$A81%1,]KV<O(*BDK+61VT=73U]
MH+F%I96U#<C6U<W=PQ/LY1WR)30L/.)K9$+B]Z3DE-0?:7GY!85%Q26E9;5U
M]9"&QJ;FEM]=W3V]??T#@Y-3TS.PV;D_\VOK&YM;VSN[>_N(T[/SB\NKZYO;
MO_U" B C_=OX+_TB?/;K!0H*,@KZWWXAO?#\6X 0!?4E+QJ1C":ZJ3/Q*[X@
M#))W\;DUG9B,_!_@I&8N$UAD3 )KS(B_7?O'L_\YQX+_/WGV[X[]AU_S !QD
MI.?#0R8$2 .N;MGR K'^-T[^[5DW'Z\L2H@!Q:9LN$+3VX^W!.JD5N)#^D6G
M9LVA6W-,<U78]I+4=.$PJ-J8<KH&(CLJC1X%M,R@/4,A,*N+21D5=!KX:].S
M*L0 (7S_JOTU @=V:Q1WKU+/9A'U6>];PIHV99\X.HV/KFQ^9?*F:U:QG-<P
M'0-"-3RRWH__0]O4L6G[5'&K.6ZSO*YVOPD43$ES508S%H7MP(M#!,E] NIM
M;U,;6EYQ8Y$YGT;#G?+3XLQY#G8>94;CU/.@+?C4X& N^AXIAI8TF H7U;&/
MC3T1CD ! 4G=\2IN5\Y.5E+NZA. [  8%T&L-JUY;+]3=_=N\0E@K6+[*E&B
M[^QAJW,M%"\ZP?'GZ_R6%BBD-EK)TQ47:G&$R_$%Y=9B^E<8(!A#(IBCS__5
M@O$!/=&G*2WUNFFS*,4$\-%)H<57M8VV7K%V /)4M>U)._WR_#[=BXECSO5D
M:E>TZ5A]G.ATI0_"=-"0D+U(9O5D+-D/K363$W*D\3)R)!I(_S^=:%8I.7,V
M5]XQ,VEB0R5CEU'!HWKDO2+G950=H15513.";!5F+=,\G]O[$8:#0R0EHEC.
M&7YO1]P^:K\6..9@'+[G76U3QB?;NZV$I0D<V&&+<MTW"Z)!O52< *S'>=&K
M/K"+CBX3W 5#X! )^5O]Q8>R>4;WE['DHVHSK #B:5TCN8]E(ZV+RI@4#?ZD
MDYP5@APD#6=<D-<%6?NB>DT> 6VS.27GZA@@*M2I)?V"4T.!=TA<PR?\3+)Y
MK\T\2LY)V^34)5IC^W\A6$/<U$E3J;4;/)-Q(K8B=6)^9Y4G,3+<?KQ\I)@\
M/!&X2]<K"+F30FMLC!35DR_QWG(-]AOYK*D@46D7^DU3CI3Q?^=%^Y^9$J=]
MO4!(7Z_!"7;_I\>1,'Q>0-S.:(^TCU3!9=78G8_"*7/V';!OX.NE$NL\L:UP
MKNCJG6[RGLFI2TOU@W? D4 %?I@4WL2]=B4X]>"-X+#0U7L%]-3!H!_9/($*
M(@"L@R0V@Q][%M$?EXZV?4*/FXO_[";:]AXO'9E'-WW[J]4P-E#(.0%<9;>V
M$CO;FV;?TS-0W]!R)QM1,:EA00AH8J)3-V[J\>KK:A.:/.MJEQBO9A0F(TOP
MBI<_=*+T':83OX\,P*I<]?'Q8UU];%TO5W%7=: 76A;_J;8I/R>R0V,M^?H.
MHV #=H# \YBWACX!/N\%V-^17R9ESY_%,8X9W3P!/$5+N2^H.9 )H-#&1KZ&
MN?L];>%LF<2!ZO3S%<R1<C 9:RU<+=^U3$UB[B*I[2]^AX/Z1K7EYNV&=A:%
M\I%5:539BOR>LIM*DM9^3@I 3@*^X:?)6ZC7=RWZ>H^V.$,$7L-1CHET^(7?
M2\>CP1#FF=\WFK2_"*XEG./'O"%%MGMD,45"=:6@WY?;@M3K/]Z[2E.>GOJ;
MCMF>95->D\O#37YGNKOU;YXYO*?SK6VV<JGEV1I@?=$L32.W R9?@\I$DD<S
M6.XW8_"QA;*-,&6E/""-%/DAX947&RZU%9!?UB[V7:W%6EJ;E*"_BC+24F]/
M4[3G.7)@CCLIT.*H?7@KH1L"ONM,4PB_MU^SEY93JM"Y(QAC<FFX1/V=F''!
MD#'S("LS!:5'#'61S>.PC&)']*5%;H:-7DBJ.Z'RF))59>T_ 9Q<6P]]*L&]
M4>MC7^G8IR\BW/3=M*/4FWD)7:E?]QI0]+K^GJV;'?-';D'$M#>NQUW+"3R(
M'0&O;[9/WQ6J[2PT;M.=E\B)#.Q-.8^TYC?!K>/<%^(H%Z\5>G1TX/N:N>"M
MQC4#9 ^,@=72_E?9\"= 7V/+TDK$$Z"QJB(',E7U7E/Q;01 OV]8J0\>&=>9
MA89X 8;M]-)Q-#6*A>0JYC2*8G\C9SK_90S8@35UA/D33$IHK].3T%JA-0<O
M[P6_-4H2YN\8=I)71(XKK:0!05@W&TXVE5W&KX9\TGWZR7STU[/([FK?KWU_
MP"B+J;8Y<+_4F:E [?6XD=\2WIFB' 'O_#XH5V551<S$'&W"03HN-"VBN%3W
M^\H;^03H:M=5NL:3 CIPII;8T#6N=^*\#):PZN.WGJB(P,!3S(U"Y:XJ3[*^
M(X'F\YZ>D;8"7,%A1"?1PT[2[Y)[51G+<E!+O*EI"="(= OZ-0EQ0X48(]I]
MQC+A0"AI"7!!J!*ULDQRZ>NWTM0D0[IFB1<B.VEQG6)Q7SY#[2U1Q[[P0$4K
ME>Y*A%5>QJ1NFJ.C9V4$BWV\0QV<]S3?@?75&^^G^:>1K)@8 ,/OBKR2^,\'
MR@E5:!"</_L3Y#?8=_^@^%#=+)&ID]PK(KAZB]?2.PBC]-.6.<#'[U4<<G\H
M?!#G<;BI.EFC2US'Q;(WZ].8XJYP2_FF:D[;7;8MD9C4+Y4Z-OE]EZWW:II1
MZ,\"N%H/.@X5=PTHWJNS%;8!1"XS<^IE[="LN@ON@#96J*Y=]2=T>V!D]*8P
M&B:[SQC)1(HTT1?480H'QN4^)?J@GUY75T[ K@ROQ'Y"U[U$8WX$U>\ K.ML
M5<3P;&G%_(!GQ&&5S.L7\4FG-WUOU?R<0..:*2VP-2%8:=:*L7D5>*-[/B66
M&_IZ]4Z%1VQ4\HI<N&#5;10]9Q'=^[RI@*@[@=MIG\)Z&9K8O8PY>6^T@3UT
M@@W^P0F5<4"?7__Z%1"7PE3-#NX\T)23/TEU;:L7].7?<"3LV5"_?G]O5+Q0
MN!A_$GP\3L]US8J^C[03*\]K='1<7;1741Y0,@],WGI_QF[];+52[G5B[S(>
MHO?'6C7IHD()<)^3B#($S30QL/,GY@XECOBT6$]VF(3,1J;YG727=W&D().4
MT=@/-\:&1H=4'"?Y-_*2L1SZ']2,=?8>;)0SXP^\8YM-BW>U]D?<'6 3O:-Q
MVR6Z##1L#C^8S*!7:QTQOEH;M%I'PHDV-7O%PTL@:K,M)Y&7KIG-#!:SS/#M
MWRM:UXX;'+COGJOFS+Q-KC63PJM\ GE)K+C!?/AWLEN>3B/S'K(W&!=UV\"H
M'E:7WN&07=XLB'$O[X?8XSV_]1W[(I]?,+>&MCNB?1VK$Y%3E(,.Z>,=P0%?
MQ>N0)P"&=E*%1_S"HLF2TD^FA( RDY/:6,7S/6-9RS7*"VED Z',U1AY51UM
M8H6*PGW3!='1I27>:UAQ#Y>8^9HZIBVP)SNE6EEG'O&G=IB$#@]/\@E Q?@.
M"R3LY)KR^EBHG6&BFBF,0M 'L_B[;WR?2_3802">NJR. X0#F_)E[/'E_+)2
M[%PR2!LG?$)&(DM!'8@X^2I%60>WH*-&< =9-$R 4MZJT%AD439Z[E2M/0%>
ME)LI0CT1O^?U(M)5QBMU/G4E\;U9E*;Y^01HY^ Q)VM.G/K0O'3H@PIN#)?0
M1_#WC)2TQW-'O*IK>O.SZ>OWK*9>_CG=^MEX7ZPG@.:ZXQU&0 R[CL;W2A\]
ME[9)@?O7"&3])\"7MGOF]3L*+G<A(]C96W\E\*A85KX(XW@L9'GY@,HJ;3]E
M/J:P_,W@UYV/K&>"F^VBKQSCC(EB5[;3!"/ZR4NHY\ZNK<KV/8PI$?C1@HV3
M]X)EX*Q[7I4?+"V$"V_OXY*:)"/Z&DGS"RF!!D9$!3,3!VF]'>8%8.\=?:^U
M!(P\$&-W&4K!BW?E;DP;+WX^TH''P4.RPIX\(-*]9-E+Q0+4_&B:UXRB]\[&
M!JO4;(+J7XRYZSOBQL)&"K(P_L2^BC=C(CQG%"R$GZC#M[/AR4^ ;JJ<A)EM
MI<HJAZ.E+Y5TB"\F+DYBFNR\T< #'TS5AA^'KZMM3HW\D@3MT)I8';\WLIE(
MI8[:O6LW0J@E%LFL1ODIR,.3+D)+?DBT&5]N>M4A9_@&GDM!W4C/X\*W$@)P
M]UR5MS9]%'^D7C#E#%3L3VHH%1E:+=0X;.\O#R)+SG1KO!<;X C5O$ZSSWS(
MRB5,'CS&3NWL!#/A2?,:2U;/5\?XBQ:'NZ?$UZ=3!_"):VR]C_G)R[JO/OLB
M?UJ@U3%\A0(JB1\NO#"_GZ/@:D53N]JPN/IH/AZBJJD#N8#TC#XJ5&=:*^,Z
M%7^HP[5_A%+.\@:TC0U=3U^F-*3 O6"Z&HL]&5[?^FE=+TC7_.G@O>GK<=&/
M7 TS>:!*AC2EOZ@'*V*@2*VTSHG ;&Q[\PDI=G"C;"UW ^%KWFX#!GOGN#[<
MZ*DDC(+#"^75HF,?2;!.&\*SVZ/]Y;3UE!DD ']NA;F\.2+9H?FF;L5N U[]
M$3$*E1!>'5'7PD&I^:U#[T6]93*] Z]&GX0\7S=9>.03H.O*,^&9Z1CS&_+>
MB1,PHV]2M[AICMW)E^.K"@[/W&(50&JMQ].JBLS@E=OE9H,]G%GK:*;?_-\-
M.N]-0KNZI!BN2]='B"1UU=+?DAT/!ZI2<UBJX2,+VOWROKH<Z^12FU=8<B[6
M'_N\T;[T)?<^5AIK \KHB<!6NK9[*%W;JS!1#MJT"AE<$>F\24=Q$;_8T\8R
M+%-162G)J)J2)/\E)3%S$4>X_YR^M!D$MLD,#7>^1TX8*.Y2.<'B6H\4X#X=
MA,7MK6W8"TX''3;?DDNXRL7FSG'DP+5PT=P^VA.@I]:VLL1.V*+/I9)NC"$Q
M@7=%A.;\UWJ)+UE+9(\$R%/</@P[GK$Q+^Y-FO9+:K4A.Q2#R:V.B !"J&S!
M==Z&$GS>0&Q.WZ\(41CEO_R8G\-Q,YMS+6UL0@Q65YMYU&1"X OPR'USZCI#
M@PIW9@G"AW4?V:;OU9W9E^SD\C"^\1^%UL7'7R#3'T;N^;^PBT^%..)[+9O)
MLL[;?Z58_'+D((TJ'2-6;Z\N!VDWI5PV./91)=$TE._\?^Z"TK^[,Y[EH.8E
MNCP!P/YN#B8G^*-)XWK U\(\5^$[\EN/\/O=%FQL.99_OBUV+--GDLN8VA0L
MXK]CZ[_(VWW>R0B+C@-R!P)?\TG:_/NCF%^>),<O)I2: Z#28O_H>DMC7QQ$
MM[#NOA*-EU.1V+7UD#+8:9(D[VG]D*TL@;VJ"[=?KA'?Q_9\R'_S'8ELC"=9
M9-_UJKSVGW=2I]QUG572*D&L'_2R])9W"-?PPSO@T8O@T)UIU$7OKLV\GI^]
M?#>4 V,K#QS2OY\ V"QP>-O/IMFMMG$'\WAJ=1N/8$.DIHR'5713X[C_,$I]
M0=W(DYQ)G54]I"6SK7GRR->N1#;WA\18+6? FQV)-XXFCKZZ,NMCX>;=0(]0
M2_M22:CWQ]PNM2+K[SCN3"%98K/.3=YQH]%QFK*5FJV+HHQV%,;\\ -P]>_&
M-#XC;*NFA;O)],NU$+?^\XLJ ^"U"7=EWK6).E7M>S<)!U<TWT/[H]:MN_8'
MNXE:23E*NKSOMLKL_0ZOCYVSN.!,62P(^= *[IR&#95OHA$]K<,W(>[]?>K>
M@F,OI&H0Z/*(M]-DS%/?7S?R6@P$]YU8Q[7M&64IE.0S3FN4C:"SDS6=H(!I
M[U_Z5!I*WBX%@ R].M\;2+3K;92.+5=U/0OIOQWX)$V5Q)*H4G*8W@3IN:;^
ME0 6NP,V^\DX/ 'JB\_>131X^=;T:66WW>I:;K->S9[E#ZN?5.^\^YX <L=F
M.?8ZCH'7<E#XJCOZE3P4K1B)<M 84/'\2'5-3,#&'ZSIZXRZ$5 2\.F@,%8M
M[L6L;R XBA4^U'.X"1S8B(4<&)L%^ 6(270_WCZZ%S>6^BQF*6:@[G2I1(WA
M[#9@KE.WJLHJ12N0SC1HTR"?'L=Y:O:)EIS'A0G;K:M(>G:W,S7#JCXW-^A$
M/'>T(=/G$@]VX_=_ZW+S^OIP<;_G YKOVORZT[+317DLH>)<?>W:34[%?#3>
M\RM6<G^GN5>>O_-D3+!MM0,]#F-.%7L_Q3NF^Z1=OXHF/EO.,,-=&KCWCV5N
M69\#5DQ&$\N%Z72P7HOG,_9(4?Q$>(0()9:@$8KB)+ NQ_3)T^\T5[T:6D,Y
M-=;#)P!GG>A,U:_C5J;W0>3%7KBXB-"'D^XM_Z,F3DCZ.7SO;4?9!T(B'0[]
MO+8[X*U'[4R)W5+TL]QNJLJ.%R-$#KJLI;T*QANYU6_/S/]QJ.8)\!PIC8R<
M$\*FXN9?UP%KB?K@!!Z"ZQ"C9M@%F_Q+D):MPC&:^E\9'F6>])A5>0BZW!*;
MK-?0R2-W<BYW1QPOJP&FP#\;"<Z]\G:3T+EG8M&12?>/1>4+']N.N14SR$,?
MJ1K#!$X(0>/[P7:JVI2O5O#'\+2_$[F>.2TOL9^$0I'0PE?MXK#WR;$#')TF
M*6D4MC:%Q'"RY,5F37:ZG@"26H^W)%[/?=+8QV?UH:Q 1P]!5>[PI#ZXCU;8
MDEL3U+Y$(;<BRVR^ &PZ"OZT,D6+,&*-;J=;N"[OTA'[RW,*V!;"(2.^K?6K
M;R0Q,=MPUO2_T"IL;%_L%WHX4VD^+&'D50PV7YN9#?<UJ%8MM17^ICBN./[M
M](TTMU@0I.%"4+J3'F\@_UH0@IT::;C_P:O)-)B1AG5GX-ZNHP4RQ9,FU!H\
MN9:_A5-2I;N7E60]^@4'T_R?=Q@L;AEYXEO=5"D9*Q7[LB*XHYC_3$HX7/(N
M#EJZQ8Z5#O3I7%7KGCTSMZS2YX/!,A&2OMG-OAHO"55Z=TD=>B52C>DK'-(U
M/SQ_7%BZ:'L[7=YXI!7]&3VDWN(LEC\K0T?VGJFY8=;QN-Z19'DOS3]OJZK2
M5/U'$-,W:@EW$9'^$6_K=/K[<_6[7<WMON<0$#_>DAK/>[;U',Z:A\'CNMS@
MO2E5>SPE?N7JTZ>DOI751$GL,J+BL1@[R(66('H,J[H)=UJLN^[$)1 Y;U+8
MDBGFYD#3F\32@1MOM\W9XK^S:>S]WYX^9\#9A/1)KD)#J<=)DX_@W*F^/XXM
M>0O^I4[N!G9K! - _[UIMT;&!4<K5^_;37/!O5NNZ!:KK^:F$D,"R>-,7*^J
MQN_D^:,SW,K]_TW5OUK^(5-_!"BKT="_(6$*W\<GVF^8GXDME$JL6 "4NF.,
MKHI9.$^Q=D!DUJK#5OYDO7SFI^%&, ?!-B/=SQ^&6W5>1COQ>?5M)1JMI&;_
M?6UXI?].6)@OM!%/SF=N RJZJB] 3W/0SF@O8V6DT<! :,^[%>)WF'%^3F(C
MA>I'WM<R^S5=0S_EPP?4IBA0'"?^\IBD)$?-&?'=P<W$/X4L=R:Q(]6%,?XZ
M:+4UC@8$\_:V-1N$O;[?2QE<MOSUBU:>-_%@OD7/K97:![P:.8E$8TNHD"P"
M^*2=_2^V_%.[4D0%\B?P4PRR?/)\>1/?01$\?R"6=VAU.#65C=\"G S$U3Q=
M [O=2#M6';&$0Z \=#',\TO?XQ?[&>?P-C+,65JD_U'&??&,K?N%.BXZGY4Q
M/SM)T5\[LH9"'=TK]JCR>HJ,=D:FTHCD\45P6Z.%&6,S=/SB?J<O27>U,TWF
MS)KC5BI76-[Q/LR_4#)TV&'8$-Q;^!LJ\_\%SA^@=T\ 1>,1"F-*."0E7$+4
MO*#"6<U^8_XT-9"/5Y1KI93EN<M8,X9T='<C/+)+%.RI608.NVF43H\D0GJ=
MBHLUC4;_ _B52YD6VC<VW_WWJ*XACBTG/"QS;_>O<<WQ,"\INOF[ N_^$^UQ
MLO_1[SW9U[N_'G"1K+A(?M#E/2.HW'CH,W.8UHS?9VM!LBGHOR"Q\(Y\YA5L
M_7F!6&--$Q7'Q:!"7>XEIVZ=4-),98V22D$W0U8V\9ZYP>?\\5%_W,R^^I/_
M2'@D?9<0L&(%L:EH+PQ_E+NB\K-J/./G^/>%N&N%^B? L=+SW4T;;VIIK(\:
M:<YB,Q\5[E^3]R_*;YC^[$A36'D$/413[F&O088+^"G@WT<=D\/L OCO!@/@
M<: GP&+BXYU P&_)XB> B_K=X4S?=(6YDK'*@KNB@47%9 G&<LP8^H&.=W2D
MU#\FH/^]][5,(7 A5V\FD)65*RWE4.-6>$>'G:DI6&DSB"6F,(YZ0P<U19)/
M7/."4_J4IRG\@^I23;99^$2'F%0/?KZ_NUE>VCJVI4Z6S;K.IS*+3SF)XZ[+
M<:6F3X!XO]\[*<[_O2CGE)PCL8K 5QI;OM%# /T'T.#@;E4TI9X%@0M&_KY>
MP*:)D^M0,_I<[KGC:%Z*"B0U>*UI+ZP\>C!2/Y4]MB #"]@"]OZX-8)1,) "
MK>3ZZ^10A>>XX^'2YK&[]O'@";!B56_+W-SHD]*@O\Z?%V83$C.(_TY!@R,_
MRVCX(4:JO_CAJ^7#['.)&:&?2S99"K@[A,60N XU^5#Y1?]G795<1_E+@F5&
M[V:Q^"8PD9PO:$&H%^E&@C]; A?9AMXS4?=-NQ>/O+G\>/>*XCQ=+]VE?#/:
MI;?P#H4NYF9:I7)/;8U<J]:*%8 =RO0(L:QB4)I$2Q-,>ZLLKX?V26S572 ]
M1;-$YG/$8R=ZOK^;7S"^_/V^%Y-B/HC)_;UFLI4(,J+DZ/BHFJ"MLELK1X2+
M.(R^D-Q\,\XT^U/(WP']>Y>[5<Z=9?7\X\!EJO]4S+(:HH.NU7O"@R;^4/B0
MP%MX1_M$0(7CP!5E?PL3MRN^OY)*SO+ST2<G)R>?\4+F,M,!NC[IYS;)..8)
M(+']!.@HBKM^=^YXLR/\\" X/BTLK'/I[-6H2RA#*;+$$4IY/E!V"1'_N15G
M3OQ(T$;]Z#7R! A0I8>'[JZ<C3K>W=KEZ.#D?@\NL"  "]3[V&9V)4C&^OS7
MDKDE^<W!^A:1HOE>KQ@4(W]]'_LK=MH'F#GGTE?SQ9<XGS"$9N7J?"I@#6U"
M>B?C"7!U/:LD1P?S&P1^=@V A]ADGXT&W-W;/-\NZF? R')]/JT- [CAPA*'
M(!3Q5UD/1>]:H.DTC6>IS67=L935_WC/K+ 'S(9N?YV-) ,MZ7?(S71\?T)O
MK?S^;M?+[YM4D@5WX?RB*]<R]>HW.](/CP*S<+JPW?Z)L3 4^A6JO9+"(]9%
M6U7Q(F=Z>)D$UW,0'3K@S"5/@%#--<>;#?<G0!"741MI>&VX>?F=+/D30)I^
M^?]6E,2'S0/_",?D_C[ JSO@=PF\\1[1\@3XE9S_2*H0VK$3,_N( O$8'-RG
M5+1D9 CI+,S_(_LSP,;L";"S<3?*^DBJ'EJ7S?*<NR^ 50&_H<_LY/ZTZ?E<
MCXQ(>RX*\]D7EV0P UJ8OG'[_RA6=7=T*)E:E"/J[]1H#<51?\L_/=/++HWU
M,\OTN6G.CCL1[;C6S:)_CI0N_=7#WY9Z/1.+FRWGYZ.<;REC;T[U"R#]QR67
M#GBUQ',>251)G]QI/@&PSI[YT=G@QN,3 .*NC3+;T'"F@#/[IH<SVYGN+65[
MX$6Q![U)3\!8WU7&SCW'&/XSZG/$W3U._U\MQK(5XF/B3DD^K*O1BQPL4%30
M@)[Z)UE%]4MU?/T7^[;@QK$198SI6&^DO4$K\+ ]^G])+O](78L'5\+[DY,W
MTFNXD\\)])Q+$\]Y[A#_;WG>4,5M?V1.9#A&PJ;'!J)A8SJGN2JU:26?Y7@"
MB-\-XU_+NL7]<PV>2REU0<"8:,?)7N7ZNV E )Z2X(L5H&1NBT$)U1_7'U\"
M<_J,O34]Z VKG]_']Q_OFTF]%R_NH>HM99FAH!>M?.\>3SH1PHA3_KK_55(J
M>[+9BZ $I=4/MG=?U\LE-Q_/A.]>]-W5_HT!A]CTQP-_(\#4/A\[*A3B4P0Q
M2 6NR0-?,BRC-QTL%\=[L"[,/%II/?ZJ>3S\&UC^;6O];GZR9,C?:U8!G_2>
M ![/]7_B(<C\X8_T21W037.(KO-H_PG _Z8('ILH4:00:]17Q2Q(?__26_C^
M+/WQ,6W7EHV[\MCS(0M<>#J7?^- ;8>7LY%[67B8.P>)KJK7"O *_Q]6BTD.
MCA++E]^C@_'14FK#3?\E_J)/@'\7>8XD>?Z_1+(J+(^<@#K$@25ZE-PYRFD1
MO4IL/;LV_-/M-N/-RO(S</R[9#E,##<VD[K/H8ITP7EQ\PSH]K%%8+XNDD6O
M;$KG>[IQH>//SMV53'K3ORNBKV=R'6<,Z3!W#:\^5M-+C'W\W,*[OUYL&E#F
MGPV>$#I0-]QN5+'[ERO<D"]:'C$OQAV^>2Z1"G.?GL&F8D)AYKDTL-^%/R]4
M7E)(4I_E_[.L8Y._7Q^0Y-?Y_#R2 [QFID$3'ZM*RD5:\9*"0TZ?:,'[9UXD
M^Q<233F UU@O!']5[WLW\V@NX'1,81-Q/<O2 IZ4\%OSB:K&[%IC V[E$P-'
MZ[!33$-C&E;9I"[VESG@;=51]:9%2XN&!KTL2E^2-]%PVL1"]&#9N)7$NG73
M[I*N^C/+ _<+X)-CY#QIJU_(:?O%.KRAV3^^YRVT2%QI=F0K3SPR&2UPHFG#
M-@"J+Y2A\3-Z! 'L>^Y^UCV-64*P>C]Z_>!>V-!?L7!RB#Z&N&M0MM9TQL;/
MRKN5L'FCA]@V$//6>A'$H]$UR7*0+V/-WSC#<P3$\^5S2K=8<BUKT]D%MF!=
M/)]0&5)T+'\:K5Z "<_URR'&<!,:<)P>?">$ZY";Z_#"R*N V*A>)EDP^IMR
MZ08K98_YP@&P^HM@=81WX6;R54MA!5D$L^(E4_0?;;/\8A0B_OG6/2FJ/2*P
M@<IXS\RAM8HK<^&A"VJ6$*<20U#L8V8H2S9\2*XV3C\6=%*=J/>5L?7.L/5/
MY.;Q4J"GQ0Z<9$992?J@^@:=,]91!E$<<7BR1?6]D:HM"G1J1!TV65!/=IJ7
M?'KZ$>T#.EKSB/=!#U7?%U_A*CNQS,*>Y-RRA<'D^(4O0CM<C3A2\%[7;-L+
M6NQ?L%NF28FTWII21IE+][#;72B(_NI=(-+Y=DUXYP.E'-3\(PP74OFK"=)@
M%SCQ5F8 J\!-ZGY*^W6ID?\[YZ08]4C#>[[9NB> U,K=FRI3B#JQZCH^'MCQ
M_8SIS^ -F5A/+ZYDHR\ /J23<?<>;_H( 3T)A9QE$/D')1IRI9KE5\)(W\#]
MC!"-!KA?4F.$VX,E-S?.I5C '.,[73M6FBS^+ XV-78A?\M!KKI!P2-'8P1/
MERK=\8FFWC'C+&K&",E;S%0APO[+7N=Q&*QY_818;IVC#6U,#VPQ^7F=1\);
MQ5#P?,MU,.>5H. ,?9BW+%A-'3^]?(6Y6O54C?9]_*":"QYOWV34$R#LTK.N
MQYT.4C%O@FW9\$Q#6Q:8)WG4WVPDGO38'8$>_3"WXD>6K^MZ6HIR5P^H7_?&
MN%<LJ%P6I$WS?ITJMS?-ZD->_.@]VE%ATW(2323>!#Q0&\]-X@XM4&%4ZM7+
ML(B[5&+0=7G$KK&W>S>#.[.AFO\>\8XI)2"5TB-A*XCI41"M=)567&=:L'6@
MJBI!U7C@\S:&+D;4>)6"294MJ;+G@OJU]*:4/HU1>_-&5Y6-F-T!C'/^(JA)
M]XZ@IXB$EYW_+,,;D3C9<A(V?UE<#?8_@GB99QT//AH(_2!@326F^(R'M%W-
M&L)I#A.05#0T]&J1+(4$N;0:*1\-.<_N1=:M5>,"K\U@I\N3H$*#\F;NQ4&9
ME]F4R #GGK]V,.4'4,RF)%RV PX=H^?'(H90&FLZ&L/VVE[]P"+R#T=+[(SB
MZNL1A+&:+-O>NL_LCEU1_M$(6&'GF*INI]D3"P''%&<=B,&CU8,[6OY<*3L?
M'*35V*\:"4T!?TZOI:T9#ZD]CD9*5'71EVZ(E^L:TS0<V/G3;RM_J0+3%@A-
M7*--BL>ASX64*%_"[<X,[3&V1K$!?$V[_+.D^RR_[?G730(_.SA(S4BVIT@X
MBC[R$5-6Y:VL/<;C!V7__E!_18;;NO,MCE?);"$(&1 ,7L^T7/51D520;?=[
M=[GN1_?G*!>DKYX:S7NVZO)VU9R6+1/\W+Z\B:;B?V3;G05>AEM:6[K;<*/.
M*S?H:GF!?!H?]2\H#R:;.]!4BW8?.;.PX_#5U_RL#,A-'7>L!MW55*+=&&G]
M^(U#UQVQ]I8Y?L;.:A#ERS(D8Z[Z);S;R']]I"_FV)7)-WFZ?OG,%#[,'&\W
M^IB(:V1[*:::)CFA\8G#G$I)U9.^K]]4Q:HK(1KJ?;77YO!JW554/^B;989E
M;RZ\0%/XMHGVV9-5NM)\;E]XF1)Z';*NCYNY=12S\JT"UF3.^*U,UH%9 WGP
MZJ+J<F@M)C1I-.X-3%"_HV9SR9*F]J7B^,5?]IOTQE \.WGI%Z!7T@0]3E9-
MX4;I(\VQ\A1:<6N_4+RORB_K82NPCDUN?1KCJ'5ITJ7EH<*1DD6C+I_B@5>V
MZ(H^II8BAD<WW]$,W:25>^')I>OXN/=2X^X393_J4Z:AK>5600&>Q*T<1#M,
M]XL[L9 ];_3@E^-5QE8P2.9;"M\OD9>'SY4F1P-PK^KJW1=B"9\-%N3"?U<[
M#6ERYS-3 3D0,&>YR.($_7+P<XVT+:#>,GZWE;Q]]<6]4J&;C@%!NF"(-E%9
M)9?YW38JN%\:?%>3F'ABZ-E#?42MA\A*6:NTU@P>4VML2-Y?V_++'[;DH+B-
M[5 ^YT$#^X+-?P/]$SQ^F,;QOWE\C<\9P&<K+HT&\KA]+*]8?-W6,JV/C5V@
MJQ<<C2H3BVI13#$RX#;7D!X32RR+2-JY9TL?.A"'4&7%T_^!CB/')07J=*X&
M%V@_8)L@M!MC!#AP[;0:VB PM\N6TXT&PH?,X.-?C(D74A?-TEU^+(KWLCBZ
MY#J7MZOJ4A@-*-'5"(:%3LE;6!#</<H.*%4RI68Q>40UR<1D[V8YK^*<L3%%
MJN9V,>7S:++-K6_C1 0^T0\WG"QHG"77;&R=T1FU6?NY8!,Q$DBD@_2CK^95
MV=+*?HM4&X)89V+KCV325L%I48^C$$&VV*G(Z@[C9,ON(\E>O)PUBG=#60.,
MW.QX=&7DW3>AHSED!\6Q4D$[K7%RF;AN[_;LXJ4#<N!H3UJ_8B1OH_6@(LVG
MLP3;MD+Q>6E8B6'MOG7?>J4=$$'7S!(\Y%P,2C.K?X/R@;7%?3G?TQ@-#:EB
M!14\>*>)0,U,+EY_372LV-\\>8$K\';=T)J0+^C73AC3JLY)UPIJ8_@]\D.2
M/QUUZ\BI$87%R_%& #K-)ALR8YM!#9RTLKVT>&5YOR6YZ-9&VDQE@/2+*,7H
MN^ ^VKFT%'9;!-6'B0S)[$@)6?20$X?S:Q$C?QONHIJ:F(+@17-N1@":XV6$
MU,4?7RD$YJQ]==TZQ84CN\Q/P>H_.Z'J(/) ==JW?:3,'5T'XJKL!ARJNA\;
MK#M\+K(P@\7ZEQ20<:!NG^P4WL(+BT*\_/RY'1P%J=>+UO<WJZZP?U%H )#G
M/F3L-;6B?$P4<:2_]K_30%2(959E%U_'4OO(T,P+7"$9TV3<1#:?Q ]4[/K*
MH8<_DA\D@$UYSLL/J#?U*ZHCOL^+MP27Q\<46-/'>-X^]T"<@B/&DL8<1[(J
MTY/2;$N@,R^'O0?8:HA&%WSE750755C8]C[X OV,N\HJQ6U26J.G35Z2/4G/
MI9 [F3BJM49%$R&?;X[ 5OO);ZUN3V;P)Q>CV=/P+,/"K4ILHZ==5!U%_[KQ
MSFS$_H*C/H:+;,;5(;2?6N]AW4D&Q;-J0_':T33_X,T!\H?IZA.S!I_/*VHT
M8H2!^#0 D77HO@G2_E4CV;QJ=?B%';5%NW[</(0I>?2/K.6P\ALER;H1;6GK
M!]\>;O,J* (]$N)(?)TD8"\_V=O7M8L4;.>TO3=()IY>%HN'<5EA<JTG=K],
M 8_&]O_4,3,)<G!'K3G[0T@1E\Q$D]AG6[<1@+LRLFXOO]_5E0;ML/\B?PJZ
MC51 G1T*VGE)22'IY/6BL7XEG%!E-0Y_KR6FIZ>HO##7YOC0<H&)NSL9J1G%
M->YWU)2FZA, &) *5&VER(;_ /<]$BQ\E>ISN]))B^P4//1VY8RSE??=#/UU
MTVI.0:ISU:T+/.D*('E([PF^J%S'0];W(N?MNU=B6'6=<HD\GNHD* I.,SOP
M7DE-?"@PIH;Q.]YF"3T!ZJ*UN.Z1BCC%^A8<'$Z.(> OPIY:M>%L: #JMYIQ
MA>KU19!&S=/^=1-]!$\8E&O-+?D1OL</]$JABLG*2A@ L+<;^JC)CXO54 JN
M@*GU[.VZ-!<'*A9L)]$M[5(9WCP@O]SMZE NM(,_?/[,:7_DJU35PYR\%>E8
MST$;CFSZH1"#8B.6P[HKBZH&WO.EH4%>%U0$VDFS&AIB=#</1-]DMU7#$W,0
M*?JQ3<<&W]IL%YJ!.!Z*\Y#/*1,)!SDHS',J4K#G2] ]\)^76L(.<ZZ]ULQS
M*&-^PM;K;2Y$$D!F6XVLPW@8APH,;E5]VM?NI@$5B_L-P*+R B.C0.[8;.>M
MBNOC+O1L;Y][L8F GP(C5$M5# T_VU0V+9V,E<@EFAEV1+>KYW\//J .7M1T
M/7-]1!H^Q;Z0]PA4!XC[V'^T/*%?:!A4W_@)Z6!VN>'<A!"<14^S-^]1'6#G
M:E\.BO&-EW,@ ,;W:TOJ^:0M9:]=IDMEKXL+M;02'DS=7*&0#EO'$L<^DW4C
M$PQ]G@BW-NNQ)OX]F/R@ ).]A>1"]';A=-%,Y;570.JTI>M87ZR$['-OGM9G
M*+QQ)V_TT0#:KNQ*GZI+T2N&UU3:$S/3U_M@"]JN3S],<QD.-GB[I76MK23-
M\<+_*D 9EKAZ'+$[7E5<7IC33*XQ'Q5H%GJ6H*UX,I6!,!(# R<D-$OLUKT>
MIWQL&A(4XFL^>M)82\<(?TCKX#%X#-9,7#S-E+JU5U>]-O5T^?G51"?[%<4'
MYK54IS( K3C6!.S>LV+.)+V<RYW'W$C3WGA^N>N!2&3(W.ZO+A;U*S6.FMIK
MYR*]/]?^\^*MO:IX6\?V0WQ;?P:8A&E%CR(+I7_[L1N N(BU9TQKA0/L(V>8
MU;DI71/D=5EWE7J?:S7+Q2.$G+/BDYT_(R+D8)E?51@8/#GV+I2;2+A>B;)=
MM0=)$JES<P>B-P'57Z^^5O)ENTTZ*H!)O0Q:.70V."*[TW)Z><.I3CG6YEX+
MIOIMD$TX.BML +E^+PP@_0T(=<EP[SQ)8X0+99..A;.2"\O54Z2).RFOO]5U
M'.O+.8J, ZG!&M>V'LVWDIX 55OXD<#H6^LP>Y9& G)[^67^G;<)T42N72_X
M3Z9U^=?Q*0]:'+]>4!LIZ*:_#1.=<;M*5"4&CI%[>'9^SO(FC#R7)KZVG>T!
M?M81=E4E<394<*(B0N(,9W#!)_U1=HV%"S382C&8F1Q\"#'2Y]R?Z/BY6/C-
MYS5)Z2@F\\L!\5W'Q4'6<:LD"R4R%9U/B <8JG><N8GPGEC,2G@[E<G>U4@F
M1S<9OXK9];KX%Y>*;#@#TGW;P>[05N,D5%C &3AZ"8,5DBW/"/=K<+_(.7:>
MA*:9YAA>$ZW\=@4;](Z!''K6F\1LSC2CR/HEI2-B,]EW!1)U)G>UEJA5*@X:
M=:4HX<DA/GAI)_ER7I*;WS#UV#1>E&5)04;!C=U4VS7P*>/::1Y&E27J#P8J
MS5Q3V!X_?CT!/!,P^XK$86&EG@6V&B!+"<F-(8XE/B1'1S^0>>VG0'.4'13Z
M8F]UX:[\SBLI*CI"1/6?JNR1M-6]S1&F'^A>9EZBR T<B@5I'B];RPTO:"7&
M"JX=A&>J>Q:3Q\FS#@8)CP'$F?E!0??EOP2J"?:2O6'I&^9E!@V5GN7*/)4H
MV5 5?2GM_B> !<[CJ[84M4DS!'Y7Z*1%$VPU;)LE=*L#R5'H6'3IV]M^"AJW
M5Q7&U_@R;?!6&RYK&B<*,B0!YY+OGW"$#MTW*LW5G$-LC0(8E5B.S%,08Y$7
ME?3=8>AMK9-N6K94RX_+OPSSA[V_8J)C2:(+I#T!HB#E]N1=LPV-)T(ISM3I
M#R;*M41)G]XTR?=KJ!O&]K8HW1-8$-Q(O8+9+W&13<K2#.I\1*9D'_PHW 28
MC'NA#]QKL4Q.+-D' O<ZO_#8B]PTNO3,!.DP)7C1[FH5)6"K:"6E]*5%&Z/7
MIJC"/D/LE9_IMY$4]5A=:C+1$DY$0 3^)]%RCV46!'KHO8)?'CCXDM9(2SGQ
M0V-S+!)VS(]!OEC>SL[*7/B*C".^$8CXH<C9T_6RN2KKK[^L'Z\9 !B7%*7U
M/$A[+5PC2XNSPBV%1XO&[QO%OK2;IW8TB0"P:/;T=\GBP]<H[]W+%?(/KJC:
M,X722Y"9+EE6K.,I]VKZ.%> ?5.^FEYH056#[BJT7'T13!#]T CKUWV85#PG
M3%(5^&UN\R:_'UA5I@^/S:<%]>TK+/C^S VYIGXR?YB(?D29RE[+^@Y+Z$YI
MG!B>S[>M,60L 5M)+]TXQYGA2GE[/@$"G\F\]EC$Q9)=I[%H;;IF!BV_=9($
MK!SGA!BG5BP:E0G' N!5G$UX<,L2L\:#+UM1[V*B%U7<H2HP"O]-\#G&3,.3
M<+SF%F'4D]+5)@23]!!U=#R>,HCF6LE^E6" XH""%#(V[MRC(XU3?U8(NLQ>
MH&I9 @VO6'08!+)^Q4#^)-*[B)=:?/3Z:&IJZ+YGB#'=D19<"N6RM#$W\+,]
MT:6RT&TDBR&JM[#XB_&36.Q<C_J:C]^'V0V=0KP:']R+>9M=U&&GB,:JB]Z/
M3OC&2=.&]U)3/!+<:;1+VX5.1([U"EZ" Z!)DQ,.NNR_S%*ZEE_4PB_;A.K3
M8O-]_"0[X@52$C&Q3_'6G3/@Z(6L'[(Y?MY8NKM*]TJQM\.S(S^S9*WBDNWW
MKE+\01]RICK1:J7<=(Z>9<T!7W7/9S;$Y2TN15P<Q.CKK$&_]]>?=A=L4.PZ
M9^CF7W=UWGK&")34/\AMQXH4Z2>M,;QA((R560VV%9' +S0 3U\7\;-![]XT
M$FYZ?0*0.U&,>@2*3?>Z30L"GP ZU-'5N9OMS.W3$![T@U"'O(98?!(*RI<-
M[\_(MQ::2B@9SA(3?&9ERD"W=[Z&4X>'D%3S&?F@!GMY%6WQ&D:+B+- I;Z?
MVRT#[51[Q+MI52G,(VMQFAW"1PSN^"10<T=:-/'M:CVPT'Q?-YGWE,F*D;&!
MGE^X>U?8&;FS_;!SPA]!AWK[XNQW7I0F:XT1//<JJW..$"&%5GV+, 6Y>7H[
M<Y$C(WNS:X,NG7;BB8XZSNTT/>ALBELWV1!-5J#.C.M(,<M&386C_;M(MA(*
M33D2P/_*_"-\H[YE?R:4V=IBW6 W5(R@[[8+H !>6Z9WR9]NSU0ER- \ZFDH
M=NZ(;DRVJ349R2IW)&ZH)98Q9U2:DB4QJ3N1;^IRSGWP\R*M9(%TF#%EA6:R
MKM,E>OJW")SVW];CC"]3V&?(TD1(>2SZ[UL(84J6^5&O\X1!CO3=%J@'<$X=
M3JD4]8G\VGP;&'$-5\+N>4L'S!%HH^OS!L(S/ ZH];4XCCHXI$'GVS50QK41
M30@7VICV^+T,39K,8MV(#_T?,TL*.F!0LM9>VLQ4<2G[A_$3\G76\'3-V'%5
MYUJ#[%H%STO/.W'5J4^)%*-V? OK]A59@C WI2-NQL:I?*:_7IKI?^/]UFAI
MR#/TL+]V<EY-OF^NGJ@])5B>*3^EIU3<:5*K@.$O4:!UYKQ"22$%F30!S<\4
MQT(-M>1;F^MA]6LTY)J?\OC>=^&.NBC]*CXLK;YVVDX4LG_DOI9:RW]Q"X8I
M#N4/?-ZO4OBH%6LPY[D.X?3U6UMX>'$&5)DBS4PD:3[;L "GCY?NL$KHXENO
MM>D+K(3QMJ>(V(OIV/6\?LP/&O)VU7:71CU(*TK?2#6M31:UAA&=SA@>DK.U
M>61OG40:CR8>/!AWCC"."\31VU M0<YAB<-4O<02\!%D!88XRD62Z/CSLA;=
M'GSL [&DS)C*Z4?[U6Y<YM8\_@!79XJE(\/VJ'P3DY%*VQ0JGHA/;6(?&^*'
M2I?Z&%6:B+>^:. ;A^5!X-O5=$'P4>+"T5K05= )N?4;O*TVMDNW)T#QIA2(
M5OK+X\N>]0#B_5O%NC0DF\VWO2PW26"S37@Q:^AYY0DAN%@9#JGGMW45JS^I
MI<B+'F"JW"T3%>S=35.#.*ZO4(!J@2M_9,K5'.PO[%R>FP0*9.F>L6+;,81N
MB. !]@C^Q^#G!F/6__<9YPA.28IB%1H6C7FTB^2>BY8KY+!C%74S?FX 0=SE
M#+:5)J#N$_-1X_KS1;5%%-_*.)]V_^LU9.TE;M=#T<%PT,_QAP3U-U7\4&[^
M1IKMIH-GDFI+?$TY/RL[DP]M@ZVU9&$/P+STD(?#;9!<%W45I+Z6"'<[DJY@
M8ZI"1B,8@NT[..-B/](#_4<3G@#AYW@@6KS<C3%\T+Q@;#G7AI*CO_0$&<:/
MS?19VZ L\=N/_+YR\&DZVL99X,7\;U!/P\77KTIOE'2,RZ-U,YX OUG7L7GP
MKSFT5*6U^$ -9S+N=I:O^ES)+D4LE^(OZ)*$\M<DY1W1%JA5L;5CMP],(D^W
MEX_=LU3S7Q;8YZ"..:O_T3KF!M%N]757X\WO-7C62:YCSUHV!LY+9ZRI87_N
M];B;ONP@\!7T+-@'5GA>UTQMGA;]^!:HMT'MT^#"@=[S;5],MSN3M=L#Z&I;
MDOP!. #"B62)8WTYS4OCP7I@*)29LY_%!@^(?.SY'.61Q4!N8AFF@4Q*::&S
M%]\:,O7J.TBF]PD 6]UB.O3N3=EX0-;].<U]5)P:8-UMU1RL1\G\L=?3GI&)
M0%S;GG'=,4RP[<.L>EU+^FBKX2^+1C<%D0&-[D_Q>X9%*7DF)C+KDFJJY-T$
M*RH% R#J?4\EQK'XS" 2O/#<8H-K'^W8OK6$ "NURF)%U=4_C_GL4E?% CYB
MWD\ (_01QCRX8[<(5+_:=M[I.?GL7A+PO^]RX4;B5L?JSFZ=)66-N]<NW<4L
MTML5&C?<O_TR7*/PAOG=JV3S0)GS,F.L^AFW "IPT>29<K.!P<%L6]@=XZ"E
M")+WCO/8WD=W=?SK[&X3XF-W#O%F 3L_[C^?ZEJ2)ZSTHS:;M<WC/M]A&?Z\
M3-G[!&WV'7%'0&=-, L0E@5.#U7B_(SO?WW7UPU#L1;IESQ(:;K^NMY&KSP%
M2;_Q%?0!N2&0K:T9H[[19R$Q67PD:Z=&T,6M!=" C54,HN:VHQ?U%GLP/F8N
MXN[GT.$Y]\&23WYYTM$TP,<B)21S.?:%:MZWQ&8QHA;V4Z<B3W2.,1[,UT>#
MBF9_< UDPC+7#18ZOE)UA&_&$EI;6^,@?GY@XKP>57..^]W<QKJND^^W47*X
M#6E0QS=:5C6W=BGSA-8$3>]0L!;3[J5]H3HJCKHWJ@+=JFZ&[2B$B4LH#"F_
MI: [R,@N-#6Z%T18Q@56)*_HD1/M'::,@THM<F&?CQF4,A+X_"&\H5(-L)5O
M"RFR"[ME\^[=C=Z6E<.7)XX"-1Q0/AR!SPKL_F$5LR]+_E?QZO_01(JJ!JO(
M($2B[JQ5(P^[LKE2DRS12U 512[+T^1CBFW$O/5 'O'S\[E,"A3'WHF+V:ZZ
M)<7#1W:['!R+;'F1LO]'_B7X.NNSF33_L G/W9^-LV)RC8]D@,:WZD  D"WG
M&YK2KV?#%3$L<0H(O% \"W->1)HF\Y*G66C2\3=E28LYO0QD",9GB 0 7Y>_
MDCJ*K:Q?7=U!GTR;)2BK$Z@)+,91P<//S<%D*UEO"C-[KZ7 (G;XR5E=1Y=2
M!T=2)@<U+Y(-\)]FO+Z!N!X-#0U=6/*S@05X%<.Y01S3R).!9)&.J5G6*6V^
MP]8.7GV3F6]123Y8./3**X@\:TJM[3T<K*H8N@H493Q0KI4?[:\JG#UADXBK
M!(A%OJY^]3YTTUV.5H4&"^!.$KU?8I2*BLS\=?V;$F7<,%Z1A+63A/G!6[R\
MM%K&OFV.\I>4BW@*.^]=F$K;A76UEM3DGG6\VZ\HTT-S;,'<G&)J"B-"J9/_
M<K[XRRJ0Z=E@(UD.-*WQD&\@F__LSO^>B9R$P(\\J7<DM?&6:__J[.58TJSO
MD"@2GN%M'EO,Y&RD3:(ME*;S3J)*5=*QLA!.\Z5"O4*]3683>'3W[I$Z4XY/
MFE#Q\C)M&N$U!?:1B]^*/K_3$DX*V7NL[$"KEE''FU-8_^K[+D^]4>DS5SK7
MJ3VZ*/)L(/\NJAQH39)EW(Z=@4^A0G'2J""<_0\%NR2ZU@5+PV7-P8,G8WQ&
M4D?4Q9(@:TM[Y.GCQ&>KYF0EM\9Z/2:Y11+>N\'%6"^*(J#=(T-+=)='HZ?.
M; /_CZ7SXH;8B2]R*799E.H<8Y*X[D+&N%-'%DO.[@$E#$&5^;&7J_WQO5TX
M.9^L&9 2$X-@/ZQ7R['EC6;GDP85D!<6^IQ=]#_)4RMJQC9M<"5&BNY=XNG3
M7 7YJEV)O4W;-K<LW!,BD(>-(?$K*B/OT/'_/"5!&L44-.\V%IQTIU84&)(T
M%E<\2;J_:W;%C"1="SX!G)AYQ'5?5B6,=9&1";?X;;6.)NKK/T30;ES5X'R2
MIEF-#NGE\[,#ZKWZH1A/6LN;@%3J&B[,)ZN95.'E&.[?5;G7CCI98.-0OV;G
M=/96;1-D]A&K2HQ(.#%DS\@ZJ._/!NQ\-\A A?:#GGVB*,87#GNZ7S6_CG34
M0^K7\D'S;GQ+!D\ ZX"^RF$^U#3^:/IT"E%T%,(0(% ^WBY/SR]A=MB2>U*)
MJ;IYTT/4RGPQ\?T^2V9'I1Q%_9@H?.06;*>/(#T<>8P*<"Y1#P[8@D!'ODG^
MH0A8$0QN\86ET97;N3LT>GX 1PXJK<4'$O7O1P\JK>+4D.Z3TV%,'%?F-Z:J
M#=#EW48\[+#(FPT7QS4I27AK[<#]TYT%AZNNJ*L<\SI\19X ^A1(SGU+-_)R
M-N7R5^2,-8,@'3N>;G$1QO&*>V%G4V+U5V]7(>=_8:UYL'W(;1;=)!#9$<0-
M*RS?:R>8DJ[K1NBW+>W,'U=62DTQB?RX?#RY*]AA1:>HNM,</Q+D4E";9@*9
MMTQM\N#$"TW*XO )TY32*ORL.%L=(JF#!,]?:=3[Z#.#BX.=JB1Z.??!#-%9
M&]%8V2#RCHNF&Y-WJHP:;3/W5-R5)Y6L[6 +O6.N\8CA$ ;:RGY19'9OFLC-
MJ77:^:4Y(Y6M "M:'K_9H?Y6WOH@UX6(.?/IR!.W3/8%N:F$P7'IY(K1$48'
M3P_F'ZE73 GJL)^6UYXY0T5+>GR&7N1BX9<A<?SQ+-YX(L;Y=%^F>S\>'X=-
MU]>,"4="Y3CWBKW.NCSMS%%F>>P+!<=^2)09@+!_LR'3%6<K3];/0AY4]!KT
M#4%./85R 9ZVL(6"E;8NUI'!8/*#R4:(.M:\K7>("?/21<QT/(95PJ CYV!(
MC@/^7QF$P?RP"KUKCRZU-H-RRWCE/X4)^5);A+E,[IO9J9N)JJ-D$]C)NB)M
MZ#W+#-,.;JU3N$L]#;EL1/-5R7ND]:H98F,3#8@,N(MSY#(B)8)'H/2\3:I[
MB&;V5*G%IA*XM?'>,+,FMF 3#TR3EC74"70/G8'&&^ZCP6"R7)"H16(43M?!
M:F,^)TP&Z\@)F!N'D3W7_4X6YE'!&=>Q_8I%O- ;)[].AF ,@8S<T30@[FN]
MC94>*89:^,QHM3M-L"3[H=>*3;W04<#GMUO:[0?!B^;!NK3[(,&'CV ?%6@S
MK.)P<WK3*V6P49B(R<*2\2L)[2:.@_E4MNUB5&>+"]?/9)^A;):3HU@'EI6=
MD6@.:9JC#<"G%^BD2'#NM'8E2.LT%QUF8?+2T3;@-S,#U.Z;_&]Y)]>0R6Q!
M7J""N.EZ-8&MTUZ#DU$/:7=+9<^71J)Y4BO%#4Z:7O7!!Y&]-#<I!H2 4.V*
MH:U0G6SQ ;)J\DN[^L7BU!+#C/O*,S<:YQ,CH>S5-A[5M&4]IE:KX%.5&3Y5
MZ \FU6@E1B;",6,(!UA=S8ZC]=TLG=',$^#R2[;(6'J;2:S4\4=GU5'R"73.
M6&-)$UWA\;W;SPT>]IY5Q@L## WH&)$&'FA\]^Z2/E/<OB:5^@LQ[$K0I;?[
MM7,/M=B,C%Y*%(G@K][M&!1[RRUSOES%G7ZXZP*/_XVUMXR*ZVGV1H= D* 1
M7(,$@MO@DH3@@0DN@R1!AV%PETP@@> NP4EP&1P&37"7X## X,[@KC?_YYY'
MSGO/<\Y9Z[T?ZD/MW?WKJNK:O:JJ>_4V%XTU*3$RZX]70=I]DWH0LMYR">N=
M?<PVYJSF?;J:_MRMAVCFU2J)&!552[>X<-VB[UNG[G6F ]D@BQ!BG@0EWMUJ
M+)A]_IR^L.3287_8K9;9&JW*)0.QZ;XMI=LMYX&M^VB7HP,O#_)-<)G8H0*!
M21<]]/6YD#I,&I-=]RO&O19<6M/4(E1<R%],2T5%]X[H7;IXD2%E(,:%H#3/
M?VEW";I)H;Q2G^@MQ(G!R^RBK_?2>-XYP*3A/K;(H'K#U\GPM#'0V_.$%J$R
M\Z8FV=OBICF&U7;%.< HO Z0^K@'0?]G<6;ZS3Q^/,WWKK')'X7>G=B9^7)A
MGM)KX8I']["%/K+:Y>SCXU$^A;SUX."Q9Q%+"@8B54X*A?G=BIP*OS]6&WEP
MJ7M+3MG9V9?D-@E<3&KUTVBRO.O.7,9Z20_8A5PI29KV'9,8N(C8\NSQ[+S6
M0[;N+J<./GVX+BVCT47>N9%P!YA"LQQX-HSS6CV'V M/QI(9?#0@8,+Z!*##
MVC3&6/$&6P+I%4[BLWU?L8:X.,=Q^GT"> >*%V=QF=RH0,WZJJCLJH*O97TN
ME4:3524#P.T.0P5*9MSIUG0%3)072">!#AO(!$6]2=H"[,,@/Y#V8DFU(?IL
M]_6PT,^C:Z-/"EYF(=O">[B02]>YXCN S:\Z57[Y5$JAO8C9A\A5JML];$>Q
M)Q TT:A+WSGOA^1#)8QJBBHD=XZXW*Z!DN&+7XP#"2X71"?TMDGI[0>/SQIC
M\)JJ)E+5VH@1Z%@"A#>=C[\S&K.HO:^?0.]%-$E;_#-GB< %PZ+1&)#<9W)%
MMV)8I.A\%<LLKM#=C7??DUI\A^NW:QKNI.&5<(RJ(\S9IB.SKB;6/'KE_2>I
ML(=C9/(ZR/W %!AY,HM1Y8P)[3)77]W:MP+-09 )*?*E!D$G5W\>Q=0=X-$F
M2GXPB2ZYOY5>L*?]4*&?@OT!_H/E\\14S.Z+$K#J[^.K\,=:36-+OEQM%6C$
M#H6@:((_ZPO2;WF[165SE9O')47M)C3( VZ*<J,Y-#@4\F4#EDV82$_0S;2<
M?U9(F8[W]>U(1\!N'<*(>3:GMX>ME9(HR^^,7T]J(2)3@X"-UHBF8:IS^)B+
M7N[-A)U5B!I7F[MSAQ1%0V.\=1:C4,4=X)[2"S:/;KIE(+S%K:RFH'"KWCAC
MRD4R)YSG*<%J<7_='#]HD3@*#YO)$F%\SDQ[P^ K>&4T4?(^63NJ"HFO#UO!
M.C2#B+&2>3T8&SY6'#'1A9EJ_3H"8-E;Z!%$[BXJ<,2-@MYJC#,X+TO;H>V?
MF,RSCMSDM?W@*U>(EB1@Z_8,U"83_*8.<@8G)B0K!M\^W10T-@2;3O?]D#H@
M6"9I[/[&Q' .G-R4 )9$6O 4XRI3&&2GZR4AA1K*+5EOQ2ZQ]+GV+UOO5U 8
MYB+,)QR:&D'V$H&'TV<8<:TH$H&=^YH%] D)E%S,^W-5AJ(1P"9*D"G?&XK?
MQCSU&3$$5!5E&M=, 7CT7)7%B,<O*G_'+._L28W.UL8LK:W)L5:44=&F3#D
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MZE?W-FTP,[J;H7:0*V7$I<G*9.1$FE_9O%X*U;YFH&POK6$UVTU)JZYT-;W
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M.&]+$_C7F!;X0(ES$0H@FXR66[JZW^"WGC&H"=I$.?* [(C]ED\OF<KHD X
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MVLC3&N7!P*I=GN%&+#2PV)(4+EM3L[B_\M(A^/@T)B'TB0A9G]=14\.\B:>
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M\7]FN;\[N*#$9<$A"I =[N))$*>ZU+/CX8E?<:WY))7UB#_X);R@2S9<N9Q
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M,>-;&-:F%FAA^T;9TM<,#*[K")MPZT_X 0Q2XA_AGW47![ACE])-9/X6*-A
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MV<V=6@OB"JTQ[B.>'[U$0C<_L'/TV-D,&\!1HO"C/=*;:]E%Q=/P^>NKMCL
MG/1<]^.@<>AIU*Z-QK]KH;&S.B6=+9D<IVOZKT]OLMS_N,O^'6"^[?:)M[@;
M*81D+8<\#A4_4F!F3XHMN_T'.T[0LZR+B0K]O7PS.9$"21.3T+917%DP2\WV
ML(5:.SJ*(FIEX>8_6\4G9H</PO '*?$_#0"WGKL###7*GOWA V3_PRP_*NX
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M/<SW!T[%]U$KR1LCJ+RF&#EZETI"E:L'NU-O)/2#1"25I:3X4"4+TN30:LH
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MWA/ZY6TA-6'_'%'/*9J>KU1\$:4TG"R,.5BM\92SE,=__J#P.]:2UVE)^!V
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M*WTCCOCL6FN;'_1B\+,SLB>?P.-W #"A-LPBO^8H.'B_E*TN6"<T\V.,)8L
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M*MG7#IH  #?    '              "  0    !A,#,N:G!G4$L! A0#%
M  @ EHD(6>/>*(0H9P  NVX  !8              ( !,YH  &-A8C%A8S0S
M,#!E,&EM9S P,2YJ<&=02P$"% ,4    " "6B0A9><]B($OH  #Y%@$ "P
M            @ &/ 0$ 8VAA<G1?,BYJ<&=02P$"% ,4    " "6B0A9WM$S
MLE0(  !S-0  #0              @ $#Z@$ 97A?-C<W,C@R+FAT;5!+ 0(4
M Q0    ( ):)"%F?3^?+/0@  -(U   -              "  8+R 0!E>%\V
M-S<R.#,N:'1M4$L! A0#%     @ EHD(6>4=*#?<!0  6AT   T
M     ( !ZOH! &5X7S8W-S(X-"YH=&U02P$"% ,4    " "6B0A9LPD2PA^7
M  #KH   "               @ 'Q  ( 9FEG-2YJ<&=02P$"% ,4    " "6
MB0A9WOT&HYI"  !V2P  #               @ $VF ( 9FEG=7)E,#$N:G!G
M4$L! A0#%     @ EHD(6>[QR_]P2@  9%    P              ( !^MH"
M &9I9W5R93 S+FIP9U!+ 0(4 Q0    ( ):)"%F$WXL%G2@  $LO   ,
M          "  90E P!F:6=U<F4P-"YJ<&=02P$"% ,4    " "6B0A9:F/G
M0191  "-5@  #@              @ %;3@, 9FEG=7)E-&(P,BYJ<&=02P$"
M% ,4    " "6B0A9R:@)&H%A  "C90  #@              @ &=GP, 9FEG
M=7)E-6(P,BYJ<&=02P$"% ,4    " "6B0A9G>/(2K /   AO@  $0
M        @ %* 00 <V%V82TR,#(T,#8S,"YX<V102P$"% ,4    " "6B0A9
MTR[G<<P)   "A   %0              @ $I$00 <V%V82TR,#(T,#8S,%]C
M86PN>&UL4$L! A0#%     @ EHD(6?IZO^^',@  \6($ !4
M ( !*!L$ '-A=F$M,C R-# V,S!?9&5F+GAM;%!+ 0(4 Q0    ( ):)"%G:
MH;Q<J4<  #,!!  5              "  >)-! !S879A+3(P,C0P-C,P7VQA
M8BYX;6Q02P$"% ,4    " "6B0A9.\*+TBLV  #HV00 %0
M@ &^E00 <V%V82TR,#(T,#8S,%]P<F4N>&UL4$L! A0#%     @ EHD(6<>=
MS33G7@$ \&</ !0              ( !',P$ '-A=F$R,#(T,#8S,%\Q,'$N
M:'1M4$L! A0#%     @ EHD(63*SP_V,I0  "+$   L              ( !
E-2L& '-L:61E,#4N:G!G4$L%!@     3 !, A00  .K0!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>sava20240630_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sava="http://www.cassavasciences.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sava-20240630.xsd" xlink:type="simple"/>
    <context id="d_2024-01-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-08-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-08-05</instant>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-01-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-05-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="i_2024-06-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sava:StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-16</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-06-30_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-28</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-05</startDate>
            <endDate>2022-07-05</endDate>
        </period>
    </context>
    <context id="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-01-03</endDate>
        </period>
    </context>
    <context id="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-07</instant>
        </period>
    </context>
    <context id="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-05-02</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-01-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2024-01-01_2024-06-30"
      id="thunderdome-EntityCentralIndexKey">0001069530</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2024-01-01_2024-06-30"
      id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2024-01-01_2024-06-30" id="ixv-6831">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2024-01-01_2024-06-30" id="ixv-6832">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2024-01-01_2024-06-30" id="ixv-6833">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2024-01-01_2024-06-30" id="ixv-6834">2024</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-06-30"
      id="c115657423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-12-31"
      id="c115657424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115657428"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c115657429"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115657430"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c115657431"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657432"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657433"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657434"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657435"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115657438"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c115657439"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115657440"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c115657441"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115657442"
      unitRef="Share">47976166</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115657444"
      unitRef="Share">47976166</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c115657443"
      unitRef="Share">42236919</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c115657445"
      unitRef="Share">42236919</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c115657898"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c115657804">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115657815"
      unitRef="Share">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c115658082"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-06-30_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c115659235"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115658098"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115659238"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      id="c115658124">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115658171"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115659233"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115658175"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115659234"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c115658255"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c115658256"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c115658257"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"
      decimals="INF"
      id="c115658262"
      unitRef="Pure">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"
      decimals="INF"
      id="c115658263"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c115658266"
      unitRef="Pure">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <sava:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658348"
      unitRef="Share">4</sava:ClassOfWarrantOrRightIssuedDuringPeriod>
    <sava:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c115658350"
      unitRef="Share">16900000</sava:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658352"
      unitRef="Share">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sava:RedemptionPercentageOfWarrants
      contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="3"
      id="c115658354"
      unitRef="Pure">0.001</sava:RedemptionPercentageOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658356"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2024-04-01_2024-06-30" id="c115658401">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2024-04-01_2024-06-30" id="c115659230">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2024-04-01_2024-06-30" id="c115659231">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2024-04-01_2024-06-30" id="c115659232">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2024-01-01_2024-06-30" id="ixv-8112">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2024-01-01_2024-06-30" id="ixv-8113">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2024-01-01_2024-06-30" id="ixv-8114">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2024-01-01_2024-06-30" id="ixv-8115">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2024-01-01_2024-06-30" id="ixv-8116">001-41905</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2024-01-01_2024-06-30" id="ixv-8117">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2024-01-01_2024-06-30" id="ixv-8118">91-1911336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2024-01-01_2024-06-30" id="ixv-8119">6801 N. Capital of Texas Highway, Building 1; Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2024-01-01_2024-06-30" id="ixv-8120">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2024-01-01_2024-06-30" id="ixv-8121">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2024-01-01_2024-06-30" id="ixv-8122">78731</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2024-01-01_2024-06-30" id="ixv-8123">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2024-01-01_2024-06-30" id="ixv-8124">501-2444</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2024-01-01_2024-06-30" id="ixv-8125">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2024-01-01_2024-06-30" id="ixv-8126">SAVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2024-01-01_2024-06-30" id="ixv-8127">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2024-01-01_2024-06-30" id="ixv-8128">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2024-01-01_2024-06-30" id="ixv-8129">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2024-01-01_2024-06-30" id="ixv-8130">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2024-01-01_2024-06-30" id="ixv-8131">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2024-01-01_2024-06-30" id="ixv-8132">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2024-01-01_2024-06-30" id="ixv-8133">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2024-08-05"
      decimals="INF"
      id="ixv-8134"
      unitRef="Share">47976166</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657397"
      unitRef="USD">207291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657398"
      unitRef="USD">121136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657399"
      unitRef="USD">14831000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657400"
      unitRef="USD">8497000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657401"
      unitRef="USD">222122000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657402"
      unitRef="USD">129633000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657403"
      unitRef="USD">21364000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657404"
      unitRef="USD">21854000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657405"
      unitRef="USD">82000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657406"
      unitRef="USD">176000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657407"
      unitRef="USD">243568000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657408"
      unitRef="USD">151663000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657412"
      unitRef="USD">52552000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657413"
      unitRef="USD">10573000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657414"
      unitRef="USD">1596000</sava:AccruedDevelopmentExpenseCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657415"
      unitRef="USD">3037000</sava:AccruedDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657416"
      unitRef="USD">218000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c115657417"
      unitRef="USD">200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657418"
      unitRef="USD">228000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657419"
      unitRef="USD">385000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657420"
      unitRef="USD">54594000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657421"
      unitRef="USD">14195000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657426"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657427"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657436"
      unitRef="USD">48000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657437"
      unitRef="USD">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657446"
      unitRef="USD">538497000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657447"
      unitRef="USD">518195000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657448"
      unitRef="USD">-349571000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657449"
      unitRef="USD">-380769000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657450"
      unitRef="USD">188974000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657451"
      unitRef="USD">137468000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657452"
      unitRef="USD">243568000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657453"
      unitRef="USD">151663000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657467"
      unitRef="USD">15198000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657468"
      unitRef="USD">24969000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657469"
      unitRef="USD">31431000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657470"
      unitRef="USD">47089000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657471"
      unitRef="USD">46204000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657472"
      unitRef="USD">3808000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657473"
      unitRef="USD">49905000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-5"
      id="c115657474"
      unitRef="USD">8200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657475"
      unitRef="USD">61402000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657476"
      unitRef="USD">28777000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657477"
      unitRef="USD">81336000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657478"
      unitRef="USD">55289000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657479"
      unitRef="USD">-61402000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657480"
      unitRef="USD">-28777000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657481"
      unitRef="USD">-81336000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657482"
      unitRef="USD">-55289000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657483"
      unitRef="USD">2316000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657484"
      unitRef="USD">2198000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657485"
      unitRef="USD">4092000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657486"
      unitRef="USD">4249000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657487"
      unitRef="USD">99000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657488"
      unitRef="USD">203000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657489"
      unitRef="USD">259000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657490"
      unitRef="USD">393000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657491"
      unitRef="USD">-65142000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657492"
      unitRef="USD">-0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657493"
      unitRef="USD">-108183000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657494"
      unitRef="USD">-0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657495"
      unitRef="USD">6155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657496"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657497"
      unitRef="USD">31198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657498"
      unitRef="USD">-50647000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657499"
      unitRef="Share">46202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657500"
      unitRef="Share">41793000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657501"
      unitRef="Share">44601000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657502"
      unitRef="Share">41766000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c115657503"
      unitRef="USDPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115657504"
      unitRef="USDPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115657505"
      unitRef="USDPerShare">0.7</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115657506"
      unitRef="USDPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657508"
      unitRef="USD">6155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657509"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657510"
      unitRef="USD">31198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657511"
      unitRef="USD">-50647000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657512"
      unitRef="USD">-0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657513"
      unitRef="USD">-0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657514"
      unitRef="USD">43793000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657515"
      unitRef="USD">-0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657516"
      unitRef="USD">6155000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657517"
      unitRef="USD">-26376000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657518"
      unitRef="USD">-12595000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657519"
      unitRef="USD">-50647000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657520"
      unitRef="Share">46202000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657521"
      unitRef="Share">41793000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657522"
      unitRef="Share">45152000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657523"
      unitRef="Share">41766000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c115657524"
      unitRef="USDPerShare">0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115657525"
      unitRef="USDPerShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115657526"
      unitRef="USDPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115657527"
      unitRef="USDPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657543"
      unitRef="Share">41735557</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657544"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657545"
      unitRef="USD">511049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657546"
      unitRef="USD">-283552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c115657547"
      unitRef="USD">227539000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657550"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c115657551"
      unitRef="USD">650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657552"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-4"
      id="c115657553"
      unitRef="USD">650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657555"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657556"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657557"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c115657558"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657559"
      unitRef="Share">13878</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657560"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657561"
      unitRef="USD">64000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657562"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c115657563"
      unitRef="USD">64000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657565"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657566"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657567"
      unitRef="USD">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c115657568"
      unitRef="USD">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657569"
      unitRef="Share">41749435</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657570"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657571"
      unitRef="USD">511786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657572"
      unitRef="USD">-307823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c115657573"
      unitRef="USD">204005000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657576"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657577"
      unitRef="USD">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657578"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c115657579"
      unitRef="USD">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657581"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657582"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657583"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-04-01_2023-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c115657584"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657585"
      unitRef="Share">170092</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657586"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657587"
      unitRef="USD">889000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657588"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657589"
      unitRef="USD">889000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657591"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657592"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657593"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657594"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657595"
      unitRef="Share">41919527</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657596"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c115657597"
      unitRef="USD">513510000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657598"
      unitRef="USD">-334199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c115657599"
      unitRef="USD">179353000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657600"
      unitRef="Share">42236919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657601"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657602"
      unitRef="USD">518195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657603"
      unitRef="USD">-380769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657604"
      unitRef="USD">137468000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657607"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657608"
      unitRef="USD">2312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657609"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c115657610"
      unitRef="USD">2312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657612"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657613"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657614"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-01-01_2024-03-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c115657615"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657617"
      unitRef="USD">-0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657618"
      unitRef="USD">113363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657619"
      unitRef="USD">-0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c115657620"
      unitRef="USD">113363000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657621"
      unitRef="Share">1011497</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657622"
      unitRef="USD">1000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657623"
      unitRef="USD">22159000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657624"
      unitRef="USD">0</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-4"
      id="c115657625"
      unitRef="USD">22160000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657627"
      unitRef="USD">0</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657628"
      unitRef="USD">4954000</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657629"
      unitRef="USD">0</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c115657630"
      unitRef="USD">4954000</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657632"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657633"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657634"
      unitRef="USD">25043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-3"
      id="c115657635"
      unitRef="USD">25043000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657636"
      unitRef="Share">43248416</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657637"
      unitRef="USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c115657638"
      unitRef="USD">434280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657639"
      unitRef="USD">-355726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c115657640"
      unitRef="USD">78597000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657643"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657644"
      unitRef="USD">2581000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657645"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c115657646"
      unitRef="USD">2581000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657648"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657649"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657650"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2024-04-01_2024-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c115657651"
      unitRef="USD">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657652"
      unitRef="Share">4727750</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657653"
      unitRef="USD">5000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657654"
      unitRef="USD">101387000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657655"
      unitRef="USD">0</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657656"
      unitRef="USD">101392000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657658"
      unitRef="USD">0</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657659"
      unitRef="USD">226000</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657660"
      unitRef="USD">0</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657661"
      unitRef="USD">226000</sava:AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657663"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657664"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657665"
      unitRef="USD">6155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657666"
      unitRef="USD">6155000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115657667"
      unitRef="Share">47976166</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c115657668"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c115657669"
      unitRef="USD">538497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c115657670"
      unitRef="USD">-349571000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657671"
      unitRef="USD">188974000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657677"
      unitRef="USD">31198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657678"
      unitRef="USD">-50647000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657680"
      unitRef="USD">4939000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657681"
      unitRef="USD">1508000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657682"
      unitRef="USD">-108183000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657683"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657684"
      unitRef="USD">496000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657685"
      unitRef="USD">544000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657686"
      unitRef="USD">117000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657687"
      unitRef="USD">238000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657689"
      unitRef="USD">6334000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657690"
      unitRef="USD">-4116000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657691"
      unitRef="USD">-0</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657692"
      unitRef="USD">17000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657693"
      unitRef="USD">41979000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657694"
      unitRef="USD">6661000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657695"
      unitRef="USD">-1441000</sava:IncreaseDecreaseInDevelopmentExpense>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657696"
      unitRef="USD">4764000</sava:IncreaseDecreaseInDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657697"
      unitRef="USD">18000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-4"
      id="c115657698"
      unitRef="USD">50000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657699"
      unitRef="USD">-157000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657700"
      unitRef="USD">-396000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657701"
      unitRef="USD">-37368000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657702"
      unitRef="USD">-33179000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657704"
      unitRef="USD">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657705"
      unitRef="USD">351000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657706"
      unitRef="USD">-29000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657707"
      unitRef="USD">-351000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657709"
      unitRef="USD">123552000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657710"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657711"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657712"
      unitRef="USD">953000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657713"
      unitRef="USD">123552000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657714"
      unitRef="USD">953000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657715"
      unitRef="USD">86155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657716"
      unitRef="USD">-32577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115657717"
      unitRef="USD">121136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c115657718"
      unitRef="USD">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657719"
      unitRef="USD">207291000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c115657720"
      unitRef="USD">168438000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657723"
      unitRef="USD">113363000</sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities>
    <sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657724"
      unitRef="USD">0</sava:IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities>
    <sava:DerecognitionOfWarrantLiabilitiesThroughExercises
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-4"
      id="c115657725"
      unitRef="USD">-5180000</sava:DerecognitionOfWarrantLiabilitiesThroughExercises>
    <sava:DerecognitionOfWarrantLiabilitiesThroughExercises
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657726"
      unitRef="USD">0</sava:DerecognitionOfWarrantLiabilitiesThroughExercises>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709907">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1.&lt;/em&gt; General and Liquidity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#x201c;Company&#x201d;) discovers and develops proprietary pharmaceutical product candidates that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and Article &lt;em style="font: inherit;"&gt;10&lt;/em&gt; of Regulation S-&lt;em style="font: inherit;"&gt;X.&lt;/em&gt; All intercompany transactions and balances have been eliminated in consolidation. Accordingly, the condensed consolidated financial statements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt; are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be expected for any other interim period or for the year &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#x2019;s Annual Report on Form&#160;&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $349.6&#160;million at &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#x2019;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c115657737"
      unitRef="USD">-349600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709908">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;"&gt;The fair value of common stock warrants of $6.71 per warrant was determined at distribution on &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;using a Monte Carlo valuation model since the warrants were&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; traded on the open market on &lt;em style="font: inherit;"&gt; January 3, 2024. &lt;/em&gt;Warrant trading on Nasdaq began on &lt;em style="font: inherit;"&gt; January 4, 2024. &lt;/em&gt;Quantitative information regarding Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; fair value measurements for common stock warrants are as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversion rate - common shares per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing price of common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c115657898"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The common stock warrants stopped&#160;trading on Nasdaq after &lt;em style="font: inherit;"&gt; May 2, 2024 &lt;/em&gt;and subsequently had little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. As of &lt;em style="font: inherit;"&gt; May 7, 2024,&#160;&lt;/em&gt;the warrants were presumed to have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Business Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c115657804"&gt;four&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) per Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be antidilutive. A net loss&#160;causes all potentially dilutive securities to be antidilutive. Potentially dilutive securities consist of outstanding common stock options,&#160;warrants and Performance Awards.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net income (loss) and comprehensive net income (loss). The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;31,198&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;44,601&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Net income (loss) per share, basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.70&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;31,198&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Adjustment for change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0pt;"&gt;Adjusted numerator, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(12,595&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,601&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Dilutive effect of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Weighted average dilutive common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;45,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Dilutive common stock options excluded from net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,703&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,001&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,674&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,018&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive Performance Awards excluded from net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti&lt;b&gt;-&lt;/b&gt;dilutive. The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti&lt;b&gt;-&lt;/b&gt;dilutive. Warrants were included for&#160;the calculation of net loss per share, diluted, for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;assuming each warrant was&#160;exercisable for &lt;span style="-sec-ix-hidden:c115657815"&gt;one&lt;/span&gt; and &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-half shares of common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201c;) Accounting Standards Codification (&#x201c;ASC&#x201c;) &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; &#x201c;Distinguishing Liabilities from Equity&#x201d; (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201c;&lt;/em&gt;), and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201c;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable, accrued expenses, accrued development expense and other&#160;liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense and other liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contracts, Prepaids&#160;and Accruals &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;CIB Plan&#x201d;) to incentivize Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;&lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; for further discussion of the CIB Plan.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize right-of-use assets or lease liabilities. As the Company`s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements. Intangible assets also include&#160;leasing commissions which are amortized over the life of the lease agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;b&gt;&lt;i&gt;Insurance Recoveries&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense. There was approximately $5.8&#160;million&#160;of insurance recoveries recorded during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024. &lt;/em&gt;There were&#160;no insurance recoveries recorded during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023. &lt;/em&gt;There was approximately $8.8&#160;million&#160;and $0.1 million of insurance recoveries recorded during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The applicable policy has a $10.0 million recovery limit.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s condensed consolidated financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;i&gt;&lt;b&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;i&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the&#160;FASB&#160;issued Accounting Standards Update, or ASU, &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses and other segment items by reportable segment. The ASU becomes effective for annual periods beginning in &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and interim periods in &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures. This standard enhances disclosures related to income taxes, including the rate reconciliation and information on income taxes paid. The ASU becomes effective &lt;em style="font: inherit;"&gt; January 1, 2025.&#160;&lt;/em&gt;The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.&lt;/p&gt;

   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2024-01-01_2024-06-30" id="c115659237">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659239">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659240">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;"&gt;The fair value of common stock warrants of $6.71 per warrant was determined at distribution on &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;using a Monte Carlo valuation model since the warrants were&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; traded on the open market on &lt;em style="font: inherit;"&gt; January 3, 2024. &lt;/em&gt;Warrant trading on Nasdaq began on &lt;em style="font: inherit;"&gt; January 4, 2024. &lt;/em&gt;Quantitative information regarding Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; fair value measurements for common stock warrants are as follows:&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversion rate - common shares per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing price of common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c115657898"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The common stock warrants stopped&#160;trading on Nasdaq after &lt;em style="font: inherit;"&gt; May 2, 2024 &lt;/em&gt;and subsequently had little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. As of &lt;em style="font: inherit;"&gt; May 7, 2024,&#160;&lt;/em&gt;the warrants were presumed to have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; value since they&#160;were redeemed for a nominal payment of $0.001 per warrant.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant
      contextRef="i_2024-01-03"
      decimals="INF"
      id="c115657793"
      unitRef="USDPerShare">6.71</sava:ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709909">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercise price per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Conversion rate - common shares per warrant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Closing price of common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c115657898"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c115657892"
      unitRef="Pure">33</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputConversionPriceMember"
      decimals="INF"
      id="c115657893"
      unitRef="Pure">1.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c115657894"
      unitRef="Pure">23.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c115657895"
      unitRef="Pure">0.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c115657896"
      unitRef="Pure">0.054</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c115657897"
      unitRef="Pure">0.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <sava:ClassOfWarrantOrRightRedemptionPricePerShare
      contextRef="i_2024-05-07"
      decimals="INF"
      id="c115657801"
      unitRef="USDPerShare">0.001</sava:ClassOfWarrantOrRightRedemptionPricePerShare>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659241">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Business Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c115657803"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659242">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model&#160;to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c115657804"&gt;four&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659243">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) per Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be antidilutive. A net loss&#160;causes all potentially dilutive securities to be antidilutive. Potentially dilutive securities consist of outstanding common stock options,&#160;warrants and Performance Awards.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net income (loss) and comprehensive net income (loss). The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;31,198&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;44,601&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Net income (loss) per share, basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.70&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;31,198&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Adjustment for change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0pt;"&gt;Adjusted numerator, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(12,595&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,601&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Dilutive effect of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Weighted average dilutive common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;45,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Dilutive common stock options excluded from net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,703&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,001&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,674&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,018&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive Performance Awards excluded from net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti&lt;b&gt;-&lt;/b&gt;dilutive. The Company excluded&#160;common stock options&#160;and Performance Awards outstanding for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;and Performance Awards&#160;would have been anti&lt;b&gt;-&lt;/b&gt;dilutive. Warrants were included for&#160;the calculation of net loss per share, diluted, for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;assuming each warrant was&#160;exercisable for &lt;span style="-sec-ix-hidden:c115657815"&gt;one&lt;/span&gt; and &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-half shares of common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709910">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;31,198&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, basic:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;44,601&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Net income (loss) per share, basic&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.70&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Numerator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Net income (loss)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;31,198&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Adjustment for change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0pt;"&gt;Adjusted numerator, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;6,155&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(26,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(12,595&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;(50,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Denominator, diluted:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Weighted average common shares outstanding&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,601&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Dilutive effect of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;551&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Weighted average dilutive common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;46,202&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,793&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;45,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;41,766&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.21&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Dilutive common stock options excluded from net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,703&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,001&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,674&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;2,018&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dilutive Performance Awards excluded from net income (loss) per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657912"
      unitRef="USD">6155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657913"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657914"
      unitRef="USD">31198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657915"
      unitRef="USD">-50647000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657917"
      unitRef="Share">46202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657918"
      unitRef="Share">41793000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657919"
      unitRef="Share">44601000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657920"
      unitRef="Share">41766000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c115657921"
      unitRef="USDPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115657922"
      unitRef="USDPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115657923"
      unitRef="USDPerShare">0.7</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115657924"
      unitRef="USDPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657926"
      unitRef="USD">6155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657927"
      unitRef="USD">-26376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657928"
      unitRef="USD">31198000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657929"
      unitRef="USD">-50647000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657930"
      unitRef="USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657931"
      unitRef="USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657932"
      unitRef="USD">-43793000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657933"
      unitRef="USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657934"
      unitRef="USD">6155000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657935"
      unitRef="USD">-26376000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657936"
      unitRef="USD">-12595000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657937"
      unitRef="USD">-50647000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657939"
      unitRef="Share">46202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657940"
      unitRef="Share">41793000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657941"
      unitRef="Share">44601000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657942"
      unitRef="Share">41766000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657943"
      unitRef="Share">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657944"
      unitRef="Share">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657945"
      unitRef="Share">551000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657946"
      unitRef="Share">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115657947"
      unitRef="Share">46202000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657948"
      unitRef="Share">41793000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115657949"
      unitRef="Share">45152000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115657950"
      unitRef="Share">41766000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c115657951"
      unitRef="USDPerShare">0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115657952"
      unitRef="USDPerShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115657953"
      unitRef="USDPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115657954"
      unitRef="USDPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c115657955"
      unitRef="Share">2703000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c115657956"
      unitRef="Share">2001000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c115657957"
      unitRef="Share">2674000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c115657958"
      unitRef="Share">2018000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="-3"
      id="c115657959"
      unitRef="Share">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="-3"
      id="c115657960"
      unitRef="Share">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="-3"
      id="c115657961"
      unitRef="Share">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="-3"
      id="c115657962"
      unitRef="Share">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DerivativesPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659244">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201c;) Accounting Standards Codification (&#x201c;ASC&#x201c;) &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; &#x201c;Distinguishing Liabilities from Equity&#x201d; (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201c;&lt;/em&gt;), and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201c;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt; text-align: justify;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value of the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability classified warrants are recognized as a non-cash gain or loss on the statements of operations. Costs associated with issuing the warrants classified as derivative liabilities are charged to operations when the warrants are issued.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2024-01-01_2024-06-30" id="c115659245">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable, accrued expenses, accrued development expense and other&#160;liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses, accrued development expense and other liabilities are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2024-01-01_2024-06-30" id="c115659246">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contracts, Prepaids&#160;and Accruals &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2024-01-01_2024-06-30" id="c115659247">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;CIB Plan&#x201d;) to incentivize Plan participants. Awards under the CIB Plan are accounted for as liability awards under ASC&#160;&lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential CIB Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;CIB Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; for further discussion of the CIB Plan.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659248">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize right-of-use assets or lease liabilities. As the Company`s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659249">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are&#160;recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      id="c115657844">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      id="c115657845">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2024-01-01_2024-06-30" id="c115659250">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements. Intangible assets also include&#160;leasing commissions which are amortized over the life of the lease agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659251">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;b&gt;&lt;i&gt;Insurance Recoveries&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;We record proceeds from our&#160;insurance policies&#160;when the loss event has&#160;occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries&#160;and proceeds received are recorded as a reduction to general and administrative expense. There was approximately $5.8&#160;million&#160;of insurance recoveries recorded during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024. &lt;/em&gt;There were&#160;no insurance recoveries recorded during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023. &lt;/em&gt;There was approximately $8.8&#160;million&#160;and $0.1 million of insurance recoveries recorded during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively. The applicable policy has a $10.0 million recovery limit.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-5"
      id="c115657849"
      unitRef="USD">5800000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115657851"
      unitRef="USD">0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-5"
      id="c115657854"
      unitRef="USD">8800000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-5"
      id="c115657855"
      unitRef="USD">100000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <sava:InsuranceSettlementsMaximumRecoveryLimit
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-7"
      id="c115657859"
      unitRef="USD">10000000</sava:InsuranceSettlementsMaximumRecoveryLimit>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659252">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s condensed consolidated financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2024-01-01_2024-06-30" id="c115659253">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;i&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the&#160;FASB&#160;issued Accounting Standards Update, or ASU, &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures. This standard requires disclosure of significant segment expenses and other segment items by reportable segment. The ASU becomes effective for annual periods beginning in &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and interim periods in &lt;em style="font: inherit;"&gt;2025.&lt;/em&gt; The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures. This standard enhances disclosures related to income taxes, including the rate reconciliation and information on income taxes paid. The ASU becomes effective &lt;em style="font: inherit;"&gt; January 1, 2025.&#160;&lt;/em&gt;The Company is evaluating the impact of adopting this standard on its consolidated financial statements and disclosures.&lt;/p&gt;
   </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sava:PrepaidExpensesAndOtherCurrentAssetsTextBock contextRef="d_2024-01-01_2024-06-30" id="c2709911">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3.&lt;/em&gt; Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Prepaid expenses and other current assets at &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt; consisted of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,432&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,489&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,433&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Insurance recoveries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;5,800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;161&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,831&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </sava:PrepaidExpensesAndOtherCurrentAssetsTextBock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709912">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,432&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,489&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,433&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Insurance recoveries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;5,800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;161&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,831&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657968"
      unitRef="USD">5000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c115657969"
      unitRef="USD">759000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositContractsAssets
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657970"
      unitRef="USD">7432000</us-gaap:DepositContractsAssets>
    <us-gaap:DepositContractsAssets
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c115657971"
      unitRef="USD">6489000</us-gaap:DepositContractsAssets>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657972"
      unitRef="USD">1433000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c115657973"
      unitRef="USD">962000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115657974"
      unitRef="USD">5800</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="i_2023-06-30"
      decimals="INF"
      id="c115657975"
      unitRef="USD">0</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657976"
      unitRef="USD">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c115657977"
      unitRef="USD">287000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115657978"
      unitRef="USD">14831000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-06-30"
      decimals="-3"
      id="c115657979"
      unitRef="USD">8497000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RealEstateOwnedTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709913">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4.&lt;/em&gt; Real Property&#160;and Other Income, Expense&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company owns a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#x2019;s potential growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are&#160;outsourced to professional real-estate managers. The office complex has&#160;approximately 90,000 square feet of rentable space. At &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, the Company occupied&#160;approximately 25% of the property with the remainder&#160;either leased or available for lease to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company records the net income from building operations and leases as other income, net, as leasing is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; core to the Company&#x2019;s operations. Building depreciation and amortization for space &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is&#160;allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;314&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;559&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;717&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,116&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(215&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(356&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(458&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(723&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;203&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;393&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:RealEstateOwnedTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c115657982"
      unitRef="SquareFoot">90000</us-gaap:NetRentableArea>
    <sava:PercentageOfOccupancy
      contextRef="i_2024-06-30_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="2"
      id="c115657983"
      unitRef="Pure">0.25</sava:PercentageOfOccupancy>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709914">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;314&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;559&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;717&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,116&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(215&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(356&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(458&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(723&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;203&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;393&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115658000"
      unitRef="USD">314000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115658001"
      unitRef="USD">559000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115658002"
      unitRef="USD">717000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115658003"
      unitRef="USD">1116000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115658004"
      unitRef="USD">215000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115658005"
      unitRef="USD">356000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115658006"
      unitRef="USD">458000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115658007"
      unitRef="USD">723000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115658008"
      unitRef="USD">99000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115658009"
      unitRef="USD">203000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115658010"
      unitRef="USD">259000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115658011"
      unitRef="USD">393000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709915">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; Property and equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of property and equipment, net, as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt; were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;873&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,138&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,779&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,364&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Depreciation expense for property and equipment was&#160;$244,000&#160;and&#160;$272,000&#160;for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, respectively.&#160;Depreciation expense for property and equipment was $496,000 and $544,000 for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709916">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;873&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,138&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,779&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,364&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c115658026"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c115658027"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c115658028"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c115658029"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-3"
      id="c115658030"
      unitRef="USD">494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-3"
      id="c115658031"
      unitRef="USD">494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c115658032"
      unitRef="USD">3062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c115658033"
      unitRef="USD">3062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c115658034"
      unitRef="USD">873000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c115658035"
      unitRef="USD">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658036"
      unitRef="USD">24143000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115658037"
      unitRef="USD">24138000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658038"
      unitRef="USD">2779000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115658039"
      unitRef="USD">2284000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658040"
      unitRef="USD">21364000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115658041"
      unitRef="USD">21854000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c115658013"
      unitRef="USD">244000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115658014"
      unitRef="USD">272000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115658017"
      unitRef="USD">496000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115658018"
      unitRef="USD">544000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709917">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6.&lt;/em&gt; Intangible assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of intangible assets, net, as of&#160;&lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt; and&#160;&lt;em style="font: inherit;"&gt; December 31, 2023&lt;/em&gt; were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;317&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,370&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,288&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for intangible assets was $56,000 and $119,000 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&#160;Amortization expense for intangible assets was&#160;$117,000 and $238,000 for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; June 30, 2024&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for finite-lived intangible assets as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt; is expected to be as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;60&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709918">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;317&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,370&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,288&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c115658059"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c115658060"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="c115658061"
      unitRef="USD">317000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="c115658062"
      unitRef="USD">293000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c115658063"
      unitRef="USD">1370000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115658064"
      unitRef="USD">1346000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658065"
      unitRef="USD">1288000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c115658066"
      unitRef="USD">1170000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658067"
      unitRef="USD">82000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c115658068"
      unitRef="USD">176000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c115658043"
      unitRef="USD">56000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115658044"
      unitRef="USD">119000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115658049"
      unitRef="USD">117000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115658050"
      unitRef="USD">238000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709919">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;60&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;2027&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i_2024-06-30"
      decimals="-4"
      id="c115658070"
      unitRef="USD">60000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658071"
      unitRef="USD">11000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658072"
      unitRef="USD">8000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658073"
      unitRef="USD">3000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c115658074"
      unitRef="USD">82000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709920">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7.&lt;/em&gt; Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity and Stock-Based Compensation Expense&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Common Stock Warrant Distribution&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;See Notes &lt;em style="font: inherit;"&gt;2&lt;/em&gt; and &lt;em style="font: inherit;"&gt;12&lt;/em&gt; regarding the distribution of common stock warrants on &lt;em style="font: inherit;"&gt; January 3, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;At-the-Market Common Stock Offering &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; May 1, 2023, &lt;/em&gt;the Company entered into an&#160;at-the-market offering program (&#x201c;ATM&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on &lt;em style="font: inherit;"&gt; May 1, 2023 &lt;/em&gt;and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock in the offering. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to sell any shares in the offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;There were &lt;span style="-sec-ix-hidden:c115658082"&gt;&lt;span style="-sec-ix-hidden:c115659235"&gt;no&lt;/span&gt;&lt;/span&gt; common stock sales under the ATM during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;the Company entered into an at-the-market offering program (&lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Program&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on &lt;em style="font: inherit;"&gt; May 5, 2020. &lt;/em&gt;The Company gave notice of termination for the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Program on &lt;em style="font: inherit;"&gt; April 26, 2023, &lt;/em&gt;which was effective &lt;em style="font: inherit;"&gt; May 1, 2023. &lt;/em&gt;There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; common stock sales under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Program through its termination.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Stock Option and Performance Award Activity in &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, stock options and unvested Performance Awards outstanding under the Company&#x2019;s stock option plans changed as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Stock Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Performance Awards&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;193,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(154,700&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,077,329&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The weighted average exercise price per share of options outstanding at &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt; was $14.57. As outstanding options vest over the current remaining vesting period of 2.4&#160;years, the Company expects to recognize stock-based compensation expense of $22.6&#160;million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $0.1 million over the implicit service period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, there were &lt;span style="-sec-ix-hidden:c115658098"&gt;&lt;span style="-sec-ix-hidden:c115659238"&gt;no&lt;/span&gt;&lt;/span&gt; stock options exercised.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;there were 262,158 stock options exercised. Of the stock options exercised, 92,066 stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options &lt;em style="font: inherit;"&gt;not&lt;/em&gt; net settled totaled $889,000 during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;During the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023, &lt;/em&gt;there were 281,175 stock options exercised. Of the stock options exercised, 97,205 stock options were net settled in satisfaction of the exercise price, with no cash proceeds received. Cash proceeds to the Company for options &lt;em style="font: inherit;"&gt;not&lt;/em&gt; net settled totaled $953,000 during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Stock-based Compensation Expense in &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;, the Company&#x2019;s stock-based compensation expense was as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;972&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;392&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,945&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,632&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;443&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,994&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;727&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;835&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,508&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) or a designated committee of the Board is responsible for administration of the Company&#x2019;s &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Omnibus Incentive Plan, as amended (the &lt;em style="font: inherit;"&gt;&#x201c;2018&lt;/em&gt; Plan&#x201d;) and determines the terms and conditions of each option granted, consistent with the terms of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, including grants of stock options and Performance Awards. Share-based awards generally expire &lt;span style="-sec-ix-hidden:c115658124"&gt;10&lt;/span&gt; years from the date of grant. The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, as amended in &lt;em style="font: inherit;"&gt; May&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <sava:EquityOfferingMaximumAmount
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-8"
      id="c115658079"
      unitRef="USD">200000000</sava:EquityOfferingMaximumAmount>
    <sava:EquityOfferingPercentageOfCommission
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="2"
      id="c115658080"
      unitRef="Pure">0.03</sava:EquityOfferingPercentageOfCommission>
    <sava:EquityOfferingMaximumAmount
      contextRef="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-8"
      id="c115658086"
      unitRef="USD">100000000</sava:EquityOfferingMaximumAmount>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709921">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Stock Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Performance Awards&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;193,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(154,700&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,077,329&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c115658136"
      unitRef="Share">3039029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c115658137"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115658138"
      unitRef="Share">193000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c115658139"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115658140"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c115658141"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-06-30"
      decimals="INF"
      id="c115658142"
      unitRef="Share">154700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2024-01-01_2024-06-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c115658143"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115658144"
      unitRef="Share">3077329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2024-06-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c115658145"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-06-30"
      decimals="INF"
      id="c115658092"
      unitRef="USDPerShare">14.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2024-04-01_2024-06-30" id="c115658093">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2024-06-30"
      decimals="-5"
      id="c115658094"
      unitRef="USD">22600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i_2024-06-30_AwardTypeAxis-PerformanceSharesMember"
      decimals="-5"
      id="c115658095"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115658100"
      unitRef="Share">262158</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="INF"
      id="c115658101"
      unitRef="Share">92066</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="-3"
      id="c115658102"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-04-01_2023-06-30"
      decimals="INF"
      id="c115658104"
      unitRef="USD">889000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115658107"
      unitRef="Share">281175</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="INF"
      id="c115658108"
      unitRef="Share">97205</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30_AwardTypeAxis-StockOptionsNetSettledInSatisfactionOfTheExercisePriceMember"
      decimals="-3"
      id="c115658109"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-06-30"
      decimals="INF"
      id="c115658111"
      unitRef="USD">953000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709922">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Three months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Six months ended&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;June 30,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;972&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;392&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,945&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,632&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;443&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,994&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;727&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;835&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,939&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,508&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c115658158"
      unitRef="USD">972000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c115658159"
      unitRef="USD">392000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c115658160"
      unitRef="USD">1945000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c115658161"
      unitRef="USD">781000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c115658162"
      unitRef="USD">1632000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c115658163"
      unitRef="USD">443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c115658164"
      unitRef="USD">2994000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c115658165"
      unitRef="USD">727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c115658166"
      unitRef="USD">2604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2023-06-30"
      decimals="-3"
      id="c115658167"
      unitRef="USD">835000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-06-30"
      decimals="-3"
      id="c115658168"
      unitRef="USD">4939000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-06-30"
      decimals="-3"
      id="c115658169"
      unitRef="USD">1508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c115658127"
      unitRef="Share">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c115658128"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709923">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8.&lt;/em&gt; Income Taxes&lt;/b&gt;&lt;b&gt;&lt;i&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;span style="-sec-ix-hidden:c115658171"&gt;&lt;span style="-sec-ix-hidden:c115659233"&gt;not&lt;/span&gt;&lt;/span&gt; provide for income taxes during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, because it has projected a taxable net loss for the full year &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&#160;for which any benefit will be offset by an increase in the valuation allowance. There was also &lt;span style="-sec-ix-hidden:c115658175"&gt;&lt;span style="-sec-ix-hidden:c115659234"&gt;no&lt;/span&gt;&lt;/span&gt; provision for income taxes for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2023&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <sava:LeasesAndCommitmentsDisclosureTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709924">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;9.&lt;/em&gt; Commitments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#x2019;s obligations under these contracts are largely based on services performed.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </sava:LeasesAndCommitmentsDisclosureTextBlock>
    <sava:CashIncentiveBonusPlanTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709925">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note&lt;/b&gt;&#160;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the Board approved the CIB Plan. The CIB Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#160;CIB Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The CIB Plan is considered &#x201c;at-risk&#x201d; because CIB Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; receive a cash bonus&#160;unless&#160;the Company&#x2019;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the CIB Plan&#160;are met.&#160;Specifically, CIB Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;be paid&#160;any cash bonuses unless (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a "Merger Transaction") or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the Compensation Committee of the Board&#160;(the "Compensation Committee") determines the Company has sufficient cash on hand, as defined in the CIB Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;CIB Plan&#160;grant date has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occurred&#160;as of &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;CIB Plan participants will be paid all earned cash bonuses allocated under the CIB&#160;Plan in the event of a Merger Transaction.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;the Company&#x2019;s independent directors were participants in the CIB Plan. However, effective &lt;em style="font: inherit;"&gt; March 16, 2023, &lt;/em&gt;the Board&#160;amended the CIB Plan to remove all independent directors as participants in the CIB Plan and the independent directors consented to such removal. The independent directors&#x2019; share of potential benefits under the CIB Plan were completely forfeited to the Company and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be allocated to any other participant under the CIB Plan. The Company&#x2019;s independent directors have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; received, and as a result of such amendment will never receive, any payments under the CIB Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s market capitalization for purposes of the CIB Plan&#160;is&#160;determined based on either (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the closing price&#160;of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share&#160;of the Company&#x2019;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;Any warrants outstanding are excluded from the determination of market capitalization. This constitutes a market condition under applicable accounting guidance.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The CIB Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#x2019;s market capitalization increases significantly, up to a maximum&#160;&lt;em style="font: inherit;"&gt;$5&lt;/em&gt;&#160;billion in market capitalization. The CIB Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#x201c;Valuation Milestone&#x201d;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the CIB Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days for&#160;CIB Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; awarded by the Compensation Committee&#160;are&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer available for distribution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If the Company were to exceed a $5&#160;billion market capitalization&#160;for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;the Company completes a Merger Transaction, or&#160;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#x201c;Performance Condition&#x201d;),&#160;neither&#160;of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;ever occur. Accordingly, there can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that&#160;CIB Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the CIB Plan, even if the Company&#x2019;s market capitalization increases&#160;significantly.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The CIB Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the CIB Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2020, &lt;/em&gt;the Company&#160;achieved&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;Valuation&#160;Milestone.&#160;Subsequently in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all CIB Plan participants (after taking into account the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;CIB Plan amendment), subject to future satisfaction of a Performance Condition.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all CIB Plan participants from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million (after taking into account the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;CIB Plan amendment), to be determined, approved and allocated by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense was recorded&#160;since &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;grant date has occurred and &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;Performance Conditions are considered probable of being met.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; continuing service requirement for CIB Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; Valuation Milestones were achieved during the years ended &lt;em style="font: inherit;"&gt; December 31, 2023&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; or the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;No actual cash payments were authorized or made to participants under the CIB Plan through the date of filing of this Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </sava:CashIncentiveBonusPlanTextBlock>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c115658213"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-8"
      id="c115658214"
      unitRef="USD">200000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c115658215"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-03-16_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c115658217">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="2"
      id="c115658218"
      unitRef="Pure">0.67</sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c115658221"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-01-01_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c115658223">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c115658224"
      unitRef="USD">111400000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c115658225"
      unitRef="USD">289700000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-03-16_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c115658229"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:CashIncentiveBonusAward
      contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-5"
      id="c115658232"
      unitRef="USD">6500000</sava:CashIncentiveBonusAward>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c115658235"
      unitRef="Pure">11</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c115658236"
      unitRef="USD">74900000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c115658237"
      unitRef="USD">202300000</sava:PerformancePlanValuationMilestoneAmount>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-3"
      id="c115658238"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <sava:PaymentsForCashIncentiveBonus
      contextRef="d_2024-01-01_2024-06-30_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-3"
      id="c115658245"
      unitRef="USD">0</sava:PaymentsForCashIncentiveBonus>
    <us-gaap:LossContingencyDisclosures contextRef="d_2024-01-01_2024-06-30" id="c2709926">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11.&lt;/em&gt; Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;The Company is, and from time to time, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assessment can be made as to their likely outcome or whether the outcome will be material to the Company other than as disclosed below. The Company believes that its total provisions for legal matters are adequate based upon currently available information.&lt;/p&gt;
   &lt;p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"&gt;&lt;i&gt;Update on Government Investigations&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;"&gt;Beginning in &lt;em style="font: inherit;"&gt; August 2021, &lt;/em&gt;the Company has received subpoenas, a Civil Investigative Demand (&#x201c;CID&#x201d;) and other requests for documents and information from the Department of Justice and document requests from the Securities and Exchange Commission, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, CID and requests for information and intends to continue to cooperate with these&#160;government&#160;inquiries. The Company cannot predict the outcome or impact of these ongoing matters, including whether a government authority &lt;em style="font: inherit;"&gt; may &lt;/em&gt;pursue an enforcement action against the Company or others.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;"&gt;The Company is in the advanced stages of discussions with the SEC staff to resolve the SEC&#x2019;s nearly &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-year investigation of the Company's disclosures regarding its Phase &lt;em style="font: inherit;"&gt;2b&lt;/em&gt; study of simufilam for the treatment of Alzheimer&#x2019;s disease (the &#x201c;Phase &lt;em style="font: inherit;"&gt;2b&lt;/em&gt; Study&#x201d;). The Company has reserved a loss contingency of &lt;em style="font: inherit;"&gt;$40&lt;/em&gt;&#160;million&#160;on its consolidated balance sheet as of &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;relating to this potential settlement with the SEC.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;"&gt;The Company continues to cooperate with the DOJ related to conduct alleged in the indictment of Dr. Hoau-Yan Wang announced by the Department of Justice on &lt;em style="font: inherit;"&gt; June 28, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"&gt;&lt;i&gt;Securities Class Actions and Shareholder Derivative Actions&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;Between &lt;em style="font: inherit;"&gt; August 27, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 26, 2021, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c115658255"&gt;four&lt;/span&gt; putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 30, 2022, &lt;/em&gt;a federal judge consolidated the &lt;span style="-sec-ix-hidden:c115658256"&gt;four&lt;/span&gt; class action lawsuits into &lt;span style="-sec-ix-hidden:c115658257"&gt;one&lt;/span&gt; case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on &lt;em style="font: inherit;"&gt; August 18, 2022 &lt;/em&gt;on behalf of a putative class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; September 14, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 26, 2022. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; May 11, 2023, &lt;/em&gt;the court dismissed with prejudice plaintiffs&#x2019; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#x2019; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on &lt;em style="font: inherit;"&gt; July 3, 2023. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; February 22, 2024, &lt;/em&gt;plaintiffs filed a motion to supplement their complaint to extend the putative class period through &lt;em style="font: inherit;"&gt; October 12, 2023.&#160; &lt;/em&gt;The court granted that Motion on &lt;em style="font: inherit;"&gt; June 12, 2024, &lt;/em&gt;and plaintiffs filed a supplemental complaint on &lt;em style="font: inherit;"&gt; June 13, 2023.&#160; &lt;/em&gt;On &lt;em style="font: inherit;"&gt; March 13, 2024, &lt;/em&gt;plaintiffs filed a Motion for Class Certification.&#160; The Company has opposed that Motion.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 4, 2021, &lt;/em&gt;a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendants&#x2019; alleged wrongful conduct. Although the plaintiff in this derivative case does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between &lt;em style="font: inherit;"&gt; November 4, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; June 20, 2023, &lt;/em&gt;four additional shareholder derivative actions were filed alleging substantially similar claims, &lt;span style="-sec-ix-hidden:c115658262"&gt;two&lt;/span&gt; in the U.S. District Court for the Western District of Texas, &lt;span style="-sec-ix-hidden:c115658263"&gt;one&lt;/span&gt; in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On &lt;em style="font: inherit;"&gt; July 5, 2022, &lt;/em&gt;the &lt;span style="-sec-ix-hidden:c115658266"&gt;three&lt;/span&gt; actions in the Western District of Texas were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On &lt;em style="font: inherit;"&gt; November 9, 2023, &lt;/em&gt;another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 2, 2024, &lt;/em&gt;a putative class action lawsuit was filed, purportedly on behalf of the Company,&#160;alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an &lt;em style="font: inherit;"&gt; October 12, 2023 &lt;/em&gt;article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; August 18, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 12, 2023. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; May 28, 2024, &lt;/em&gt;the Northern District of Illinois transferred this action to the Western District of Texas.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;Beginning on &lt;em style="font: inherit;"&gt; March 18, 2024, &lt;/em&gt;two related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. The complaints rely on an &lt;em style="font: inherit;"&gt; October 12, 2023 &lt;/em&gt;article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaints allege, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative cases seek, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiffs in these derivative cases do &lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;not&lt;/em&gt; seek relief against the Company, the Company has certain indemnification obligations to the individual defendants.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;The Company believes the foregoing claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; August 19, 2022, &lt;/em&gt;a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan in &lt;em style="font: inherit;"&gt; August 2020. &lt;/em&gt;The complaints seek unspecified compensatory damages and other relief. On &lt;em style="font: inherit;"&gt; January 6, 2023, &lt;/em&gt;the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on &lt;em style="font: inherit;"&gt; March 10, 2023, &lt;/em&gt;and moved to partially dismiss the amended complaint on &lt;em style="font: inherit;"&gt; March 14, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; May 28, 2024, &lt;/em&gt;the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the &#x201c;Stipulation&#x201d;) to resolve the Action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the &#x201c;Notice&#x201d;) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the &#x201c;Scheduling Order&#x201d;), were filed in the Delaware Court of Chancery on &lt;em style="font: inherit;"&gt; May 28, 2024.&#160; &lt;/em&gt;The Stipulation is subject to final approval by the Delaware Court of Chancery. The Stipulation, if finally approved, will cause the dismissal with prejudice of the Action.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 26, 2024, &lt;/em&gt;the Delaware Court of Chancery entered the Scheduling Order, which includes approval of the Notice.&#160; Resolution of the Action is subject to approval from the Delaware Court of Chancery. The Delaware Court of Chancery set a final settlement hearing for &lt;em style="font: inherit;"&gt; September 9, 2024, &lt;/em&gt;at &lt;em style="font: inherit;"&gt;3:15&lt;/em&gt; p.m. ET in the Delaware Court of Chancery, Leonard L. Williams Justice Center, &lt;em style="font: inherit;"&gt;500&lt;/em&gt; North King Street, Wilmington, Delaware &lt;em style="font: inherit;"&gt;19801.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;i&gt;Anti-SLAPP Lawsuit&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; August 6, 2024, &lt;/em&gt;a lawsuit was filed in the District Court for the Southern District of New York asserting claims under the New York Anti-SLAPP Law.&#160; The complaint seeks costs and damages relating to a defamation action filed by the Company against the plaintiffs and subsequently dismissed voluntarily and without prejudice by the Company.&#160;The Company will defend the lawsuit vigorously.&#160;The Company is unable to estimate the possible loss or range of loss, if any, associated with this lawsuit.&lt;/p&gt;
  </us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"
      decimals="INF"
      id="c115658261"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"
      decimals="INF"
      id="c115658265"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2024-03-18_2024-03-18_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c115658268"
      unitRef="Pure">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <sava:WarrantDividendDistributionTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709927">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -11pt; text-indent: 9pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;12.&lt;/em&gt; Warrant Dividend Distribution&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 3, 2024, &lt;/em&gt;the Company&#160;made a distribution&#160;to the holders of record of the Company&#x2019;s&#160;common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on &lt;em style="font: inherit;"&gt; December 22, 2023 &lt;/em&gt;received &lt;span style="-sec-ix-hidden:c115658348"&gt;four&lt;/span&gt; warrants for every 10&#160;shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately &lt;span style="-sec-ix-hidden:c115658350"&gt;16.9&lt;/span&gt; million&#160;warrants.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;Each warrant entitled&#160;the holder to purchase, at the holder&#x2019;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, &lt;span style="-sec-ix-hidden:c115658352"&gt;one&lt;/span&gt; and &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-half shares of common stock (rounded down&#160;for any fractional shares). Payment for shares of common stock upon exercise of warrants was required to&#160;be in cash.&lt;/p&gt;
   &lt;p style="margin: 0pt 0pt 0pt -9pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; April 15, 2024, &lt;/em&gt;the Company announced&#160;that all outstanding warrants would&#160;be redeemed on &lt;em style="font: inherit;"&gt; May 7, 2024&#160;(&lt;/em&gt;the &#x201c;Redemption Date&#x201d;). The redemption price was equal to &lt;span style="-sec-ix-hidden:c115658354"&gt;1/10&lt;/span&gt; of $0.01 per warrant. The warrants were exercisable at any time starting on &lt;em style="font: inherit;"&gt; January 3, 2024&#160;&lt;/em&gt;until the business day prior to the Redemption Date. There are &lt;span style="-sec-ix-hidden:c115658356"&gt;no&lt;/span&gt; remaining warrants currently outstanding.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"&gt;The warrants were subject to the terms and conditions of the Warrant Agreement (including Form of Warrant), dated &lt;em style="font: inherit;"&gt; January 3, 2024, &lt;/em&gt;between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A. as filed in a Current Report on&#160;Form &lt;em style="font: inherit;"&gt;8&lt;/em&gt;-K with the SEC on &lt;em style="font: inherit;"&gt; January 3, 2024. &lt;/em&gt;The warrants were&#160;listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#x201c;SAVAW&#x201d;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;From &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;to &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;a total of approximately 674,000&#160;warrants were exercised resulting in net proceeds to the Company of approximately $22.3&#160;million. The Company issued approximately 1.0 million&#160;shares of common stock&#160;from the exercise of warrants through &lt;em style="font: inherit;"&gt; March 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;Subsequent to &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;and through the Redemption Date, a total of approximately &lt;em style="font: inherit;"&gt;3.15&lt;/em&gt; million&#160;warrants were exercised resulting in gross proceeds to the Company of approximately &lt;em style="font: inherit;"&gt;$104.0&lt;/em&gt;&#160;million. The Company issued approximately 4.7 million shares of common stock&#160;from the exercise of warrants from &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;through the Redemption Date.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;Gross proceeds in &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; from the warrant distribution totaled approximately $126.3&#160;million from the issuance of approximately 5.7 million common shares at $22.00 per share. Total net proceeds of the warrant distribution were approximately $123.6&#160;million&#160;after deducting estimated exercise&#160;expenses.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;After the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; $20 million of gross proceeds, the Company was&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock from&#160;warrant exercises&#160;to the Company's financial advisor for the warrant distribution. Total cost&#160;of warrant exercises through the Redemption Date were approximately $2.7&#160;million.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;Costs of the warrant distribution totaling&#160;approximately $537,000 were recorded&#160;as general and administrative expenses in the statements of operations upon distribution of the warrants on &lt;em style="font: inherit;"&gt; January 3, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;The outstanding warrants are classified as liabilities in accordance with ASC &lt;em style="font: inherit;"&gt;480&lt;/em&gt; and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; which requires&#160;the warrants to be measured at initial fair value&#160;on &lt;em style="font: inherit;"&gt; January 3, 2024&#160;&lt;/em&gt;and at each reporting period thereafter, with the changes in fair value recognized as a non-cash gain or loss&#160;in our consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;During the period from common stock warrant distribution on &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;to the Redemption Date, changes in the Company's common stock warrants liability and&#160;warrants outstanding were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Common Stock Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Common Stock Warrant Liability&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Distribution of common stock warrants on January 3, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,895&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(674&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,954&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balance at March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,368&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,152&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(226&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(65,142&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Redemption of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(13,069&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;See Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; for additional information regarding common stock warrants and associated warrant liability.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;


  </sava:WarrantDividendDistributionTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658349"
      unitRef="Share">10</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658351"
      unitRef="USDPerShare">33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sava:WarrantRedemptionPrice
      contextRef="i_2024-05-07_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658355"
      unitRef="USDPerShare">0.01</sava:WarrantRedemptionPrice>
    <sava:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658358"
      unitRef="Share">674000</sava:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c115658359"
      unitRef="USD">22300000</us-gaap:ProceedsFromWarrantExercises>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658360"
      unitRef="Share">1</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-04-01_2024-05-02_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658363"
      unitRef="Share">4.7</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:GrossProceedsFromIssuanceOfWarrants
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c115658365"
      unitRef="USD">126300000</sava:GrossProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c115658366"
      unitRef="Share">5700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658367"
      unitRef="USDPerShare">22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c115658368"
      unitRef="USD">123600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-7"
      id="c115658371"
      unitRef="USD">20000000</sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission>
    <sava:CommissionPercentageOfGrossProceeds
      contextRef="d_2024-01-04_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="3"
      id="c115658372"
      unitRef="Pure">0.025</sava:CommissionPercentageOfGrossProceeds>
    <sava:PaymentsOfWarrantExerciseCosts
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-5"
      id="c115658373"
      unitRef="USD">2700000</sava:PaymentsOfWarrantExerciseCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c115658374"
      unitRef="USD">537000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709928">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of Common Stock Warrants&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Common Stock Warrant Liability&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Distribution of common stock warrants on January 3, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,895&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113,363&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(674&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,954&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;"&gt;Balance at March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;65,368&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Warrants exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,152&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(226&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 9pt;"&gt;Gain from change in fair value of warrant liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(65,142&lt;/td&gt;&lt;td style="width: 1%; padding-left: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Redemption of common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(13,069&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of June 30, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-01-02"
      decimals="INF"
      id="c115658382"
      unitRef="Share">16895</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-01-02"
      decimals="INF"
      id="c115658384"
      unitRef="USD">113363</us-gaap:WarrantsAndRightsOutstanding>
    <sava:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658385"
      unitRef="Share">674000</sava:ClassOfWarrantOrRightExercisedDuringPeriod>
    <sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability
      contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658387"
      unitRef="USD">4954000</sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-01-03_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658389"
      unitRef="USD">43041000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658390"
      unitRef="Share">16221000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658391"
      unitRef="USD">65368000</us-gaap:WarrantsAndRightsOutstanding>
    <sava:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658392"
      unitRef="Share">3152000</sava:ClassOfWarrantOrRightExercisedDuringPeriod>
    <sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658393"
      unitRef="USD">226000</sava:ExerciseOfWarrantsResultingInDecreaseInWarrantLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658395"
      unitRef="USD">65142000</us-gaap:FairValueAdjustmentOfWarrants>
    <sava:ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed
      contextRef="d_2024-04-01_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658396"
      unitRef="Share">13069000</sava:ClassOfWarrantsOrRightsCommonStockWarrantsRedeemed>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658398"
      unitRef="Share">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-06-30_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="c115658399"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2024-01-01_2024-06-30" id="c2709929">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="other" title="other"&gt;&lt;/a&gt;Item &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; &lt;/b&gt;&lt;b&gt;&lt;i&gt;Other Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the quarter ended &lt;em style="font: inherit;"&gt; June 30, 2024&lt;/em&gt;, &lt;span style="-sec-ix-hidden:c115658401"&gt;&lt;span style="-sec-ix-hidden:c115659230"&gt;&lt;span style="-sec-ix-hidden:c115659231"&gt;&lt;span style="-sec-ix-hidden:c115659232"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or officers (as defined in Rule &lt;em style="font: inherit;"&gt;16a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;(f) of the Exchange Act) informed us of the adoption or termination of a &#x201c;Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement&#x201d; or &#x201c;non-Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement,&#x201d; as those terms are defined in Regulation S-K, Item &lt;em style="font: inherit;"&gt;408.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

  </ecd:MtrlTermsOfTrdArrTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
